Form 10-Q

Large accelerated filer

Accelerated filer

Non-accelerated filer

¨ (Do not check if a smaller reporting company)

Smaller reporting company

0001193125-13-440494.txt : 20131114 0001193125-13-440494.hdr.sgml : 20131114 20131113181227 ACCESSION NUMBER: 0001193125-13-440494 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 9 CONFORMED PERIOD OF REPORT: 20130930 FILED AS OF DATE: 20131114 DATE AS OF CHANGE: 20131113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Regulus Therapeutics Inc. CENTRAL INDEX KEY: 0001505512 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 264738379 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35670 FILM NUMBER: 131215998 BUSINESS ADDRESS: STREET 1: 3545 JOHN HOPKINS COURT STREET 2: SUITE 210 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-202-6300 MAIL ADDRESS: STREET 1: 3545 JOHN HOPKINS COURT STREET 2: SUITE 210 CITY: SAN DIEGO STATE: CA ZIP: 92121 10-Q 1 d599924d10q.htm FORM 10-Q Form 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2013

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM TO

Commission file number: 001-35670

Regulus Therapeutics Inc.

(Exact name of registrant as specified in its charter)


Delaware		26-4738379
(State or Other Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification No.)

3545 John Hopkins Ct., Suite 210, San Diego CA		92121
(Address of Principal Executive Offices)		(Zip Code)

858-202-6300

(Registrant’s Telephone Number, Including Area Code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ¨ Yes x No

As of November 8, 2013, the registrant had 41,777,326 shares of Common Stock ($0.001 par value) outstanding.

REGULUS THERAPEUTICS INC.

TABLE OF CONTENTS


PART I. FINANCIAL INFORMATION
Item 1.	Financial Statements
	Condensed Balance Sheets as of September 30, 2013 (Unaudited) and December 31, 2012	3
	Condensed Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2013 and 2012 (Unaudited)	4
	Condensed Statements of Cash Flows for the nine months ended September 30, 2013 and 2012 (Unaudited)	5
	Notes to Condensed Financial Statements (Unaudited)	6
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	15
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	21
Item 4.	Controls and Procedures	21
PART II. OTHER INFORMATION
Item 1.	Legal Proceedings	22
Item 1A.	Risk Factors	22
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	41
Item 3.	Defaults Upon Senior Securities	42
Item 4.	Mine Safety Disclosures	42
Item 5.	Other Information	42
Item 6.	Exhibits	42

PART I. FINANCIAL INFORMATION

ITEM 1.

FINANCIAL STATEMENTS

Regulus Therapeutics Inc.

CONDENSED BALANCE SHEETS

(In thousands, except share and per share data)


	September 30, 2013			December 31, 2012
	(Unaudited)
Assets
Current assets:
Cash and cash equivalents	$	33,490		$	40,552
Short-term investments		90,413			57,548
Contracts and other receivables		95			—
Prepaid and other current assets		1,288			829

Total current assets		125,286			98,929
Property and equipment, net		3,981			3,310
Intangibles, net		1,145			1,154
Other assets		178			125

Total assets	$	130,590		$	103,518

Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	1,140		$	311
Accrued liabilities		1,705			658
Accrued compensation		1,228			1,348
Current portion of deferred revenue		9,454			10,451

Total current liabilities		13,527			12,768
Convertible notes payable, at fair value		13,921			10,134
Deferred revenue, less current portion		7,138			17,756
Other long-term liabilities		1,558			767

Total liabilities		36,144			41,425
Stockholders’ equity:
Common stock, $0.001 par value; 200,000,000 shares authorized, 41,774,442 and 35,831,808 shares issued and outstanding at September 30, 2013 (unaudited) and December 31, 2012, respectively		42			36
Additional paid-in capital		171,608			122,528
Accumulated other comprehensive loss		(44	)		(52	)
Accumulated deficit		(77,160	)		(60,419	)

Total stockholders’ equity		94,446			62,093

Total liabilities and stockholders’ equity	$	130,590		$	103,518

See accompanying notes to these condensed financial statements.

Regulus Therapeutics Inc.

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands, except share and per share data)


	Three months ended September 30,						Nine months ended September 30,
	2013			2012			2013			2012
	(Unaudited)
Revenues:
Revenue under strategic alliances and collaborations	$	6,118		$	2,809		$	14,115		$	9,462

Total revenues		6,118			2,809			14,115			9,462
Operating expenses:
Research and development		7,106			5,248			21,710			14,735
General and administrative		1,917			1,093			5,545			2,998

Total operating expenses		9,023			6,341			27,255			17,733

Loss from operations		(2,905	)		(3,532	)		(13,140	)		(8,271	)
Other income (expense):
Interest and other income		72			20			207			74
Interest expense		(7	)		(110	)		(25	)		(294	)
Loss on extinguishment of debt		—			(1,738	)		—			(1,738	)
Gain (loss) from changes in valuation of convertible note payable		671			(331	)		(3,787	)		(331	)

Loss before income taxes		(2,169	)		(5,691	)		(16,745	)		(10,560	)
Income tax benefit		(5	)		(6	)		(4	)		(28	)

Net loss	$	(2,164	)	$	(5,685	)	$	(16,741	)	$	(10,532	)

Other comprehensive loss:
Unrealized gain on short-term investments, net		37			10			8			44

Comprehensive loss	$	(2,127	)	$	(5,675	)	$	(16,733	)	$	(10,488	)

Net loss per share:
Basic	$	(0.05	)	$	(15.98	)	$	(0.45	)	$	(41.03	)

Diluted	$	(0.07	)	$	(15.98	)	$	(0.45	)	$	(41.03	)

Weighted average shares used to compute net loss per share:
Basic		40,154,812			355,735			37,367,368			256,682

Diluted		41,555,660			355,735			37,367,368			256,682

See accompanying notes to these condensed financial statements.

Regulus Therapeutics Inc.

Condensed Statements of Cash Flows

(In thousands)


	Nine months ended September 30,
	2013			2012
	(Unaudited)
Operating activities
Net loss	$	(16,741	)	$	(10,532	)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization expense		996			741
Loss on extinguishment of debt		—			1,738
Loss from valuation of convertible note payable		3,787			331
Stock-based compensation		2,524			732
Amortization of premium on investments, net		1,018			311
Gain on investments		(6	)		—
Change in operating assets and liabilities:
Contracts and other receivables		(95	)		(3,000	)
Prepaid and other assets		(512	)		56
Accounts payable		829			148
Accrued liabilities		851			73
Accrued compensation		(120	)		302
Deferred revenue		(11,615	)		(527	)
Deferred rent and other liabilities		68			55

Net cash used in operating activities		(19,016	)		(9,572	)

Investing activities
Purchases of short-term investments		(50,390	)		(9,287	)
Maturities and sales of short-term investments		16,520			24,550
Purchases of property and equipment		(608	)		(724	)
Acquisition of intangibles		(46	)		(185	)

Net cash (used in) provided by investing activities		(34,524	)		14,354

Financing activities
Proceeds from issuance of common stock, net		46,562			102
Proceeds from issuance of convertible notes payable		—			5,000
Principal payments on other long-term obligations		(84	)		(326	)
Costs paid in connection with initial public offering		—			(1,307	)

Net cash provided by financing activities		46,478			3,469

Net (decrease) increase in cash and cash equivalents		(7,062	)		8,251
Cash and cash equivalents at beginning of period		40,552			9,175

Cash and cash equivalents at end of period	$	33,490		$	17,426

Supplemental disclosure of cash flow information
Interest paid	$	—		$	32

Income taxes paid	$	1		$	207

Supplemental disclosure of non-cash investing and financing activities
Amounts accrued for property and equipment, net	$	57		$	—

Amounts accrued for patent expenditures, net	$	—		$	10

See accompanying notes to these financial statements.

Regulus Therapeutics Inc.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

1. Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management’s opinion, the accompanying financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results for the interim periods presented.

Interim financial results are not necessarily indicative of results anticipated for the full year. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and footnotes included in the Annual Report on Form 10-K for the year ended December 31, 2012 for Regulus Therapeutics Inc. (“we,” “us,” “our,” or the “Company”), from which the balance sheet information herein for the year ended December 31, 2012 was derived.

On September 7, 2012, our board of directors approved a one-for-two reverse stock split of our common stock. The accompanying condensed financial statements and notes to the condensed financial statements give retroactive effect to the reverse split for all periods presented. No further splits (or reverse splits) of our common stock have been contemplated as of September 30, 2013.

In October 2012, we completed an initial public offering and concurrent private placement of 18,980,982 shares of common stock at an offering price of $4.00 per share. In addition, principal and interest of $10.8 million from convertible notes outstanding were automatically converted upon the closing of the initial public offering into an aggregate of 2,703,269 shares of our common stock. We raised a total of $70.0 million in net proceeds from our initial public offering and concurrent private placement, after deducting underwriter discounts, commissions and other offering expenses.

In July 2013, we completed a public offering of 5,175,000 shares of common stock at an offering price of $9.50 per share. The shares were registered pursuant to a registration statement on Form S-1. We raised a total of $45.8 million in net proceeds, after deducting underwriting discounts, commissions and other offering expenses.

Use of Estimates

Our financial statements are prepared in accordance with GAAP. The preparation of our financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions.

Revenue Recognition

As of September 30, 2013, we have ongoing strategic alliance agreements and collaborations with GlaxoSmithKline plc (“GSK”), Sanofi, AstraZeneca AB (“AstraZeneca”) and Biogen Idec MA Inc. (“Biogen Idec”). Our revenues generally consist of upfront payments for licenses or options to obtain licenses in the future, research and development funding and milestone payments. We recognize revenues when all four of the following criteria are met: (1) persuasive evidence that an arrangement exists; (2) delivery of the products and/or services has occurred; (3) the selling price is fixed or determinable; and (4) collectability is reasonably assured.

For these multiple element arrangements, deliverables under our agreements are accounted for as separate units of accounting provided that (i) a delivered item has value to the customer on a stand-alone basis; and (ii) if the agreement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item is considered probable and substantially in the control of the vendor. The allocation of consideration amongst the units of accounting under our strategic alliance agreements and collaborations are derived using a “best estimate of selling price” if vendor specific objective evidence and third-party evidence of fair value is not available.

Milestones

We recognize revenue from milestone payments when earned, provided that (i) the milestone event is substantive in that it can only be achieved based in whole or in part on either our performance or on the occurrence of a specific outcome resulting from our performance and its achievability was not reasonably assured at the inception of the agreement; (ii) we do not have ongoing performance obligations related to the achievement of the milestone; and (iii) it would result in the receipt of additional payments. A milestone payment is considered substantive if all of the following conditions are met: (i) the milestone payment is non-refundable; (ii) achievement of the milestone was not reasonably assured at the inception of the arrangement; (iii) substantive effort is involved to achieve the milestone; and (iv) the amount of the milestone payments appears reasonable in relation to the effort expended, the other milestones in the arrangement and the related risk associated with the achievement of the milestone. Any amounts received under the agreements in advance of performance, if deemed substantive, are recorded as deferred revenue and recognized as revenue as we complete our performance obligations.

Generally, the milestone events contained in our strategic alliance agreements and collaborations coincide with the progression of our product candidates from target selection, to clinical candidate selection, to clinical trial, to regulatory approval and then to commercialization. The process of successfully discovering a new development candidate, having it approved and ultimately sold for a profit is highly uncertain. As such, the milestone payments we may earn from our partners involve a significant degree of risk to achieve. Therefore, as a product candidate progresses through the stages of its life-cycle, the value of the product candidate generally increases.

Deferred Revenue

Amounts received prior to satisfying the above revenue recognition criteria are recorded as deferred revenue in the accompanying condensed balance sheets. Amounts not expected to be recognized within the next 12 months are classified as non-current deferred revenue.

Stock-Based Compensation

We account for stock-based compensation expense related to stock options granted to employees and members of our board of directors by estimating the fair value of each stock option on the date of grant using the Black-Scholes model. We recognize stock-based compensation expense using the accelerated multiple-option approach. Under the accelerated multiple-option approach (also known as the graded-vesting method), we recognize compensation expense over the requisite service period for each separately vesting tranche of the award as though the award was in substance multiple awards, resulting in accelerated expense recognition over the vesting period.

We account for stock options granted to non-employees other than members of our board of directors, which primarily consist of members of our scientific advisory board, using the fair value approach. Stock options granted to non-employees are subject to periodic revaluation over their vesting terms.

Fair Value Option

Applicable accounting guidance permits entities to choose, at specified election dates, to measure specified items at fair value if the decision about the election is: 1) applied instrument by instrument, 2) irrevocable, and 3) applied to an entire instrument.

In July 2012, we amended and restated our $5.0 million convertible promissory note originally issued in February 2010 to GSK (“2010 GSK Note”), which was accounted for as a debt extinguishment of the original note. We elected to measure the 2010 GSK Note under the fair value option. Upon initial measurement, the difference between the carrying value of the original note and the fair value of the 2010 GSK Note was recorded as a loss on extinguishment of debt to non-operating earnings. Thereafter, any change to the fair value of the 2010 GSK Note is recorded as a gain (loss) from valuation of convertible note payable to non-operating earnings.

Recent Accounting Pronouncements

In February 2013, the FASB issued Accounting Standards Update No. 2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income (“ASU 2013-02”). This update will require companies to present information about amounts reclassified out of accumulated other comprehensive income and their corresponding effect on net income in one place and reference the amounts to the related footnote disclosures. Current accounting standards present this information in different places throughout the financial statements. ASU 2013-02 was effective for us for the nine months ended September 30, 2013. The adoption of ASU 2013-02 had no impact on our financial condition, results of operations, or cash flows.

In July 2013, the FASB issued Accounting Standards Update No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (“ASU 2013-11”). This update provides explicit guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. This guidance is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013, with an option for early adoption. We intend to adopt this guidance in 2014, and do not believe the adoption of this standard will have a material impact on our financial condition, results of operations or related financial statement disclosures.

2. Net Loss Per Share

Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted average number of common stock equivalents outstanding for the period determined using the treasury-stock method.

Dilutive common stock equivalents are comprised of convertible preferred stock, options outstanding under our stock option plan and convertible notes payable. Applicable accounting guidance provides that a contract that is reported as an asset or liability for accounting purposes may require an adjustment to the numerator of the diluted earnings per share calculation for any changes in income or loss that would result if the contract had been reported as an equity instrument for accounting purposes during the period. Securities are assumed to be converted at the beginning of the period, and the resulting common shares are included in the denominator of the diluted earnings per share calculation for the entire period presented. Adding back the gain from the change in valuation of the convertible note payable for the three months ended September 30, 2013 to the numerator and adding the number of shares to be issued upon conversion of the convertible note payable into the denominator of the diluted earnings per share calculation resulted in an increase to the loss per share for the period. The convertible note payable was anti-dilutive for the nine months ended September 30, 2013.

The following table summarizes the adjustment to net loss for the diluted net loss per share calculation for the three months ended September 30, 2013 (in thousands):


Net loss	$	(2,164	)
Less: gain from change in valuation of note payable		671

Net loss used to compute diluted net loss per share	$	(2,835	)

Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common equivalent shares):


	Three months ended September 30,				Nine months ended September 30,
	2013		2012		2013		2012
Convertible preferred stock outstanding		—		13,699,999		—		13,699,999
Common stock options		3,041,033		2,845,675		2,474,614		2,823,463
Convertible note payable		—		—		1,400,848		—

Total		3,041,033		16,545,674		3,875,462		16,523,462

In October 2012, all convertible preferred stock converted into common stock in conjunction with our initial public offering. As of September 30, 2013 we had a convertible note payable outstanding with a principal balance of $5.4 million that was convertible into common shares at $4.00 per share, at the option of the note holder.

3. Investments

We invest our excess cash in commercial paper and debt instruments of financial institutions, corporations, U.S. government-sponsored agencies, and the U.S. Treasury. For investments in debt securities with unrealized losses, we do not intend to sell these investments, nor is it more than likely that we will be required to do so, prior to the recovery of their amortized cost basis, which may be their maturity. As of September 30, 2013, our short-term investments had a weighted average maturity of less than two years.

The following tables summarize our short-term investments (dollars in thousands):


	Maturity (in years)		Amortized cost		Unrealized					Estimated fair value
	Maturity (in years)		Amortized cost		Gains		Losses			Estimated fair value
As of September 30, 2013
Corporate debt securities		2 or less	$	68,649	$	18	$	(50	)	$	68,617
Commercial paper		1 or less		999		—		—			999
Certificates of deposit		2 or less		13,770		—		—			13,770
Debt securities of U.S. government-sponsored agencies		1 or less		7,025		2		—			7,027

Total			$	90,443	$	20	$	(50	)	$	90,413


	Maturity (in years)		Amortized cost		Unrealized					Estimated fair value
	Maturity (in years)		Amortized cost		Gains		Losses			Estimated fair value
As of December 31, 2012
Corporate debt securities		2 or less	$	44,898	$	7	$	(49	)	$	44,856
Commercial paper		2 or less		6,492		—		—			6,492
Certificates of deposit		1 or less		6,200		—		—			6,200

Total			$	57,590	$	7	$	(49	)	$	57,548

4. Fair Value Measurements

We have certain financial assets and liabilities recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.

Applicable accounting guidance defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants as of the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact. The guidance provides an established hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs that reflect our assumptions about the factors that market participants would use in valuing the asset or liability. The guidance prioritizes the inputs used in measuring the fair value into the following hierarchy:

•

Level 1 includes financial instruments for which quoted market prices for identical instruments are available in active markets.

•

Level 2 includes financial instruments for which there are inputs other than quoted prices included within Level 1 that are observable for the instrument such as quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets with insufficient volume or infrequent transactions (less active markets) or model-driven valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

•

Level 3 includes financial instruments for which fair value is derived from valuation techniques in which one or more significant inputs are unobservable, including management’s own assumptions.

The following table presents our fair value hierarchy for assets and liabilities measured at fair value on a recurring basis at September 30, 2013 and December 31, 2012 (in thousands):


	Fair value as of September 30, 2013
	Total		Level 1		Level 2		Level 3
Assets:
Cash equivalents	$	33,377	$	33,377	$	—	$	—
Corporate debt securities		68,617		—		68,617		—
Commercial paper		999		—		999		—
Certificates of deposit		13,770		—		13,770		—
Debt securities of U.S. government-sponsored agencies		7,027		—		7,027		—

	$	123,790	$	33,377	$	90,413	$	—
Liabilities:
Convertible notes payable	$	13,921	$	—	$	—	$	13,921

	Fair value as of December 31, 2012
	Total		Level 1		Level 2		Level 3
Assets:
Cash equivalents	$	39,363	$	39,363	$	—	$	—
Corporate debt securities		44,856		—		44,856		—
Commercial paper		6,492		—		6,492		—
Certificates of deposit		6,200		—		6,200		—

	$	96,911	$	39,363	$	57,548	$	—
Liabilities:
Convertible notes payable	$	10,134	$	—	$	—	$	10,134

Changes in the estimated fair value of convertible notes payable from December 31, 2012 through September 30, 2013 are as follows (in thousands):


	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
Balance at December 31, 2012	$	10,134
Change in estimated fair value of convertible notes payable		3,787

Balance at September 30, 2013	$	13,921

We obtain pricing information from quoted market prices or quotes from brokers/dealers. We generally determine the fair value of our investment securities using standard observable inputs, including reported trades, broker/dealer quotes, bids and/or offers.

In July 2012, we amended and restated the 2010 GSK Note, which resulted in a debt extinguishment for accounting purposes. Concurrently with the debt extinguishment, we elected the fair value option for the 2010 GSK Note. The amended and restated 2010 GSK Note provided for a rollover of the 2010 GSK Note into a new promissory note effective as of the closing date of a qualifying initial public offering (“Post-IPO GSK Note”). We used a third party valuation firm to value the Post-IPO GSK Note at September 30, 2013 and recorded a gain from the change in valuation of the Post-IPO GSK Note of $0.7 million for the three months ended September 30, 2013 and a loss of $3.8 million for the nine months ended September 30, 2013 on the condensed statements of operations and comprehensive loss for the respective periods. The gain from the change in valuation of the Post-IPO GSK Note for the three months ended September 30, 2013 was principally driven by a reduction in our stock price to $9.43 as of September 30, 2013, compared to $9.81 as of June 30, 2013.

The third-party valuation firm used an income approach in the form of a convertible bond valuation model to value the Post-IPO GSK Note. The convertible bond model considered the debt and option characteristics of the Post-IPO GSK Note. The key inputs to the model as of September 30, 2013 were stock price, volatility (65%), risk-free rate (0.32%), and credit spread (8.5%). The volatility inputs were based on historical and implied volatility of peer companies. Peer companies were materially consistent with those used previously in our 409A analyses and in previous valuations of this instrument. The risk-free rate inputs were based on the yield of U.S. Treasury Strips as of each date. The credit spread inputs were based on a creditworthiness analysis of the Company and market rates for comparable straight debt instruments.

5. Convertible Notes Payable

2012 Amendment of the 2010 GSK Note

In July 2012, we amended and restated our 2010 GSK Note. In October 2012, in conjunction with our initial public offering, we issued the Post-IPO GSK Note in the principal amount of $5.4 million, which was equivalent to the original principal amount of $5.0 million plus accrued but unpaid interest of approximately $0.4 million. The amended and restated 2010 GSK Note was then simultaneously cancelled and our obligations thereunder terminated. The Post-IPO GSK Note has a maturity date of October 9, 2015. At GSK’s option, the Post-IPO GSK Note may be converted into shares of our common stock at any time prior to the maturity at a conversion price per share equal to the initial public offering price of $4.00, subject to complying with certain threshold ownership percentage limitations set forth in the Post-IPO GSK Note. At September 30, 2013, the fair value of the Post-IPO GSK Note is $13.9 million and is classified as “Convertible note payable, at fair value” on the condensed balance sheet.

6. Stockholders’ Equity

Shares Reserved for Future Issuance

The following shares of common stock are reserved for future issuance at September 30, 2013:


	September 30, 2013		December 31, 2012
Common stock options outstanding		4,160,215		4,661,549
Common stock options available for future grant		2,161,410		946,403
Employee Stock Purchase Plan		460,283		150,000
Convertible note payable		1,400,848		1,366,787

Total common shares reserved for future issuance		8,182,756		7,124,739

The following table summarizes our stock option activity under all stock option plans for the nine months ended September 30, 2013 (in thousands):


	Number of options			Weighted average exercise price
Options outstanding at December 31, 2012		4,720		$	2.11
Granted		361		$	7.91
Exercised		(720	)	$	0.80
Canceled/forfeited/expired		(201	)	$	3.44

Options outstanding at September 30, 2013		4,160		$	2.78

Stock-Based Compensation

The following table summarizes the weighted average assumptions we used in our Black-Scholes calculations:


	Three months ended September 30,					Nine months ended September 30,
	2013			2012		2013			2012
Employee Stock Options:
Risk-free interest rate		1.7	%		*		1.4	%		1.1	%
Expected dividend yield		0.0	%		*		0.0	%		0.0	%
Expected volatility		72.7	%		*		67.8	%		71.0	%
Expected term (years)		6.1			*		6.1			6.1

*	No stock options were granted during the three months ended September 30, 2012.

The following table summarizes the allocation of our stock compensation expense (in thousands):


	Three months ended September 30,				Nine months ended September 30,
	2013		2012		2013		2012
Research and development	$	594	$	278	$	1,664	$	461
General and administrative		384		136		860		271

Total	$	978	$	414	$	2,524	$	732

7. Strategic Alliances and Collaborations

The following table summarizes the amounts included in our revenues which resulted from our strategic alliances and collaborations (in thousands):


	Three months ended September 30,				Nine months ended September 30,
	2013		2012		2013		2012
Sanofi	$	5,422	$	2,500	$	10,828	$	7,530
GSK		144		186		1,634		1,809
AstraZeneca		465		94		1,394		94
Biogen Idec		87		29		259		29

Total	$	6,118	$	2,809	$	14,115	$	9,462

Sanofi

In July 2012, we amended and restated our collaboration and license agreement with Sanofi to expand the potential therapeutic applications of the microRNA alliance targets to be developed under such agreement. The modification made to the agreement was considered a material modification, which required the application of the new authoritative guidance adopted by us in January 2011 for multiple element arrangements. We determined that the elements within the strategic alliance agreement with Sanofi should be treated as a single unit of accounting because the delivered elements did not have stand-alone value to Sanofi. The following elements were delivered as part of the strategic alliance with Sanofi: (1) a license for up to four microRNA targets; and (2) a research license under our technology alliance.

In June 2013, the original research term expired, upon which we and Sanofi entered into an option agreement pursuant to which we granted Sanofi an exclusive right to negotiate the co-development and commercialization of certain of our unencumbered microRNA programs and we were granted the exclusive right to negotiate with Sanofi for co-development and commercialization of certain miR-21 anti-miRs in oncology and Alport’s Syndrome. These options expire in December 2013, subject to a 30-day extension in certain circumstances. In July 2013, we received an upfront payment of $2.5 million, of which $1.25 million is creditable against future amounts payable by Sanofi to us under any future co-development and commercialization agreement we enter pursuant to the option agreement. The non-creditable portion of this payment, $1.25 million, will be recognized as revenue over the option period from the effective date of the option agreement in June 2013 until the expiration of the option period in December 2013. Revenue associated with the creditable portion of this option payment will be deferred until the option period expires, or is re-evaluated in connection with a creditable transaction. In addition, we agreed to continue specified research on the miR-21 programs during the option period. As a result of the expiration of the original research term and subsequent option agreement, we re-evaluated our estimated period of performance and are now amortizing the remaining deferred revenue of $10.1 million associated with the initial upfront payment of $25.0 million ratably from June 2013 until the expiration of the option period in December 2013.

We have evaluated the remaining contingent event-based payments under our strategic alliance agreement with Sanofi and determined that the preclinical payments meet the definition of a substantive milestone because they are related to events: (i) that can be achieved based in whole or in part on our performance or on the occurrence of a specific outcome resulting from our performance, (ii) for which there was substantive uncertainty at the date the agreement was entered into that the event would be achieved, and (iii) that would result in additional payments being due to us. Accordingly, revenue for these achievements will be recognized in its entirety in the period when the milestone is achieved and collectability is reasonably assured. Other contingent event-based payments under the strategic alliance agreement for which payment is contingent upon the results of Sanofi’s performance will not be accounted for using the milestone method. Such payments will be recognized as revenue over the remaining estimated period of performance, if any, and when collectability is reasonably assured. As of the expiration of the research term in June 2013, Sanofi no longer has rights to select additional microRNA targets. As such, we can earn a preclinical milestone of $15.0 million upon the filing of an Investigational New Drug application (“IND”) for the selected microRNA target. We can also receive milestone payments of up to $33.0 million for clinical milestones and up to $165.0 million for regulatory and commercial milestones. In addition, we are entitled to receive royalties based on a percentage of net sales which will range from 8 to 12%, depending upon the volume of sales.

GSK

In April 2008, we entered into a strategic alliance with GSK to discover, develop and commercialize novel microRNA-targeted therapeutics to treat inflammatory diseases (the “immuno-inflammatory alliance”). In February 2010, we and GSK expanded the strategic alliance to include hepatitis C virus infection (“HCV”) to discover, develop and commercialize microRNA therapeutics targeting miR-122 for the treatment of HCV (the “HCV alliance”). In June 2012, we amended our product development and commercialization agreement with GSK to extend the target selection period for the fourth collaboration target under the agreement. The modification made to the agreement was considered a material modification, which required the application of the new authoritative guidance adopted by us in January 2011 for multiple element arrangements. We determined that the elements within the strategic alliance should be treated as a single unit of accounting because the delivered elements, the opt-in licenses for microRNA product candidates, did not have stand-alone value to GSK. As a result of the extension of the target selection period, we extended the amortization period for the remaining deferred revenue to approximately eight years, which represented our new estimated performance period under the amended agreement. As of September 30, 2013, deferred revenue associated with the product development and commercialization agreement was $3.7 million.

In June 2013, the product development and commercialization agreement with GSK was amended to state that RG-101, and other formulations thereof, will be developed by us independently of our alliance with GSK for the treatment of chronic HCV infection. This amendment removed any further milestone or royalty obligations owed by GSK to us as it relates to RG-101. Concurrent with the amendment, we accelerated the remaining unamortized $1.1 million in deferred revenue associated with the upfront payment from the February 2010 amendment that expanded our agreement with GSK to include potential microRNA therapeutics for the treatment of HCV, which represents that our estimated performance period under the amended agreement is complete.

HCV Alliance

Notwithstanding the foregoing, GSK has retained its interest in the miR-122 program in HCV, and miR-122 remains a collaboration target under the alliance. If the HCV program is successful, we could receive contractual milestone payments up to $144.5 million, including up to $5.5 million for preclinical milestones, up to $29.0 million for clinical milestones, up to $50.0 million for regulatory milestones and up to $60.0 million for commercialization milestones. In addition, we will receive tiered royalties which can increase up to the low end of the 10 to 20% range on sales from any product that GSK successfully commercializes under this alliance.

We have evaluated the remaining contingent event-based payments under our strategic alliance agreement with GSK and determined that the preclinical and clinical payments meet the definition of a substantive milestone because they are related to events: (i) that can be achieved based in whole or in part on our performance or on the occurrence of a specific outcome resulting from our performance, (ii) for which there was substantive uncertainty at the date the agreement was entered into that the event would be achieved, and (iii) that would result in additional payments being due to us. Accordingly, revenue for these achievements will be recognized in its entirety in the period when the milestone is achieved and collectability is reasonably assured. Other contingent event-based payments under the strategic alliance agreement for which payment is contingent upon the results of GSK’s performance will not be accounted for using the milestone method. Such payments will be recognized as revenue over the remaining estimated period of performance, if any, and when collectability is reasonably assured. We can earn a preclinical milestone of $5.5 million upon the selection of a development candidate. We can also earn the following clinical milestones: $4.0 million for initiation of a Phase 1 clinical trial; $5.0 million for the initiation of a Phase 2 clinical trial; and $20.0 million if GSK chooses to opt-in to the program following the completion of a proof-of-concept trial.

Immuno-Inflammatory Alliance

The immuno-inflammatory alliance with GSK includes contractual milestones. If all the product candidates are successfully developed and commercialized through pre-agreed sales targets we could receive milestone payments up to $432.5 million, including up to $15.5 million for preclinical milestones, up to $87.0 million for clinical milestones, up to $150.0 million for regulatory milestones and up to $180.0 million for commercialization milestones. We are also entitled to receive tiered royalties as a percentage of annual sales which can increase up to the low end of the 10 to 20% range.

We have evaluated the remaining contingent event-based payments under our strategic alliance agreement with GSK and determined that the preclinical and clinical payments meet the definition of a substantive milestone because they are related to events: (i) that can be achieved based in whole or in part on our performance or on the occurrence of a specific outcome resulting from our performance, (ii) for which there was substantive uncertainty at the date the agreement was entered into that the event would be achieved, and (iii) that would result in additional payments being due to us. Accordingly, revenue for these achievements will be recognized in its entirety in the period when the milestone is achieved and collectability is reasonably assured. Other contingent event-based payments under the strategic alliance agreement for which payment is contingent upon the results of GSK’s performance will not be accounted for using the milestone method. Such payments will be recognized as revenue over the remaining estimated period of performance, if any, and when collectability is reasonably assured. We can earn the following preclinical milestones: $0.5 million upon the selection of a fourth microRNA target and $5.0 million upon the selection of a development candidate for each of the selected three targets. We can also earn the following clinical milestones for each of the selected three targets: $4.0 million for the initiation of a Phase 1 clinical trial; $5.0 million for the initiation of a Phase 2 clinical trial; and $20.0 million if GSK chooses to opt-in to the program following the completion of a proof-of-concept trial.

AstraZeneca

In August 2012, we entered into a collaboration and license agreement with AstraZeneca. Under the terms of the agreement, we have agreed to collaborate with AstraZeneca to identify, research and develop compounds targeting three microRNA alliance targets primarily in the fields of cardiovascular diseases, metabolic diseases and oncology. Pursuant to the agreement, we granted AstraZeneca an exclusive, worldwide license to thereafter develop, manufacture and commercialize lead compounds designated by AstraZeneca in the course of the collaboration activities against the alliance targets for all human therapeutic uses. Under the terms of the agreement we are required to use commercially reasonable efforts to perform all research, development and manufacturing activities described in the research plan, at our cost, until the acceptance of an IND or the end of the research term, which extends until the fourth anniversary of the date of the agreement, and may be extended only by mutual written agreement of us and AstraZeneca. Following the earlier to occur of the acceptance of an IND in a major market or the end of the research term, AstraZeneca will assume all costs, responsibilities and obligations for further development, manufacture and commercialization of alliance product candidates.

Under the terms of the agreement, we received an upfront payment of $3.0 million in October 2012. We determined the elements within the strategic alliance agreement should be treated as a single unit of accounting because the delivered element, the license, does not have stand-alone value. As a result, we are recognizing revenue related to the upfront payment on a straight-line basis over our estimated period of performance, which is four years based on the expected term of the research and development plan. If all three targets are successfully developed and commercialized through pre-agreed sales targets, we could receive milestone payments up to $498.0 million, including up to $5.0 million for preclinical milestones, up to $123.0 million for clinical milestones, and up to

$370.0 million for commercialization milestones. In addition, we are entitled to receive royalties based on a percentage of net sales which will range from the mid-single digits to the low end of 10 to 20%, depending upon the product and the volume of sales, which royalties may be reduced in certain, limited circumstances.

We have evaluated the contingent event-based payments under our strategic alliance agreement with AstraZeneca and determined that the preclinical payments meet the definition of substantive milestones because they are related to events: (i) that can be achieved based in whole or in part on our performance or on the occurrence of a specific outcome resulting from our performance, (ii) for which there was substantive uncertainty at the date the agreement was entered into that the event would be achieved, and (iii) that would result in additional payments being due to us. Accordingly, revenue for these achievements will be recognized in its entirety in the period when the milestone is achieved and collectability is reasonably assured. Other contingent event-based payments under the strategic alliance agreement for which payment is contingent upon the results of AstraZeneca’s performance will not be accounted for using the milestone method. Such payments will be recognized as revenue over the remaining estimated period of performance, if any, and when collectability is reasonably assured.

Concurrently with the collaboration and license agreement, we entered into a Common Stock Purchase Agreement (“CSPA”) with AstraZeneca, pursuant to which we agreed to sell to AstraZeneca an aggregate of $25.0 million of our common stock in a private placement concurrently with our initial public offering, at a price per share equal to the initial public offering price. In October 2012, in accordance with the CSPA, we sold AstraZeneca 6,250,000 shares of our common stock at a price per share of $4.00. Further, the CSPA stipulated that AstraZeneca could not sell, transfer, make any short sale of, or grant any option for the sale of any common stock for a 365-day period following the effective date of our initial public offering. Accounting guidance for multiple element arrangements contains a presumption that separate contracts negotiated and/or entered into at or near the same time with the same entity were negotiated as a package and should be evaluated as a single agreement. We valued the discount applied to the shares of common stock due to the one-year restriction. Based upon restricted stock studies of similar duration and a Black-Scholes valuation to measure the lack of marketability discount, $4.3 million was attributed to the collaboration and license agreement. We continue to recognize the $4.3 million into revenue ratably over the estimated period of performance of the collaboration.

Biogen Idec

In August 2012, we entered into a collaboration and license agreement with Biogen Idec pursuant to which we and Biogen Idec have agreed to collaborate on microRNA biomarkers for multiple sclerosis (“MS”). Under the terms of the agreement, we granted Biogen Idec an exclusive, royalty free, worldwide license to our interest in the collaboration intellectual property for the purpose of commercializing non-microRNA products for the treatment, diagnosis and prevention of MS and non-MS diseases and disorders. We also granted Biogen Idec an exclusive, royalty-free, worldwide license, with the right to sublicense, to our interest in the collaboration intellectual property (and a non-exclusive license to our background intellectual property) for the purpose of commercializing products for the diagnosis of MS. We also granted Biogen Idec a right of first negotiation on certain commercial transactions relating to microRNA products which utilize intellectual property developed during the collaboration. Pursuant to the terms of the agreement, in August 2012 we received an upfront payment of $0.8 million. We are also eligible to receive research milestone payments up to an aggregate of $1.3 million. We considered the elements within the collaboration and license agreement as a single unit of accounting because the delivered element, the license, does not have stand-alone value. As a result, we are recognizing revenue relating to the upfront payment of $0.8 million on a straight-line basis over our estimated period of performance, which is approximately two years based on the expected term of the research and development plan.

In June 2013, we amended the collaboration and license agreement with Biogen Idec to provide for revised terms with respect to phase 1 of the research plan under the Biogen Idec agreement and revised payment provisions relating to the phase 1 milestones. The Biogen Idec amendment does not modify the maximum dollar amount we were originally eligible to receive in connection with phase 1 milestones under the Biogen Idec agreement, or our estimated period of performance.

We have evaluated the contingent event-based payments under our collaboration and license agreement with Biogen Idec and determined that the research payments meet the definition of substantive milestones because they are related to events: (i) that can be achieved based in whole or in part on our performance or on the occurrence of a specific outcome resulting from our performance, (ii) for which there was substantive uncertainty at the date the agreement was entered into that the event would be achieved, and (iii) that would result in additional payments being due to us. Accordingly, revenue for these achievements will be recognized in its entirety in the period when the milestone is achieved and collectability is reasonably assured. We can earn the following research milestones: $0.25 million for identification of a microRNA biomarker; $0.5 million for validation of the microRNA biomarker in a second independent sample set; and $0.5 million upon the refinement of the microRNA biomarker signature from a longitudinal study of patient samples on MS therapy.

Concurrently with the collaboration and license agreement, we entered into a note purchase agreement with Biogen Idec, pursuant to which we issued Biogen Idec a convertible promissory note in the principal amount of $5.0 million. The $5.0 million note plus accrued interest converted into 1,256,232 shares of our common stock upon the closing of our initial public offering in October 2012 at a conversion price of $4.00 per share.

8. Related Party Transactions

We have entered into several agreements with related parties in the ordinary course of business to license intellectual property and to procure administrative and research and development support services. These agreements include a Services Agreement with our founding companies Isis Pharmaceuticals, Inc. (“Isis”) and Alnylam Pharmaceuticals, Inc. (“Alnylam”). Total costs incurred from services provided from Alnylam under the Services Agreement were $0.1 million and $0.5 million for the three and nine months ended September 30, 2013, respectively. Activities under the Services Agreement for the nine months ended September 30, 2012 were immaterial.

In August, 2013, we entered into an amendment to the Amended and Restated License and Collaboration Agreement with Isis and Alnylam dated January 1, 2009, as amended in June 2010 and October 2011 (as amended, the “Amendment”). Under the terms of the Amendment, the parties agreed to our use of certain Alnylam-controlled intellectual property concerning the use and manufacture of GalNAc conjugates (“GalNAc Process Technology”) on a non-exclusive basis. We will generally not be permitted to sublicense or otherwise transfer the GalNAc Process Technology and other Alnylam licensed intellectual property rights relating to GalNAc conjugate technology without the prior written consent of Alnylam, subject to certain limited exceptions for sublicenses to third party collaboration partners. There were no financial terms related to this Amendment.

9. Subsequent Events

In October 2013, we received a payment of $0.1 million from Biogen Idec for work performed pursuant to the terms of our collaboration and license agreement based on our research to discover microRNAs as biomarkers for MS.

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The interim unaudited condensed financial statements and this Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the financial statements and notes thereto for the year ended December 31, 2012 and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations for Regulus Therapeutics Inc., or we, us, our, or the Company, both of which are contained in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 19, 2013. Past operating results are not necessarily indicative of results that may occur in future periods.

FORWARD-LOOKING STATEMENTS

This quarterly report on Form 10-Q may contain “forward-looking statements” within the meaning of the federal securities laws made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth below under Part II, Item 1A, “Risk Factors” in this quarterly report on Form 10-Q. Except as required by law, we assume no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise. These statements, which represent our expectations or beliefs concerning various future events, may contain words such as “may,” “will,” “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate” or other words indicating future results. Such statements may include, but are not limited to, statements concerning the following:

•

the initiation, cost, timing, progress and results of our research and development activities, preclinical studies and future clinical trials, including our expected timeline for nominating clinical development candidates under our strategic alliances and our expected timeline for filing our first applications with regulatory authorities and potentially commencing Phase 1 clinical trials;

•

our ability to obtain and maintain regulatory approval of our future product candidates, and any related restrictions, limitations, and/or warnings in the label of an approved product candidate;

•

our ability to obtain funding for our operations;

•

our plans to research, develop and commercialize our future product candidates;

•

our strategic alliance partners’ election to pursue development and commercialization;

•

our ability to attract collaborators with development, regulatory and commercialization expertise;

•

our ability to obtain and maintain intellectual property protection for our future product candidates;

•

the size and growth potential of the markets for our future product candidates, and our ability to serve those markets;

•

our ability to successfully commercialize our future product candidates;

•

the rate and degree of market acceptance of our future product candidates;

•

our ability to develop sales and marketing capabilities, whether alone or with potential future collaborators;

•

regulatory developments in the United States and foreign countries;

•

the performance of our third-party suppliers and manufacturers;

•

the success of competing therapies that are or become available;

•

the loss of key scientific or management personnel;

•

our expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act of 2012, or the JOBS Act;

•

our use of the proceeds from our initial public offering and concurrent private placement or subsequent public offerings; and

•

the accuracy of our estimates regarding expenses, future revenues, capital requirements and need for additional financing.

OVERVIEW

We are a biopharmaceutical company focused on discovering and developing first-in-class drugs that target microRNAs to treat a broad range of diseases. We were formed in 2007 when Alnylam, and Isis contributed significant intellectual property, know-how and financial and human capital to pursue the development of drugs targeting microRNAs pursuant to a license and collaboration agreement. microRNAs are recently discovered, naturally occurring ribonucleic acid, or RNA, molecules that play a critical role in regulating key biological pathways. Scientific research has shown that the improper balance, or dysregulation, of microRNAs is directly linked to many diseases. We believe we have assembled the leading position in the microRNA field, including expertise in microRNA biology and oligonucleotide chemistry, a broad intellectual property estate, key opinion leaders and disciplined drug discovery and development processes. We refer to these assets as our microRNA product platform. We are using our microRNA product platform to develop chemically modified, single-stranded oligonucleotides that we call anti-miRs. We use these anti-miRs to modulate microRNAs and by doing so return diseased cells to their healthy state. We are pursuing several microRNA targets and are focusing our proprietary efforts in oncology and orphan diseases. We believe microRNAs may be transformative in the field of drug discovery and that anti-miRs may become a new and major class of drugs with broad therapeutic application much like small molecules, biologics and monoclonal antibodies.

We are currently optimizing anti-miRs in several distinct programs, both independently and with our strategic alliance partners, AstraZeneca AB, or AstraZeneca, GlaxoSmithKline plc, or GSK, and Sanofi. We also have a collaboration agreement with Biogen Idec MA Inc., or Biogen Idec, to evaluate the potential use of microRNA signatures as a biomarker for human patients with multiple sclerosis, or MS. Under these strategic alliances, we are eligible to receive up to approximately $1.3 billion in milestone payments upon successful commercialization of microRNA therapeutics for the programs contemplated by our agreements. These payments include up to $42.0 million upon achievement of preclinical and investigational new drug application, or IND, milestones, up to $272.0 million upon achievement of clinical development milestones, up to $305.0 million upon achievement of regulatory milestones and up to $670.0 million upon achievement of commercialization milestones.

We are currently executing on our ‘Road to the Clinic’ Strategy which set forth certain corporate goals that seek to advance our microRNA therapeutic pipeline toward the clinic. Specifically, we set the goal of nominating two microRNA candidates for clinical development in 2013, be positioned to file our first applications with regulatory authorities by the first half of 2014 and maintain a strong year-end cash position to support these goals. In May 2013, we announced our first clinical candidate, RG-101, for which we have full ownership and commercial rights. RG-101 is a GalNAc-conjugated anti-miR, which targets microRNA-122, for the treatment of patients with chronic hepatitis C virus infection, or HCV. We expect to file our first application with regulatory authorities for RG-101 in the near term and potentially commence Phase 1 clinical trials of RG-101 in early 2014. Additionally, our strong financial position continues to support these stated goals and we continue to expect to end 2013 with approximately $110 million in cash, cash equivalents and short-term investments. Lastly, we anticipate that we will nominate a second microRNA candidate for clinical development by the end of 2013, which we expect may come from our microRNA-21 (“miR-21”) fibrosis program.

On July 22, 2013, we completed a public offering whereby we sold 5,175,000 shares of common stock at $9.50 per share and received net proceeds of $45.8 million, after deducting underwriting discounts, commissions and other offering expenses. On October 10, 2012, we completed our initial public offering whereby we issued and sold 11,250,000 shares of common stock at a public offering price of $4.00 per share, resulting in net proceeds to us of approximately $39.5 million. Concurrently with the completion of our initial public offering on October 10, 2012, $5.0 million of outstanding principal plus accrued interest of $0.8 million underlying a convertible note that we issued to GSK in April 2008 and amended and restated in July 2012, together with $5.0 million of outstanding principal plus accrued interest of $25,000 underlying a convertible note that we issued to Biogen Idec in August 2012, was automatically converted upon the closing of our initial public offering into an aggregate of 2,703,269 shares of our common stock. Upon the closing of our initial public offering, all shares of our outstanding convertible preferred stock automatically converted into an aggregate of 13,699,999 shares of common stock. On October 23, 2012, the underwriters for our initial public offering partially exercised an over-allotment option to purchase 1,480,982 shares of our common stock at $4.00 per share, resulting in net proceeds to us of approximately $5.5 million.

Recent Developments

•

In November 2013, we presented positive new preclinical data demonstrating that miR-21 plays an important role in Alport Syndrome at the American Society of Nephrology’s Kidney Week 2013 meeting. In a poster presentation, we and Genzyme, a Sanofi company, presented new preclinical data demonstrating that miR-21 plays an important role in the disease progression of Alport Syndrome in collagen 4A3 deficient mice. Treatment with an anti-miR-21 candidate significantly improved renal function, significantly reversed regulated genes and pathways associated with renal pathology, and increased the lifespan of the mice by 20 percent.

•

In November 2013, we presented positive data on RG-101, a GalNAc-conjugated anti-miR targeting miR-122 for the treatment of HCV, in a late-breaking poster at the 64^th Annual American Association for the Study of Liver Diseases from preclinical studies evaluating RG-101 for in vitro and in vivo potency, pharmacokinetic/pharmacodynamics, toxicology and safety pharmacology and inhibition of HCV replication. Pharmacologic potency of RG-101 was significantly enhanced by approximately 20 fold in vivo in both mice and non-human primates, relative to the unconjugated oligonucleotide of RG-101. In addition to the potency studies, we tested the efficacy of RG-101 to reduce HCV viral load titer in a human chimeric liver mouse model infected with HCV and observed up to a 2 log reduction in HCV viral load titer with a single dose, which is similar to that observed for oral direct-acting antivirals as monotherapy in this mouse model. The duration of action observed for RG-101 supports the potential for a once-a-month dosing regimen. Additionally, RG-101 has demonstrated an excellent preclinical safety profile to date, although additional preclinical toxicology and safety pharmacology studies are currently ongoing.

•

In October 2013, we announced the selection of an undisclosed oncology target by AstraZeneca under the strategic alliance to discover, develop, and commercialize microRNA therapeutics. We and AstraZeneca continue to collaborate on three exclusive microRNA targets in cardiovascular and metabolic diseases and oncology.

FINANCIAL OPERATIONS OVERVIEW

Revenues

Our revenues generally consist of upfront payments for licenses or options to obtain licenses in the future, research and development funding and milestone payments under strategic alliance agreements.

In the future, we may generate revenue from a combination of license fees and other upfront payments, research and development payments, milestone payments, product sales and royalties in connection with strategic alliances. We expect that any revenue we generate will fluctuate from quarter-to-quarter as a result of the timing of our achievement of preclinical, clinical, regulatory and commercialization milestones, if at all, the timing and amount of payments relating to such milestones and the extent to which any of our products are approved and successfully commercialized by us or our strategic alliance partners. If our strategic alliance partners do not elect or otherwise agree to fund our development costs pursuant to our strategic alliance agreements, or we or our strategic alliance partners fail to develop product candidates in a timely manner or obtain regulatory approval for them, our ability to generate future revenues, and our results of operations and financial position would be adversely affected.

Research and development expenses

Research and development expenses consist of costs associated with our research activities, including our drug discovery efforts, the preclinical development of our therapeutic programs, and our microRNA biomarker program. Our research and development expenses include:

•

employee-related expenses, including salaries, benefits, travel and stock-based compensation expense;

•

external research and development expenses incurred under arrangements with third parties, such as contract research organizations, or CROs, contract manufacturing organizations, or CMOs, consultants and our scientific advisory board;

•

license fees; and

•

facilities, depreciation and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities, depreciation of leasehold improvements and equipment, and laboratory and other supplies.

We expense research and development costs as incurred. We account for nonrefundable advance payments for goods and services that will be used in future research and development activities as expenses when the service has been performed or when the goods have been received.

To date, we have conducted research on many different microRNAs with the goal of understanding how they function and identifying those that might be targets for therapeutic modulation. We are pursuing several microRNA targets and focusing our proprietary efforts in oncology and orphan diseases. Our organization is structured to allow for the rapid deployment and shifting of resources to focus on the best targets based on our ongoing research. As a result, in the early phase of our development, our research and development costs are not tied to any specific target. However, we are currently spending the vast majority of our research and development resources on our lead development programs.

Since our conversion to a corporation in January 2009, we have grown from 15 research and development personnel to 56 and have incurred approximately $88.6 million in research and development expenses through September 30, 2013.

We expect our research and development expenses to increase for the foreseeable future as we advance our research programs toward the clinic and initiate clinical trials. The process of conducting preclinical studies and clinical trials necessary to obtain regulatory approval is costly and time consuming. We or our strategic alliance partners may never succeed in achieving marketing approval for any of our product candidates. The probability of success for each product candidate may be affected by numerous factors, including preclinical data, clinical data, competition, manufacturing capability and commercial viability. Under our strategic alliance with GSK, we may be responsible for the development of product candidates through clinical proof-of-concept, depending on the time at which GSK may choose to exercise its option to obtain an exclusive license to develop, manufacture and commercialize product candidates on a program-by-program basis. Under our strategic alliance agreement with AstraZeneca, we are responsible for certain research and development activities with respect to each alliance target under a mutually agreed upon research and development plan until the earlier of IND approval in a major market or the end of the research term under the agreement. We also have several independent programs for which we are responsible for all of the research and development costs, unless and until we partner any of these programs in the future.

Most of our product development programs are at an early stage, and successful development of future product candidates from these programs is highly uncertain and may not result in approved products. Completion dates and completion costs can vary significantly for each future product candidate and are difficult to predict. We anticipate we will make determinations as to which programs to pursue and how much funding to direct to each program on an ongoing basis in response to our ability to maintain or enter into new strategic alliances with respect to each program or potential product candidate, the scientific and clinical success of each future product candidate, as well as ongoing assessments as to each future product candidate’s commercial potential. We will need to raise additional capital and may seek additional strategic alliances in the future in order to advance our various programs.

General and administrative expenses

General and administrative expenses consist primarily of salaries and related benefits, including stock-based compensation, related to our executive, finance, legal, business development and support functions. Other general and administrative expenses include allocated facility-related costs not otherwise included in research and development expenses, travel expenses and professional fees for auditing, tax and legal services. We expect that general and administrative expenses will increase in the future as we expand our operating activities and incur additional costs associated with being a publicly-traded company. These increases will likely include legal fees, accounting fees, directors’ and officers’ liability insurance premiums and fees associated with investor relations.

Other income (expense), net

Other income (expense) consists primarily of interest income and expense, changes in convertible note payable valuation each reporting period, and on occasion income or expense of a non-recurring nature. We earn interest income from interest-bearing accounts and money market funds for cash and cash equivalents and marketable securities, such as interest-bearing bonds, for our short-term investments. Interest expense has historically represented interest payable under convertible notes payable and equipment and tenant improvement financing arrangements.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

The preparation of our financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and the revenues and expenses incurred during the reported periods. We believe that the estimates, assumptions and judgments involved in the accounting policies described in Management’s Discussion and Analysis of Financial Condition and Results of Operations in Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2012 have the greatest potential impact on our financial statements, so we consider them to be our critical accounting policies and estimates. There were no material changes to our critical accounting policies and estimates during the quarter ended September 30, 2013.

RESULTS OF OPERATIONS

The following table summarizes our results of operations for the periods indicated (in thousands):


	Three months ended September 30,					Nine months ended September 30,
	2013		2012			2013			2012
Revenue under strategic alliances	$	6,118	$	2,809		$	14,115		$	9,462
Research and development expenses		7,106		5,248			21,710			14,735
General and administrative expenses		1,917		1,093			5,545			2,998
Loss on extinguishment of debt		—		(1,738	)		—			(1,738	)
Gain (loss) from changes in valuation of convertible note payable		671		(331	)		(3,787	)		(331	)

Revenue under strategic alliances

Our revenues are generated from ongoing strategic alliance and collaborations, and generally consist of upfront payments for licenses or options to obtain licenses in the future, research and development funding and milestone payments. The following table summarizes our total revenues for the periods indicated (in thousands):


	Three months ended September 30,				Nine months ended September 30,
	2013		2012		2013		2012
Sanofi	$	5,422	$	2,500	$	10,828	$	7,530
GSK		144		186		1,634		1,809
AstraZeneca		465		94		1,394		94
Biogen Idec		87		29		259		29

Total net revenues from research collaborators	$	6,118	$	2,809	$	14,115	$	9,462

Revenue under strategic alliances were $6.1 million and $14.1 million for the three and nine months ended September 30, 2013, compared to $2.8 million and $9.5 million for the same periods in 2012.

In June 2013, the research term expired under the Sanofi alliance, upon which we and Sanofi entered into an option agreement pursuant to which we granted Sanofi an exclusive right to negotiate the co-development and commercialization of certain of our unencumbered microRNA programs and we were granted the exclusive right to negotiate with Sanofi for co-development and commercialization of certain miR-21 anti-miRs in oncology and Alport Syndrome. These options expire in December 2013, subject to a 30-day extension in certain circumstances. In addition, we agreed to continue specified research on the miR-21 programs during the option period. Upon the expiration of the research term and subsequent option agreement, we re-evaluated our estimated period of performance and are amortizing the remaining deferred revenue of $10.1 million associated with the initial upfront payment of $25.0 million ratably from June 2013 until the expiration of the option period in December 2013. As a result of the change in our estimated period of performance in June 2013, revenue recognized from the amortization of the upfront payment increased by $3.6 million and $3.9 million in the three and nine months ended September 30, 2013, compared to the three and nine months ended September 30, 2012.

In June 2013, the product development and commercialization agreement with GSK was amended to state that RG-101, and other formulations thereof, will be developed by us independently of our alliance with GSK for the treatment of chronic HCV infection. As a result, we accelerated the remaining unamortized deferred revenue of $1.1 million associated with the upfront payment from the February 2010 amendment that expanded our agreement with GSK to include potential microRNA therapeutics for the treatment of HCV, due to the completion of our remaining performance obligations. As such, revenue of $0.1 million and $1.6 million was recognized for the three and nine months ended September 30, 2013.

In June 2012, we amended our product development and commercialization agreement with GSK to extend the target selection period for the fourth collaboration target under the agreement. As a result of the extension of the target selection period, we extended our estimated period of performance for the then remaining deferred revenue to approximately eight years, which represented our new estimated performance period under the amended agreement. Revenue of $0.2 million and $1.8 million was recognized for the three and nine months ended September 30, 2012.

In August 2012, we entered into a strategic alliance and concurrent Common Stock Purchase Agreement, or CPSA, with AstraZeneca. The strategic alliance included an upfront payment of $3.0 million and is being amortized over an estimated performance period of 48 months, which resulted in approximately $0.2 million and $0.6 million for the three and nine months ended September 30, 2013. In October 2012, pursuant to the CSPA, we sold AstraZeneca 6,250,000 shares of our common stock at a price per share of $4.00. Accounting guidance for multiple element arrangements contains a presumption that separate contracts negotiated and/or entered into at or near the same time with the same entity were negotiated as a package and should be evaluated as a single agreement. We valued the discount applied to the shares of common stock due to the one-year restriction. Based upon restricted stock studies of similar duration and a Black-Scholes valuation to measure the lack of marketability discount, $4.3 million was attributed to the collaboration and license agreement, which is being amortized over the estimated period of performance of the collaboration. As such, revenue of $0.3 million and $0.8 million was recognized for the three and nine months ended September 30, 2013.

In August 2012, we entered into a collaboration and license agreement with Biogen Idec, which included an upfront payment of $0.8 million. We are recognizing revenue related to the upfront payment over our estimated period of performance, which is approximately two years. As such, revenue of $0.1 million and $0.3 million was recognized for the three and nine months ended September 30, 2013.

Research and development expenses

Research and development expenses were $7.1 million and $21.7 million for the three and nine months ended September 30, 2013, respectively, compared to $5.2 million and $14.7 million for the same periods in 2012. The increase was attributable to an expansion of our research and development personnel and increase in IND-enabling activities for RG-101. We expect our research and development expenses to increase over the coming quarters to the extent we commence clinical studies and initiate additional IND-enabling activities.

General and administrative expenses

General and administrative expenses were $1.9 million and $5.5 million for the three and nine months ended September 30, 2013, respectively, compared to $1.1 million and $3.0 million for the same periods in 2012. The increase was primarily attributable to an increase in headcount, incremental operating expenses and other costs associated with being a public reporting company.

Loss on extinguishment of debt

In July 2012, we amended and restated our $5.0 million convertible promissory note originally issued in February 2010 to GSK, or the 2010 GSK Note, which resulted in a debt extinguishment for accounting purposes. As a result, we recognized a $1.7 million loss on extinguishment of debt in the three and nine months ended September 30, 2012.

Loss from valuation of convertible note payable

The amended and restated 2010 GSK Note provided for a rollover of the 2010 GSK Note into a new promissory note effective as of the closing date of a qualified initial public offering, or the Post-IPO GSK Note. We used a third party valuation firm to value the Post-IPO GSK Note at September 30, 2013 and 2012. Changes in the fair value of the Post-IPO GSK Note are recorded in non-operating earnings. We recorded a gain from the change in the valuation of the Post-IPO GSK Note of $0.7 million in the three months ended September 30, 2013, which was principally caused by a decrease in our stock price at September 30, 2013 compared to June 30, 2013. We recorded a loss from the change in the valuation of the Post-IPO GSK Note of $3.8 million for the nine months ended September 30, 2013, which was principally caused by an increase in our stock price at September 30, 2013 compared to December 31, 2012. We recorded a loss from the change in the valuation of the Post-IPO GSK Note of $0.3 million for the three and nine months ended September 30, 2012.

LIQUIDITY AND CAPITAL RESOURCES

Since our inception through September 30, 2013, we have received $66.3 million principally from upfront payments, research funding and preclinical milestones from our strategic alliances, collaborations, government grants and loans, and $170.7 million from the sale of our equity and convertible debt securities, including $70.0 million in net proceeds from our initial public offering and concurrent private placement of our common stock in October 2012 and $45.8 million in net proceeds from our public offering in July 2013. We expect that our existing cash and cash equivalents, together with interest and potential milestones, will be sufficient to fund our current operations into 2017. However, changing circumstances may cause us to consume capital more rapidly than we currently anticipate.

As of September 30, 2013, we had $123.9 million in cash, cash equivalents and short-term investments. The following table shows a summary of our cash flows for the nine months ended September 30, 2013 and 2012 (in thousands):


	Nine months ended September 30,
	2013			2012
	(Unaudited)
Net cash provided by (used in):
Operating activities	$	(19,016	)	$	(9,572	)
Investing activities		(34,524	)		14,354
Financing activities		46,478			3,469

Total	$	(7,062	)	$	8,251

Operating activities

Net cash used in operating activities increased to $19.0 million for the nine months ended September 30, 2013, compared $9.6 million for the nine months ended September 30, 2012. The increase in net loss to $16.7 million for the nine months ended September 30, 2013 from $10.5 million for the nine months ended September 30, 2012 included an increase of $3.5 million in non-cash charges associated with an increase in valuation of the Post-IPO GSK Note. Additionally, non-cash stock-based compensation charges increased by $1.8 million for the nine months ended September 30, 2013 compared to the nine months ended September 30, 2012. Changes in working capital resulted in a net increase in cash used in operating activities of $7.7 million for the nine months ended September 30, 2013 compared to the nine months ended September 30, 2012, principally as a result of a $11.1 million increase in the amortization of deferred revenue, offset by a decrease in contract and other receivables of $2.9 million.

Investing activities

Net cash provided by or used in investing activities for the periods presented primarily relate to the purchase, sale and maturity of investments used to fund the day-to-day needs of our business. In October 2012, we completed an initial public offering and concurrent private placement, resulting in net proceeds of $70.0 million, and in July 2013, we completed a public offering, resulting in net proceeds of $45.8 million. As such, net cash used in investing activities in the nine months ended September 30, 2013 included the net investment of short-term investments of $34.1 million. Conversely, net cash provided by investing activities in the nine months ended September 30, 2012 included the net maturity and sale of short term investments of $15.3 million.

Financing activities

Net cash provided by financing activities was $46.5 million for the nine months ended September 30, 2013, compared to $3.5 million provided by financing activities for the nine months ended September 30, 2012. The change in cash from financing activities for the nine months ended September 30, 2013 was primarily due to $45.8 million in net proceeds from our public offering in July 2013. Net cash provided by financing activities for the nine months ended September 30, 2012 was a result of $5.0 million in proceeds from a convertible note issued by Biogen Idec in August 2012, offset by $1.3 million in payments related to our initial public offering.

CONTRACTUAL OBLIGATIONS AND COMMITMENTS

As of September 30, 2013, there were no material changes, outside of the ordinary course of business, in our outstanding contractual obligations from those disclosed within “Management’s Discussion and Analysis of Financial Condition and Results of Operations”, as contained in our Annual Report on Form 10-K filed by us with the Securities and Exchange Commission, or the SEC, on February 19, 2013.

Off-Balance Sheet Arrangements

As of September 30, 2013, we did not have any off-balance sheet arrangements.

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Some of the securities that we invest in have market risk in that a change in prevailing interest rates may cause the principal amount of the marketable securities to fluctuate. Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. We invest our excess cash primarily in commercial paper and debt instruments of financial institutions, corporations, U.S. government-sponsored agencies and the U.S. Treasury. The primary objectives of our investment activities are to ensure liquidity and to preserve principal while at the same time maximizing the income we receive from our marketable securities without significantly increasing risk. Additionally, we established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.

Because of the short-term maturities of our cash equivalents and marketable securities, we do not believe that an increase in market rates would have any significant impact on the realized value of our marketable securities. If a 10% change in interest rates were to have occurred on September 30, 2013, this change would not have had a material effect on the fair value of our investment portfolio as of that date.

ITEM 4.

CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our periodic and current reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, control may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

As of September 30, 2013, we carried out an evaluation, under the supervision and with the participation of our management, including our chief executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act. Based on this evaluation, our chief executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of September 30, 2013.

An evaluation was also performed under the supervision and with the participation of our management, including our chief executive officer and our principal financial officer, of any change in our internal control over financial reporting that occurred during our last fiscal quarter and that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. That evaluation did not identify any change in our internal control over financial reporting that occurred during our latest fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS

None.

ITEM 1A.

RISK FACTORS

You should carefully consider the following risk factors, as well as the other information in this report, before deciding whether to purchase, hold or sell shares of our common stock. The occurrence of any of the following risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. You should consider all of the factors described when evaluating our business. The risk factors set forth below that are marked with an asterisk (*) contain changes to the similarly titled risk factors included in Item 1A of our Annual Report. If any of the following risks actually occurs, our business, financial condition, results of operations and future growth prospects would likely be materially and adversely affected. In these circumstances, the market price of our common stock would likely decline.

RISKS RELATED TO OUR FINANCIAL CONDITION AND NEED FOR ADDITIONAL CAPITAL

We have a limited operating history, have incurred significant losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future.*

We are a preclinical-stage, biopharmaceutical discovery and development company, formed in 2007, with a limited operating history. Since inception, our operations have been primarily limited to organizing and staffing our company, acquiring and in-licensing intellectual property rights, developing our microRNA product platform, undertaking basic research around microRNA targets and conducting preclinical studies for our initial programs. We have not yet initiated a clinical trial or obtained regulatory approval for any product candidates. Consequently, any predictions about our future success or viability, or any evaluation of our business and prospects, may not be accurate.

We have incurred losses in each year since our inception in September 2007. Our net losses were $2.2 million and $5.7 million for the three months ended September 30, 2013 and 2012, respectively and $16.7 million and $10.5 million for the nine months ended September 30, 2013 and 2012, respectively. As of September 30, 2013, we had an accumulated deficit of $77.2 million.

We have devoted most of our financial resources to research and development, including our preclinical development activities. To date, we have financed our operations primarily through the sale of equity securities and convertible debt and from revenue received from our strategic alliance partners. We have entered into strategic alliances with Sanofi to develop our miR-21 programs for hepatocellular carcinoma, or HCC, and kidney fibrosis, with GSK, to develop our miR-122 program for HCV, and with AstraZeneca, to develop our miR-33 program for atherosclerosis. Under our agreement with GSK, GSK has an option to obtain exclusive worldwide licenses for the development, manufacture and commercialization of potential product candidates selected from our microRNA product platform. If GSK exercises its option to obtain a license to develop, manufacture and commercialize such product candidates, GSK will assume responsibility for funding and conducting further clinical development and commercialization activities for such product candidates. However, if GSK does not exercise its option within the timeframes that we expect, or at all, or if Sanofi terminates its agreement with us, we will be responsible for funding further development of these product candidates and may not have the resources to do so unless we are able to enter into another strategic alliance for these product candidates. The size of our future net losses will depend, in part, on the rate of future expenditures and our ability to obtain funding through equity or debt financings, strategic alliances or grants. We have not initiated clinical development of any product candidate to date and it will be several years, if ever, before we have a product candidate ready for commercialization. Even if we or our strategic alliance partners successfully obtain regulatory approval to market a product candidate, our revenues will also depend upon the size of any markets in which our product candidates have received market approval, and our ability to achieve sufficient market acceptance and adequate market share for our products.

We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. The net losses we incur may fluctuate significantly from quarter to quarter. We anticipate that our expenses will increase substantially if and as we: continue our research and preclinical development of our future product candidates, both independently and under our strategic alliance agreements; seek to identify additional microRNA targets and product candidates; acquire or in-license other products and technologies; initiate clinical trials for our product candidates; seek marketing approvals for our product candidates that successfully complete clinical trials; ultimately establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval; maintain, expand and protect our intellectual property portfolio; hire additional clinical, quality control and scientific personnel; and create additional infrastructure to support our operations as a public company and our product development and planned future commercialization efforts.

We have never generated any revenue from product sales and may never be profitable.

Our ability to generate revenue and achieve profitability depends on our ability, alone or with strategic alliance partners, to successfully complete the development of, obtain the necessary regulatory approvals for and commercialize product candidates. We do not anticipate generating revenues from sales of products for the foreseeable future, if ever. Our ability to generate future revenues from product sales depends heavily on our success in:

•

identifying and validating new microRNAs as therapeutic targets;

•

completing our research and preclinical development of future product candidates;

•

initiating and completing clinical trials for future product candidates;

•

seeking and obtaining marketing approvals for future product candidates that successfully complete clinical trials;

•

establishing and maintaining supply and manufacturing relationships with third parties;

•

launching and commercializing future product candidates for which we obtain marketing approval, with an alliance partner or, if launched independently, successfully establishing a sales force, marketing and distribution infrastructure;

•

maintaining, protecting and expanding our intellectual property portfolio; and

•

attracting, hiring and retaining qualified personnel.

Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to predict the timing or amount of increased expenses and when we will be able to achieve or maintain profitability, if ever. In addition, our expenses could increase beyond expectations if we are required by the FDA or foreign regulatory agencies to perform studies and trials in addition to those that we currently anticipate.

Even if one or more of the future product candidates that we independently develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. Even if we are able to generate revenues from the sale of any approved products, we may not become profitable and may need to obtain additional funding to continue operations.

We may need to raise additional capital, which may not be available on acceptable terms, or at all.*

Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is expensive. We expect our research and development expenses to substantially increase in connection with our ongoing activities, particularly as we advance our product candidates toward clinical programs. We may need to raise additional capital to support our operations and such funding may not be available to us on acceptable terms, or at all.

We expect that our existing cash and cash equivalents, together with interest and potential milestones, will be sufficient to fund our current operations into 2017. However, changing circumstances may cause us to consume capital more rapidly than we currently anticipate. For example, as we move our lead compounds through toxicology and other preclinical studies, also referred to as nonclinical studies, required to file an IND, and as we conduct clinical development of RG-101 and any other future product candidates, we may have adverse results requiring mitigation strategies that may cause us to consume additional capital. Additionally, our strategic alliance partners may not elect to pursue the development and commercialization of any of our microRNA product candidates that are subject to their respective strategic alliance agreements with us. Any of these events may increase our development costs more than we expect. We may need to raise additional capital or otherwise obtain funding through strategic alliances if we choose to initiate clinical trials for new product candidates other than programs currently partnered. In any event, we will require additional capital to obtain regulatory approval for, and to commercialize, future product candidates. Raising funds in the current economic environment, when the capital markets have been affected by the global recession, may present additional challenges.

If we are required to secure additional financing, such additional fundraising efforts may divert our management from our day-to-day activities, which may adversely affect our ability to develop and commercialize future product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. If we are unable to raise additional capital when required or on acceptable terms, we may be required to:

•

significantly delay, scale back or discontinue the development or commercialization of any future product candidates;

•

seek strategic alliances for research and development programs at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available; or

•

relinquish or license on unfavorable terms, our rights to technologies or any future product candidates that we otherwise would seek to develop or commercialize ourselves.

If we are required to conduct additional fundraising activities and we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we will be prevented from pursuing development and commercialization efforts, which will have a material adverse effect on our business, operating results and prospects.

Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.*

We expect that significant additional capital will be needed in the future to continue our planned operations. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. These sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders. Pursuant to our 2012 equity incentive plan, or the 2012 Plan, our management is authorized to grant stock options and other equity-based awards to our employees, directors and consultants. The number of shares available for future grant under the 2012 Plan will automatically increase each year by up to 4% of all shares of our capital stock outstanding as of December 31 of the prior calendar year, subject to the ability of our board of directors to take action to reduce the size of the increase in any given year. Any such increase, of the maximum amount or a lesser amount, will cause our stockholders to experience additional dilution, which could cause our stock price to fall. Currently, we plan to register the increased number of shares available for issuance under the 2012 Plan each year.

RISKS RELATED TO THE DISCOVERY AND DEVELOPMENT OF PRODUCT CANDIDATES

The approach we are taking to discover and develop drugs is novel and may never lead to marketable products.

We have concentrated our therapeutic product research and development efforts on microRNA technology, and our future success depends on the successful development of this technology and products based on our microRNA product platform. Neither we nor any other company has received regulatory approval to market therapeutics targeting microRNAs. The scientific discoveries that form the basis for our efforts to discover and develop product candidates are relatively new. The scientific evidence to support the feasibility of developing product candidates based on these discoveries is both preliminary and limited. If we do not successfully develop and commercialize product candidates based upon our technological approach, we may not become profitable and the value of our common stock may decline.

Further, our focus solely on microRNA technology for developing drugs as opposed to multiple, more proven technologies for drug development increases the risks associated with the ownership of our common stock. If we are not successful in developing any product candidates using microRNA technology, we may be required to change the scope and direction of our product development activities. In that case, we may not be able to identify and implement successfully an alternative product development strategy.

We may not be successful in our efforts to identify or discover potential product candidates.

The success of our business depends primarily upon our ability to identify, develop and commercialize microRNA therapeutics. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons, including:

•

our research methodology or that of our strategic alliance partners may be unsuccessful in identifying potential product candidates;

•

potential product candidates may be shown to have harmful side effects or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval; or

•

our strategic alliance partners may change their development profiles for potential product candidates or abandon a therapeutic area.

If any of these events occur, we may be forced to abandon our development efforts for a program or programs, which would have a material adverse effect on our business and could potentially cause us to cease operations. Research programs to identify new product candidates require substantial technical, financial and human resources. We may focus our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful.

All of our programs are still in preclinical development. Preclinical testing and clinical trials of our future product candidates may not be successful. If we are unable to successfully complete preclinical testing and clinical trials of our product candidates or experience significant delays in doing so, our business will be materially harmed.

We have invested a significant portion of our efforts and financial resources in the identification and preclinical development of product candidates that target microRNAs. Our ability to generate product revenues, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of our future product candidates.

The success of our future product candidates will depend on several factors, including the following:

•

successful completion of preclinical studies and clinical trials;

•

receipt of marketing approvals from applicable regulatory authorities;

•

obtaining and maintaining patent and trade secret protection for future product candidates;

•

establishing and maintaining manufacturing relationships with third parties or establishing our own manufacturing capability; and

•

successfully commercializing our products, if and when approved, whether alone or in collaboration with others.

If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully complete the development of, or commercialize, our product candidates, which would materially harm our business.

If clinical trials of our future product candidates fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our future product candidates.*

Before obtaining marketing approval from regulatory authorities for the sale of future product candidates, we or our strategic alliance partners must then conduct extensive clinical trials to demonstrate the safety and efficacy of the product candidates in humans. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical studies and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval for their products.

Events which may result in a delay or unsuccessful completion of clinical development include:

•

delays in reaching an agreement with the FDA or other regulatory authorities on final trial design;

•

imposition of a clinical hold following an inspection of our clinical trial operations or trial sites by the FDA or other regulatory authorities;

•

delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites;

•

our inability to adhere to clinical trial requirements directly or with third parties such as CROs;

•

delays in obtaining required institutional review board approval at each clinical trial site;

•

delays in recruiting suitable patients to participate in a trial;

•

delays in the testing, validation, manufacturing and delivery of the product candidates to the clinical sites;

•

delays in having patients complete participation in a trial or return for post-treatment follow-up;

•

delays caused by patients dropping out of a trial due to product side effects or disease progression;

•

clinical sites dropping out of a trial to the detriment of enrollment;

•

time required to add new clinical sites; or

•

delays by our contract manufacturers to produce and deliver sufficient supply of clinical trial materials.

If we or our strategic alliance partners are required to conduct additional clinical trials or other testing of any future product candidates beyond those that are currently contemplated, are unable to successfully complete clinical trials of any such product candidates or other testing, or if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we or our strategic alliance partners may:

•

be delayed in obtaining marketing approval for our future product candidates;

•

not obtain marketing approval at all;

•

obtain approval for indications or patient populations that are not as broad as intended or desired;

•

obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;

•

be subject to additional post-marketing testing requirements; or

•

have the product removed from the market after obtaining marketing approval.

Our product development costs will also increase if we experience delays in testing or marketing approvals. We do not know whether any clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do, which would impair our ability to successfully commercialize our product candidates and may harm our business and results of operations. Any inability to successfully complete preclinical and clinical development, whether independently or with our strategic alliance partners, could result in additional costs to us or impair our ability to generate revenues from product sales, regulatory and commercialization milestones and royalties.

Any of our future product candidates may cause adverse effects or have other properties that could delay or prevent their regulatory approval or limit the scope of any approved label or market acceptance.

Adverse events, or AEs, caused by our future product candidates could cause us, other reviewing entities, clinical trial sites or regulatory authorities to interrupt, delay or halt clinical trials and could result in the denial of regulatory approval. Certain oligonucleotide therapeutics have shown injection site reactions and pro-inflammatory effects and may also lead to impairment of kidney or liver function. There is a risk that our future product candidates may induce similar adverse events.

If AEs are observed in any clinical trials of our future product candidates, including those that our strategic partners may develop under our alliance agreements, our or our partners’ ability to obtain regulatory approval for product candidates may be negatively impacted.

Further, if any of our future products, if and when approved for commercial sale, cause serious or unexpected side effects, a number of potentially significant negative consequences could result, including:

•

regulatory authorities may withdraw their approval of the product or impose restrictions on its distribution in the form of a modified risk evaluation and mitigation strategy;

•

regulatory authorities may require the addition of labeling statements, such as warnings or contraindications;

•

we may be required to change the way the product is administered or conduct additional clinical trials;

•

we could be sued and held liable for harm caused to patients; or

•

our reputation may suffer.

Any of these events could prevent us or our partners from achieving or maintaining market acceptance of the affected product and could substantially increase the costs of commercializing our future products and impair our ability to generate revenues from the commercialization of these products either by us or by our strategic alliance partners.

Even if we complete the necessary preclinical studies and clinical trials, we cannot predict whether or when we will obtain regulatory approval to commercialize a product candidate and we cannot, therefore, predict the timing of any revenue from a future product.

Neither we nor our strategic alliance partners can commercialize a product until the appropriate regulatory authorities, such as the FDA, have reviewed and approved the product candidate. The regulatory agencies may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA Advisory Committee recommends restrictions on approval or recommends non-approval. In addition, we or our strategic alliance partners may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory agency policy during the period of product development, clinical trials and the review process.

Even if we obtain regulatory approval for a product candidate, we will still face extensive regulatory requirements and our products may face future development and regulatory difficulties.

Even if we obtain regulatory approval in the United States, the FDA may still impose significant restrictions on the indicated uses or marketing of our future product candidates, or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance. The holder of an approved new drug application, or NDA, is obligated to monitor and report AEs and any failure of a product to meet the specifications in the NDA. The holder of an approved NDA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws.

In addition, drug product manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with current good manufacturing practices, or cGMP, and adherence to commitments made in the NDA. If we or a regulatory agency discovers previously unknown problems with a product such as AEs of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions relative to that product or the manufacturing facility, including requiring recall or withdrawal of the product from the market or suspension of manufacturing.

If we or our partners fail to comply with applicable regulatory requirements following approval of any of our future product candidates, a regulatory agency may:

•

issue a warning letter asserting that we are in violation of the law;

•

seek an injunction or impose civil or criminal penalties or monetary fines;

•

suspend or withdraw regulatory approval;

•

suspend any ongoing clinical trials;

•

refuse to approve a pending NDA or supplements to an NDA submitted by us;

•

seize product; or

•

refuse to allow us to enter into supply contracts, including government contracts.

Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our future products and generate revenues.

We may not be successful in obtaining or maintaining necessary rights to microRNA targets, drug compounds and processes for our development pipeline through acquisitions and in-licenses.

Presently we have rights to the intellectual property, through licenses from third parties and under patents that we own, to modulate only a subset of the known microRNA targets. Because our programs may involve a range of microRNA targets, including targets that require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary rights. In addition, our future product candidates may require specific formulations to work effectively and efficiently and these rights may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.

For example, we sometimes collaborate with U.S. and foreign academic institutions to accelerate our preclinical research or development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution’s rights in technology resulting from the collaboration. Regardless of such right of first negotiation for intellectual property, we may be unable to negotiate a license within the specified time frame or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our program.

In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain rights to required third-party intellectual property rights, our business, financial condition and prospects for growth could suffer.

We may use our financial and human resources to pursue a particular research program or product candidate and fail to capitalize on programs or product candidates that may be more profitable or for which there is a greater likelihood of success.

Because we have limited financial and human resources, we intend to leverage our existing strategic alliance agreements and enter into new strategic alliance agreements for the development and commercialization of our programs and potential product candidates in indications with potentially large commercial markets such as HCC, fibrosis and HCV, while focusing our internal development resources and any internal sales and marketing organization that we may establish on research programs and future product candidates for selected markets, such as orphan diseases. As a result, we may forego or delay pursuit of opportunities with other programs or product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and future product candidates for specific indications may not yield any

commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through strategic alliance, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate, or we may allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a partnering arrangement.

If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.

We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.

Although we maintain workers’ compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.

RISKS RELATED TO OUR RELIANCE ON THIRD PARTIES

We will depend upon our strategic alliances for the development and eventual commercialization of certain future microRNA product candidates. If these strategic alliances are unsuccessful or are terminated, we may be unable to commercialize certain product candidates and we may be unable to generate revenues from our development programs.

We are likely to depend upon third party alliance partners for financial and scientific resources for the clinical development and commercialization of certain of our microRNA product candidates. These strategic alliances will likely provide us with limited control over the course of development of a future microRNA product candidate, especially once a candidate has reached the stage of clinical development. For example, in our alliance with GSK, GSK has the option to obtain an exclusive worldwide license to develop, manufacture and commercialize product candidates upon the achievement of relevant efficacy and safety endpoints in the first clinical trial designed to show efficacy, safety and tolerability with respect to each of four potential programs or earlier, at GSK’s option. However, GSK is not under any obligation to exercise its option to progress any of our microRNA development candidates. While each of AstraZeneca GSK and Sanofi have development obligations with respect to programs that they may elect to pursue under their respective agreements, our ability to ultimately recognize revenue from these relationships will depend upon the ability and willingness of our alliance partners to successfully meet their respective responsibilities under our agreements with them. Our ability to recognize revenues from successful strategic alliances may be impaired by several factors including:

•

an alliance partner may shift its priorities and resources away from our programs due to a change in business strategies, or a merger, acquisition, sale or downsizing of its company or business unit;

•

an alliance partner may cease development in therapeutic areas which are the subject of our strategic alliances;

•

an alliance partner may change the success criteria for a particular program or potential product candidate thereby delaying or ceasing development of such program or candidate;

•

a significant delay in initiation of certain development activities by an alliance partner will also delay payment of milestones tied to such activities, thereby impacting our ability to fund our own activities;

•

an alliance partner could develop a product that competes, either directly or indirectly, with an alliance product;

•

an alliance partner with commercialization obligations may not commit sufficient financial or human resources to the marketing, distribution or sale of a product;

•

an alliance partner with manufacturing responsibilities may encounter regulatory, resource or quality issues and be unable to meet demand requirements;

•

an alliance partner may exercise its rights under the agreement to terminate a strategic alliance;

•

a dispute may arise between us and an alliance partner concerning the research, development or commercialization of a program or product candidate resulting in a delay in milestones, royalty payments or termination of a program and possibly resulting in costly litigation or arbitration which may divert management attention and resources; and

•

an alliance partner may use our proprietary information or intellectual property in such a way as to invite litigation from a third party or fail to maintain or prosecute intellectual property rights such that our rights in such property are jeopardized.

Specifically, with respect to termination rights, Sanofi may terminate the entire alliance or its current alliance target program for any or no reason upon 30 days’ written notice to us. The agreement with Sanofi may also be terminated by either party for material breach by the other party, including a failure to comply with such party’s diligence obligations that remains uncured after 120 days. Similarly, GSK may terminate the entire alliance or any alliance target program for any or no reason upon 90 days’ written notice to us and the agreement may also be terminated by either party for material breach by the other party, including a failure to comply with such party’s diligence obligations that remains uncured after a specified notice period. The agreement with AstraZeneca may be terminated by either party in the event of the other party’s material breach which remains uncured after 40 business days following notice thereof (or 30 business days in the case of nonpayment). In addition, AstraZeneca may terminate the agreement in its entirety for any reason upon 60 business days’ written notice to us. Depending on the timing of any such termination, we may not be entitled to receive the option exercise fees or milestone payments, as these payments terminate with termination of the respective program or agreement.

If any of our alliance partners do not elect to pursue the development and commercialization of our microRNA development candidates or if they terminate the strategic alliance, then, depending on the event:

•

in the case of Sanofi, under certain circumstances, we may owe Sanofi royalties with respect to product candidates covered by our agreement with Sanofi that we elect to continue to commercialize, depending upon the stage of development at which such product commercialization rights reverted back to us, or additional payments if we license such product candidates to third parties;

•

the development of our product candidates subject to the AstraZeneca agreement, the GSK agreement or the Sanofi agreement, as applicable, may be terminated or significantly delayed;

•

our cash expenditures could increase significantly if it is necessary for us to hire additional employees and allocate scarce resources to the development and commercialization of product candidates that were previously funded, or expected to be funded, by AstraZeneca, GSK or Sanofi, as applicable;

•

we would bear all of the risks and costs related to the further development and commercialization of product candidates that were previously the subject of the AstraZeneca agreement, the GSK agreement or the Sanofi agreement, as applicable, including the reimbursement of third parties; and

•

in order to fund further development and commercialization, we may need to seek out and establish alternative strategic alliances with third-party partners; this may not be possible, or we may not be able to do so on terms which are acceptable to us, in which case it may be necessary for us to limit the size or scope of one or more of our programs or increase our expenditures and seek additional funding by other means.

Any of these events would have a material adverse effect on our results of operations and financial condition.

We expect to rely on third parties to conduct some aspects of our compound formulation, research and preclinical testing, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such formulation, research or testing.

We do not expect to independently conduct all aspects of our drug discovery activities, compound formulation research or preclinical testing of product candidates. We currently rely and expect to continue to rely on third parties to conduct some aspects of our preclinical testing.

Any of these third parties may terminate their engagements with us at any time. If we need to enter into alternative arrangements, it would delay our product development activities. Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities. For example, for product candidates that we develop and commercialize on our own, we will remain responsible for ensuring that each of our IND-enabling studies and clinical trials are conducted in accordance with the study plan and protocols for the trial.

If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our studies in accordance with regulatory requirements or our stated study plans and protocols, we will not be able to complete, or may be delayed in completing, the necessary preclinical studies to enable us or our strategic alliance partners to select viable product candidates for IND submissions and will not be able to, or may be delayed in our efforts to, successfully develop and commercialize such product candidates.

We intend to rely on third-party manufacturers to produce our preclinical supplies, and we intend to rely on third parties to produce clinical supplies of any product candidates that we advance into clinical trials and commercial supplies of any approved product candidates.

Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured the product candidates ourselves, including:

•

the inability to meet any product specifications and quality requirements consistently;

•

a delay or inability to procure or expand sufficient manufacturing capacity;

•

manufacturing and product quality issues related to scale-up of manufacturing;

•

costs and validation of new equipment and facilities required for scale-up;

•

a failure to comply with cGMP and similar foreign standards;

•

the inability to negotiate manufacturing agreements with third parties under commercially reasonable terms;

•

termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that is costly or damaging to us;

•

the reliance on a limited number of sources, and in some cases, single sources for raw materials, such that if we are unable to secure a sufficient supply of these product components, we will be unable to manufacture and sell future product candidates in a timely fashion, in sufficient quantities or under acceptable terms;

•

the lack of qualified backup suppliers for any raw materials that are currently purchased from a single source supplier;

•

operations of our third-party manufacturers or suppliers could be disrupted by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier;

•

carrier disruptions or increased costs that are beyond our control; and

•

the failure to deliver products under specified storage conditions and in a timely manner.

Any of these events could lead to clinical study delays or failure to obtain regulatory approval, or impact our ability to successfully commercialize future products. Some of these events could be the basis for FDA action, including injunction, recall, seizure or total or partial suspension of production.

We expect to rely on limited sources of supply for the drug substance of future product candidates and any disruption in the chain of supply may cause a delay in developing and commercializing these product candidates.

We intend to establish manufacturing relationships with a limited number of suppliers to manufacture raw materials and the drug substance of any product candidate for which we are responsible for preclinical or clinical development. Each supplier may require licenses to manufacture such components if such processes are not owned by the supplier or in the public domain. As part of any marketing approval, a manufacturer and its processes are required to be qualified by the FDA prior to commercialization. If supply from the approved vendor is interrupted, there could be a significant disruption in commercial supply. An alternative vendor would need to be qualified through an NDA supplement which could result in further delay. The FDA or other regulatory agencies outside of the United States may also require additional studies if a new supplier is relied upon for commercial production. Switching vendors may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines.

In addition, if our alliance partners elect to pursue the development and commercialization of certain programs, we will lose control over the manufacturing of the product candidate subject to the agreement. For example, if Sanofi elects to develop and commercialize a product candidate targeting miR-21 for HCC or kidney fibrosis under its strategic alliance with us, Sanofi will be responsible for the manufacture of the product candidates for clinical trials. Sanofi will be free to use a manufacturer of its own choosing or manufacture the product candidates in its own manufacturing facilities. In such a case, we will have no control over Sanofi’s processes or supply chains to ensure the timely manufacture and supply of the product candidates. In addition, we will not be able to ensure that the product candidates will be manufactured under the correct conditions to permit the product candidates to be used in such clinical trials. Each of AstraZeneca and GSK will have similar obligations to manufacture product candidates which it takes into clinical trials under its strategic alliance with us and we will face similar risks as to those product candidates.

These factors could cause the delay of clinical trials, regulatory submissions, required approvals or commercialization of our future product candidates, cause us to incur higher costs and prevent us from commercializing our products successfully. Furthermore, if our suppliers fail to deliver the required commercial quantities of active pharmaceutical ingredients on a timely basis and at commercially reasonable prices, and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical trials may be delayed or we could lose potential revenue.

Manufacturing issues may arise that could increase product and regulatory approval costs or delay commercialization.

As we scale-up manufacturing of future product candidates and conduct required stability testing, product, packaging, equipment and process-related issues may require refinement or resolution in order to proceed with any clinical trials and obtain regulatory approval for commercial marketing. We may identify significant impurities, which could result in increased scrutiny by the regulatory agencies, delays in clinical programs and regulatory approval, increases in our operating expenses, or failure to obtain or maintain approval for future product candidates or any approved products.

We expect to rely on third parties to conduct, supervise and monitor our clinical trials, and if those third parties perform in an unsatisfactory manner, it may harm our business.*

If we or our strategic alliance partners commence clinical trials, we expect to rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials. While we will have agreements governing their activities, we and our strategic alliance partners will have limited influence over their actual performance. We will control only certain aspects of our CROs’ activities. Nevertheless, we or our strategic alliance partners will be responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards and our reliance on the CROs does not relieve us of our regulatory responsibilities.

We, our alliance partners and our CROs are required to comply with the FDA’s current good clinical practices, or cGCPs, for conducting, recording and reporting the results of IND-enabling studies and clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of clinical trial participants are protected. The FDA enforces these cGCPs through periodic inspections of trial sponsors, principal investigators and clinical trial sites. If we or our CROs fail to comply with applicable cGCPs, the clinical data generated in our future clinical trials may be deemed unreliable and the FDA may require us to perform additional clinical trials before approving any marketing applications. Upon inspection, the FDA may determine that our clinical trials did not comply with cGCPs. In addition, our future clinical trials will require a sufficiently large number of test subjects to evaluate the safety and effectiveness of a potential drug product. Accordingly, if our CROs fail to comply with these regulations or fail to recruit a sufficient number of patients, we may be required to repeat such clinical trials, which would delay the regulatory approval process.

Our CROs will not be our employees, and we will not be able to control whether or not they devote sufficient time and resources to our clinical and nonclinical programs. These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials, or other drug development activities which could harm our competitive position. If our CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements, or for any other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize our future product candidates. As a result, our financial results and the commercial prospects for such products and any future product candidates that we develop would be harmed, our costs could increase, and our ability to generate revenues could be delayed.

We also expect to rely on other third parties to store and distribute drug products for any clinical trials that we may conduct. Any performance failure on the part of our distributors could delay clinical development or marketing approval of our future product candidates or commercialization of our products, if approved, producing additional losses and depriving us of potential product revenue.

RISKS RELATED TO OUR INTELLECTUAL PROPERTY

If we are unable to obtain or protect intellectual property rights related to our future products and product candidates, we may not be able to compete effectively in our markets.

We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our future products and product candidates. The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or in-license may fail to result in issued patents with claims that cover the products in the United States or in other countries. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found; such prior art which can invalidate a patent or prevent a patent from issuing based on a pending patent application. Even if patents do successfully issue, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed or invalidated. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing around our claims.

If the patent applications we hold or have in-licensed with respect to our programs or product candidates fail to issue or if their breadth or strength of protection is threatened, it could dissuade companies from collaborating with us to develop product candidates, and threaten our ability to commercialize, future products. We cannot offer any assurances about which, if any, patents will issue or whether any issued patents will be found invalid and unenforceable or will be threatened by third parties. In particular, we are aware that Santaris Pharma A/S, or Santaris, has initiated reexamination of and filed oppositions to patents owned by Stanford University and licensed to us, in each case relating to miR-122, and has filed oppositions to a patent owned by us relating to miR-122 and to a patent owned by Isis relating to chemical modification of oligonucleotides. Any successful opposition to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any product candidates

that we or our strategic alliance partners may develop. Since patent applications in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we were the first to file any patent application related to a product candidate. Furthermore, in certain situations, if we and one or more third parties have filed patent applications in the United States and claiming the same subject matter, an administrative proceeding can be initiated to determine which applicant is entitled to the patent on that subject matter. In addition, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions may be available however the life of a patent, and the protection it affords, is limited. Once the patent life has expired for a product, we may be open to competition from generic medications. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced.

In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable, processes for which patents are difficult to enforce and any other elements of our drug discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. Although each of our employees agrees to assign their inventions to us through an employee inventions agreement, and all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed or that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. In addition, others may independently discover our trade secrets and proprietary information. For example, the FDA, as part of its Transparency Initiative, is currently considering whether to make additional information publicly available on a routine basis, including information that we may consider to be trade secrets or other proprietary information, and it is not clear at the present time how the FDA’s disclosure policies may change in the future, if at all.

Further, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent material disclosure of the non-patented intellectual property related to our technologies to third parties, and there is no guarantee that we will have any such enforceable trade secret protection, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, results of operations and financial condition.

Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts.

Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions and inter partes reexamination proceedings before the U.S. Patent and Trademark Office, or U.S. PTO, and corresponding foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we and our strategic alliance partners are pursuing development candidates. For example, we are aware that Santaris has patents and patent applications in the microRNA therapeutics space, including patents and patent applications related to targeting microRNAs, such as miR-122, for the treatment of disease. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our future product candidates may be subject to claims of infringement of the patent rights of third parties.

Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our future product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our future product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our future product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire. Similarly, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy, the holders of any such patents may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all.

Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our future product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys’ fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.

If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.

We are a party to a number of intellectual property license agreements that are important to our business and expect to enter into additional license agreements in the future. Our existing license agreements impose, and we expect that future license agreements will impose, various diligence, milestone payment, royalty and other obligations on us. For example, under our exclusive license agreement for Max-Planck-Innovation GmbH’s proprietary technology and know-how covering microRNA sequences, we are required to use commercially reasonable diligence to develop and commercialize a product and to satisfy specified payment obligations. If we fail to comply with our obligations under our agreement with Max-Planck-Innovation GmbH or our other license agreements, or we are subject to a bankruptcy, the licensor may have the right to terminate the license, in which event we, or our strategic alliance partners, would not be able to market products covered by the license. In addition, our exclusive license agreements with our founding companies, Alnylam and Isis, provide us with rights to nucleotide technologies in the field of microRNA therapeutics based on oligonucleotides that modulate up-regulated microRNAs. Some of these technologies, such as intellectual property relating to the chemical modification of oligonucleotides, are relevant to our product candidate development programs. If our license agreements with Alnylam or Isis are terminated, or our business relationships with either of these companies or our other licensors are disrupted by events that may include the acquisition of either company, our access to critical intellectual property rights will be materially and adversely affected.

We may need to obtain licenses from third parties to advance our research or allow commercialization of our future product candidates, and we have done so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or more of our future product candidates, which could harm our business significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our future products, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties.

We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming and unsuccessful.

Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing.

Interference proceedings provoked by third parties or brought by us may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our alliance partners or licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States.

Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.

We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.

We employ individuals who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees’ former employers or other third parties. We may also be subject to claims that former employers or other third parties have an ownership interest in our patents. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims, and if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees.

RISKS RELATED TO COMMERCIALIZATION OF PRODUCT CANDIDATES

The commercial success of our miR-21, miR-122 and miR-33 programs, which are part of our strategic alliance agreements with Sanofi, GSK and AstraZeneca, respectively, will depend in large part on the development and marketing efforts of our alliance partners. If our alliance partners are unable to perform in accordance with the terms of our agreements, our potential to generate future revenue from these programs would be significantly reduced and our business would be materially and adversely harmed.

If any of Sanofi, GSK or AstraZeneca elects to pursue the development and commercialization of any of the microRNA product candidates that are subject to their respective strategic alliance agreements with us, we will have limited influence and/or control over their approaches to development and commercialization. If Sanofi, GSK, AstraZeneca or any potential future strategic alliance partners do not perform in the manner that we expect or fail to fulfill their responsibilities in a timely manner, or at all, the clinical development, regulatory approval and commercialization efforts related to product candidates we have licensed to such strategic alliance partners could be delayed or terminated. If we terminate any of our strategic alliances or any program thereunder due to a material breach by Sanofi, GSK or AstraZeneca, we have the right to assume the responsibility at our own expense for the development of the applicable microRNA product candidates. Assuming sole responsibility for further development will increase our expenditures, and may mean we will need to limit the size and scope of one or more of our programs, seek additional funding and/or choose to stop work altogether on one or more of the affected product candidates. This could result in a limited potential to generate future revenue from such microRNA product candidates and our business could be materially and adversely affected. Further, under certain circumstances, we may owe Sanofi, GSK or AstraZeneca, as applicable, royalties on any product candidate that we may successfully commercialize.

We face significant competition from other biotechnology and pharmaceutical companies and our operating results will suffer if we fail to compete effectively.*

The biotechnology and pharmaceutical industries are intensely competitive. We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, biotechnology companies and universities and other research institutions. We are aware of several companies that are working specifically to develop microRNA therapeutics including Groove Biopharma, Inc., InteRNA Technologies B.V., miRagen Therapeutics, Inc., MiReven Pty Ltd, Mirna Therapeutics, Inc., and Santaris. Our competitors may have substantially greater financial, technical and other resources, such as larger research and development staff and experienced marketing and manufacturing organizations. Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors may succeed in developing, acquiring or licensing on an exclusive basis, drug products that are more effective or less costly than any product candidate that we may develop.

All of our programs are in a preclinical development stage and are targeted toward indications for which there are approved products on the market or product candidates in clinical development. We will face competition from other drugs currently approved or that will be approved in the future for the same therapeutic indications. Our ability to compete successfully will depend largely on our ability to leverage our experience in drug discovery and development to:

•

discover and develop therapeutics that are superior to other products in the market;

•

attract qualified scientific, product development and commercial personnel;

•

obtain patent and/or other proprietary protection for our microRNA product platform and future product candidates;

•

obtain required regulatory approvals; and

•

successfully collaborate with pharmaceutical companies in the discovery, development and commercialization of new therapeutics.

The availability of our competitors’ products could limit the demand, and the price we are able to charge, for any products that we may develop and commercialize. We will not achieve our business plan if the acceptance of any of these products is inhibited by price competition or the reluctance of physicians to switch from existing drug products to our products, or if physicians switch to other new drug products or choose to reserve our future products for use in limited circumstances. The inability to compete with existing or subsequently introduced drug products would have a material adverse impact on our business, financial condition and prospects.

Established pharmaceutical companies may invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make our future product candidates less competitive. In addition, any new product that competes with an approved product must demonstrate compelling advantages in efficacy, convenience, tolerability and safety in order to overcome price competition and to be commercially successful. Accordingly, our competitors may succeed in obtaining patent protection, receiving FDA approval or discovering, developing and commercializing product candidates before we do, which would have a material adverse impact on our business.

The commercial success of our product candidates will depend upon the acceptance of these product candidates by the medical community, including physicians, patients and healthcare payors.

The degree of market acceptance of any product candidates will depend on a number of factors, including:

•

demonstration of clinical safety and efficacy compared to other products;

•

the relative convenience, ease of administration and acceptance by physicians, patients and healthcare payors;

•

the prevalence and severity of any AEs;

•

limitations or warnings contained in the FDA-approved label for such products;

•

availability of alternative treatments;

•

pricing and cost-effectiveness;

•

the effectiveness of our or any collaborators’ sales and marketing strategies;

•

our ability to obtain hospital formulary approval;

•

our ability to obtain and maintain sufficient third party coverage or reimbursement; and

•

the willingness of patients to pay out-of-pocket in the absence of third party coverage.

Unless other formulations are developed in the future, we expect our compounds to be formulated in an injectable form. Injectable medications may be disfavored by patients or their physicians in the event drugs which are easy to administer, such as oral medications, are available. If a product is approved, but does not achieve an adequate level of acceptance by physicians, patients and healthcare payors, we may not generate sufficient revenues from such product and we may not become or remain profitable.

If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our future product candidates, we may be unable to generate any revenues.

We currently do not have an organization for the sales, marketing and distribution of pharmaceutical products and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. In order to market any products that may be approved, we must build our sales, marketing, managerial and other non-technical capabilities or make arrangements with third parties to perform these services. With respect to our current programs which are the subject of existing strategic alliances, such as miR-21 with Sanofi, miR-122 with GSK and miR-33 with AstraZeneca, we intend to rely completely on our alliance partner for sales and marketing. In addition, we intend to enter into strategic alliances with third parties to commercialize other future product candidates, including in markets outside of the United States or for other large markets that are beyond our resources. Although we intend to establish a sales organization if we are able to obtain approval to market any product candidates for niche markets in the United States, we will also consider the option to enter into strategic alliances for future product candidates in the United States if commercialization requirements exceed our available resources. This will reduce the revenue generated from the sales of these products.

Our current and future strategic alliance partners, if any, may not dedicate sufficient resources to the commercialization of our future product candidates or may otherwise fail in their commercialization due to factors beyond our control. If we are unable to establish effective alliances to enable the sale of our future product candidates to healthcare professionals and in geographical regions, including the United States, that will not be covered by our own marketing and sales force, or if our potential future strategic alliance partners do not successfully commercialize the product candidates, our ability to generate revenues from product sales will be adversely affected.

If we are unable to establish adequate sales, marketing and distribution capabilities, whether independently or with third parties, we may not be able to generate sufficient product revenue and may not become profitable. We will be competing with many companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.

If we obtain approval to commercialize any approved products outside of the United States, a variety of risks associated with international operations could materially adversely affect our business.

Our strategic alliance agreements with Sanofi, GSK and AstraZeneca provide that our partners will be responsible for the commercialization of future product candidates, if any, from our miR-21, miR-122 and miR-33 programs, as applicable. If any other future product candidates that we may develop are approved for commercialization, we may also enter into agreements with third parties to market them on a worldwide basis or in more limited geographical regions. We expect that we will be subject to additional risks related to entering into international business relationships, including:

•

different regulatory requirements for drug approvals in foreign countries;

•

reduced protection for intellectual property rights;

•

unexpected changes in tariffs, trade barriers and regulatory requirements;

•

economic weakness, including inflation, or political instability in particular foreign economies and markets;

•

compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;

•

foreign taxes, including withholding of payroll taxes;

•

foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;

•

workforce uncertainty in countries where labor unrest is more common than in the United States;

•

production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and

•

business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires.

Coverage and adequate reimbursement may not be available for our future product candidates, which could make it difficult for us to sell products profitably.

Market acceptance and sales of any future product candidates that we develop will depend on coverage and reimbursement policies and may be affected by future healthcare reform measures. Government authorities and third party payors, such as private health insurers, hospitals and health maintenance organizations, decide which drugs they will pay for and establish reimbursement levels. We cannot be sure that coverage and adequate reimbursement will be available for any future product candidates. Also, inadequate reimbursement amounts may reduce the demand for, or the price of, our future products. If reimbursement is not available, or is available only at limited levels, we may not be able to successfully commercialize future product candidates that we develop.

In addition, we cannot be certain if and when we will obtain formulary approval to allow us to sell any products that we may develop and commercialize into our target markets. Obtaining formulary approval from hospitals and from payers can be an expensive and time consuming process. Failure to obtain timely formulary approval will limit our commercial success.

There have been a number of legislative and regulatory proposals to change the healthcare system in the United States and in some foreign jurisdictions that could affect our ability to sell products profitably. These legislative and/or regulatory changes may negatively impact the reimbursement for drug products, following approval. The availability of numerous generic treatments may also substantially reduce the likelihood of reimbursement for our future products. The potential application of user fees to generic drug products may expedite the approval of additional generic drug treatments. We expect to experience pricing pressures in connection with the sale of any products that we develop, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. If we fail to successfully secure and maintain reimbursement coverage for our future products or are significantly delayed in doing so, we will have difficulty achieving market acceptance of our future products and our business will be harmed.

In addition, in some non-U.S. jurisdictions, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the EU provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the EU do not follow price structures of the U.S. and generally tend to be priced significantly lower.

RISKS RELATED TO OUR BUSINESS OPERATIONS AND INDUSTRY

Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.

We are highly dependent on principal members of our executive team, the loss of whose services may adversely impact the achievement of our objectives. While we have entered into employment agreements with each of our executive officers, any of them could leave our employment at any time, as all of our employees are “at will” employees. Recruiting and retaining other qualified employees for our business, including scientific and technical personnel, will also be critical to our success. There is currently a shortage of skilled executives in our industry, which is likely to continue. As a result, competition for skilled personnel is intense and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical companies for individuals with similar skill sets. In addition, failure to succeed in preclinical studies and clinical trials may make it more challenging to recruit and retain qualified personnel. The inability to recruit or loss of the services of any executive or key employee might impede the progress of our research, development and commercialization objectives.

We may need to expand our organization and may experience difficulties in managing this growth, which could disrupt our operations.*

As of September 30, 2013, we had 69 full-time employees. As our company matures, we expect to expand our employee base to increase our managerial, scientific and operational, commercial, financial and other resources and to hire more consultants and contractors. Future growth would impose significant additional responsibilities on our management, including the need to identify, recruit, maintain, motivate and integrate additional employees, consultants and contractors. Also, our management may need to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of additional product candidates. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and/or grow revenues could be reduced, and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize future product candidates and compete effectively will depend, in part, on our ability to effectively manage any future growth.

Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.

We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with the regulations of the FDA and non-U.S. regulators, provide accurate information to the FDA and non-U.S. regulators, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of conduct, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.

Any future relationships with customers and third party payors may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.

If we obtain FDA approval for any of our product candidates and begin commercializing those products in the United States, our operations may be directly, or indirectly through our customers, subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act. These laws may impact, among other things, our proposed sales, marketing and education programs. In addition, we may be subject to patient privacy regulation by the federal government and by the U.S. states and foreign jurisdictions in which we conduct our business. The laws that may affect our ability to operate include:

•

the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, either the referral of an individual, or the purchase or recommendation of an item or service for which payment may be made under a federal healthcare program, such as the Medicare and Medicaid programs;

•

federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third party payers that are false or fraudulent;

•

the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters;

•

HIPAA, as amended by the Health Information Technology and Clinical Health Act of 2009, or HITECH, and its implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information; and

•

state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third party payer, including commercial insurers, and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.

If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including, without limitation, civil and criminal penalties, damages, fines, possible exclusion from Medicare, Medicaid and other government healthcare programs, and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.

We face potential product liability, and, if successful claims are brought against us, we may incur substantial liability and costs.

The use of our future product candidates in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. Certain oligonucleotide therapeutics have shown injection site reactions and pro-inflammatory effects and may also lead to impairment of kidney or liver function. There is a risk that our future product candidates may induce similar adverse events. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in:

•

impairment of our business reputation;

•

withdrawal of clinical trial participants;

•

costs due to related litigation;

•

distraction of management’s attention from our primary business;

•

substantial monetary awards to patients or other claimants;

•

the inability to commercialize our future product candidates; and

•

decreased demand for our future product candidates, if approved for commercial sale.

We do not currently have any product liability insurance coverage. We anticipate obtaining such insurance prior to the commencement of any clinical trials but any such insurance coverage that we obtain may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and in the future we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If and when we obtain marketing approval for future product candidates, we intend to expand our insurance coverage to include the sale of commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated adverse effects. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business.

Business interruptions could delay us in the process of developing our future products.

Our headquarters are located in San Diego County. We are vulnerable to natural disasters such as earthquakes and wild fires, as well as other events that could disrupt our operations. We do not carry insurance for earthquakes or other natural disasters and we may not carry sufficient business interruption insurance to compensate us for losses that may occur. Any losses or damages we incur could have a material adverse effect on our business operations.

RISKS RELATED TO OUR COMMON STOCK

The market price of our common stock may be highly volatile.*

Since shares of our common stock were sold in our initial public offering in October 2012 at a price of $4.00 per share, our closing stock price as reported on The NASDAQ Global Market has ranged from $4.15 to $12.41, through November 8, 2013. The trading price of our common stock is likely to continue to be volatile.

Our stock price could be subject to wide fluctuations in response to a variety of factors, including the following:

•

adverse results or delays in preclinical testing or clinical trials;

•

inability to obtain additional funding;

•

any delay in filing an IND or NDA for any of our future product candidates and any adverse development or perceived adverse development with respect to the FDA’s review of that IND or NDA;

•

failure to maintain our existing strategic alliances or enter into new alliances;

•

failure of our strategic alliance partners to elect to develop and commercialize product candidates under our alliance agreements or the termination of any programs under our alliance agreements;

•

failure by us or our licensors and strategic alliance partners to prosecute, maintain or enforce our intellectual property rights;

•

failure to successfully develop and commercialize our future product candidates;

•

changes in laws or regulations applicable to our preclinical and clinical development activities, product candidates or future products;

•

inability to obtain adequate product supply for our future product candidates or the inability to do so at acceptable prices;

•

adverse regulatory decisions;

•

introduction of new products, services or technologies by our competitors;

•

failure to meet or exceed financial projections we may provide to the public;

•

failure to meet or exceed the estimates and projections of the investment community;

•

the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community;

•

announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us, our strategic alliance partners or our competitors;

•

disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;

•

additions or departures of key scientific or management personnel;

•

significant lawsuits, including patent or stockholder litigation;

•

changes in the market valuations of similar companies;

•

sales of our common stock by us or our stockholders in the future; and

•

trading volume of our common stock.

In addition, companies trading in the stock market in general, and The NASDAQ Global Market in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance.

Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.*

As of September 30, 2013, our executive officers, directors, 5% stockholders and their affiliates beneficially owned approximately 69% of our outstanding voting stock. Therefore, these stockholders will have the ability to influence us through this ownership position. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders, acting together, may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may believe are in your best interest as one of our stockholders.

We are an “emerging growth company,” and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common stock less attractive to investors.

We are an “emerging growth company,” as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth companies,” including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. We could be an emerging growth company through December 31, 2017, although circumstances could cause us to lose that status earlier, including if the market value of our common stock held by non-affiliates exceeds $700.0 million as of any June 30 before that time or if we have total annual gross revenue of $1.0 billion or more during any fiscal year before that time, in which cases we would no longer be an emerging growth company as of the following December 31 or, if we issue more than $1.0 billion in non-convertible debt during any three year period before that time, we would cease to be an emerging growth company immediately. Even after we no longer qualify as an emerging growth company, we may still qualify as a “smaller reporting company” which would allow us to take advantage of many of the same exemptions from disclosure requirements including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.

Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.

The requirements of being a public company may strain our resources and divert management’s attention.

As a public company, we have incurred, and will continue to incur, significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act, as well as rules subsequently implemented by the SEC and The NASDAQ Global Market have imposed various requirements on public companies. In July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas such as “say on pay” and proxy access. Recent legislation permits smaller “emerging growth companies” to implement many of these requirements over a longer period and up to five years from the pricing of our initial public offering. We intend to take advantage of this new legislation but cannot guarantee that we will not be required to implement these requirements sooner than budgeted or planned and thereby incur unexpected expenses. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain our current levels of such coverage.

Sales of a substantial number of shares of our common stock in the public market by our existing stockholders could cause our stock price to fall.*

If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, the trading price of our common stock could decline. Certain lock-up agreements pertaining to our recently completed public offering expired on October 14, 2013 and certain lock-up agreements pertaining to our initial public offering expired on October 4, 2013. Upon the expiration of these lock-up agreements, a substantial number of shares of common stock became eligible for sale in the public market, subject to volume limitations under Rule 144 under the Securities Act of 1933, as amended, or the Securities Act, with respect to any of these shares held by directors, executive officers and other affiliates. In addition, shares of common stock that are either subject to outstanding options or reserved for future issuance under our employee benefit plans are or may become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules and Rule 144 and Rule 701 under the Securities Act. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.

Certain holders of our securities are entitled to rights with respect to the registration of their shares under the Securities Act, subject to the applicable lock-up arrangement described above. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares held by our affiliates as defined in Rule 144 under the Securities Act. Any sales of securities by these stockholders could have a material adverse effect on the trading price of our common stock.

Pursuant to our 2012 Plan, our management is authorized to grant stock options and other equity-based awards to our employees, directors and consultants. The number of shares available for future grant under the 2012 Plan will automatically increase each year by up to 4% of all shares of our capital stock outstanding as of December 31 of the prior calendar year, subject to the ability of our board of directors to take action to reduce the size of the increase in any given year. Currently, we plan to register the increased number of shares available for issuance under the 2012 Plan each year.

We could be subject to securities class action litigation.

In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because pharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management’s attention and resources, which could harm our business.

Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.

Under Section 382 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an “ownership change,” generally defined as a greater than 50% change (by value) in its equity ownership over a three year period, the corporation’s ability to use its pre-change net operating loss carryforwards, or NOLs, and other pre-change tax attributes (such as research tax credits) to offset its post-change income may be limited. We believe that, with our initial public offering and other transactions that have occurred over the past three years, we may have triggered an “ownership change” limitation. We may also experience ownership changes in the future as a result of subsequent shifts in our stock ownership. As a result, if we earn net taxable income, our ability to use our pre-change net operating loss carryforwards to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.

We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.

We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock.

Provisions in our amended and restated certificate of incorporation and bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders or remove our current management.

Some provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders and may prevent attempts by our stockholders to replace or remove our current management. These provisions include:

•

authorizing the issuance of “blank check” preferred stock, the terms of which may be established and shares of which may be issued without stockholder approval;

•

limiting the removal of directors by the stockholders;

•

prohibiting stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of our stockholders;

•

eliminating the ability of stockholders to call a special meeting of stockholders; and

•

establishing advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at stockholder meetings.

In addition, we are subject to Section 203 of the Delaware General Corporation Law, which generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with an interested stockholder for a period of three years following the date on which the stockholder became an interested stockholder, unless such transactions are approved by our board of directors. This provision could have the effect of delaying or preventing a change in control, whether or not it is desired by or beneficial to our stockholders. Further, other provisions of Delaware law may also discourage, delay or prevent someone from acquiring us or merging with us.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Recent Sales of Unregistered Securities

None.

Use of Proceeds

On October 4, 2012, we commenced our initial public offering pursuant to a registration statement on Form S-1 (File No. 333-183384) that was declared effective by the SEC on October 4, 2012 and that registered an aggregate of 12,937,500 shares of our common stock for sale to the public at a price of $4.00 per share and an aggregate offering price of $51,750,000. On October 10, 2012 and October 23, 2012, we sold 11,250,000 shares and 1,480,982 shares of our common stock, respectively, to the public at a price of $4.00 per share for an aggregate gross offering price of $50,923,928. Lazard Capital Markets, Cowen and Company and BMO Capital Markets acted as joint book-running managers for the offering, and Needham & Company and Wedbush PacGrow Life Sciences served as co-managers for the offering.

The underwriting discounts and commissions in connection with the offering totaled approximately $3.4 million. We incurred additional costs of approximately $2.6 million in offering expenses, which when added to the underwriting discounts and commissions paid by us, amounts to total fees and costs of approximately $6.0 million. Thus, the net offering proceeds to us, after deducting underwriting discounts, commissions and offering costs, were approximately $44.9 million. No offering costs were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning ten percent or more of any class of our equity securities or to any other affiliates.

As of November 8, 2013, we have not used any of the net proceeds from the offering. We intend to use the net proceeds for preclinical and clinical development of our initial microRNA development candidates, for the identification and validation of additional microRNA targets, and for capital expenditures, working capital and other general corporate purposes, including costs and expenses associated with being a public company. We may also use a portion of the net proceeds to in-license, acquire or invest in complementary microRNA businesses, technologies, products or assets. We cannot specify with certainty all of the particular uses for the net proceeds from our initial public offering. Accordingly, our management will have broad discretion in the application of the net proceeds.

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4.

MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5.

OTHER INFORMATION

Our policy governing transactions in our securities by directors, officers and employees permits our officers, directors and certain other persons to enter into trading plans complying with Rule 10b5-1 under the Exchange Act. We have been advised that certain of our directors and executive officers have entered into trading plans in accordance with Rule 10b5-1 and our policy governing transactions in our securities. Generally, under these trading plans, the individual relinquishes control over the transactions once the trading plan is put into place. Accordingly, sales under these plans may occur at any time, including possibly before, simultaneously with, or immediately after significant events involving the Company.

We anticipate that, as permitted by Rule 10b5-1 and our policy governing transactions in our securities, some or all of our officers, directors and employees may establish trading plans in the future. However, we undertake no obligation to update or revise the information provided herein, including for revision or termination of an established trading plan.

ITEM 6.

EXHIBITS


Exhibit Number		Description

3.1		Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on October 11, 2012).

3.2		Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K, filed with the SEC on October 11, 2012).

4.1		Reference is made to Exhibits 3.1 and 3.2.

4.2		Form of Common Stock Certificate of the Registrant (incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-183384), originally filed with the SEC on August 17, 2012).

10.1†		Amendment Number Three to the Amended and Restated License and Collaboration Agreement among the Company, Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., dated August 2, 2013 (incorporated by reference to Exhibit 99.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on August 7, 2013).

31.1		Certification of the Principal Executive Officer and Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.

32.1*		Certification of the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.


Exhibit Number		Description

101.INS**		XBRL Instance Document.

101.SCH**		XBRL Taxonomy Extension Schema Document.

101.CAL**		XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF**		XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB**		XBRL Taxonomy Extension Label Linkbase Document.

101.PRE**		XBRL Taxonomy Extension Presentation Linkbase Document.

†	We have received confidential treatment for certain portions of this agreement, which have been omitted and filed separately with the SEC pursuant to Rule 406 under the Securities Act of 1933, as amended.

These certifications are being furnished solely to accompany this quarterly report pursuant to 18 U.S.C. Section 1350, and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934 and are not to be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Pursuant to applicable securities laws and regulations, we are deemed to have complied with the reporting obligation relating to the submission of interactive data files in such exhibits and are not subject to liability under any anti-fraud provisions of the federal securities laws as long as we have made a good faith attempt to comply with the submission requirements and promptly amend the interactive data files after becoming aware that the interactive data files fail to comply with the submission requirements. Users of this data are advised that, pursuant to Rule 460T, these interactive data files are deemed not filed and otherwise are not subject to liability.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

EXHIBIT INDEX


Exhibit Number		Description

3.1		Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on October 11, 2012).

3.2		Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K, filed with the SEC on October 11, 2012).

4.1		Reference is made to Exhibits 3.1 and 3.2.

4.2		Form of Common Stock Certificate of the Registrant (incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-183384), originally filed with the SEC on August 17, 2012).

10.1†		Amendment Number Three to the Amended and Restated License and Collaboration Agreement among the Company, Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., dated August 2, 2013 (incorporated by reference to Exhibit 99.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on August 7, 2013).

31.1		Certification of the Principal Executive Officer and Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.

32.1*		Certification of the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS**		XBRL Instance Document.

101.SCH**		XBRL Taxonomy Extension Schema Document.

101.CAL**		XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF**		XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB**		XBRL Taxonomy Extension Label Linkbase Document.

101.PRE**		XBRL Taxonomy Extension Presentation Linkbase Document.

†	We have received confidential treatment for certain portions of this agreement, which have been omitted and filed separately with the SEC pursuant to Rule 406 under the Securities Act of 1933, as amended.

EX-31.1 2 d599924dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Kleanthis G. Xanthopoulos, Ph.D., certify that:

1. I have reviewed this quarterly report on Form 10-Q of Regulus Therapeutics Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;

b. evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

c. disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: November 13, 2013

						/s/ Kleanthis G. Xanthopoulos
						Kleanthis G. Xanthopoulos, Ph.D.
						President and Chief Executive Officer
						(Principal Executive Officer and Principal Financial Officer)

EX-32.1 3 d599924dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Regulus Therapeutics Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2013 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Kleanthis G. Xanthopoulos, Ph.D., President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: November 13, 2013

						/s/ Kleanthis G. Xanthopoulos
						Kleanthis G. Xanthopoulos, Ph.D.
						President and Chief Executive Officer
						(Principal Executive Officer and Principal Financial Officer)

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.

EX-101.INS 4 rgls-20130930.xml XBRL INSTANCE DOCUMENT

5000000

10800000

4.00

5000000

10100000

1250000

41777326

9.81

17426000

4.00

41774442

8182756

2.78

4160000

9.43

200000000

0.001

41774442

7138000

13527000

-44000

1228000

171608000

1140000

1558000

94446000

-77160000

9454000

1705000

5400000

36144000

42000

13921000

130590000

178000

95000

1145000

123790000

3981000

130590000

33490000

90413000

1288000

125286000

90443000

13770000

999000

68617000

68649000

7027000

7025000

1400848

4160215

2161410

460283

3700000

13770000

33377000

999000

68617000

7027000

1300000 180000000 370000000 50000000 150000000 500000 250000 4000000 4000000 500000 15000000 5500000 15500000 5000000 60000000 5000000 33000000 29000000 87000000 123000000 500000 20000000 20000000 5000000 5000000

33377000

90413000

13921000

165000000 144500000 432500000

6250000

4300000

25000000

498000000 P2Y

9175000

35831808

7124739

2.11

4720000

200000000

0.001

35831808

17756000

12768000

-52000

1348000

122528000

311000

767000

62093000

-60419000

10451000

658000

41425000

36000

10134000

103518000

125000

1154000

96911000

3310000

103518000

40552000

57548000

829000

98929000

57590000

6200000

6492000

44856000

44898000

1366787

4661549

946403

150000

6200000

39363000

6492000

44856000

39363000

57548000

10134000

RGLS REGULUS THERAPEUTICS INC. false Smaller Reporting Company 2013 10-Q 2013-09-30 0001505512 --12-31 Q3

-0.45

<div> Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common equivalent shares):   <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"> <tr> <td width="58%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Three months ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Nine months ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Convertible preferred stock outstanding </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,699,999</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,699,999</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Common stock options </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,041,033</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,845,675</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,474,614</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,823,463</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Convertible note payable </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,400,848</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,041,033</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16,545,674</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,875,462</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16,523,462</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> </div>

<div> 5. Convertible Notes Payable 2012 Amendment of the 2010 GSK Note In July 2012, we amended and restated our 2010 GSK Note. In October 2012, in conjunction with our initial public offering, we issued the Post-IPO GSK Note in the principal amount of $5.4 million, which was equivalent to the original principal amount of $5.0 million plus accrued but unpaid interest of approximately $0.4 million. The amended and restated 2010 GSK Note was then simultaneously cancelled and our obligations thereunder terminated. The Post-IPO GSK Note has a maturity date of October 9, 2015. At GSK’s option, the Post-IPO GSK Note may be converted into shares of our common stock at any time prior to the maturity at a conversion price per share equal to the initial public offering price of $4.00, subject to complying with certain threshold ownership percentage limitations set forth in the Post-IPO GSK Note. At September 30, 2013, the fair value of the Post-IPO GSK Note is $13.9 million and is classified as “Convertible note payable, at fair value” on the condensed balance sheet. </div>

361000

<div> Revenue Recognition As of September 30, 2013, we have ongoing strategic alliance agreements and collaborations with GlaxoSmithKline plc (“GSK”), Sanofi, AstraZeneca AB (“AstraZeneca”) and Biogen Idec MA Inc. (“Biogen Idec”). Our revenues generally consist of upfront payments for licenses or options to obtain licenses in the future, research and development funding and milestone payments. We recognize revenues when all four of the following criteria are met: (1) persuasive evidence that an arrangement exists; (2) delivery of the products and/or services has occurred; (3) the selling price is fixed or determinable; and (4) collectability is reasonably assured. For these multiple element arrangements, deliverables under our agreements are accounted for as separate units of accounting provided that (i) a delivered item has value to the customer on a stand-alone basis; and (ii) if the agreement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item is considered probable and substantially in the control of the vendor. The allocation of consideration amongst the units of accounting under our strategic alliance agreements and collaborations are derived using a “best estimate of selling price” if vendor specific objective evidence and third-party evidence of fair value is not available. Milestones We recognize revenue from milestone payments when earned, provided that (i) the milestone event is substantive in that it can only be achieved based in whole or in part on either our performance or on the occurrence of a specific outcome resulting from our performance and its achievability was not reasonably assured at the inception of the agreement; (ii) we do not have ongoing performance obligations related to the achievement of the milestone; and (iii) it would result in the receipt of additional payments. A milestone payment is considered substantive if all of the following conditions are met: (i) the milestone payment is non-refundable; (ii) achievement of the milestone was not reasonably assured at the inception of the arrangement; (iii) substantive effort is involved to achieve the milestone; and (iv) the amount of the milestone payments appears reasonable in relation to the effort expended, the other milestones in the arrangement and the related risk associated with the achievement of the milestone. Any amounts received under the agreements in advance of performance, if deemed substantive, are recorded as deferred revenue and recognized as revenue as we complete our performance obligations.   Generally, the milestone events contained in our strategic alliance agreements and collaborations coincide with the progression of our product candidates from target selection, to clinical candidate selection, to clinical trial, to regulatory approval and then to commercialization. The process of successfully discovering a new development candidate, having it approved and ultimately sold for a profit is highly uncertain. As such, the milestone payments we may earn from our partners involve a significant degree of risk to achieve. Therefore, as a product candidate progresses through the stages of its life-cycle, the value of the product candidate generally increases. </div>

<div> 7. Strategic Alliances and Collaborations The following table summarizes the amounts included in our revenues which resulted from our strategic alliances and collaborations (in thousands):   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="71%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"> Three months ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000">Nine months ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2012</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2012</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Sanofi </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,422</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,500</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,828</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,530</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> GSK </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">144</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">186</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,634</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,809</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> AstraZeneca </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">465</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">94</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,394</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">94</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Biogen Idec </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">87</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">29</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">259</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">29</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,118</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,809</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14,115</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,462</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> </table>   Sanofi In July 2012, we amended and restated our collaboration and license agreement with Sanofi to expand the potential therapeutic applications of the microRNA alliance targets to be developed under such agreement. The modification made to the agreement was considered a material modification, which required the application of the new authoritative guidance adopted by us in January 2011 for multiple element arrangements. We determined that the elements within the strategic alliance agreement with Sanofi should be treated as a single unit of accounting because the delivered elements did not have stand-alone value to Sanofi. The following elements were delivered as part of the strategic alliance with Sanofi: (1) a license for up to four microRNA targets; and (2) a research license under our technology alliance. In June 2013, the original research term expired, upon which we and Sanofi entered into an option agreement pursuant to which we granted Sanofi an exclusive right to negotiate the co-development and commercialization of certain of our unencumbered microRNA programs and we were granted the exclusive right to negotiate with Sanofi for co-development and commercialization of certain miR-21 anti-miRs in oncology and Alport’s Syndrome. These options expire in December 2013, subject to a 30-day extension in certain circumstances. In July 2013, we received an upfront payment of $2.5 million, of which $1.25 million is creditable against future amounts payable by Sanofi to us under any future co-development and commercialization agreement we enter pursuant to the option agreement. The non-creditable portion of this payment, $1.25 million, will be recognized as revenue over the option period from the effective date of the option agreement in June 2013 until the expiration of the option period in December 2013. Revenue associated with the creditable portion of this option payment will be deferred until the option period expires, or is re-evaluated in connection with a creditable transaction. In addition, we agreed to continue specified research on the miR-21 programs during the option period. As a result of the expiration of the original research term and subsequent option agreement, we re-evaluated our estimated period of performance and are now amortizing the remaining deferred revenue of $10.1 million associated with the initial upfront payment of $25.0 million ratably from June 2013 until the expiration of the option period in December 2013. We have evaluated the remaining contingent event-based payments under our strategic alliance agreement with Sanofi and determined that the preclinical payments meet the definition of a substantive milestone because they are related to events: (i) that can be achieved based in whole or in part on our performance or on the occurrence of a specific outcome resulting from our performance, (ii) for which there was substantive uncertainty at the date the agreement was entered into that the event would be achieved, and (iii) that would result in additional payments being due to us. Accordingly, revenue for these achievements will be recognized in its entirety in the period when the milestone is achieved and collectability is reasonably assured. Other contingent event-based payments under the strategic alliance agreement for which payment is contingent upon the results of Sanofi’s performance will not be accounted for using the milestone method. Such payments will be recognized as revenue over the remaining estimated period of performance, if any, and when collectability is reasonably assured. As of the expiration of the research term in June 2013, Sanofi no longer has rights to select additional microRNA targets. As such, we can earn a preclinical milestone of $15.0 million upon the filing of an Investigational New Drug application (“IND”) for the selected microRNA target. We can also receive milestone payments of up to $33.0 million for clinical milestones and up to $165.0 million for regulatory and commercial milestones. In addition, we are entitled to receive royalties based on a percentage of net sales which will range from 8 to 12%, depending upon the volume of sales. GSK In April 2008, we entered into a strategic alliance with GSK to discover, develop and commercialize novel microRNA-targeted therapeutics to treat inflammatory diseases (the “immuno-inflammatory alliance”). In February 2010, we and GSK expanded the strategic alliance to include hepatitis C virus infection (“HCV”) to discover, develop and commercialize microRNA therapeutics targeting miR-122 for the treatment of HCV (the “HCV alliance”). In June 2012, we amended our product development and commercialization agreement with GSK to extend the target selection period for the fourth collaboration target under the agreement. The modification made to the agreement was considered a material modification, which required the application of the new authoritative guidance adopted by us in January 2011 for multiple element arrangements. We determined that the elements within the strategic alliance should be treated as a single unit of accounting because the delivered elements, the opt-in licenses for microRNA product candidates, did not have stand-alone value to GSK. As a result of the extension of the target selection period, we extended the amortization period for the remaining deferred revenue to approximately eight years, which represented our new estimated performance period under the amended agreement. As of September 30, 2013, deferred revenue associated with the product development and commercialization agreement was $3.7 million. In June 2013, the product development and commercialization agreement with GSK was amended to state that RG-101, and other formulations thereof, will be developed by us independently of our alliance with GSK for the treatment of chronic HCV infection. This amendment removed any further milestone or royalty obligations owed by GSK to us as it relates to RG-101. Concurrent with the amendment, we accelerated the remaining unamortized $1.1 million in deferred revenue associated with the upfront payment from the February 2010 amendment that expanded our agreement with GSK to include potential microRNA therapeutics for the treatment of HCV, which represents that our estimated performance period under the amended agreement is complete.   HCV Alliance Notwithstanding the foregoing, GSK has retained its interest in the miR-122 program in HCV, and miR-122 remains a collaboration target under the alliance. If the HCV program is successful, we could receive contractual milestone payments up to $144.5 million, including up to $5.5 million for preclinical milestones, up to $29.0 million for clinical milestones, up to $50.0 million for regulatory milestones and up to $60.0 million for commercialization milestones. In addition, we will receive tiered royalties which can increase up to the low end of the 10 to 20% range on sales from any product that GSK successfully commercializes under this alliance. We have evaluated the remaining contingent event-based payments under our strategic alliance agreement with GSK and determined that the preclinical and clinical payments meet the definition of a substantive milestone because they are related to events: (i) that can be achieved based in whole or in part on our performance or on the occurrence of a specific outcome resulting from our performance, (ii) for which there was substantive uncertainty at the date the agreement was entered into that the event would be achieved, and (iii) that would result in additional payments being due to us. Accordingly, revenue for these achievements will be recognized in its entirety in the period when the milestone is achieved and collectability is reasonably assured. Other contingent event-based payments under the strategic alliance agreement for which payment is contingent upon the results of GSK’s performance will not be accounted for using the milestone method. Such payments will be recognized as revenue over the remaining estimated period of performance, if any, and when collectability is reasonably assured. We can earn a preclinical milestone of $5.5 million upon the selection of a development candidate. We can also earn the following clinical milestones: $4.0 million for initiation of a Phase 1 clinical trial; $5.0 million for the initiation of a Phase 2 clinical trial; and $20.0 million if GSK chooses to opt-in to the program following the completion of a proof-of-concept trial. Immuno-Inflammatory Alliance The immuno-inflammatory alliance with GSK includes contractual milestones. If all the product candidates are successfully developed and commercialized through pre-agreed sales targets we could receive milestone payments up to $432.5 million, including up to $15.5 million for preclinical milestones, up to $87.0 million for clinical milestones, up to $150.0 million for regulatory milestones and up to $180.0 million for commercialization milestones. We are also entitled to receive tiered royalties as a percentage of annual sales which can increase up to the low end of the 10 to 20% range. We have evaluated the remaining contingent event-based payments under our strategic alliance agreement with GSK and determined that the preclinical and clinical payments meet the definition of a substantive milestone because they are related to events: (i) that can be achieved based in whole or in part on our performance or on the occurrence of a specific outcome resulting from our performance, (ii) for which there was substantive uncertainty at the date the agreement was entered into that the event would be achieved, and (iii) that would result in additional payments being due to us. Accordingly, revenue for these achievements will be recognized in its entirety in the period when the milestone is achieved and collectability is reasonably assured. Other contingent event-based payments under the strategic alliance agreement for which payment is contingent upon the results of GSK’s performance will not be accounted for using the milestone method. Such payments will be recognized as revenue over the remaining estimated period of performance, if any, and when collectability is reasonably assured. We can earn the following preclinical milestones: $0.5 million upon the selection of a fourth microRNA target and $5.0 million upon the selection of a development candidate for each of the selected three targets. We can also earn the following clinical milestones for each of the selected three targets: $4.0 million for the initiation of a Phase 1 clinical trial; $5.0 million for the initiation of a Phase 2 clinical trial; and $20.0 million if GSK chooses to opt-in to the program following the completion of a proof-of-concept trial. AstraZeneca In August 2012, we entered into a collaboration and license agreement with AstraZeneca. Under the terms of the agreement, we have agreed to collaborate with AstraZeneca to identify, research and develop compounds targeting three microRNA alliance targets primarily in the fields of cardiovascular diseases, metabolic diseases and oncology. Pursuant to the agreement, we granted AstraZeneca an exclusive, worldwide license to thereafter develop, manufacture and commercialize lead compounds designated by AstraZeneca in the course of the collaboration activities against the alliance targets for all human therapeutic uses. Under the terms of the agreement we are required to use commercially reasonable efforts to perform all research, development and manufacturing activities described in the research plan, at our cost, until the acceptance of an IND or the end of the research term, which extends until the fourth anniversary of the date of the agreement, and may be extended only by mutual written agreement of us and AstraZeneca. Following the earlier to occur of the acceptance of an IND in a major market or the end of the research term, AstraZeneca will assume all costs, responsibilities and obligations for further development, manufacture and commercialization of alliance product candidates. Under the terms of the agreement, we received an upfront payment of $3.0 million in October 2012. We determined the elements within the strategic alliance agreement should be treated as a single unit of accounting because the delivered element, the license, does not have stand-alone value. As a result, we are recognizing revenue related to the upfront payment on a straight-line basis over our estimated period of performance, which is four years based on the expected term of the research and development plan. If all three targets are successfully developed and commercialized through pre-agreed sales targets, we could receive milestone payments up to $498.0 million, including up to $5.0 million for preclinical milestones, up to $123.0 million for clinical milestones, and up to $370.0 million for commercialization milestones. In addition, we are entitled to receive royalties based on a percentage of net sales which will range from the mid-single digits to the low end of 10 to 20%, depending upon the product and the volume of sales, which royalties may be reduced in certain, limited circumstances. We have evaluated the contingent event-based payments under our strategic alliance agreement with AstraZeneca and determined that the preclinical payments meet the definition of substantive milestones because they are related to events: (i) that can be achieved based in whole or in part on our performance or on the occurrence of a specific outcome resulting from our performance, (ii) for which there was substantive uncertainty at the date the agreement was entered into that the event would be achieved, and (iii) that would result in additional payments being due to us. Accordingly, revenue for these achievements will be recognized in its entirety in the period when the milestone is achieved and collectability is reasonably assured. Other contingent event-based payments under the strategic alliance agreement for which payment is contingent upon the results of AstraZeneca’s performance will not be accounted for using the milestone method. Such payments will be recognized as revenue over the remaining estimated period of performance, if any, and when collectability is reasonably assured. Concurrently with the collaboration and license agreement, we entered into a Common Stock Purchase Agreement (“CSPA”) with AstraZeneca, pursuant to which we agreed to sell to AstraZeneca an aggregate of $25.0 million of our common stock in a private placement concurrently with our initial public offering, at a price per share equal to the initial public offering price. In October 2012, in accordance with the CSPA, we sold AstraZeneca 6,250,000 shares of our common stock at a price per share of $4.00. Further, the CSPA stipulated that AstraZeneca could not sell, transfer, make any short sale of, or grant any option for the sale of any common stock for a 365-day period following the effective date of our initial public offering. Accounting guidance for multiple element arrangements contains a presumption that separate contracts negotiated and/or entered into at or near the same time with the same entity were negotiated as a package and should be evaluated as a single agreement. We valued the discount applied to the shares of common stock due to the one-year restriction. Based upon restricted stock studies of similar duration and a Black-Scholes valuation to measure the lack of marketability discount, $4.3 million was attributed to the collaboration and license agreement. We continue to recognize the $4.3 million into revenue ratably over the estimated period of performance of the collaboration. Biogen Idec In August 2012, we entered into a collaboration and license agreement with Biogen Idec pursuant to which we and Biogen Idec have agreed to collaborate on microRNA biomarkers for multiple sclerosis (“MS”). Under the terms of the agreement, we granted Biogen Idec an exclusive, royalty free, worldwide license to our interest in the collaboration intellectual property for the purpose of commercializing non-microRNA products for the treatment, diagnosis and prevention of MS and non-MS diseases and disorders. We also granted Biogen Idec an exclusive, royalty-free, worldwide license, with the right to sublicense, to our interest in the collaboration intellectual property (and a non-exclusive license to our background intellectual property) for the purpose of commercializing products for the diagnosis of MS. We also granted Biogen Idec a right of first negotiation on certain commercial transactions relating to microRNA products which utilize intellectual property developed during the collaboration. Pursuant to the terms of the agreement, in August 2012 we received an upfront payment of $0.8 million. We are also eligible to receive research milestone payments up to an aggregate of $1.3 million. We considered the elements within the collaboration and license agreement as a single unit of accounting because the delivered element, the license, does not have stand-alone value. As a result, we are recognizing revenue relating to the upfront payment of $0.8 million on a straight-line basis over our estimated period of performance, which is approximately two years based on the expected term of the research and development plan. In June 2013, we amended the collaboration and license agreement with Biogen Idec to provide for revised terms with respect to phase 1 of the research plan under the Biogen Idec agreement and revised payment provisions relating to the phase 1 milestones. The Biogen Idec amendment does not modify the maximum dollar amount we were originally eligible to receive in connection with phase 1 milestones under the Biogen Idec agreement, or our estimated period of performance. We have evaluated the contingent event-based payments under our collaboration and license agreement with Biogen Idec and determined that the research payments meet the definition of substantive milestones because they are related to events: (i) that can be achieved based in whole or in part on our performance or on the occurrence of a specific outcome resulting from our performance, (ii) for which there was substantive uncertainty at the date the agreement was entered into that the event would be achieved, and (iii) that would result in additional payments being due to us. Accordingly, revenue for these achievements will be recognized in its entirety in the period when the milestone is achieved and collectability is reasonably assured. We can earn the following research milestones: $0.25 million for identification of a microRNA biomarker; $0.5 million for validation of the microRNA biomarker in a second independent sample set; and $0.5 million upon the refinement of the microRNA biomarker signature from a longitudinal study of patient samples on MS therapy. Concurrently with the collaboration and license agreement, we entered into a note purchase agreement with Biogen Idec, pursuant to which we issued Biogen Idec a convertible promissory note in the principal amount of $5.0 million. The $5.0 million note plus accrued interest converted into 1,256,232 shares of our common stock upon the closing of our initial public offering in October 2012 at a conversion price of $4.00 per share. </div>

-0.45

37367368000

<div> The following table summarizes our stock option activity under all stock option plans for the nine months ended September 30, 2013 (in thousands):   <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="79%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Number of options</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted average exercise price</td> <td valign="bottom"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Options outstanding at December 31, 2012 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,720</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.11</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">361</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7.91</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(720</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.80</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Canceled/forfeited/expired </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(201</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.44</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Options outstanding at September 30, 2013 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,160</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.78</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> </div>

<div> The following table presents our fair value hierarchy for assets and liabilities measured at fair value on a recurring basis at September 30, 2013 and December 31, 2012 (in thousands):   <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"> <tr> <td width="67%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center">Fair value as of September 30, 2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Level 1</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Level 2</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Level 3</td> <td valign="bottom"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Assets: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Cash equivalents </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">33,377</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">33,377</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Corporate debt securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">68,617</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">68,617</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Commercial paper </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">999</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">999</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Certificates of deposit </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,770</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,770</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Debt securities of U.S. government-sponsored agencies </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,027</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,027</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">123,790</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">33,377</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">90,413</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Liabilities: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Convertible notes payable </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,921</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,921</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td height="16"></td> <td height="16" colspan="16"></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center">Fair value as of December 31, 2012</td> <td valign="bottom"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Level 1</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Level 2</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Level 3</td> <td valign="bottom"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Assets: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Cash equivalents </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">39,363</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">39,363</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Corporate debt securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">44,856</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">44,856</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Commercial paper </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,492</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,492</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Certificates of deposit </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,200</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,200</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">96,911</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">39,363</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">57,548</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Liabilities: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Convertible notes payable </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,134</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,134</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> </div>

7.91

<div> Changes in the estimated fair value of convertible notes payable from December 31, 2012 through September 30, 2013 are as follows (in thousands):   <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"> <tr> <td width="73%"></td> <td valign="bottom" width="21%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"> Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Balance at December 31, 2012 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,134</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Change in estimated fair value of convertible notes payable </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,787</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Balance at September 30, 2013 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,921</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Deferred Revenue Amounts received prior to satisfying the above revenue recognition criteria are recorded as deferred revenue in the accompanying condensed balance sheets. Amounts not expected to be recognized within the next 12 months are classified as non-current deferred revenue. </div>

<div> 4. Fair Value Measurements We have certain financial assets and liabilities recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements. Applicable accounting guidance defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants as of the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact. The guidance provides an established hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs that reflect our assumptions about the factors that market participants would use in valuing the asset or liability. The guidance prioritizes the inputs used in measuring the fair value into the following hierarchy:   <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">Level 1 includes financial instruments for which quoted market prices for identical instruments are available in active markets.</td> </tr> </table>   <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">Level 2 includes financial instruments for which there are inputs other than quoted prices included within Level 1 that are observable for the instrument such as quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets with insufficient volume or infrequent transactions (less active markets) or model-driven valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.</td> </tr> </table>   <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">Level 3 includes financial instruments for which fair value is derived from valuation techniques in which one or more significant inputs are unobservable, including management’s own assumptions.</td> </tr> </table> The following table presents our fair value hierarchy for assets and liabilities measured at fair value on a recurring basis at September 30, 2013 and December 31, 2012 (in thousands):   <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"> <tr> <td width="67%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center">Fair value as of September 30, 2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Level 1</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Level 2</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Level 3</td> <td valign="bottom"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Assets: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Cash equivalents </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">33,377</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">33,377</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Corporate debt securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">68,617</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">68,617</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Commercial paper </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">999</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">999</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Certificates of deposit </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,770</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,770</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Debt securities of U.S. government-sponsored agencies </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,027</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,027</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">123,790</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">33,377</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">90,413</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Liabilities: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Convertible notes payable </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,921</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,921</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr> <td height="16"></td> <td height="16" colspan="16"></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center">Fair value as of December 31, 2012</td> <td valign="bottom"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Level 1</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Level 2</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Level 3</td> <td valign="bottom"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Assets: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Cash equivalents </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">39,363</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">39,363</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Corporate debt securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">44,856</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">44,856</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Commercial paper </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,492</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,492</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Certificates of deposit </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,200</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,200</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">96,911</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">39,363</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">57,548</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Liabilities: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Convertible notes payable </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,134</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,134</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table>   Changes in the estimated fair value of convertible notes payable from December 31, 2012 through September 30, 2013 are as follows (in thousands):   <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"> <tr> <td width="73%"></td> <td valign="bottom" width="21%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"> Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Balance at December 31, 2012 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,134</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Change in estimated fair value of convertible notes payable </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,787</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Balance at September 30, 2013 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,921</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> We obtain pricing information from quoted market prices or quotes from brokers/dealers. We generally determine the fair value of our investment securities using standard observable inputs, including reported trades, broker/dealer quotes, bids and/or offers. In July 2012, we amended and restated the 2010 GSK Note, which resulted in a debt extinguishment for accounting purposes. Concurrently with the debt extinguishment, we elected the fair value option for the 2010 GSK Note. The amended and restated 2010 GSK Note provided for a rollover of the 2010 GSK Note into a new promissory note effective as of the closing date of a qualifying initial public offering (“Post-IPO GSK Note”). We used a third party valuation firm to value the Post-IPO GSK Note at September 30, 2013 and recorded a gain from the change in valuation of the Post-IPO GSK Note of $0.7 million for the three months ended September 30, 2013 and a loss of $3.8 million for the nine months ended September 30, 2013 on the condensed statements of operations and comprehensive loss for the respective periods. The gain from the change in valuation of the Post-IPO GSK Note for the three months ended September 30, 2013 was principally driven by a reduction in our stock price to $9.43 as of September 30, 2013, compared to $9.81 as of June 30, 2013. The third-party valuation firm used an income approach in the form of a convertible bond valuation model to value the Post-IPO GSK Note. The convertible bond model considered the debt and option characteristics of the Post-IPO GSK Note. The key inputs to the model as of September 30, 2013 were stock price, volatility (65%), risk-free rate (0.32%), and credit spread (8.5%). The volatility inputs were based on historical and implied volatility of peer companies. Peer companies were materially consistent with those used previously in our 409A analyses and in previous valuations of this instrument. The risk-free rate inputs were based on the yield of U.S. Treasury Strips as of each date. The credit spread inputs were based on a creditworthiness analysis of the Company and market rates for comparable straight debt instruments. </div>

<div> 6. Stockholders’ Equity Shares Reserved for Future Issuance The following shares of common stock are reserved for future issuance at September 30, 2013:   <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="72%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">September 30, 2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2012</td> <td valign="bottom"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Common stock options outstanding </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,160,215</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,661,549</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Common stock options available for future grant </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,161,410</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">946,403</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Employee Stock Purchase Plan </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">460,283</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">150,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Convertible note payable </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,400,848</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,366,787</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Total common shares reserved for future issuance </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,182,756</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,124,739</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> The following table summarizes our stock option activity under all stock option plans for the nine months ended September 30, 2013 (in thousands):   <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="79%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Number of options</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted average exercise price</td> <td valign="bottom"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Options outstanding at December 31, 2012 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,720</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.11</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">361</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7.91</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(720</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.80</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Canceled/forfeited/expired </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(201</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.44</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Options outstanding at September 30, 2013 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,160</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.78</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> Stock-Based Compensation The following table summarizes the weighted average assumptions we used in our Black-Scholes calculations:   <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"> <tr> <td width="69%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Three months ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Nine months ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Employee Stock Options: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Risk-free interest rate </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.7</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">*</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.4</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.1</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Expected dividend yield </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.0</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">*</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.0</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.0</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Expected volatility </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">72.7</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">*</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">67.8</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">71.0</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Expected term (years) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">*</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.1</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table>   <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td valign="top" width="2%" align="left">*</td> <td valign="top" align="left">No stock options were granted during the three months ended September 30, 2012.</td> </tr> </table> The following table summarizes the allocation of our stock compensation expense (in thousands):   <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"> <tr> <td width="75%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Three months ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Nine months ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Research and development </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">594</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">278</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,664</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">461</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> General and administrative </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">384</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">136</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">860</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">271</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">978</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">414</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,524</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">732</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> </div>

0.65

0.085

<div> The following tables summarize our short-term investments (dollars in thousands):   <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr> <td width="71%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="2" colspan="2" align="center">Maturity (in years)</td> <td valign="bottom" rowspan="2"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="2" colspan="2" align="center">Amortized cost</td> <td valign="bottom" rowspan="2"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Unrealized</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="2" colspan="2" align="center">Estimated fair value</td> <td valign="bottom" rowspan="2"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gains</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Losses</td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> As of September 30, 2013 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Corporate debt securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2 or less</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">68,649</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">18</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(50</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">68,617</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Commercial paper </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1 or less</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">999</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">999</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Certificates of deposit </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2 or less</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,770</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,770</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Debt securities of U.S. government-sponsored agencies </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1 or less</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,025</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,027</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">90,443</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">20</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(50</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">90,413</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr> <td width="71%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="2" colspan="2" align="center">Maturity (in years)</td> <td valign="bottom" rowspan="2"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="2" colspan="2" align="center">Amortized cost</td> <td valign="bottom" rowspan="2"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Unrealized</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="2" colspan="2" align="center">Estimated fair value</td> <td valign="bottom" rowspan="2"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gains</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Losses</td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> As of December 31, 2012 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Corporate debt securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2 or less</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">44,898</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(49</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">44,856</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Commercial paper </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2 or less</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,492</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,492</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Certificates of deposit </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1 or less</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,200</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,200</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">57,590</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(49</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">57,548</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

0.0032

<div> Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management’s opinion, the accompanying financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results for the interim periods presented. Interim financial results are not necessarily indicative of results anticipated for the full year. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and footnotes included in the Annual Report on Form 10-K for the year ended December 31, 2012 for Regulus Therapeutics Inc. (“we,” “us,” “our,” or the “Company”), from which the balance sheet information herein for the year ended December 31, 2012 was derived. On September 7, 2012, our board of directors approved a one-for-two reverse stock split of our common stock. The accompanying condensed financial statements and notes to the condensed financial statements give retroactive effect to the reverse split for all periods presented. No further splits (or reverse splits) of our common stock have been contemplated as of September 30, 2013. In October 2012, we completed an initial public offering and concurrent private placement of 18,980,982 shares of common stock at an offering price of $4.00 per share. In addition, principal and interest of $10.8 million from convertible notes outstanding were automatically converted upon the closing of the initial public offering into an aggregate of 2,703,269 shares of our common stock. We raised a total of $70.0 million in net proceeds from our initial public offering and concurrent private placement, after deducting underwriter discounts, commissions and other offering expenses. In July 2013, we completed a public offering of 5,175,000 shares of common stock at an offering price of $9.50 per share. The shares were registered pursuant to a registration statement on Form S-1. We raised a total of $45.8 million in net proceeds, after deducting underwriting discounts, commissions and other offering expenses. </div>

-19016000

1256232

<div> 2. Net Loss Per Share Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted average number of common stock equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of convertible preferred stock, options outstanding under our stock option plan and convertible notes payable. Applicable accounting guidance provides that a contract that is reported as an asset or liability for accounting purposes may require an adjustment to the numerator of the diluted earnings per share calculation for any changes in income or loss that would result if the contract had been reported as an equity instrument for accounting purposes during the period. Securities are assumed to be converted at the beginning of the period, and the resulting common shares are included in the denominator of the diluted earnings per share calculation for the entire period presented. Adding back the gain from the change in valuation of the convertible note payable for the three months ended September 30, 2013 to the numerator and adding the number of shares to be issued upon conversion of the convertible note payable into the denominator of the diluted earnings per share calculation resulted in an increase to the loss per share for the period. The convertible note payable was anti-dilutive for the nine months ended September 30, 2013. The following table summarizes the adjustment to net loss for the diluted net loss per share calculation for the three months ended September 30, 2013 (in thousands):   <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"> <tr> <td width="88%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Net loss </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2,164</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Less: gain from change in valuation of note payable </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">671</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Net loss used to compute diluted net loss per share </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2,835</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common equivalent shares):   <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"> <tr> <td width="58%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Three months ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Nine months ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2012</td> <td valign="bottom"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Convertible preferred stock outstanding </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,699,999</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,699,999</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Common stock options </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,041,033</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,845,675</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,474,614</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,823,463</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Convertible note payable </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,400,848</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,041,033</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16,545,674</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,875,462</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16,523,462</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> In October 2012, all convertible preferred stock converted into common stock in conjunction with our initial public offering. As of September 30, 2013 we had a convertible note payable outstanding with a principal balance of $5.4 million that was convertible into common shares at $4.00 per share, at the option of the note holder. </div>

720000

<div> 8. Related Party Transactions We have entered into several agreements with related parties in the ordinary course of business to license intellectual property and to procure administrative and research and development support services. These agreements include a Services Agreement with our founding companies Isis Pharmaceuticals, Inc. (“Isis”) and Alnylam Pharmaceuticals, Inc. (“Alnylam”). Total costs incurred from services provided from Alnylam under the Services Agreement were $0.1 million and $0.5 million for the three and nine months ended September 30, 2013, respectively. Activities under the Services Agreement for the nine months ended September 30, 2012 were immaterial. In August, 2013, we entered into an amendment to the Amended and Restated License and Collaboration Agreement with Isis and Alnylam dated January 1, 2009, as amended in June 2010 and October 2011 (as amended, the “Amendment”). Under the terms of the Amendment, the parties agreed to our use of certain Alnylam-controlled intellectual property concerning the use and manufacture of GalNAc conjugates (“GalNAc Process Technology”) on a non-exclusive basis. We will generally not be permitted to sublicense or otherwise transfer the GalNAc Process Technology and other Alnylam licensed intellectual property rights relating to GalNAc conjugate technology without the prior written consent of Alnylam, subject to certain limited exceptions for sublicenses to third party collaboration partners. There were no financial terms related to this Amendment. </div>

3.44

3875462

<div> The following table summarizes the allocation of our stock compensation expense (in thousands):   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="75%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"> Three months ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"> Nine months ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2012</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2012</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Research and development </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">594</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">278</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,664</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">461</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> General and administrative </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">384</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">136</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">860</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">271</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">978</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">414</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,524</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">732</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> </table> </div>

<div> Use of Estimates Our financial statements are prepared in accordance with GAAP. The preparation of our financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions. </div>

<div> 1. Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management’s opinion, the accompanying financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results for the interim periods presented. Interim financial results are not necessarily indicative of results anticipated for the full year. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and footnotes included in the Annual Report on Form 10-K for the year ended December 31, 2012 for Regulus Therapeutics Inc. (“we,” “us,” “our,” or the “Company”), from which the balance sheet information herein for the year ended December 31, 2012 was derived. On September 7, 2012, our board of directors approved a one-for-two reverse stock split of our common stock. The accompanying condensed financial statements and notes to the condensed financial statements give retroactive effect to the reverse split for all periods presented. No further splits (or reverse splits) of our common stock have been contemplated as of September 30, 2013. In October 2012, we completed an initial public offering and concurrent private placement of 18,980,982 shares of common stock at an offering price of $4.00 per share. In addition, principal and interest of $10.8 million from convertible notes outstanding were automatically converted upon the closing of the initial public offering into an aggregate of 2,703,269 shares of our common stock. We raised a total of $70.0 million in net proceeds from our initial public offering and concurrent private placement, after deducting underwriter discounts, commissions and other offering expenses. In July 2013, we completed a public offering of 5,175,000 shares of common stock at an offering price of $9.50 per share. The shares were registered pursuant to a registration statement on Form S-1. We raised a total of $45.8 million in net proceeds, after deducting underwriting discounts, commissions and other offering expenses. Use of Estimates Our financial statements are prepared in accordance with GAAP. The preparation of our financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions. Revenue Recognition As of September 30, 2013, we have ongoing strategic alliance agreements and collaborations with GlaxoSmithKline plc (“GSK”), Sanofi, AstraZeneca AB (“AstraZeneca”) and Biogen Idec MA Inc. (“Biogen Idec”). Our revenues generally consist of upfront payments for licenses or options to obtain licenses in the future, research and development funding and milestone payments. We recognize revenues when all four of the following criteria are met: (1) persuasive evidence that an arrangement exists; (2) delivery of the products and/or services has occurred; (3) the selling price is fixed or determinable; and (4) collectability is reasonably assured. For these multiple element arrangements, deliverables under our agreements are accounted for as separate units of accounting provided that (i) a delivered item has value to the customer on a stand-alone basis; and (ii) if the agreement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item is considered probable and substantially in the control of the vendor. The allocation of consideration amongst the units of accounting under our strategic alliance agreements and collaborations are derived using a “best estimate of selling price” if vendor specific objective evidence and third-party evidence of fair value is not available. Milestones We recognize revenue from milestone payments when earned, provided that (i) the milestone event is substantive in that it can only be achieved based in whole or in part on either our performance or on the occurrence of a specific outcome resulting from our performance and its achievability was not reasonably assured at the inception of the agreement; (ii) we do not have ongoing performance obligations related to the achievement of the milestone; and (iii) it would result in the receipt of additional payments. A milestone payment is considered substantive if all of the following conditions are met: (i) the milestone payment is non-refundable; (ii) achievement of the milestone was not reasonably assured at the inception of the arrangement; (iii) substantive effort is involved to achieve the milestone; and (iv) the amount of the milestone payments appears reasonable in relation to the effort expended, the other milestones in the arrangement and the related risk associated with the achievement of the milestone. Any amounts received under the agreements in advance of performance, if deemed substantive, are recorded as deferred revenue and recognized as revenue as we complete our performance obligations.   Generally, the milestone events contained in our strategic alliance agreements and collaborations coincide with the progression of our product candidates from target selection, to clinical candidate selection, to clinical trial, to regulatory approval and then to commercialization. The process of successfully discovering a new development candidate, having it approved and ultimately sold for a profit is highly uncertain. As such, the milestone payments we may earn from our partners involve a significant degree of risk to achieve. Therefore, as a product candidate progresses through the stages of its life-cycle, the value of the product candidate generally increases. Deferred Revenue Amounts received prior to satisfying the above revenue recognition criteria are recorded as deferred revenue in the accompanying condensed balance sheets. Amounts not expected to be recognized within the next 12 months are classified as non-current deferred revenue. Stock-Based Compensation We account for stock-based compensation expense related to stock options granted to employees and members of our board of directors by estimating the fair value of each stock option on the date of grant using the Black-Scholes model. We recognize stock-based compensation expense using the accelerated multiple-option approach. Under the accelerated multiple-option approach (also known as the graded-vesting method), we recognize compensation expense over the requisite service period for each separately vesting tranche of the award as though the award was in substance multiple awards, resulting in accelerated expense recognition over the vesting period. We account for stock options granted to non-employees other than members of our board of directors, which primarily consist of members of our scientific advisory board, using the fair value approach. Stock options granted to non-employees are subject to periodic revaluation over their vesting terms. Fair Value Option Applicable accounting guidance permits entities to choose, at specified election dates, to measure specified items at fair value if the decision about the election is: 1) applied instrument by instrument, 2) irrevocable, and 3) applied to an entire instrument. In July 2012, we amended and restated our $5.0 million convertible promissory note originally issued in February 2010 to GSK (“2010 GSK Note”), which was accounted for as a debt extinguishment of the original note. We elected to measure the 2010 GSK Note under the fair value option. Upon initial measurement, the difference between the carrying value of the original note and the fair value of the 2010 GSK Note was recorded as a loss on extinguishment of debt to non-operating earnings. Thereafter, any change to the fair value of the 2010 GSK Note is recorded as a gain (loss) from valuation of convertible note payable to non-operating earnings. Recent Accounting Pronouncements In February 2013, the FASB issued Accounting Standards Update No. 2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income (“ASU 2013-02”). This update will require companies to present information about amounts reclassified out of accumulated other comprehensive income and their corresponding effect on net income in one place and reference the amounts to the related footnote disclosures. Current accounting standards present this information in different places throughout the financial statements. ASU 2013-02 was effective for us for the nine months ended September 30, 2013. The adoption of ASU 2013-02 had no impact on our financial condition, results of operations, or cash flows. In July 2013, the FASB issued Accounting Standards Update No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (“ASU 2013-11”). This update provides explicit guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. This guidance is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013, with an option for early adoption. We intend to adopt this guidance in 2014, and do not believe the adoption of this standard will have a material impact on our financial condition, results of operations or related financial statement disclosures. </div>

<div> Stock-Based Compensation The following table summarizes the weighted average assumptions we used in our Black-Scholes calculations:   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="69%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"> Three months ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"> Nine months ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2013</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2012</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2013</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2012</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Employee Stock Options: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Risk-free interest rate </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.7</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">*</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.4</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.1</td> <td nowrap="nowrap" valign="bottom">% </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Expected dividend yield </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.0</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">*</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.0</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.0</td> <td nowrap="nowrap" valign="bottom">% </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Expected volatility </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">72.7</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">*</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">67.8</td> <td nowrap="nowrap" valign="bottom">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">71.0</td> <td nowrap="nowrap" valign="bottom">% </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Expected term (years) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.1</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">*</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.1</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.1</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> </table>   <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="2%" valign="top" align="left">*</td> <td align="left" valign="top">No stock options were granted during the three months ended September 30, 2012.</td> </tr> </table> </div>

<div> 3. Investments We invest our excess cash in commercial paper and debt instruments of financial institutions, corporations, U.S. government-sponsored agencies, and the U.S. Treasury. For investments in debt securities with unrealized losses, we do not intend to sell these investments, nor is it more than likely that we will be required to do so, prior to the recovery of their amortized cost basis, which may be their maturity. As of September 30, 2013, our short-term investments had a weighted average maturity of less than two years. The following tables summarize our short-term investments (dollars in thousands):   <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr> <td width="71%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="2" colspan="2" align="center">Maturity (in years)</td> <td valign="bottom" rowspan="2"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="2" colspan="2" align="center">Amortized cost</td> <td valign="bottom" rowspan="2"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Unrealized</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="2" colspan="2" align="center">Estimated fair value</td> <td valign="bottom" rowspan="2"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gains</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Losses</td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> As of September 30, 2013 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Corporate debt securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2 or less</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">68,649</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">18</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(50</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">68,617</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Commercial paper </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1 or less</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">999</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">999</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Certificates of deposit </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2 or less</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,770</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,770</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Debt securities of U.S. government-sponsored agencies </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1 or less</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,025</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,027</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">90,443</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">20</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(50</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">90,413</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr> <td width="71%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="2" colspan="2" align="center">Maturity (in years)</td> <td valign="bottom" rowspan="2"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="2" colspan="2" align="center">Amortized cost</td> <td valign="bottom" rowspan="2"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Unrealized</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="2" colspan="2" align="center">Estimated fair value</td> <td valign="bottom" rowspan="2"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gains</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Losses</td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> As of December 31, 2012 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Corporate debt securities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2 or less</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">44,898</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(49</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">44,856</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Commercial paper </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2 or less</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,492</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,492</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Certificates of deposit </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1 or less</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,200</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,200</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">57,590</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(49</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">57,548</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

0.80

<div> 9. Subsequent Events In October 2013, we received a payment of $0.1 million from Biogen Idec for work performed pursuant to the terms of our collaboration and license agreement based on our research to discover microRNAs as biomarkers for MS. </div>

37367368000

201000

<div> Recent Accounting Pronouncements In February 2013, the FASB issued Accounting Standards Update No. 2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income (“ASU 2013-02”). This update will require companies to present information about amounts reclassified out of accumulated other comprehensive income and their corresponding effect on net income in one place and reference the amounts to the related footnote disclosures. Current accounting standards present this information in different places throughout the financial statements. ASU 2013-02 was effective for us for the nine months ended September 30, 2013. The adoption of ASU 2013-02 had no impact on our financial condition, results of operations, or cash flows. In July 2013, the FASB issued Accounting Standards Update No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (“ASU 2013-11”). This update provides explicit guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. This guidance is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013, with an option for early adoption. We intend to adopt this guidance in 2014, and do not believe the adoption of this standard will have a material impact on our financial condition, results of operations or related financial statement disclosures. </div>

<div> Stock-Based Compensation We account for stock-based compensation expense related to stock options granted to employees and members of our board of directors by estimating the fair value of each stock option on the date of grant using the Black-Scholes model. We recognize stock-based compensation expense using the accelerated multiple-option approach. Under the accelerated multiple-option approach (also known as the graded-vesting method), we recognize compensation expense over the requisite service period for each separately vesting tranche of the award as though the award was in substance multiple awards, resulting in accelerated expense recognition over the vesting period. We account for stock options granted to non-employees other than members of our board of directors, which primarily consist of members of our scientific advisory board, using the fair value approach. Stock options granted to non-employees are subject to periodic revaluation over their vesting terms. </div>

<div> Fair Value Option Applicable accounting guidance permits entities to choose, at specified election dates, to measure specified items at fair value if the decision about the election is: 1) applied instrument by instrument, 2) irrevocable, and 3) applied to an entire instrument. In July 2012, we amended and restated our $5.0 million convertible promissory note originally issued in February 2010 to GSK (“2010 GSK Note”), which was accounted for as a debt extinguishment of the original note. We elected to measure the 2010 GSK Note under the fair value option. Upon initial measurement, the difference between the carrying value of the original note and the fair value of the 2010 GSK Note was recorded as a loss on extinguishment of debt to non-operating earnings. Thereafter, any change to the fair value of the 2010 GSK Note is recorded as a gain (loss) from valuation of convertible note payable to non-operating earnings. </div>

608000

-3787000

8000

1000

-16741000

50390000

-16745000

57000

20000

14115000

512000

84000

-16733000

6000

-13140000

46000

95000

207000

-16741000

-1018000

68000

-120000

5545000

46478000

2524000

-7062000

50000

27255000

5000000

-4000

-11615000

851000

25000

829000

46562000

996000

2524000

-34524000

21710000

16520000

<div> The following table summarizes the adjustment to net loss for the diluted net loss per share calculation for the three months ended September 30, 2013 (in thousands):   <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"> <tr> <td width="88%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Net loss </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2,164</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <td valign="top"> Less: gain from change in valuation of note payable </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">671</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"> <td valign="top"> Net loss used to compute diluted net loss per share </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2,835</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> <div> The following shares of common stock are reserved for future issuance at September 30, 2013:   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="72%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"> September 30, 2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">December 31, 2012</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Common stock options outstanding </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,160,215</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,661,549</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Common stock options available for future grant </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,161,410</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">946,403</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Employee Stock Purchase Plan </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">460,283</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">150,000</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Convertible note payable </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,400,848</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,366,787</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Total common shares reserved for future issuance </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,182,756</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,124,739</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> <div> The following table summarizes the amounts included in our revenues which resulted from our strategic alliances and collaborations (in thousands):   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="71%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"> Three months ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000">Nine months ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2012</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2012</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Sanofi </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,422</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,500</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,828</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,530</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> GSK </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">144</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">186</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,634</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,809</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> AstraZeneca </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">465</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">94</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,394</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">94</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Biogen Idec </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">87</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">29</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">259</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">29</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,118</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,809</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14,115</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,462</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> </table> </div>

14115000

2 or less 1 or less

18000

50000

2 or less

2000

1 or less 0.08 0.10 0.10 0.10 0.12 0.20 0.20 0.20

500000

860000

1664000

14115000

10828000

1634000

1394000

259000

1400848

2474614

0.014

0.678

P6Y1M6D

0.000

3787000

1100000

P8Y

4.00

3000000

3 P1Y P365D August 2012

800000

August 2012

-41.03

256682000

-9572000

16523462

256682000

724000

-331000

44000

207000

-10532000

9287000

-10560000

-1738000

32000

1307000

9462000

-56000

326000

-10488000

-8271000

185000

3000000

74000

-10532000

-311000

55000

302000

2998000

3469000

732000

10000

8251000

17733000

-28000

-527000

73000

294000

148000

102000

5000000

741000

732000

14354000

14735000

24550000

9462000

271000

461000

9462000

7530000

1809000

94000

29000

2823463

13699999

0.011

0.710

P6Y1M6D

0.000

2703269

18980982

4.00

70000000

2013-12 P30D

5400000

2015-10-09

400000

P4Y

5175000

9.50

45800000

25000000

1250000

2500000

100000

7000

49000

1 or less 2 or less

7000

49000

2 or less

-15.98

355735000

16545674

355735000

-331000

10000

-5691000

-1738000

2809000

-5675000

-3532000

20000

-5685000

1093000

6341000

-6000

110000

414000

5248000

2809000

136000

278000

2809000

2500000

186000

94000

29000

2845675

13699999

-0.05

-0.07

41555660000

3041033

40154812000

671000

37000

-2169000

-2835000

6118000

-2127000

-2905000

72000

-2164000

1917000

9023000

-5000

7000

978000

7106000

6118000

100000

384000

594000

6118000

5422000

144000

465000

87000

3041033

0.017

0.727

P6Y1M6D

0.000

0001505512 us-gaap:EmployeeStockOptionMember 2013-07-01 2013-09-30 0001505512 us-gaap:EmployeeStockOptionMember 2013-07-01 2013-09-30 0001505512 rgls:BiogenIdecMemberrgls:ReferralAndStrategicAllianceAgreementMember 2013-07-01 2013-09-30 0001505512 rgls:AstraZenecaMemberrgls:ReferralAndStrategicAllianceAgreementMember 2013-07-01 2013-09-30 0001505512 rgls:GskMemberrgls:ReferralAndStrategicAllianceAgreementMember 2013-07-01 2013-09-30 0001505512 rgls:SanofiAventisMemberrgls:ReferralAndStrategicAllianceAgreementMember 2013-07-01 2013-09-30 0001505512 rgls:ReferralAndStrategicAllianceAgreementMember 2013-07-01 2013-09-30 0001505512 us-gaap:ResearchAndDevelopmentExpenseMember 2013-07-01 2013-09-30 0001505512 us-gaap:GeneralAndAdministrativeExpenseMember 2013-07-01 2013-09-30 0001505512 rgls:AlnylamMember 2013-07-01 2013-09-30 0001505512 rgls:ReferralAndStrategicAllianceAgreementMember 2013-07-01 2013-09-30 0001505512 2013-07-01 2013-09-30 0001505512 us-gaap:ConvertiblePreferredStockMember 2012-07-01 2012-09-30 0001505512 us-gaap:EmployeeStockOptionMember 2012-07-01 2012-09-30 0001505512 rgls:BiogenIdecMemberrgls:ReferralAndStrategicAllianceAgreementMember 2012-07-01 2012-09-30 0001505512 rgls:AstraZenecaMemberrgls:ReferralAndStrategicAllianceAgreementMember 2012-07-01 2012-09-30 0001505512 rgls:GskMemberrgls:ReferralAndStrategicAllianceAgreementMember 2012-07-01 2012-09-30 0001505512 rgls:SanofiAventisMemberrgls:ReferralAndStrategicAllianceAgreementMember 2012-07-01 2012-09-30 0001505512 rgls:ReferralAndStrategicAllianceAgreementMember 2012-07-01 2012-09-30 0001505512 us-gaap:ResearchAndDevelopmentExpenseMember 2012-07-01 2012-09-30 0001505512 us-gaap:GeneralAndAdministrativeExpenseMember 2012-07-01 2012-09-30 0001505512 rgls:ReferralAndStrategicAllianceAgreementMember 2012-07-01 2012-09-30 0001505512 2012-07-01 2012-09-30 0001505512 us-gaap:CorporateDebtSecuritiesMember 2012-01-01 2012-12-31 0001505512 us-gaap:CommercialPaperMember 2012-01-01 2012-12-31 0001505512 us-gaap:CertificatesOfDepositMember 2012-01-01 2012-12-31 0001505512 2012-01-01 2012-12-31 0001505512 rgls:BiogenIdecMemberus-gaap:SubsequentEventMember 2013-10-01 2013-10-31 0001505512 rgls:SanofiAventisMemberrgls:DevelopmentCommercializationAndLicenseAgreementMember 2013-07-01 2013-07-31 0001505512 rgls:SanofiAventisMemberrgls:ResearchAndDevelopmentMember 2013-07-01 2013-07-31 0001505512 2013-07-01 2013-07-31 0001505512 rgls:AstraZenecaMember 2012-10-01 2012-10-31 0001505512 rgls:OctoberTwoThousandAndTwelveMember 2012-10-01 2012-10-31 0001505512 rgls:GskMemberus-gaap:ConvertibleDebtMemberrgls:OctoberTwoThousandAndTwelveMember 2012-10-01 2012-10-31 0001505512 rgls:SanofiAventisMember 2013-06-01 2013-06-30 0001505512 us-gaap:IPOMember 2012-10-01 2012-10-30 0001505512 rgls:ConvertibleNotesMember 2012-10-01 2012-10-30 0001505512 us-gaap:EmployeeStockOptionMember 2012-01-01 2012-09-30 0001505512 us-gaap:ConvertiblePreferredStockMember 2012-01-01 2012-09-30 0001505512 us-gaap:EmployeeStockOptionMember 2012-01-01 2012-09-30 0001505512 rgls:BiogenIdecMemberrgls:ReferralAndStrategicAllianceAgreementMember 2012-01-01 2012-09-30 0001505512 rgls:AstraZenecaMemberrgls:ReferralAndStrategicAllianceAgreementMember 2012-01-01 2012-09-30 0001505512 rgls:GskMemberrgls:ReferralAndStrategicAllianceAgreementMember 2012-01-01 2012-09-30 0001505512 rgls:SanofiAventisMemberrgls:ReferralAndStrategicAllianceAgreementMember 2012-01-01 2012-09-30 0001505512 rgls:ReferralAndStrategicAllianceAgreementMember 2012-01-01 2012-09-30 0001505512 us-gaap:ResearchAndDevelopmentExpenseMember 2012-01-01 2012-09-30 0001505512 us-gaap:GeneralAndAdministrativeExpenseMember 2012-01-01 2012-09-30 0001505512 rgls:ReferralAndStrategicAllianceAgreementMember 2012-01-01 2012-09-30 0001505512 2012-01-01 2012-09-30 0001505512 rgls:BiogenIdecMember 2013-01-01 2013-09-30 0001505512 rgls:AstraZenecaMember 2013-01-01 2013-09-30 0001505512 rgls:GskMember 2013-01-01 2013-09-30 0001505512 us-gaap:FairValueInputsLevel3Member 2013-01-01 2013-09-30 0001505512 us-gaap:EmployeeStockOptionMember 2013-01-01 2013-09-30 0001505512 us-gaap:EmployeeStockOptionMember 2013-01-01 2013-09-30 0001505512 us-gaap:ConvertibleNotesPayableMember 2013-01-01 2013-09-30 0001505512 rgls:BiogenIdecMemberrgls:ReferralAndStrategicAllianceAgreementMember 2013-01-01 2013-09-30 0001505512 rgls:AstraZenecaMemberrgls:ReferralAndStrategicAllianceAgreementMember 2013-01-01 2013-09-30 0001505512 rgls:GskMemberrgls:ReferralAndStrategicAllianceAgreementMember 2013-01-01 2013-09-30 0001505512 rgls:SanofiAventisMemberrgls:ReferralAndStrategicAllianceAgreementMember 2013-01-01 2013-09-30 0001505512 rgls:ReferralAndStrategicAllianceAgreementMember 2013-01-01 2013-09-30 0001505512 us-gaap:ResearchAndDevelopmentExpenseMember 2013-01-01 2013-09-30 0001505512 us-gaap:GeneralAndAdministrativeExpenseMember 2013-01-01 2013-09-30 0001505512 rgls:AlnylamMember 2013-01-01 2013-09-30 0001505512 rgls:AstraZenecaMemberus-gaap:MaximumMember 2013-01-01 2013-09-30 0001505512 rgls:ImmunoInflammatoryAllianceMemberrgls:GskMemberus-gaap:MaximumMember 2013-01-01 2013-09-30 0001505512 rgls:HCVAllianceMemberrgls:GskMemberus-gaap:MaximumMember 2013-01-01 2013-09-30 0001505512 rgls:HCVAllianceMemberrgls:SanofiAventisMemberus-gaap:MaximumMember 2013-01-01 2013-09-30 0001505512 rgls:AstraZenecaMemberus-gaap:MinimumMember 2013-01-01 2013-09-30 0001505512 rgls:ImmunoInflammatoryAllianceMemberrgls:GskMemberus-gaap:MinimumMember 2013-01-01 2013-09-30 0001505512 rgls:HCVAllianceMemberrgls:GskMemberus-gaap:MinimumMember 2013-01-01 2013-09-30 0001505512 rgls:HCVAllianceMemberrgls:SanofiAventisMemberus-gaap:MinimumMember 2013-01-01 2013-09-30 0001505512 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2013-01-01 2013-09-30 0001505512 us-gaap:CorporateDebtSecuritiesMember 2013-01-01 2013-09-30 0001505512 us-gaap:CommercialPaperMember 2013-01-01 2013-09-30 0001505512 us-gaap:CertificatesOfDepositMember 2013-01-01 2013-09-30 0001505512 rgls:ReferralAndStrategicAllianceAgreementMember 2013-01-01 2013-09-30 0001505512 2013-01-01 2013-09-30 0001505512 us-gaap:ConvertibleNotesPayableMember 2012-12-31 0001505512 us-gaap:FairValueInputsLevel3Memberus-gaap:ConvertibleNotesPayableMember 2012-12-31 0001505512 us-gaap:FairValueInputsLevel3Member 2012-12-31 0001505512 us-gaap:FairValueInputsLevel2Member 2012-12-31 0001505512 us-gaap:FairValueInputsLevel1Member 2012-12-31 0001505512 us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member 2012-12-31 0001505512 us-gaap:CorporateDebtSecuritiesMember 2012-12-31 0001505512 us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Member 2012-12-31 0001505512 us-gaap:CommercialPaperMember 2012-12-31 0001505512 us-gaap:CashEquivalentsMemberus-gaap:FairValueInputsLevel1Member 2012-12-31 0001505512 us-gaap:CashEquivalentsMember 2012-12-31 0001505512 us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Member 2012-12-31 0001505512 us-gaap:CertificatesOfDepositMember 2012-12-31 0001505512 us-gaap:EmployeeStockMember 2012-12-31 0001505512 us-gaap:CommonStockMember 2012-12-31 0001505512 us-gaap:ConvertibleNotesPayableMember 2012-12-31 0001505512 us-gaap:CorporateDebtSecuritiesMember 2012-12-31 0001505512 us-gaap:CommercialPaperMember 2012-12-31 0001505512 us-gaap:CertificatesOfDepositMember 2012-12-31 0001505512 2012-12-31 0001505512 2011-12-31 0001505512 rgls:BiogenIdecMember 2013-09-30 0001505512 rgls:AstraZenecaMember 2013-09-30 0001505512 rgls:ImmunoInflammatoryAllianceMemberrgls:GskMember 2013-09-30 0001505512 rgls:HCVAllianceMemberrgls:GskMember 2013-09-30 0001505512 rgls:HCVAllianceMemberrgls:SanofiAventisMember 2013-09-30 0001505512 us-gaap:ConvertibleNotesPayableMember 2013-09-30 0001505512 us-gaap:FairValueInputsLevel3Memberus-gaap:ConvertibleNotesPayableMember 2013-09-30 0001505512 us-gaap:FairValueInputsLevel3Member 2013-09-30 0001505512 us-gaap:FairValueInputsLevel2Member 2013-09-30 0001505512 us-gaap:FairValueInputsLevel1Member 2013-09-30 0001505512 rgls:ImmunoInflammatoryAllianceMemberrgls:GskMemberrgls:PhaseTwoClinicalTrialMember 2013-09-30 0001505512 rgls:HCVAllianceMemberrgls:GskMemberrgls:PhaseTwoClinicalTrialMember 2013-09-30 0001505512 rgls:ImmunoInflammatoryAllianceMemberrgls:GskMemberrgls:ProofofConceptTrialMember 2013-09-30 0001505512 rgls:HCVAllianceMemberrgls:GskMemberrgls:ProofofConceptTrialMember 2013-09-30 0001505512 rgls:BiogenIdecMemberrgls:LongitudinalStudyOfPatientSamplesOnMsTherapyMember 2013-09-30 0001505512 rgls:AstraZenecaMemberrgls:ClinicalMember 2013-09-30 0001505512 rgls:ImmunoInflammatoryAllianceMemberrgls:GskMemberrgls:ClinicalMember 2013-09-30 0001505512 rgls:HCVAllianceMemberrgls:GskMemberrgls:ClinicalMember 2013-09-30 0001505512 rgls:HCVAllianceMemberrgls:SanofiAventisMemberrgls:ClinicalMember 2013-09-30 0001505512 rgls:ImmunoInflammatoryAllianceMemberrgls:GskMemberrgls:DevelopmentCandidateMember 2013-09-30 0001505512 rgls:HCVAllianceMemberrgls:GskMemberrgls:CommercializationMilestonesMember 2013-09-30 0001505512 rgls:AstraZenecaMemberrgls:PreclinicalMember 2013-09-30 0001505512 rgls:ImmunoInflammatoryAllianceMemberrgls:GskMemberrgls:PreclinicalMember 2013-09-30 0001505512 rgls:HCVAllianceMemberrgls:GskMemberrgls:PreclinicalMember 2013-09-30 0001505512 rgls:HCVAllianceMemberrgls:SanofiAventisMemberrgls:PreclinicalMember 2013-09-30 0001505512 rgls:ImmunoInflammatoryAllianceMemberrgls:GskMemberrgls:FourthMicroRnaTargetMember 2013-09-30 0001505512 rgls:ImmunoInflammatoryAllianceMemberrgls:GskMemberrgls:PhaseOneClinicalTrialMember 2013-09-30 0001505512 rgls:HCVAllianceMemberrgls:GskMemberrgls:PhaseOneClinicalTrialMember 2013-09-30 0001505512 rgls:BiogenIdecMemberrgls:IdentificationOfMicroRnaBiomarkerMember 2013-09-30 0001505512 rgls:BiogenIdecMemberrgls:ValidationOfMicroRnaBiomarkerMember 2013-09-30 0001505512 rgls:ImmunoInflammatoryAllianceMemberrgls:GskMemberrgls:RegulatoryMember 2013-09-30 0001505512 rgls:HCVAllianceMemberrgls:GskMemberrgls:RegulatoryMember 2013-09-30 0001505512 rgls:AstraZenecaMemberrgls:CommercializationMember 2013-09-30 0001505512 rgls:ImmunoInflammatoryAllianceMemberrgls:GskMemberrgls:CommercializationMember 2013-09-30 0001505512 rgls:BiogenIdecMemberus-gaap:ResearchMember 2013-09-30 0001505512 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member 2013-09-30 0001505512 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2013-09-30 0001505512 us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member 2013-09-30 0001505512 us-gaap:CorporateDebtSecuritiesMember 2013-09-30 0001505512 us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Member 2013-09-30 0001505512 us-gaap:CommercialPaperMember 2013-09-30 0001505512 us-gaap:CashEquivalentsMemberus-gaap:FairValueInputsLevel1Member 2013-09-30 0001505512 us-gaap:CashEquivalentsMember 2013-09-30 0001505512 us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Member 2013-09-30 0001505512 us-gaap:CertificatesOfDepositMember 2013-09-30 0001505512 rgls:GskMemberrgls:DevelopmentCommercializationAndLicenseAgreementMember 2013-09-30 0001505512 us-gaap:EmployeeStockMember 2013-09-30 0001505512 us-gaap:CommonStockMember 2013-09-30 0001505512 us-gaap:ConvertibleNotesPayableMember 2013-09-30 0001505512 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2013-09-30 0001505512 us-gaap:CorporateDebtSecuritiesMember 2013-09-30 0001505512 us-gaap:CommercialPaperMember 2013-09-30 0001505512 us-gaap:CertificatesOfDepositMember 2013-09-30 0001505512 2013-09-30 0001505512 2012-09-30 0001505512 2013-06-30 0001505512 2013-11-08 0001505512 rgls:SanofiAventisMemberrgls:DevelopmentCommercializationAndLicenseAgreementMember 2013-07-31 0001505512 rgls:SanofiAventisMemberrgls:ResearchAndDevelopmentMember 2013-07-31 0001505512 rgls:OctoberTwoThousandAndTwelveMember 2012-10-31 0001505512 2012-10-30 0001505512 2012-07-31 iso4217:USD iso4217:USD shares shares pure rgls:Agreement EX-101.SCH 5 rgls-20130930.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Condensed Balance Sheets link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Condensed Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Condensed Statements of Operations and Comprehensive Loss link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Condensed Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 107 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Net Loss Per Share link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Investments link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Fair Value Measurements link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Convertible Notes Payable link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Strategic Alliances and Collaborations link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Related Party Transactions link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Subsequent Events link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Net Loss Per Share (Tables) link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Investments (Tables) link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Fair Value Measurements (Tables) link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Stockholders' Equity (Tables) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Strategic Alliances and Collaborations (Tables) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Business, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Summary of Adjustment for Net Loss for Diluted Net Loss per Share Calculation (Detail) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Detail) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Net Loss Per Share - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Summary of Short-Term Investments (Detail) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Changes in Estimated Fair Value of Convertible Notes Payable (Detail) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Fair Value Measurements - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Convertible Notes Payable - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Common Stock Reserved for Future Issuance (Detail) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Stock Option Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Assumptions Used to Estimate Fair Value of Stock Options Using Black-Scholes Option Pricing Model (Detail) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - Stock-Based Compensation (Detail) link:calculationLink link:presentationLink link:definitionLink 135 - Disclosure - Revenue from Strategic Alliance (Detail) link:calculationLink link:presentationLink link:definitionLink 136 - Disclosure - Strategic Alliances and Collaborations - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 137 - Disclosure - Related Party Transactions - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 138 - Disclosure - Subsequent Events - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 6 rgls-20130930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 rgls-20130930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 rgls-20130930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounting Policies [Abstract] Accounting Policies [Abstract] Accounts And Other Receivables Net Current Contracts and other receivables Accounts Payable Current Accounts payable Accretion Amortization Of Discounts And Premiums Investments Amortization of premium on investments, net Accrued Liabilities Current Accrued liabilities Accumulated Other Comprehensive Income Loss Net Of Tax Accumulated other comprehensive loss Additional Paid In Capital Additional paid-in capital Adjustment For Amortization Acceleration of remaining amortization of upfront payment Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities Agreement [Axis] Agreement [Axis] Agreement [Axis] Agreement [Domain] Agreement [Domain] Agreement [Domain] Allocated Share Based Compensation Expense Stock-based compensation expenses Alnylam [Member] Alnylam [Member] Alnylam Amendment Flag Amendment Flag Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Potentially dilutive securities not included in calculation of diluted net loss per share Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Name [Domain] Antidilutive Securities, Name [Domain] Arrangements And Nonarrangement Transactions [Member] Arrangements and Non-arrangement Transactions [Domain] Assets Total assets Assets [Abstract] Assets Assets Current Total current assets Assets Current [Abstract] Current assets: Assets Fair Value Disclosure Recurring Assets measured at fair value on a recurring basis Astra Zeneca Astra Zeneca [Member] Astra Zeneca Award Type [Axis] Award Type [Axis] Basis Of Presentation And Significant Accounting Policies [Text Block] Basis of Presentation Biogen Idec Biogen Idec [Member] Biogen Idec Capital Expenditures Incurred But Not Yet Paid Amounts accrued for property and equipment, net Cash And Cash Equivalents At Carrying Value Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Cash and cash equivalents Cash And Cash Equivalents Period Increase Decrease Net (decrease) increase in cash and cash equivalents Cash Equivalents [Member] Cash Equivalents Certificates Of Deposit [Member] Certificates of Deposit Class Of Stock [Domain] Class of Stock [Domain] Clinical Clinical [Member] Clinical Collaboration and License Agreement Entered Date Collaboration And License Agreement Entered Date Collaboration and license agreement date Collaborative Areas Granted Collaborative Areas Granted Number of collaborative areas granted Collaborative Arrangement Disclosure [Text Block] Strategic Alliances and Collaborations Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Commercialization Commercialization [Member] Commercialization Commercialization Milestones Commercialization Milestones [Member] Commercialization Milestones Commercial Paper [Member] Commercial Paper Common Stock Capital Shares Reserved For Future Issuance Total common shares reserved for future issuance Common Stock [Member] Common Stock Common Stock Par Or Stated Value Per Share Common stock, par value Common Stock Shares Authorized Common stock, shares authorized Common Stock Shares Issued Common stock issued Common stock, shares issued Common Stock Shares Outstanding Common stock, shares outstanding Common Stock Transaction Restriction Period Common Stock Transaction Restriction Period Number of days during which AstraZeneca could not sell, transfer, make any short sale of, or grant any option for the sale of any common stock Common Stock Value Common stock issue Common stock, $0.001 par value; 200,000,000 shares authorized, 41,774,442 and 35,831,808 shares issued and outstanding at September 30, 2013 (unaudited) and December 31, 2012, respectively Comprehensive Income Net Of Tax Comprehensive loss Convertible Debt Fair Value Disclosures Convertible note payable, at fair value Convertible notes payable, at fair value Convertible Debt [Member] Convertible Debt Convertible Long Term Notes Payable Convertible notes payable Convertible Notes [Member] Convertible Notes [Member] Convertible Notes Convertible Notes Payable Outstanding principal amount Convertible Notes Payable [Member] Convertible Notes Payable Convertible Preferred Stock [Member] Convertible Preferred Stock Corporate Debt Securities [Member] Corporate Debt Securities Current Fiscal Year End Date Current Fiscal Year End Date Customer Advances Current Upfront payment creditable against future accounts receivables Debt Conversion Converted Instrument Shares Issued 1 Conversion of convertible notes into common stock shares Conversion to common stock Debt Disclosure [Abstract] Debt Disclosure [Abstract] Debt Disclosure [Text Block] Convertible Notes Payable Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument Convertible Conversion Price 1 Conversion rate Conversion price per share of convertible notes payable Conversion price per shares Debt Instrument [Line Items] Debt Instrument [Line Items] Debt Instrument Maturity Date Conversion rate Debt Instrument Name [Domain] Debt Instrument, Name [Domain] Debt Instrument [Table] Schedule of Long-term Debt Instruments [Table] Deferred Revenue Deferred revenue Deferred Revenue Current Current portion of deferred revenue Deferred Revenue Noncurrent Deferred revenue, less current portion Deferred Revenue Recognition Period Deferred Revenue Recognition Period Deferred revenue recognition period Depreciation Depletion And Amortization Depreciation and amortization expense Development Candidate Development Candidate [Member] Development Candidate Development Commercialization And License Agreement [Member] Development Commercialization And License Agreement [Member] Development Commercialization And License Agreement Dilutive Securities Included In Computation Of Earnings Per Share [Line Items] Dilutive Securities Included In Computation Of Earnings Per Share [Line Items] Dilutive Securities Included In Computation Of Earnings Per Share [Line Items] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Information [Line Items] Document Information [Line Items] Document Period End Date Document Period End Date Document Type Document Type Earnings Per Share [Abstract] Earnings Per Share [Abstract] Earnings Per Share Basic Basic Earnings Per Share Basic And Diluted [Abstract] Net loss per share: Earnings Per Share Diluted Diluted Earnings Per Share [Text Block] Net Loss Per Share Employee Related Liabilities Current Accrued compensation Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Employee Stock [Member] Employee Stock Purchase Plan Employee Stock Option [Member] Common stock options Entities [Table] Entities [Table] Entity Central Index Key Entity Central Index Key Entity Common Stock Shares Outstanding Entity Common Stock, Shares Outstanding Entity [Domain] Entity [Domain] Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Entity Wide Information Revenue From External Customer [Line Items] Revenue from External Customer [Line Items] Equity [Abstract] Equity [Abstract] Equity Issuance Per Share Amount Common stock shares, par value Price per share Equity [Line Items] Equity [Line Items] Equity [Line Items] Equity [Table] Equity [Table] Equity [Table] Expected Terms Of Option Agreement Expected Terms Of Option Agreement Option expiry date Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table] Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table] Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain] Asset Class [Domain] Fair Value Assumptions Risk Free Interest Rate Fair value assumption, risk free rate Fair Value Assumptions Weighted Average Volatility Rate Fair value assumption, volatility rate Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value By Asset Class [Axis] Asset Class [Axis] Fair Value By Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Fair Value By Fair Value Hierarchy Level [Axis] Fair Value, Hierarchy [Axis] Fair Value By Shareholders Equity Class [Domain] Fair Value by Shareholders' Equity Class [Domain] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Fair Value Disclosures [Text Block] Fair Value Measurements Fair Value Inputs Entity Credit Risk Fair value assumption, credit spread Fair Value Inputs Level 1 [Member] Fair Value, Inputs, Level 1 Fair Value Inputs Level 2 [Member] Fair Value, Inputs, Level 2 Fair Value Inputs Level 3 [Member] Fair Value, Inputs, Level 3 Fair Value Inputs Period Fair Value Inputs Period Restricting common stock valuation measurement period Fair Value Liabilities Measured On Recurring Basis Obligations Ending Balance Beginning Balance Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block] Changes in Estimated Fair Value of Convertible Notes Payable Fair Value Measurement Policy Policy [Text Block] Fair Value Option Fair Value Measurements Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Fourth Micro Rna Target Fourth Micro Rna Target [Member] Fourth Micro RNA Targets Gain Loss On Investments Gain on investments Gains Losses On Extinguishment Of Debt Loss on extinguishment of debt Loss on extinguishment of debt General And Administrative Expense General and administrative General And Administrative Expense [Member] General and administrative Gsk Gsk [Member] GSK HCV Alliance H C V Alliance [Member] HCV Alliance Identification Of Micro Rna Biomarker Identification Of Micro Rna Biomarker [Member] Identification Of Micro Rna Biomarker Immuno-Inflammatory Alliance Immuno Inflammatory Alliance [Member] Immuno-Inflammatory Alliance Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest Loss before income taxes Income Statement [Abstract] Income Statement [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Income Taxes Paid Income taxes paid Income Tax Expense Benefit Income tax benefit Increase Decrease In Accounts And Other Receivables Contracts and other receivables Increase Decrease In Accounts Payable Accounts payable Increase Decrease In Accrued Liabilities Accrued liabilities Increase Decrease In Deferred Liabilities Deferred rent and other liabilities Increase Decrease In Deferred Revenue Deferred revenue Increase Decrease In Employee Related Liabilities Accrued compensation Increase Decrease In Operating Capital [Abstract] Change in operating assets and liabilities: Increase Decrease In Prepaid Deferred Expense And Other Assets Prepaid and other assets Intangible Assets Net Excluding Goodwill Intangibles, net Interest And Other Income Interest and other income Interest Expense Interest expense Interest On Convertible Debt Net Of Tax Accrued interest on convertible notes Interest Paid Interest paid Investment [Line Items] Investment [Line Items] Investments Debt And Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block] Investments Investment [Table] Investment [Table] Investment Type [Axis] Investment Type [Axis] Investment Type Categorization [Member] Investments [Domain] I P O [Member] Initial Public Offering Legal Entity [Axis] Legal Entity [Axis] Liabilities Total liabilities Liabilities And Stockholders Equity Total liabilities and stockholders' equity Liabilities And Stockholders Equity [Abstract] Liabilities and stockholders' equity Liabilities Current Total current liabilities Liabilities Current [Abstract] Current liabilities: Liabilities Fair Value Disclosure Recurring Liabilities measured at fair value on a recurring basis Longitudinal Study Of Patient Samples On Ms Therapy Longitudinal Study Of Patient Samples On Ms Therapy [Member] Longitudinal Study Of Patient Samples On Ms Therapy Longterm Debt Type [Axis] Long-term Debt, Type [Axis] Longterm Debt Type [Domain] Long-term Debt, Type [Domain] Maturity Period Of Short Term Investments Maturity Period Of Short Term Investments Maturity Maximum [Member] Maximum Minimum [Member] Minimum Net Cash Provided By Used In Financing Activities Net cash provided by financing activities Net Cash Provided By Used In Financing Activities [Abstract] Financing activities Net Cash Provided By Used In Investing Activities Net cash (used in) provided by investing activities Net Cash Provided By Used In Investing Activities [Abstract] Investing activities Net Cash Provided By Used In Operating Activities Net cash used in operating activities Net Cash Provided By Used In Operating Activities [Abstract] Operating activities Net Income Loss Net loss Net loss Net Income Loss Available To Common Stockholders Basic Net loss used to compute diluted net loss per share Net Income Loss Available To Common Stockholders Basic And Diluted [Table Text Block] Net Income Loss Available To Common Stockholders Basic And Diluted Table [Text Block] Summary of Adjustment for Net Loss for Diluted Net Loss per Share Calculation New Accounting Pronouncements Policy Policy [Text Block] Recent Accounting Pronouncements Noncash Investing And Financing Items [Abstract] Supplemental disclosure of non-cash investing and financing activities Noncash Or Part Noncash Acquisition Intangible Assets Acquired 1 Amounts accrued for patent expenditures, net Nonoperating Gains Losses Gain (Loss) from valuation of convertible notes payable Less: gain from change in valuation of note payable Change in estimated fair value of convertible notes payable Gain (loss) from changes in valuation of convertible note payable Loss from valuation of convertible note payable Nonoperating Income Expense [Abstract] Other income (expense): Notes Issued 1 Convertible notes issued October Two Thousand And Twelve [Member] October Two Thousand And Twelve [Member] October 2012 Operating Expenses Total operating expenses EX-101.PRE 9 rgls-20130930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 10 R17.htm IDEA: XBRL DOCUMENT

Investments (Tables)

9 Months Ended

Sep. 30, 2013

Summary of Short-Term Investments

The following tables summarize our short-term investments (dollars in thousands):


	Maturity (in years)		Amortized cost		Unrealized					Estimated fair value
	Maturity (in years)		Amortized cost		Gains		Losses			Estimated fair value
As of September 30, 2013
Corporate debt securities		2 or less	$	68,649	$	18	$	(50	)	$	68,617
Commercial paper		1 or less		999		—		—			999
Certificates of deposit		2 or less		13,770		—		—			13,770
Debt securities of U.S. government-sponsored agencies		1 or less		7,025		2		—			7,027

Total			$	90,443	$	20	$	(50	)	$	90,413


	Maturity (in years)		Amortized cost		Unrealized					Estimated fair value
	Maturity (in years)		Amortized cost		Gains		Losses			Estimated fair value
As of December 31, 2012
Corporate debt securities		2 or less	$	44,898	$	7	$	(49	)	$	44,856
Commercial paper		2 or less		6,492		—		—			6,492
Certificates of deposit		1 or less		6,200		—		—			6,200

Total			$	57,590	$	7	$	(49	)	$	57,548

EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0"I^C`/Y@$``,P7```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F-%JVS`8A>\+>P>CVQ$K MDM:N&W%ZL767;:'=`VC6G]C$EH2DMLG;5W;:4DJ6$A;8N8E)+/WGB\`?^,PN MUGU7/%"(K;,5$^64%61K9UJ[K-CONU^3^[MM8ID_(':]ZE3)X3RKQS7!.; MUL?/&8/QG0G#G;\'/.^[SD<36D/%C0[I2O<9@Z\[_NC"ZH]SJW+_D!V4;K%H M:S*NON_S"931!](F-D2I[\KQ6O:ZM2_<>_+'Q9&/%W%DD.'_C8,/Y)`@'`J$ MXPL(QRD(QQD(QU<0CG,0CF\@'&**`H)B5(&B5('B5($B58%B58&B58'B58$B M5H%B5HEB5HEB5HEB5HEB5HEB5HEB5HEB5HEB5HEB5HEB5H5B5H5B5H5B5H5B M5H5B5H5B5H5B5O6_S)IR5TI\_/SW!W<<\T%9%].FHWCD%^SMT(^2&QW(W*:0 M6^6C`[R=O8\C=ZXWP?F8V^=`AY_"2[T\[)[X/(A":NFU8-Y5U+XFYN;Z\,!W M33$-W;@ALR.;CUW\_`D``/__`P!02P,$%``&``@````A`+55,"/U````3`(` M``L`"`)?]=J>*V?5@^@8B)G:13'&HX<85?=WFQ?>*24 MFV+7^ZBRBXL:NI3\(V(T'4\4"_'L)MI<3_3_MCAQ(DN)T$C@\SS?BG-`Z^N!+I]HJ?B]SCSBIX3A M363X8<'%#U1?````__\#`%!+`P04``8`"````"$`\*#N9/0!``#)%@``&@`( M`7AL+U]R96QS+W=O_4G9E2_HBT%[12 MKRP\@)6X346;1+9AZ=MC%384B?UV#]%<(ME1QI\^C^?YU>FB,FUM=MUK2_-P4>S7)S]N+WW.Y?R1['9]K'( M4=I8FB:E_L;:6#5^[^*DZWV;WZR[L'3J=VW`:PRR^Q"Q6 M=6G"JB8QQ<.ASTO_.WBW7F\K?]=5SWO?IF_6L+^[\!0;[U,.ZL+&I](,4]$> MWY!,LF9C_R(G^Z$KYPK)X;FR')XC.7(]IIR8#KN<;L-.O8_1^DQCKC]DQJ>$ M8>HC69B0')DIRY$9DG.IK.82B2%65D,,Y6B;0]`=OE!VAR^0.Z)=A`4681FU M"*<,*Y_M_N#!<6B/3WBXM?,7IZ\V!PAR@',;H4I)GJ+TY5&Q-##@,V>&J3]8 MN$9RM"$%TU@[<6#>D+HUT!O6YC=#?HMVR1%8"53K0KLN"2/.JQ^@]W M"**0'+[Y0?TX@T``/__`P!02P,$%``&``@````A`#AA3]`+ M!```W0L```\```!X;"]W;W)K8F]O:RYX;6R,EEUSVCH0AN\[<_Z#Q_>G8!NG M32:D0PB9,M.F3*#II4:Q!=:)+%%)AO#ONY(3G\4BG5R!,/MZ/Y[=U>67YUI$ M.Z8-5W(<)Q^'<<1DH4HN-^/XY^KVW\]Q9"R5)15*LG%\8";^#,Q6,UJ:BC%;BT$Z')X- M:LIEW"IU9T<_Z&9[W7`!3\^S818/KKH@%SHJV9HVPJX@O%=U MR%,GG]Q6:J]^RND]M"=,G!@[Q_]XJ6MX/EP..Q^ M^\KXIK*O/X+\`.G[#,)[_&5_EFAKN7[[0 MS(`CGC2?Y653UT@E.TYI5R3!RH:1KXS:AK=)A';I^B=YWU[``%F@N6/@I$[91GX30\4 M3E@!US`9]B665A5/E1(E="*9_6Z`2&R,2Y<$("XM%)IM>$$F0G!'HO$YGRHA MZ"/6P<5+`A[OW6@`G`$_:(B5IM+0PL\*K'&&4I$$-"Z;1\-^-U![,MLY%+'I M)VP:(/AW>*""73^,<%LE`84A/F3ERG'D"P8P"0A$&(6V.28P"1!\`Z<3.IC* M),#R!!,G-#"928#FW]'`.\/NNC%<,FC)DU5"MOXLH,]@<%,A#N2&B\;R';$@JL#\Y[ITT@-?-MY>XEI72=L5T#3OE91CAN(YT`G81/%\Y M#'!=5`>?GHDQ#$_S'/=ANU7Q")U65&Y@#G!)9L9RN%9`8W?BV!_'0 MXZ<5^+%UA283F'([=PFX899RN/MTDR;#+0J'G@H4I:F]AB$_W4W`JB[=1ULS MPS3#H:?CO8'.`@4($"Z#IMVN9Q'GAG MX0I84%'`W=1]N,N=9V+P>C._^@,``/__`P!02P,$%``&``@````A`$/=EOUV M!@``K1P``!@```!X;"]W;W)KP?`^XVR>,AHGB0W8C9:75:@_7'C"#%<#(]F22M]]J5X.[RL2&7"09ZG.Y M_Z[JJAKZZNB.==%ONT>.AX6TG&"Q3$O3S9Z6-7W^*AVNW)3I-7F[5B<6G12%X>\ MA?4W^_+<7+P=-_>X.^;UU[?S;%,=S^#BI3R4[8_.J6T=-ZO/KZ>JSE\.H/N[ M\/+-Q7?WP\#]L=S455/MVCFX6^!"AYJC1;0`3\]/VQ(4J&VWZF*WMC^*528C M>_'\U&W0OV7QWAC_MYI]]?Y;76Z_E*<"=AOBI"+P4E5?%?IYJSZ"AQ>#IS]U M$?BSMK;%+G\[M']5[[\7Y>N^A7#[H$@)6VU_I$6S@1T%-W/I*T^;Z@`+@+^M M8ZE2`W8D_][]^UYNV_W:=H.Y'SJN`-QZ*9KV4ZET*G4CM M!)[03H28"DF7&`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`T$G/-&(/HHB=/NRAD=MVDH"^'X07]FJ3S5 MU>^7AS,`B1M+KE@@HP/#TC>A5A;SE%K[,]6%-*-6V;^8*E(]_7Y%.`$012P> ML3"GA)D4QB\8.A<)X`=+ICJE'@0$C(4T8X1C]D3B/D MR+$$BR4R6EXX=^B?,)NQI$[H$S?U$I^W]!)@3*^:$PR]]Y4:B=,%O.1:,Y>L MF<6:&LE&$!O>A849]5SJ9N^8HXCG"]Y9B$$Z3<7W?_.I`IR\A M0A>*4-#7&%V%3$;Z06#40BKRH9%&#D<:WKYCS6"1]83OP]M9%TT(%!YJ=?W<+]CSK7:+_QW2VQW_KRE@`W MOKW%VR&\/#D6]6N1%(=#8VVJ-W7S(Z'/73_%6ZE8K.!*`VXFV.OQ1]Y_5J>&NM0[,"E,P^A.M1XW80_M-6YNZ!XJ5JX)NK^NX=KP0(N M2YPYP+NJ:B\_J"N1ZT7C\_\```#__P,`4$L#!!0`!@`(````(0#,7:H7%P,` M`(X)```9````>&PO=V]R:W-H965TVV*?KU\_XF08Z0N"MQPSJ2HA6PJ6V\T/23FH13AHLP;^H:2^.:FUQC5R+^>.NORE8VX/$ MAC94O@RBR&F+Q<.V8QQO&HC[.9CBXJ@]7)S)M[3@3+!*NB#G::/G,<^]N0=* MJV5)(0*5=H>3*D5WP2)/D+=:#OGY3G'QW1,WVGSDMO]*.0+*A3*H`&\8> M%?I0JENPV3O;?3\4X#MW2E+A72-_L/T70K>UA&K/("`5UZ)\R8DH(*$@XX8S MI52P!@S`N]-2U1F0$/P\?.YI*>L432)W%ON3`'!G0X2\ITH2.<5.2-;^T5!P MD-(BX4%D"N[U>AA<*^)I0T-\.99XM>1L[T#/P"-%CU4'!@L05H%-P9*V,8;Z M6J00HA*Y4RHIBI$#VP54YVDU29*E]P0I+0[,6C/P/C+1Q$2RY/(SXEH.HH87B?O\:K@%('X MF+4@BD9=;5\S4+V1F9E$]B:17R(,]_"8ZS.M8.CU$V?AS"KI6C.7W+])Y)<( MPSVT]O7N%6SF/IQ9C;'6S#09FCYP8]]X!9]NK`V9M6%Z1N06X<_-U^D&([;H M/;$IV([-ZIJU9@ZQ^59+75K,7UDT[,)I<7TI%&S;M7\&FCG:=>,P,A)GG4>9 MA4=Q8I3.2D9NX?&_-C:B4@/_Y#R]?!`IV(XJ-O.\ULSISV.2S$TFNX*!Z:B> M]9J.CD'//ST?6L*W)"--(YR"[=1L"Z''Q[OCV+T+U3EJW<]@'`_#RQL78!SV M>$N^8;ZEG7`:4H&D[\;0[5P/5'TA63],I0V3,`B'KS7\[R%P3OLNP!5C\GBA MIH`:Y,-86_T%``#__P,`4$L#!!0`!@`(````(0`]RL(K!@,``.L)```9```` M>&PO=V]R:W-H965TP$`@B4*J M5E6W29LT3?MX=L`$JX"1[33MO]^U32B0)DOV$N+D^)Q[[KV^9G7[4E?.,Q62 M\29%V/610YN,YZS9INC7S\>;.7*D(DU.*M[0%+U2B6[7'S^L]EP\R9)2Y0!# M(U-4*M4N/4]F):V)='E+&_BGX*(F"I9BZ\E64)*;377E!;X?>S5A#;(,2W$) M!R\*EM$'GNUJVBA+(FA%%,0O2];*`UN=74)7$_&T:V\R7K=`L6$54Z^&%#EU MMORR;;@@FPI\O^"(9`=NLSBBKUDFN.2%>UYX"P^8UJN<@0.==D?0 M(D5W>'F/(^2M5R9!OQG=R\%W1Y9\_TFP_"MK*&0;ZJ0KL.'\24._Y/HGV.P= M[7XT%?@NG)P69%>I'WS_F;)MJ:#<,W"DC2WSUP,Z0NZS#WQQC<(SP0[95!;:BL-(XB#GMX$>7\,>4., M`@C'`9P7UF`($#D#Z]%$V6*B`6;6(T;*`+G>NMZ4(G`WB."-WWJWF-B4)DH" M_WUYZ+FA_'GC&CR6#:*I<8N);$?$)^H=7Z.JP5/5J5F+L:HW)\TFU\AJ\%0V MZ9-HO8,JGX^[=A.JK'RD6<+LLJ^.^^[8310\%6SS*#'R0ZB:<$[D!4.W<&9'RO_ MURR#R_K?G=Z!#N5.IM[M=6UOLY9LZ3&EBL+5YKL`+CA7AX5^'>A?T]9_`0``__\#`%!+`P04``8`"``` M`"$`?E)Z:',#``#K"P``&0```'AL+W=OV`"58!(^PV[;_?,:8$0TJ2 M]2(-[>/7[_G@V,O;UR(W7DC-*2M7)IK9ID'*F"6TW*_,W[\>;B+3X`*7")A0BD&DW:I*NS#NTV"+/M-;+)D%_*#GPWG>#9^SP MI:;)-UH2R#;4259@Q]B31!\3^2=8;(U6/S05^%$;"4GQ9@'+[ M$)$,;)&\W1,>0T9!9N;X4BEF.1B`3Z.@LC4@(_BU^7V@B#& MCG#Q0*6D:<3/7+#BKX)0*Z5$G%;$!??M_YV9$_G(#\ZK6,I1$^`]%GB]K-G! M@*Z!/7F%90^B!2C+R%S(S^G(("2YYDXN:I8"S:$<+VLWG"^M%TAAW#*;,>/H MQ/8$$76(!?XZDQ!ZW^2T.0E#$*9Q-!?9G6X3P$8Q7H_Q=6([16C>8*/+O4EX M98)VY\UQ!VG9*"9HTNJAP(:?@3>-"&$6]`C-&P38]W99<>6BH<=!=C:*41XC M%#FA'PP\]HD0.5[H'AM$\P@O0-_C=&TEK'MS(Z3OO%$,[-_E>.!^.T5HWH)K MO$GX7-\I9LK;%*%Y"Z_Q)F$];^.^4\RQ[QPTS)M&!`'RO0]J*L^]JX>*7*1[ M=*/ANZ$8Y=%!`?+0\-WH$W,O\&RW:P\M?7/=XG3;25BWYKA>IZM&BF*F2CM% M:-X0#.!^_J;--?2YQFNA*7N3B.[O_PX-->_[PV]<8*2@M@L#VXF.]6ORO-4( MY'\\_)`FD5R9DUE4.J<1/8M7G1Q(#7WX[,::.SK6 M6NCTYFWZE,YI1/<'3#]_EYT><`T;ORN#0;)I(55EY-EVY!U/_M:GTFD1-PC" M*.S>..537=?4;:;">_(=UWM:3(GH4PYVMU65,/@E7-K67'!%RRFJ\9 M7*H)7&GL&<`I8^+]05X'NVOZ^A\```#__P,`4$L#!!0`!@`(````(0#*J^PN M#P0``#X0```9````>&PO=V]R:W-H965TZ_[]@F;.Q$F,U%")/' MP\P['F.OO[_7E?&&6UJ29F,BRS$-W.2D*)OCQOSU,_FV-`W:94V15:3!&_,# M4_/[]O??UE?2OM(3QIT!'AJZ,4]==PYLF^8G7&?4(F?G\DQOWNI\ MBKLZ:U\OYV\YJ<_@8E]69??!G9I&G0<_C@UILWT%>;^C69;??/.;!_=UF;>$ MDD-G@3M;!/J8\\I>V>!INRY*R(#);K3XL#%?4)`B9-K;-1?HWQ)?Z=UO@Y[( M-6W+XL^RP:`VU(E58$_(*T-_%,P$@^V'T0FOP-^M4>!#=JFZ?\CU#UP>3QV4 MVX>,6&)!\1%AFH.BX,9R?>8I)Q4$`-]&7;*I`8ID[_QZ+8ONM#&]N>4O'`\! M;NPQ[9*2N32-_$([4O\G()[1X,3MG7@0??^_:[E+'_GS+WB9]5[@.GB9'`($ MR_.`ZVTPLF:NOUA^)9%Y[P6N-R^0VT05%OU@N-X&SR>K8(NZ\#)'69=MURVY M&M`[H#P]9ZP340">G]<5"LK8%P9O3,"@9!0FX]O66SAK^PTF4-XSNT?&E8GP M";&4D>@1\1"2F?@9HSPJ$0Q\WP6L^$G'&1MT&L2"8DT7B\%,+-843+V=:@A5 M0Z0:8M60",-LQ<6?(;3T9%72$4!*!7II>BH,EE)1#:%JB%1#K!H281"=SO1) M;X;[8GT65(H>>GAZ]`R6HE<-H6J(5$.L&A)AN(O^9OB,WIW/AN)(T<,B,CUZ M!L.J*4UAI>@[P4`$PS3WAR?SN1=JB4A+Q%HBT1+I&"%I!$OD=(T8O#%AZ@_Y M>XM/[47W"69,(RT1:8E82R1:(A7$DK>X/W/89ZBFI!$LQ-,U8K"B$5*6W9U@ MQC32$I$@YCQZY"SE\'DIXGO$Y\!G@IQ(M$0Z%H@D$MN)3G[!,5@1::&TTDXP M8R)IB4A+Q%HB$8006IDE7,1TS(4DT>HK$C%8E6@^S$_1:X(9DTA+1%HBUA*) M('SQLG3=I1)G.N9!4@C!QGGZ+.*TJM%"T:B'1)LKBU78_SFB8*1'8CV2C$61 MCHZ7]6&;J,E=!@>6QSFDKD4])/1!WLI%]^L@GV>AS#C(8WT@ZQSUS(B4L1Y) M]`@[AK&LGC](J"6.66+_7>/VB$-<5=3(R84=H=@\':S#\>YEQG:0BGV'@MTS M>X@"V,P\\A$*8$_S:(]1`%L;L-O#`^#T=LZ.^*^L/98--2I\@-`<:P%O[E:< M_\1-1\[\]+`G'9S;^,\3G-,Q[.0<"^`#(=WMACU@./EO_P<``/__`P!02P,$ M%``&``@````A`&VGAV!U`P``T0L``!D```!X;"]W;W)K&ULE%9=;YLP%'V?M/^`>`^$D)`/):F:`-ND39JF?3P[8()5P,AVFO;? M[QH'"J:%-@])L,\]N>?(6[3$!>PD ME.5(P",[V[QD&,554)[9L^G4LW-$"E,Q;-A[.&B2D`C[-+KDN!"*A.$,"O8;;N:`,G3+0_>3,451S5P\] M^IQ$C'*:"`OH;)5H7_/:7MO`M-_&!!1(VPV&DYUY[VS"E6GOMY4_?PF^\M9W M@Z?T^H61^#LI,)@-99(%.%'Z(*'?8KD$P78O.JP*\),9,4[0)1._Z/4K)N=4 M0+47($CJVL3//N81&`HTUFPAF2*:00+P;N1$=@88@IZJSRN)1;HS7<]:+*>N M`W#CA+D(B:0TC>C"!,C@?9;1J\&=!PDS$LD^]?9`&%MBQ+1&/663V"0)+F7+!476,"AMH][ MUYMM[4>(EQNB%!C:A#0K50^6Z#QD8H M>*\+=:&+7J]_K4L&=77U9/4AFO!C'^'-NRK\/D0C"?H(G23L0]R6PQTSW+X9 M\S%&95'09OJ;7ML;T[<5UMV^]N+U?+KHE!=U\/#]4VO#?YO63740\U M;ZL?/@P2K*OVNHD=%&9=J5Y;<_V`J^W7$U,G?I@@&"4(NP2K%V<[PN&O[OW" M)5@7KE7DH#`#RHZC"/^&4#TSM?26"D89PB%$1S_\#;]?OP3K^E=:X15F2/\H MPK\AE'[7@@&I_9H%$ZV=@E'*<`C1,42.>:U[$ M,F1E+=IVP/083/1;8I021BR9^NMI*4/4"*6&A!RS,S[B+.-&1"]R/)K!T6Y6 MU>1V<#9P<\,%K*W[S@:N9UBWFPV8J$ITQC\0.Y."&QE.@')J+>'0,C63J0=! MR^K:/5$!LU3U-871&<-,,+4`G%`JZ@?Y`\TPOO\/``#__P,`4$L#!!0`!@`( M````(0"8&US=4P,``&<+```9````>&PO=V]R:W-H965T,>.$5AO3M1S3P%5"4U(=-^:OG_)0B=U*ET0(7'-+SO/6#^=I^ACU-+LQ.,7/3 MZ)C0UY%]B\@=E+I1._`OQM5#XI:0Z0-+G2_8K;XO'_+^=L9:&S)(M^'U7;R! MZ"O:#XEPIB/1$/%T(AX25R*:47]H=/9N:;9&91`4X54N_&"A+V&GF-D5$^C$ M?I*()HEXC-!\PD+^/Z$R:&/"9G8UY[E]GXI9-%4;SGOUM;^>O?']WG2D3\\7 MO7*)]?FK<,T;Y.O:VWB12ECWY`=+/3,[Q<"?=[[[N9LDHDDB'B,T?Z'N3QXR MTS4J@Z9J5#%C/B>):)*(QPC-)QQN'\^CA'MY#)U>'A4SYF^2B!01-O7M.J[? M.XSB,07-G6QF>E?%])$J@W27PS=0,6,N)XE($_5_,CYJ,)!6A\Y"K>5E#>5&.C[OT2LR/>XZ+@1D)/ MLFGQH#2Z4=5/[=P57,9PI_;&(^BSFG&[FX`^IT9'_`VQ(ZFX4>`,)!UK#H<# M4YV2>A"T;J[6`Q70X30_&PO=V]R:W-H965TW%P7F55Y^5QZ?J3J>O(8U9N\N-N MZ?[S]^.7.]>IF_2X20_E42[=#UF[7U>__G+_5E;/]5[*QH$,QWKI[IOFM/"\ M.MO+(JTGY4D>X0A;8!_O<]/]3E;D8U)5Z35\\OI2U86)TCQE!_RYJ--ZCI% MMOB^.Y95^G2`<;_[89J=<[5:5=;EM)I#.0Z+78XZ]V(-,J_M-#B-0 M97E^^_5;EFS_RHX1J@TY*@:>R?%;0 M[QMU"8*]J^C'5H$_*VX\R;IYS%5*U\E>ZJ8L M_D.0KU-ADD`G$WP\FP5WD1[/A+!XR:@?XD#;IZKXJWQR8-?"=]2E5<]!? M0&8ULO#3D<&05,PW%=2&`KH&.5Y7(@SOO5$H!21\0 MSV+?[^X3@C"M^@1Y]128$@L"T>5%^1`#W]Z1-XO'(0BW&>4VK@U4T)#`B.$X M<@C"$7JI7S_%<5A@%43K*$*S#1`S0X%%'%ST:^NE^U!F,<.H3S5LF[P'&YF'\V`U/-JN=8@U'IV-_.OM,8L"`C#N^@R6RA' M&$>?XX#6"FW.0\,IUCZ"[`7"Q8:%4'Z&H8S4&CUA0&O..#1/#D)Y6LQEA-;H M"P-:G\U#/8/%<4P-,O'QMIX*87QY`J,$#6<9$-IF*9?,N'3["&*%YB"4G^$L M(X5&_OB$"BY!G&2LQ#*T_"9<9('Z#>\Y!K$\L0\=@CEJ5;\GU['`Q5EUO.R M"NMZ(@@EGT_-S4NBDXPAJ1;\'DF^OP.%-LD9*\M:@^Q?CGW#0F@1(4V?WTBQ M5=30XUF`()8G!Z$\+88SW-]J%N\9H3EZ!K^F!PAB M-"<`1G/#=P;ZV^(WD;'E6P<(L@NI:\A!2`U5O7Z^O]NHH?[6((XG"Z$\+::C MHOEZ"C0+7FL-0JWC:>@;[ID00#2/PLLVB7)4KM!;RU7?C."(7D(X1N8SFT`0 M6TL.0GD:GC.NOP5Z#]_?&L3RQ#QV".4)F!OJJ:*,]?)J(R80A)K;-F($P&S$ MQ$V^TT89'"-CVJTUR%XH[',60FMI\9X1KTG15@8T'_8>P4$H3XOWC.@A]`S2 M0]>:GXW%OB$3>%M/B4\W9.(FTVFC3,$O[^K0Q#6(%1QMQPZAA32,9V23HW$, M",ZYBYZ8'(3P#"T&-"QX&V74\TIP#4)%;1LS`OA\8Q9:O&>X=]HH@V)DO`1? M:Y!=3RPE"Z&E5`Y@^,\(GN@;O.0A9RZ:)P>A/)4#&#Q'2*ZBC'I>2XX@E-RR M,0OQOKW>E"1@;B"IH@R2O7=XV.!JK1G<]<'X"I M-#`8EB<'H3PM!C1"=#0.F%H]GL9+TS4<+RN>^A3,_BW`@EGG],)@+=EV9P_J`/Q M[A\55O\#``#__P,`4$L#!!0`!@`(````(0#;&J(`YP0``-D5```9````>&PO M=V]R:W-H965T:=T#<-V`@!Z(D6YM4 MG=G2;&DTFL,U)4Z"&G`$M&G??I:]#-B&$+AIDOIC\7L=P9MOG]G%^J!%F;)\ M:Y.9:ULT3]@AS4];^Y^_7YY6ME56<7Z(+RRG6_N+EO:WW:^_;&ZL>"O/E%86 M6,C+K7VNJNO:<ZRZ<+$YS M&RVLBS$VV/&8)O29)>\9S2LT4M!+7('^\IQ>R]I:EHPQE\7%V_OU*6'9%4R\ MII>T^A)&;2M+UC]..2OBUPOL^Y,$<5+;%C\ZYK,T*5C)CM4,S#DHM+OGT`D= ML+3;'%+8`7>[5=#CUOY.UGO?M9W=1CCHWY3>2N6[59[9[;R(;VQ]^'JF M90(>!3,S;\XM)>P"`N"OE:4\-<`C\:?XO*6'ZKRU_<5LOG1]`KCU2LOJ)>4F M;2MY+RN6_8<0D:;0B">-P*8Y[)9`V6N7\@'G?\`X[AUWSG%XE+@2XAJ!\[WR<;YP,"D4@F MZC(&L>\2ON\U5AP0V*@$STU7R2_257K+QKS82-2#Z,2^AU@UB*81O*=J[,^P MVH,79\OYZ';7*_I@AH:KXO#IB[#(Q$R@=#EM3<5#MVKBVTF:((64P1QV!2T M:#:*040&!3W-347::A`VUVJ:EE,T<=C4U.X5-2&SJ(-'S."IZQ"\X$["\QFI MM([AA.>PJ:NUB[J0@=1I$L\([WZ(T'P63M'&X4?%B,R0MB%"TT:@OXYWG*!U MSY&E68X24N7Y?IM.F/X/(%VC,1>&@TNPE0^W#`EAVBU6"R7=I3ZT@D`0K,(V M/W1MO">/3CR"'5S79N15)"$L4]+>5PI#$[C:%I,NBO?B\:*P<^NBS-9!ZO;. M!VRW=^C+BC=U7;P3C]?%:3W9?+_=,98I0:@))#&`O09`(.?MSG1MD]H_?VPS MM05&0XTDI!:"$>O](*+KFS0-"#9S"%K3OGS?:*V1A`;UU4.AM=-N0=V6L6(EI$:U32GL<8.(%E%OTF@0]*/A M*J%!?3@<^A%='^_6HSN>A[U=[<3=JI"0>O/N>.V#E-+1-4Z:%E[?M#"K0D*8 M7<1?+HW6N->`!9Q#]#]M>K#+">[CM)%^G8$A3&[M`6EH15;&?6G&O!CWLLI? MU$V)YOM*)"$UPIT*03O]B![=27/#&S,W)-1_&-VEN"%H/<4^%](P$ M)?FEPB[4.EGWX*2IX8V9&A+"'%NZ7GMG*:Z>*@_'KC=I<@A:=Y_O&S>/)"3? M6YO"E,KJL?)0&3^Y&5^[@C:5&<]RD83P31_<9JSSPSM>7?V)B3'%PSD\=;K& M)_HS+DYI7EH7>H0G)7>VA,(J\&@.?U3L*LYM7ED%1VKBZQF.4"D&ULE);;CILP$(;O*_4=$/<;3@D) M49+5)K#M2JU453U<.^`DU@)&MK/9??N.[[A6UQ@A`3D'/T1ON>(R=R0&FSR@@X MD&FW&#ZL[0=OF7BN[6Q6*D&_"+[PUF^+G^CE$R/9%U)BR#;4259@3^FS1)\R M>0N"G5[THZK`-V9E^(#.N?A.+Y\Q.9X$E'L&CJ2Q9?868YY"1D%FXL^D4DIS MV`!\6@61K0$90:_J^T(R<5K;03B9S=W``]S:8RX>B92TK?3,!2U^:\B[2FD1 M_RH"$5<1SY_XBYDW"\=5'+TC93!&`FU6C%XLZ!IX)J^0[$%O")1(ADB M#)]PH-U>1@F;9>SWI6:FJB]G4:>U=NU5O]NUL5X-5:P7MHX,=9PF[>!I^/[" M&X;DT-+Z1QA^T21L&@HC\TW::F2H7J-$/$HD0X1A+S+MW=:7,FBL+S4SY'.4 MB$>)9(@P?,(\]!]U5+19R'YG7B%]9`:+;FL:RUX0FGT0&\N+L#,>R/E-YEB+ M^_-N<^K93(\N!69'O,-YSJV4GN7\T" MC&H5.N*OB!U)R:T<'T#2G&ULG)C?;Z,X$,??3[K_`?&^`4-" M0Y1DM0%ZM]*>=#K=CV="G`05<`2D:?_[F\&$V":UTWUI`_/QX*]GL(=9?GTK M"^N5UDW.JI5-)JYMT2ICN[PZK.Q__G[^,K>MIDVK75JPBJ[L=]K87]>__K*\ ML/JE.5+:6N"A:E;VL6U/"\=ILB,MTV;"3K0"RY[59=K"97UPFE--TUTWJ"P< MSW4#ITSSRN8>%O4C/MA^GVVLE]T"_9O32R/\MIHCN_Q6Y[L? M>45AM2%.&($M8R^(?M_A+1CLC$8_=Q'XL[9V=)^>B_8O=OF=YH=C"^&>@2(4 MMMB]Q[3)8$7!S<2;H:>,%3`!^&N5.:8&K$CZUOV_Y+OVN++]8#)[UNQB M0=;`,YM3BCE(%N#YJHS/8]#ZD530B$Z^H9?.%ZAH(#ZO:S_TE\XKK&G6,QO. M/-G6P`0*$ET17$'T&U]OW,80V6MR)3!\(&G0!:NEZO(A[O(YY,)&-"<"()]7]&*`Z")!1BX8?*)#>/:HKVCU,3 M2Q?E7##'#@?)VOQ0R<`-9W2Q,Q*QD4ATA!2[\&=TXB!3CG)&I]-(Q$8BT1&2 M3@*'GQA0_?[9T7(D1UG:,SQ-9U/OML=U9W$BTBJ\7R0%!KR%I>3,`$BTBJ\6" M00CB@VIYF0'Q&()Y)V5UM4B_#1F1&#_E8&$U"Y)H$5DME@V"6D/*\B)#G[+7 M0@13=AHH!VI$1+-:Q<>]M<_8T0HF'XV6-6'-(&AZ,(*\TA"U^:&RR6\(AS1K M'YF1V(PD6D16B\7#Y]7RDL.0K[JZI,]7(Q(3(Y)H$5DMEA""6D.^\H)#C.EX MB^4,_[12OU$BZ-/@R\:MGOI=)5MGBAF;/'<'GJXR_M&&[*`G@.T#I3[,?:3NH[08(!VSBD]T#_2^I!7C570/;AT)T^P M==2\(<0O6G;J.@A;UD(CI_MYA,8=A6Z&.P%XSUA[O<">Q=`*7/\/``#__P,` M4$L#!!0`!@`(````(0".8.\J7A8```K)```9````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`H'V_EX$5<1THJUT8^WKC!B_CC-V_?R\7;-G_80[UG M9QGOH8*=6CPW[UDI\3XJ?]A)Y=[19?/Q7BIX\2?S$W=9B;NXSKOF)^Z[^4/? MS;UC%UZ(^V[AT&G>,S^%N/<$+Z+U\X[-7HA[3_`B7LV79S>7E\6KFVOI"LK. M7(B[3^'/-GLAWNR%H\WUGM4<;Z[B81?QGM52NW[Y^BO&^HGA8 MS^^:GW@]%P^:%O3[G&)L9_`B[C67;S^$*,:;*7@1UWF'Y<78SN!%7$=]I'<> M'C7N#T(K][O[3Q]>-[].Y-!>5LCVQWTP4,C=!97CP\_P8#$Y(/W=\:@AYS;TW8:!VS!T M&T9NP]AMF+@-4[=AYC;,W8:%V[",&WZ[DEE<]BG)CD7V MXM:.Q3^>C?@@T46BAT0?B0$20R1&2(R1F"`Q16*&Q!R)!1)+)%9(&,-( M)%Z&#R;R[A@I7!5LK4RDWC'D>&58/@JFKV`&"F:H8$8* M9JQ@)@IFJF!F"F:N8!8*9JE@5@K&&`U4TD"1A+9BJ7CR57(AKZPNY+75A;RZ MNI#75Q?R"NM"7F-=R*-L,>?LBHS'V33DD38->:Q-0QYMTY#'VS3D$3<->(P2F56MQP&*_EKR_M-5GW,AS[FT(/V9\U&"F;L8Z[M;3I1,%,?XPS#9PIF M[F.<$X@+#^.>-UCZ&*=OK!2,,3[(Z1RFI($BXPX^F4@Y*\6NW=J)A@?K4K88 MCYK%"V=QCC$_.G-.)C<_.G#LYGYXY=^D2/^.30L9G8\[I_<:KH[,+ M,5X?W;GT"NDNK\_(U/+ZE$PM;^)DLKP^`W..R<:G8,[1U/@,VE-V&BMM0#1L.BM3V/(Q M3K=K^QBG3L?'.'6Z/L:IT_,Q3IV^@ADHF*&"&?D89Y['/L:9YXF/<>I,?8Q3 M9^9CG#IS!;.(F5C(9=R0T:%6/L:9N#$^R%D*4_)!;J5(G(,6)C+GJ"51YWBV MW4*)3EE02C&3.!:O(Z,QRGB5"I? MQR1!5,P[HZQ2R&2%%1(5)*I(U)"H(]%`HHE$"XDV$ATDNDCTD.@C,4!BB,0( MB3$2$R2F2,R0F".Q0&*)Q`H)8QAAZTPY7:68=P_1V3S#ZAEVS[!\ANTSK)]A M_PP+:-A`PPH:=M"PA(8M-*RA80\-BVC81,,JFDP7K;B2*UK?$%&1329)EIA%3Q*P$HK MW>5G^X^YL>5(WU&!HP, M&1DQ,F9DPLB4D1DC[EY#H*(XU" M2:-P4FX`#>?G:A]K\AP;7ZPIYEFAI=P2RLNN$%/N$>4Z"C7EME&NHY!3;BWE M.@H]Y6Y3KJ,05.Y(Y3H*1>6NU:PZ=LK))9CO2;G@8V[*.5?EE7(AE&%>F9$* M(U5&:HS4&6DPTF2DQ4B;D0XC749ZC/09&3`R9&3$R)B1"2-31F:,S!E9,+)D M9,6(I!RZ)BG'C$)(>6`!UU$H*2G'=6(ILU..ZRBTE)3C.@HQ)>6XCD)-23FN MHY!34H[K*/24E.,Z"D$EY;B.0E%)N:PZ=LH%M\P>/P3 MER(F,]S",AE(A:M4&:DQ4F>DP4B3D18C;48ZC'09Z3'29V3`R)"1$2-C1B:, M3!F9,3)G9!$AX:ZY<.TYK;/D*BM&)-Q0)`DW9LH*1F&D#.%X6@HG90C'=6(K MHP"\R'E6LSS5APLIQ)0'_7"=6,UPAHKA^4GG=*K"34DWGI;"3DDWKJ/P4]*- MZR@,E73C.@I')=VRZMCI%MSM_89T"V\.E_)'ERVFXBV$,K*KG$.DPDB5D5J$ MQ#W.>PJ_;D&Y8M%WGK]A0Y<^IFDQ7J1E(3?AGL\Y1=^VF/SM7EN'Z5A,+IP; M][N)K@7YF9[%Y,(S[&ZAO@7Y%GW@(9Q9'EJ(W(T9_&?;/V)D;"'1,ME5)HQ, M+40>[+W_SRXS4S!SB[GRUEE$3(8/2T96C$C8H582=LPH])217%@G"IQH%A,[FL7$DF8QL:19C"UI\3:2R^YFQFNIPSB6 MYOWKR-8T.JQR'9/4XQX0NYJU=+&L68QM:\Z;^+:NWI/1MJZ^_8]DWG%/]K.!]B;G( MLKB`>^E]HN'O`(6$$G#HLL0;,PH/933'=10FRF#.63,7SK&YG*ATB-2S%A0B MRFE*GE^%BC*0XSH*&272W*5R\C-Q\7<]0F&B/`:6YU;AHCPJENMDVVCG67`S M_!N&<.&]\]80KN`"GUFA'$.DPE6J'J18<'8(-0_D?`U?9Z3!2).1%B-M M1CJ,=!GI,=)G9,#(D)$1(V-&)HQ,&9DQ,F=DPHD@S;F"DK&(63 MDFH\+863DFI<1V&EI!K747@IIRBYCL),&;!Q'86;\KQRKJ.PTRCTE%.4/"V% MH'**DNLH%)7A6E8=.]^"!PP=(L93#AQ>4&:DP4HV0Z&R) M[TQ\C:O4&6DPTF2DQ4B;D0XC749ZC/09&3`R9&3$R)B1"2-31F:,S!E9,+)D M9,6(I!RZ)BG'C$)(&;MQG5A).19/OLMPCBKE,A.NHY!23DQR'866,GKC.@HQ M9?S&=11JROB-ZRCDE/$;UU'H*2G'=12"2LIQ'86BDG)9=>R4"YXI<)QR<)E) M^`@".]W<&[*#'^JC41PB%:Y29:3&2)V1!B--1EJ,M!GI,-)EI,=(GY$!(T-& M1HR,&9DP,F5DQLB"EC.*YS,'/_:VO.J4"%E))K/!6%EI)K7$ND METPAJ21=NI*[AA2:2M)EU;&3+GANP3N2+GS<@9UTJ9N^\9D(Y>#GT+/#L,)( ME9$:(W5&&HPT&6DQTF:DPTB7D1XC?48&C`P9&3$R9F3"R)21&2-S1A:,+!E9 M,2))AR))TC&C$%+.4W(=A9)RGI+K**24\Y1<1Z&EG*?D.CXQBP7G/F`Y4\F5 M%')*TG$=A9Z2=%Q'(:@D'==1*"HYQW44DDK.9=6Q8Z"B?EEXZYCL)*H]!2?NB8IZ40T\1FACNTZ,8D9YAJ%G_)[QSPMA:'RB\=<1^&H_.9Q5AT[VH*[PM\0;>%-Y/;0 MS;TE()]UI_E>N7*$1-&6N[XN%HO.E2H5BRE1'B-]1@:,#!D9,3)F9,+(E)$9(W-&%HPL&5DQ(@&'MDG`,1,K MF15>L9)9C$))HW!2`H[G66&E!!S747AI%&)*P(73"G=K5]X;NQ1J&H6;DF^\ M7`H[)=^XCL)/HQ!4\HVGI5!4\BVKCIUO$E5OR;<`=X9N1><0I90/H=O]L^1N MSYR3K.7H[0Q)*HQ4&:DQ4F>DP4B3D18C;48ZC'09Z3'29V3`R)"1$2-C1B:, M3!F9,3)G9,'(DI$5(Y)LH6<9(DFR,:,0TBB,E*$;3TOAI"0;UU%8* M2K)QG=C,\&8RYZH$&;-Q!865DFE<1^&E9!K749@IF<9U%&X:A9R2:5G3LC,M MN._[>,P67&!R+7<7P&G)\'9QF4QR]6^QZ-QX5LKCG?)E1BJ,5!FI,5)GI,%( MDY$6(VU&.HQT&>DQTF=DP,B0D1$C8T8FC$P9F3$R9V3!R)*1%2.2;^B:Y!LS M"B$EW[B.0DD9N7$=A91&8:7D&T]+X:7D&]?QF9DZ(R4YQY44=DK.<1V%GY)S M7$=AJ.004YN0<\''W#&<>Z-`/H0RCBW+C%08 MJ3)28Z3.2(.1)B,M1MJ,=!CI,M)CI,_(@)$A(R-&QHQ,&)DR,F-DSLB"D24C M*T8DY]`UR3EF%$)*SG$=A9*26S;C:/OH-#I,)5JHS4&*DSTF"DR4B+D38C'4:ZC/08Z3,R8&3( MR(B1,2,31J:,S!B9,[)@9,G(BA')-Q1)\HV9LH)1&"GG*7E:"B?E/"7745@I MXSBNH_!2QG%<1V&FI!O74;@IHSBNH[!3THWK^/PL%IUKYB7?N)+"4DPTF6DQTB?D0$C0T9&C(P9F3`R963&R)R1!2-+1E:,2+ZA:Y)OS)05 MC,)(R3>>EL))R3>NH[!2\HWK*+R4?.,Z"C,EW[B.PDW)-ZZCL%/RC>LH_)1T MXSH*0R7=N$ZVHW:Z!3>&OR'=POO([71S+FLLY;-N-H_2+43"2XWD!PVO\H74 M!918IEL))&;5Q'865,FKC M.@HO9=3&=11FRJB-ZRCUZ_?UN7UT]/VY&'S\T4NBY2?D3MJ/GE=?_UX*D^_OI,G5Y^> MI]\9R#LC[SMC>6?F>Z>4ORM=>FJ5\W=E7WLE?U?QM1N9@*^]EKM;^*:[%+[D M>T,>R7`GCU/PS)(\*NA.'I#@>Z&PO=V]R:W-H965T&ULE%C;CJ,X$'U?:?\!\=X! M&P,A2C(::/7N2#O2:K679YHX">J`(Z`O\_=;IAR,32<37M(-/BZ.3Y5/@==? M/JJ3\\:;MA3UQB4+WW5X78A=61\V[C]_/STL7:?M\GJ7GT3--^X/WKI?MK_^ MLGX7S4M[Y+QS($+=;MQCUYU7GM<61U[E[4*<>0TC>]%4>0>7S<%KSPW/=_VD MZN11WX^\*B]K%R.LFGMBB/V^+/BC*%XK7G<8I.&GO`/^[;$\MY=H57%/N"IO M7E[/#X6HSA#BN3R5W8\^J.M4Q>K;H19-_GR"=7\0EA>7V/W%)'Q5%HUHQ;Y; M0#@/B4[7G'B)!Y&VZUT)*Y"R.PW?;]RO9)71Q/6VZUZ@?TO^WH[^=]JC>/^M M*7=_E#4'M2%/,@//0KQ(Z+>=O`63O'8P?I M#F%%C=,%788DC'X>Q4-&_0(?\R[? MKAOQ[D#5P#/;O*1C<,`B#( MF,#M!TLP$!RO/+$>C!`V@H0F(KN%,*A!D/NI2?#&A54.20E\\\$I0I9]4H.` M)=9X-AYG?AC28;Y!"\KY?EH2;-$B0UA,%4*BGE;B,Q*8X]EX/(Q#=J62HCFT M)-BBI5>+M!#"D):=P\N@5ELC#+%@E]POE@1;K"PQ4H2@6(0NM18]Z0R'D?22 MZMHT.,F6=;:KE-8O-L'2W9\`?; M,PEBL'I(;->6.4PU;9.6--J[JXN@+1NTK.>F"J/T"OQP8EPFP@]"HF.8Y*3W MWD\.G1I^M:?J+84U1FZY.>[)FQ"3WBS')U/+9[J(%3W$#+5FC64\S& M72*.]'23UZPV0*=M8+2UL,X4!GD%$;$+,3,`C+!K'8K.:@(]VGSG9W834!CP MVJ%1V(9V$V(J9S4!^4F4_/R3:-H,0LOL4XH8-%7;^C)C-+A6;K,Z@?QFM3K! MR)=46LU.0")_LA4,!*7P@CF\@)K*6>W@SH_):5L8??DHDHA!Y1ZFE6<,CV:; M]&8U!8J&/GXS"NVFH#"X)1[B&,0;E%&;==P6'B+XNM*U:Y*;U1?HM"_8'2E5 M&"27,,9T22ENX\8143_1RS.I67WASK1.^T-H;(7,?GLS=)$?/9F MB0=*>-Y2\>;`,WXZM4XA7N5A$87/Q^$N'F2E9)52>2YAW<_D`9>\[PT#<+YT MS@_\>]X18=G"SU_Q[A))'#N8>_`/!> MB.YR(1\PG$UN_P<``/__`P!02P,$%``&``@````A`,!7:`QN`@``.@8``!@` M``!X;"]W;W)KR42DMJ8:E7Q+2:T\('R9KTXGA`)!4-#@X3?8V' M*DO!^+UB:\D;&TPTKZD%?E.)UAS<)+O&3E+]M&YOF)(M6"Q%+>RS-\5(LLGC MJE&:+FO(>Y?T*3MX^\6%O11,*Z-*&X$=":"7.8_)F(#3;%H(R,"5'6E>YO@N MF2PR3&937Y_?@F_-R3TRE=I^UJ+X*AH.Q88VN08LE7IRTL?"/8)@3WMXD!?K]?B_JC;(D M&_S;A00BG^`]M70VU6J+X-#`.TU+W1%,)N#L,DNA/J]G!C0NYLX%^5!0&^C& M9I8-IF0#%61[R?Q2TNLJ%J\H1D<)`;PC(V1^RO@^FQ/G&*XO;,.CK<>?!\G8 M@R>?;M+N]N+-[0X4%.MZ*"<^@WK)-4`%R/QD.^_W^>4-/)6DV2I-1_))D!PX._?6U<^(NW"`^@PN2=^%.)6_` MA?$/T]'2%?]&]4HT!M6\A+,41T/PT&'XP\*JUD_!4ED86G];P3>:PXC$$8A+ MI>QAX3XOQZ_^["\```#__P,`4$L#!!0`!@`(````(0#4^ZH9RT8``!+[```4 M````>&POMN'->UY[\/,.]0$!R8'I`4+Y(M M.[8/:-KR86++.J*4S`7SH=E=)"MN=G>ZNB4QG_(0\V6`&4"81]&CY$GF]U]K M[UV[+DU2BI,#Z!C(A:K>M2_K?MNKOOR7UU?3XF6YK*OY[*M[^[M[]XIR-IY/ MJMG%5_=>/'^\\^A>4:]&L\EH.I^57]V[+NM[__+U?_Y/7];UJN#=6?W5OU]_65=??[GZ^MOY>'U5 MSE8%^RB^FZVJU75Q,O,%V/>7]U=??WE?0WWXY\6/\]GJLF;HI)QT?STM%[O% MX=YV<;"W?]C]\U?^S.]O'W0=IAN?7 MB[+[X\?[>SO_UGUXQ+DG=O;'T]%%]]>/ST?3NC=16N5IN:SF@MBD^':TVCSN M<56/1]/BOY6C9?$86->]=89@E98)KX?5AB?XMQZHGR]'HK+B]/KJ;#[MK?CL M^Q].NP\#ZI^5%U6]6HX@B">CJ]ZQ/G[VW?'3W][L7SD^/3 MXN3)\>Z&^8XAK27G/X%<7A>_+Z^[XS[>V]O;?[CW\.'^0?>GX_5R*CE:EG7QTWIEW,SKW5TCZ6@V+GD' M?JV+K1>GWQ8??=(=?S(KGE_.US4\66_#N].RKHOYZK)?!/OBIJT,_Q9) M>%J-SJIIM:K*/N"/QB:IZV(QNA9LNGOC]^4:TLGFV#1D#-5"9Z/5@.2.6S$* MAWCGY\6D/"]AL0F(>5G.UKV5VT"^87V0C9Y;"7[%;+Z"&<)9MHO1JC@?5'!@E'CXE*MRLDG M]@8\'T8$OM\&G9(0J^IE.>U)L*,)[T(><(\8;J>:%>/1HH*;NF"&[M97ZRDR M,_*OR&M97D)A3%U,YW6/C?-WH*YJ7/58S5%BL.S`O;N!'O+LO'=Y<[.\?8JH MQGXI5Q5:^9--\C?(]X#PA.GN!MO#>IB_TW#'_9V&SAO:Z(^/"N9T!<),(HO# M?T(`FC1P,F(;K`_;Z<`<6I4=]H MW5'^I:D=0!ZMG1WG$'^?#F_*L+8^:Q_`%,Y%0[#55ELA4-\TI-- M:*X2?G?[W=6LO]-=,PT,4W5_MSVA%\K7VOJZJB_--#8U<=;CXN]Q,8HMB8!/ M"CO(^!(%BN#GL42]$9TH<-Q1#5$S#"Y_5N)XE,QAAUZ-7O<-A9/T6W$&7L[[ M`N9)N1J43:XVF#EC`1V@!](7,SRJJ61W<:%C`I1ZT.89-!7:/*8%ND>-&RR@ M$U];ZOI&F'H8-'%YB'KH+6LC=7`] MF3T&EQN6/<5DPT2NQL71%*6)H1KEQG0Z.IL'4=+=0"-MV\+'+,K'T_FKC5*F M85(LQ>JEV4?=V8\F?UH'&U.GP8:*JSF=UJAQ;.$@]NGOG;$DH8 M5TZJ4KZC*UG_?_$'-[&)4?Q[D?FI;(B=LY%P(\1LLM:.\JW`1NSTJEHC+V:Y MT3U(@,::[7%=F!X;LXI7,SB96V!"+K.7>I3YM&>H#UN^7=.NNX7L]Q!\<.&5 MK=U]17SSSD@^,1=%PG@S(3Q=HP5`"3[6^096[^[EQ]%JO31Z=:,$5^D=WFXM MN!AT4[H+'HUQ8&HSW;3+JG%8NB,3F+8",WP"]'IQ:U*.431U^0G+^5_\X10N:72;'V[B=6B@'(%BLJKOY&]\G,K;YS=/U8C$U(Q,030APH>76Z&WA7L&#'>-IL7VP"Z.P40!E]' MER+;3)'@=`&A>E!@2]F;\$"VUKS1**33]=75:'DMP)Y6%S-B/F-%YO"RM%D= M[^D<^B2JT(7B_BZAIE]^VL$YNVL_ORP%1K0;$31M,GFLXK,0"`LX@8`(FD6/ MY1(3!M(M9])WN%U(+#A"PW0NLTQ)S;@B`N\19 MBZO1#"M0,O%O?_W?T-4"83:?V3[::!F:@47/ITA"V^&H,;VVA3KHR8B.G<^4 M@9@R6K$:X[/>6$(J[!VQ2O!21"S8CSP8!'8;0@]PX-%Z"@-JF,/%T>3""U'@ M[Y237JC9Q$D+H7$N*,C`'C=102[5;`(7R7L3!M)(V$GZ1'04=W"^!DO7N(B[ M1&/9\-WI&'=A/05O)?./C(:!WI_6LTS#Z(@ACC.(R@XM!,*QN?3JT6RV!OX> ML)95^#C0Y^_3]K7S`CG.B6*,Z.V;&!RV44:WZUJG6XX6Y1H0U%`0,60QS:MR M&YXI^&M=Q[_FZZ7]&7#$;\?.YN*N;3<%7EU6^-3:Y%D(=EMR"L`#6-)64K(L M6,+9$=(W;_75J"94N01C?=S_1!0^QLC>OOG,(]_;!?LLSN:CI2FQ"4PT7LV7 M"/>%%#4`&0&R1H(((K>,OQ!5+LO50VA4)%L8]-$#@K:-YVN"F]_;_=1<57A#D,& M'NGH1#0`31.8X[C('**_.8#)/H)J82Z9-DM"G.UAFP[AY\#"CM`YN;H"L MP/P+@/8%\@_H?(>&AW+[!N5/T,6@P2`=N[C!6OL>R\4EIX]R!H)NC_:O0S@C#NR^0$(8?UU4(@9L2E>#[(2;#$5HCBB.Z#1<]2'J(@N]2D MX90EL:274V`D.9M>+-EQ:Q"&`%IBR.>R<=ET\,SF`XEO6@:QZ03,Q"E)HO6% M*4O`GYT1F'J,"'DA./T\F[^:EA.">Z+@D!G5_N6QV.P.#(3MU>@:0P6V6PEN M;$NG.5_+_8"*QBN9#='JL;%3QSAL-:GDY[J4XZWVEK1*`_8>:SYS:&*1C.=X M*MK.EYW:D:--2L18V30/.;VY"%HE"!Z(1():(!(9N"Q#8L/E4!Z2=*_]^^GH M]?ST"@?^]U-5CBRF8S?_3W_O]LGI:#8_K[:+(\W_W_$@QJ/BZ!L;DSTR3T%K M?%/-07EQ@J->_'C46$;9?T:P>'LH.'TA8@&=,6X&GK:"S("2,GK>ABQ['S M%[%)H/Y7Y//,CC@7H;%5HY?Y%!]>DXU->%>C0GQ^5:Z^*+;V/WG[!J,#H6=Y MP%*A)=4T."@VC\^8$CVA)9D;Y\]\:`+8> M\-*88V`_>>X=TU\^U:@F^7D&M8N:F;]'R8^9SZF?[.=*3F11>K0C/UF]S:)V M'*MG<)8S7LT)5;:`>Z7LTPRVFE/@V4J74Y/%V26>K0+J2K"WH!SD18C^=.SR8[5E$F(5$!?%+%5:;+*\9OVB(`PCQ0< M1,(MELHG:%]8HNOEC/_#")1E&LS0<.ZPG00'PA2$3,HEQ\0%A1X"+4D8&:#B M_D&#<08RBD<0P9E`:)NLUV?:OF)O8"@0/H.QB)/##-U.YNZ3B6[G1`62BY(5`!N'G-M)+VEG#)T0R3 MZ&D<*R)8T"G8/1-O7%:,QU,F#&J^[2MJ`J`1V"KY]D2$O0^O" M._B>@?CT(+$50LO8#7T\\Z/UHA03GQ-3&U:OB ME44<_*"1<4!Q69&WAVRBKX/RCRH(^Z.9+CX5XB(;L9$6#IFE"5N=-QJ"F)[I M>P"8=(1VU=IOOH#"M,298$"1;8353:(!9S"6+N M"Z4Y+:-NM-43?%B:UEYS!!BD(_,_0@L%*-EHQ M>2;;T7:2J-GV,)J\C%(](]]MB;2)#+,6L6!I0@H2,4N<0;;&&$Q+R?M@>-@9 MD@RR(>F7.@\:]/F^89B>Q`NE&B'LFI&W224C;=E6;`/Y(C'PSJ)_C'TZ1@`V M,$8B8IJ:-RN*,.'BAHUDW:2B5@:3Q@3/:K2\P.-&+4CD6U"6_#PVC2(%S>A- M`U9+]")4HHB519RI90TQ+5YWK8$QQ^]R MUXIQRO#'-<$J[Q&IJJII7-+1ZJ" M\@PQV"46!;\1`)5;4LT@/>F'\:63?"+VAH&"(R.MD\EL%`*E.(EA9>QD:9%) M*1=!AS-^:)C9#H_`H;8$PI2IP]9D>39'TQ/#(JA:72ZC5R9C2E4MS"D%,:W. MRYWQ-9%_W[A;8?PH7NO/V>0HH!E+]?5#&BD/'ARHGM/4Y4^,7QFH\T)EGO6Y M)5B,U<_`8.*NP%FFG%HF_(T\&0RNEJ^*-@@IFU8XMP:'86M2DI)A8XD>-H9B MSQA;LBC,.Z.VJ-@_*##,=(5`(F(\16Q9+;,08_F[X-UV!4:/UT^ME(*,%*L> M$V'<5$J!K1,,;*-+3.7!"@S/T^'S1J$J$%M`.+IF%RJ+]R,J,#J_+J$,<=V5 M%6`:E8C[!P+/9'""=R_V$;HR.P[Z*5$[K=5D]VB8A(>HS]8.MJ:>?T-8].>= MT[',I1J`8F)W'+Q;S^F&JY$.HH#R=U,=T>?9\5,[G[.[W>)%HQCN,+[8XOK$ MW`(7."5BJE*'0!OLJ&9<8,";O)Q/2!O`[(E@)+H2*A-.))QL"HL-408A9]"< M19F$NH@AY\JA&-PKY$U<"&=_Q@4:P=&.^TJ)`=M3XO.1/9.5`:T&*P$7)D*C ML-_Q^1I+DG&058);""#%@[A5&'<=-^)[[5'R$(6F@$!&=6*/AO+<4,`,)^5W M&P$"8\O*(#Q(*"L-9D:>QR8Z;]?DD_'`R#5C-;ZL:BD9(VD*/LW7$0PS\C5- M8!1B''G[QL7W@%ANC\2%`X75T/]-Y6``G2K'`[FL\/#[\O.QBLO_H.)RBET% M]9X`I58!]6H>9N-G4^#H&656)V!4DRA;8<1*^J,]+^?S6JH"51VO6B@&8#K; M6!)*8-P5P01""-D@^>?(A%4.G^!R$T2B?@>VII!NS<$!8IJRJK\H]C\1KTVY MU0$)8I:LS6A#<#3_(KOU25%A1;W$Z>5`[!#I<]B\R)Z@!AV%737O]0CN9%;$ M.+IG:+CJ`W?#%,P'B2LC3UP%6?;1PRQA`,V`%B_S1]LIA"_B0/[#6T0-B+^8 MVTY@Q4Y1/"[/EFOE?@G8[PEBWY_^WJ)M]F_]XPGO>FS."50<&*0U4XBI]0!S MY$PZ1F(CKTP5$./"M@V3@096WLXPI(&M-4.\ID/*+O,0=0OP%+,@`G<"0:^J15VZRJSX0##:< M5=*A*>>3Y02T4-//E6RUQ(SH!<[WXC_>N,M.L-[:&[&2V+SR-V-:"\$D$C&Z M"!=!A(P-&^PR[#.\5B*E1PVS/B5T2N;(\X"=6,:22XRZ+/E%O2!1^-6]!>2+ M9BCO?0V1Y_1WZ,A[?'3Z#2:I46BVQ*F"9JB%&MR;SGTRWWW[!J0<[NS!(KY' MUM)_GO(_U7UN1/Y%I<[<[-R[Q[^(--9?*A2- M%JTPP-;84C\A8?1;=H7C)[:V-$.I.WGOL/:#^_!*Z M6SLF7I%\A0:M%L:L@]$LR&G#-2#.*PM;0,4B5V`@GBY\5X+MKIB1A*% M@`SM@A,+42$2++H>4O*PHI*G83#&@,7:E:P.0O0XNR^/D4CY3T73<%.8@3#"(WW5U;#-4#2-Q@-P3K4328S7]),[,TB"KOO27!/C>L M>LSR#Y0$3R7+8CV@*'>&$2YI3()-MQ.>CUX7W_@EB.*/EL9!Q*SBI1_$PP^Z MX7,LO00N9>&B`:@D1/!0&J2W-<"@.K)_'A.@P6//WRB^LPQ.[]C_?C)B?[\O M([!&%)7&C'LM:X\S)`,/*A,+-E1FUHT95X&9/%W@\%WG\.4""LZL73+Q(/C( M>+Y1LE1Q$%/JP+<.\-7;&A#@JW\2!!!\\S?8L3)D4M-P=-HU?S>,R.F:"WW& MEN=^JUQU4\PO416K&MV:)H(6W6XL62MB8]Q9*@KV.HVF+&S_H5_+QT_@/1%: M8&#)`!9!446>-A-+JTD^8F^*U8%P:_,S2?,'OK&)Q[_/R`$14W)QF(D'>S/* M-U9'UENH?$0B&XM?1=CO*RXD+9*H]:)L9FO0WZ3XAT3)ZFOQDG'04Q3GJ2[5 M.!_=XMP[:C9T#_P!-W541";#H-/((_0@KF-7[I2F&V]O-[QT(V'&,(9I-,V M'=.#4;*\K&;*@)H[.S%Z;=/"T2%;GV]O;?$1:31?.W`0NAB?#V;)O:=9?DD: M'7R+CQJEFV?8-1,A#7G/JGV!\YJ:%YPEA5NXX2_JCP4JH?BV,2BH65H@&(@< M42T2;2N]F:IXQ=M&AOBAD`F3`1,]F/@M-$D%="STMX>R@ M*V"RX?V\#=:.YF M:L8N52H$;\&2*#J(AA-4O\WNZY.+`*2L([O2.HVT"F5T#O#@B5EAI&_%8B0! MV!LW9X61FI;0]'N"U!'GR('RP95%Z.-!.K(Z0L,A[]F4C;NS(`9!F!WCE6A* M&Q3N9$-WU2W;]Z^Z1[EH^Z#K8/M_4\?=)^29^T^^H%LU1=^(=?H>@-- MSQ2,"C3))U,%KY0R`$RQK5V,W@Z<[!=M]=/BP^_0IBX)OBWXEG->-H&%3 M/6&0"TO(??,6D$OC$3O6AB?D).8AUX^X4J5,0V0NS@*E4/(-=H),:O1Y*&+M M(^NYV/SM&^?SMV_,P>L>L^WO=7]]`FW?,L%Q*X#8TJFYIN_._+>__J\A6CK. M:O.C1NZ^FJ\XNX$T[.9^]^636:>67?4/.=2U_&",'85CF,;BMOCY4=?[&7TF6^.T^"QZH,X7Y8%P[#/3N>6]D@&2XH"$3(&_R2%0::NM`7#0$;^SR8G[NZ MCQ/V:6?4YFP?F50P5TL.9V@V()6C&4$O?`[P>"FZ6:HD$X01`WYZFY7KA%H& MZVJ%AL;B`(4J'/U9F7A'IPH5>!5A$`^]#J<*=`@NXXZY+>O%A#&3),.127T@KIILJNL;B!:;69;Q8!^%0,T]#R=.*].3 M-*>9C%A2W-@QQ[='4\_[>E)E!D%1WK2!K0GE3"K8`4VJR:[!:MT7DC^&#S[J,L??FC9Q,'1>(#!$J3Z+QI).+1XB>ATB:+>YE7*/^PU4K,V-Z+M%I9 M2T_'V53F@F7)!33$#RH/*M1P2H`]-!UCK-/*#%/3,8WY;!*I(V1P6W(X-)C]UO\9HI(,$B(7[=3,IF)(LK7M\C=)ELBL) M42NC4U$10@;O>_DS-FFTTM-2S;S,P\RJHE,,SI;6U4`<[)AZ#',LJ(VR&ZQV M)<1X04?-`&B)Z]WB1U^S/1[5<;:^5FF5R$/*QLNL#%S-(<):IEED;5I].A=J MRX7L1>5'O>PU75?Q+#4/57QI?DL$(*=PW;E5J:I22LIP#2 M83MAZT8U+0PZ^>H84(RT0?2[!VA*9Q+V0HT?>_#R:X@J()@,*#=D[1H*OYJ[ ME6$9%X2&*66MDJ#^N3SP85BPW<8+Y5+_;";=VVK*(,Y!MF[G_A*'ZQ$-Q7($ M>R*>-Y*'>"43%"F^T+C=BG&'I]9I@)7AQKLT7;^^`V MM00\97@[$]T+R2)MMFO')=`O?)4(32ER5XTOK+YT= M5>EP`PGGVW#L7(121VYT)+'5;6#QRI1P%!R],SWO6_TQ,HH:1.ID9TA,[-I] ML.55U)D(R99%A'C4]5ZBQQ931F;B>#%DR$.7B.W;@Q:2N<&]>-SH*#@"?30P M]:"D>?NFU_C8,$T%RX;QA]WG1P:+GFP[OJ49\`_-C=K^NUFT9X9X2UUANVOW MSMT'7?>58S/@C-XDNC$(W#W*D0T`\TA&:PM.POUU4$)>_#T`>A.'(,9U@@?8 M;L'FVS=_D&?V]LU-)OL+JZK,&OQT#]M2LR=FX72';`7.[OF?WX0>'!!J_[3= M61RJL.*[`[0[5;;N`"B[H_%:PJU7:14)@;RVQ0R000V)A+'G($7=-,^6\Y\Q M7.]/"*GP_Y:J;HKP4\+0K-I,*LCR0TXT@97,KPTUKRE#G0E:E^"YY$IY*O0% M_@X9=]M0V$_8*D\KZLP0$;KS:DT/^@K[Q"LTK03MAA)-T7ZKW48;+#EM MC4.*A[N&MM>".Z!3*P0'7[V#@SU<"Q5HO-)[K=K4II+"Q:I>5L\RT5DLL!^! M'>)P?I]B0TS6:M6>XL7MG#S]R6I9GR#6O!H%"C9SGFX;NKE)^%$W-QL=>5[1 M/XH=ZHF%S6C=U9GH)F6BX)Q[Z5D*Q,[AGFRP^E,IBW[J+P#@Z%[]68KX1O3< M,=]CCD.H1&6FPZQ?19SI3D5BJORRO:>K):DHP]1>*+`AUFKN*-'G15.S:(FY MN!QD'CI=AQ('>/XY1[]S^K,/HSCU'6&B7%]NH@7K#U=0QH+U0>&TH$<2QK,$ M9CB+%C[Z?/?!H8Q?\#(@)*U/"G2$B>>#'^V'P;];*]6RL0>/(&!4&.X/=ZC0 MZ=12GE;HN(!?=/^$30HK`(`^HU2;M;3G&;C*R-E,W5OHV5&1JV";Q%_EL=W5 MUN%8U,2+Z"L(#@(TJG#`!D:SCPU"&M9#EZ_Q,QW6@CT-I#30%]D(6F+LLDLM M,6/HV);=#_?0+.FZV/KTX6^XEJ);9#NX`(3&"2\66WN[AP=ZKFV&2B[_^$JQ M]6B7-WPOV3QA2[96"I!8*OJR_`,Y[RLB#4Q*A#A@[W/CSC#:'I-ML$.PP]Q M6(/B`',E%])U!#]A!RZ#IQ0.KJN2NX";>Q*+L#RK<)G2GF&S??4H%=.^GD MSA]*Y$42XA&A#)QUINCX4:PPR8I0>21:&HF<=*\\R M1@-%V3;*VXCC=A29*BI,HH85LSWK-ZHUEZ?5@ M[,9*?E2D\WQ(@A&NYR#0J:?0DD$2T/7VS>=6F@EA':UD5 M<%TI\2E5;MDP*&;#P%,GB6>EPM[0B6R?Q]8JJC@A5"L:[\XM&G8'6-9S0U-M M>D*Y@KAF4N\_!?Q"EVC(:0`1O0A"RV/M[N0XIV`W&]``3;WHG<:GYBEV]K!- MNW+9??V[<.7705O$%M[%4^H[NV/].Q`1)`[DF^#1>[\%Y%[!5V-*!FO)8I&R M7%SFJ$S%;9OPNVI07?N)TN]FH]]2W/7$JH])\IYW-Q]0T7T146>@'D5+,1@ M%K9OE&?5:?T/9'18(1RAQ[W/DOVL.A;HGUXZJ.+N.7[3K_7[+]TQW\7V`E8B MC\7DQN7&88TUO7&(%'.Q-5RT0?_4G'_4CP2)%F]B9T7%=W(2#WI"_`ZH@X>S MSE8-QTM1QDX'NNVB!G*WQ94_DSX0Z-_URQYWV6=H`I'20(&<<#OT23%`9Q?/ MP3[FDU2,XG1^G+@CCII]:T0]VYIOC=QV-!4=XNQ9/PG(HL]SI];RKTL%V%'= M1T=J!>,]`;L_9?W^VC_=Z;K9#>$[P:%U7C,H0N._IIN4.W5^$ME8H%U6ISA\ M@7%AE:=F&7OV!!\WT%7A M;72'97TOSN";(!-T"V MLOGCBCVDEZ.[TQ3?@32[Y^_HB5Z?PI;AFW$R:$GEIL('NV'%"H24<'E@K]^- MZ/U-G1[:9-_,EM2E@F"LN9)9!T8/@J?0MZ@&S2C2"8.SJV**B'29<@,58I2' M#N>Z<2/&-B]&(56*T]5NSQRPYDI&*F)F9;*DG%!02WN@39)5/%K!D07;0P?# M$"^=%T[^CI[&`$T3F(1N)F8WBL!&\`Z34IE.!R]!B-`+$.47B:J5<+U?=+PBO!/X*Z@VY M[1P0&M=E"/XV&4D.*Q`I.SJ:+@@66N#D]'HVP0+Q<".64W!6I%*]9TIR M&@*%9HUJ1GR$')A=4@V*HA%BH="V&%=+D"W19:51)TVD#CH')F1P MO*X0BNMT`Y:4^NA@]V$,*U#.<1XH_J/]W8/T7/$'#WY:^'*D+`=&=?!:8Y.! M>($+?1%H'()&43X!& ML59A0!#C9';EEUU*56T34,E."*12M7JZYHXL#]9DD?I`A36)!5GS)QF51F?6 M!URL'/-Z0QLT)0IW&HJ!"V%_?UM$T$JAM969\V6XD@_IU-I;25`T,*RW`DMDQ`P(L'.5ZQBJ-P0@&;GR\!6 M.]KY^@&(-2QC&^A*%.#`<,^:&B6Y#/H$SL!OB>DS?ZBU7;L-8,H$TS]J8CM" M&\:AHP`HS)W(,/)4!0"*WJ0,)E`&Y\9=26N)+DT^J2:.= M>KS=H#"63L4']F`G2PG'2SV)ZF!/O@.Q'_ES$-TQZ#G(VWD7)2@,A'@Q%VV8 M?@$R3+KE#OKWCZ$^O"&<]N$=_Q1-T&\)#VX5OE48V#5*$<%ZP*9*V&EY+,+D MD`&Z0"3&WI=I_BN^BV[XL/)M.$? M4K;]\^@@CNU'=89<]I1L88SP-_9;SA622O:ZF8)*&#KRC7D MIU3'(],M!/:"S6Y230C+(,U;X*FQA!H#7_AK"MOCJ6/9M=5DV^#V)6S*W/)O M1(=^]6=\KX=J"=4N2)O`V]CVZ1M7D5-T)+:'8@VK2<;+PXA7D))01US%MFNT M&;?DI,X5V-:*HO7O!M/(NW@"8V/YS71DB]V:31SV>KL7WO7H;D2M]6XDZ@9A M@5Q-(9O`-(8Q2U6S>+3#7&]7P69[Y,1D$)EQQ)M M1_.$CD#Z9&.YM%28V>#FJW,-02T",VI,@NX_3`PC>&>F2KUA+MI:8DSM%P@Z MY#*TH1?9D_OH'*[CZEX%8BN1YCDE#C`R(YC$KUF&3V22OU.#LF^7:SXAX0TI M3/KJ6V`G3[Y5F9,1J+&)H>9#=VL<^%9%*)!;0]-@QF>"*?$C,/6@P4>'AUG7 M1#%UTG,)1^XKA?'[G^8&@E[(&SRC/AMWLUD8&7S2R&JSAZ0`$;C52HEIY'3< M[')^/:)%,]'85(8"Z31Y5':NS@"U?<4V>,H2V9B,%Z3[9%T_TGS[![_1YQX( M.EM?AT14A-NM9IZVTIKB70,"1R1UIEC4>X_L%"UMIN]9]&)2YC&J?21[BKVK MM3'K61VT0^.?R]S3=34+K1#RV'&\"D3HW1`S-8ECL2PLZ?/IB$NCE.E8:VSN MH`&Y+=$]K%!=75&XOM,:%",A7@H(5O+&@R2Z96>T8"/S.J:TEN42"S/K]@X/$ MXP:,6)G"6@D"^KMWXBC6V]%NLZ%"K^W;0RB94:,N5`'!YFT;KD*L2O?3`AB" MN2".$7H4K>/%=DC=L1W<7XU*R_P:Z^U\8^D7CNJ&^-YB!;?$V*JGH3]416X1 M51SC=G-Y'/;;X]M0^P:'.0:;D-(BWT#/729PT:G(5)0NX?J^.]L=3FF,PA1T MB#8\XJ1=.&6-QV(/N9C.P_!0;T($F7A!E+=D^KDWV(B[&XJT1("_DX3!5*:".=5"OZO.BO*.X)Y.]5Y;B$).CE^L M10/Z5@S-K/A\S[[?V=_CFK6TA]_`$V##QX:M,FU9SL]!?7"P`@0`;\P6I;NY M1!P@("$KRFYWTB5EH_QLB?PQ-V'X,$4A<8^VK-=SNHYO(M!A&/:@,$Y(S<>S==[$?/KR/X?A,-:757 MK5D;=OW:T#8?GH[M%Q1G;`(XR*,[458WF&.FD-9H*?@,&H:UI.,-VC&SV(`[ MT_%-_O:#%HF`K#&T!JD-*@.9H58@"!<1.$P@*+ZO<'$/G=(MF@4.L/CJ:U'W M44AD.0J:6[-/YBM9FI:.E(4DQ+-Y8<2M.7!=H]VEF18]@!?NHBS$&804J)Z,3 MH""(:NI5J-DP:/)>HBORX,'NP^0WYI>;PH"'V<\F.$#6@'NCO)W,\X\./K_= M%TJ#'_)]VK2XS9XY0FG30`IY&.;_M/=*XRS%W%SS9M]G,M$9882/I&1=XR\Y M1*,[;T08H(-=X)PE'?[QCXG%@[L&8!3=>PZ=NS,3O4R.\O M[.Y`6T5XYJW)%#U%*7,];K^10O;AM-_:QTS:KVJ]#:\?]%Z78/OHH*5N")A+ M+([M@S%FMI*GE+>+YM/<43R&2%5CC(9HDW7]Z]L'"C*"0&*!X3@=S]9R;BTM MUK@@I@ARG:8@CM^NQV;8,0>0'*\%'=VI5:$MT,FMEH3Z)N\1%/^#0THF$CH' M+!4BX`]EZ5@`7$;G+9;*H\^ZQD=28VD7N/)A^?WWL%7V'[6H1WO*E;Y[ZLU: MQB"*Z5KD>2BPV[-7Y$EV(KNC&>6"7`C(@KOO9<]TZ)$4S(9/+?QJE)A])R!; M=H^F(W*0/?2.;!CZQJU\'$(E4(2'3:",7Y/-OR:;_:-MH4P(1R!+9"=5FR6; M_T,9)5)(C5X=ENV8"WN9$D@PZY@G(6_P88=@_-NS9L3DV<9-,!DTV=U0"+=_"9,4./O8]G=<6HW`%MJ780P:,05PR;@'5^^P0!,,_P3[+\[EU4? MK2_65(/JFIM%?SIIU'923&00B[M3)-Z-PNPB3/[13]5OI#J/](JMY!]L49P3 M.E`)8;S!H^;#Y..R&?6[]V<[I\XD%8=H.X'@9!$M^/`5+7*MS3(31V#H5$)+(3+JFH ML>-:YJLB0KDC0#=G^IY,S$B3IG)GN"#B35O;PI+N" MD+$X.NA(O`G=W:EU`2F@(R^USNC)CV2="'PVI,-\!HQ`\167S/%)7M&;DX1E MDPO4E$H&`8V,"M1-/<8$;/-\D(I`K62)E6+&C0P>&`K2W:P_M+O"\:]!A,-,<_I]14#E\@ZR56C=H>+&PUZ.*WV*".2L@ M%JWU`"5R4DF2&L?L$*"B<[)U@O3.9.M.JDJW$X!MYMI%#L.:M\ME=@.YJ.SGS^*(NF#$1G6N6) MXI;%S7FD_8.:644Y*ZZ-7=1>F@0^O%3AU>)+5FOZ$S##FN]1AQ#)>' M$O-M]#F]5'C6OL=TMX13YI9:T?W?(`EE5UT%)T/%&H5]Z0R@/BEZ%4R%^]U"MH<__. M.6.X/;V:T[ M+060JD7X1JHI@'Q%MT9D]@D7O!2^S2'_\V?9U]?^R2'+?H`.NSEI7J[]%BX5 MRIC0R90B$<[T6@M#&L#MWT\?VO5?P&N73ML^2>_FZ0W8\MM3\JTP/%.C!ZUR M8RL'D81*C2S'@ST86J*S=X!:4RVN0GD;I#H?S.%XBUTFOW4;;K/'2M[@C,1K M.#W=WZP%7$)U39D?KB)%Z%`@E3&M&6T7?&]2C=BDJ!OSOKE;:.FH8.,DU]"< M">OKX%:+5?`##+]UXC$D0T=J6-="1KB#IA$TF=^1_8P$QR2OPN76;TC_R@B$ MP>)S_NV\5J_6$[EK8#E^7X#KJ^YWZ1"CHMT'J6F="I^'CZD8MGS6+^Y3Q M%EH\"M>:'^P>IC"A%7BNV"&-"IOSW4&F>2#5;IAY,@0;V;_^;9MH+6)M$)(7 M$RZ9I@O3K0*ZOE>BHPBBK3W=.>.'X?Q+11^S7CL;Q"]8R@?=$'R$`%R[Z+K8 MA]7UQ@K-SZJYD1_?3FG)CGI,]W/:6W-I!?WVXZE?2[E3C"!&`',(H]*R"&`L MYU5C7-3`4#S0)1]F.T0G+=(C+![2DE.7.!0%PHM!I")BHAQ&[2[4P!::%.?' M/AL2ENHJ\*'BM'A]-?VB7J#_O[J'AU.K?>*]_$9!T\(O%6KC%E:CBYDA6_*+ M]W3K-Y26_'AJDEE`X\\8)K9G_,.^*E6;B+$"@SOCWIHB#^">1PKW"]VIDPKN M5XK1*%YG)LR[DP;?UY)PUDD2+283,,RKCQ]?4%_"R$'Z:JXOWD!@P:5N0-W` M%W+\\?06<(6#,Y2&[U!_5,&&D.1M9V3=_K2,!9]$YQSI0R7S-D6[6;,6DVT-54OL:&@P5"Z"G&4J2K%]&\+B^XU;>X=^)MK8O-:6OB/[=H=?$ MIZG[QNIK#*+L@I"<1H+_NO745X7#R#-!FBMA:`S1]%*9-ZE)Q#Q)/^8S,K?1 MD)Z^A2!J7*@"DNQW,.H242I4G.K*RY89E:QSTPYQ^I@>L*75\4C!DBGFLHLH MG2:NE0@>C?*'FZS\&BH5N'[ML6+EBJ(FD2&<%;W; M#:%2B#U5B@N`35%6HKQ&.%A%5M;23,(L%(3H*[[!7,4JN=% M:X(088@*N@S0$9"3UOG`'-L[P$9 MAU1!JI`C(.5R7ERU7I!"2L`6"WY)Y0$M6.#@!>]%,JE\^/S^IZ_3/3.[0G(> M_":Q/7TYW7WN??[*J^>7E:MFV2)CS',#D)1HDF5=>/GX1Z5EVTE@,(Q"F>"& MJJ('Y4ZING,OAQCX*6A9ZQM+Z5#1"8DH1TUTZ#EFCP0)^3+/G=D'X\I3K1.Z MA0PS-S)CX2DPF\T`O`PN80ULM'28I):4XJ['.^\Q2EK:AS0$(6&8LHXJTP(' M\QHU_O?Y[/X)0GC]@[,!;DG,B'!*3?X791O(7Z]\%8]#$A]_^@'#JO9QC.,< M/SP8Z;VN349N(H'*4;HLB`+\G;2PTYR;SVMJ+>8:/'8-.:[W`;+`;],[7C]8?Q[)F#*)74KLX&G8&U"IL@)3.FU#9F[=KFLIK MD']DQ/N1N!+!IGQMIS>[_?O-;FKIC'<\OS9'37K0`1Q;N>_"#;0;BH'I?'9* M=(25S."B!*#"M/5@;2581N;>?0=IP#=65E-44S=:=IX$1[=OKQ_.1C,QKY_7 M"IPZQ[7_ZV3QJ$?MS66L/&W7PUP#;7^@)6*9"\6R]A+R)YQ:3W'P,I/CXB,P MR3&I*)@5U_B$21U#B+;+O5.P5;B*'&$+/3/JHX2O:Y>;S^6R\^+:$G>`V=@L MD$U,,21+0B557M%V^*';2$I^BT(^#^Y2LD#-=->U2;$'LO]T+.%L\3I671VTI*&[A(GSUYPPHEH+4YFFE"N+(A&!#7^'5+V6%F>!:!#[-9-3Y+.;:+I M;`>A%$5<\C#I@RAS()B%"Q&(?UAM7AHH'(RZ<^U0%7[TJ'1G;C,BMYP@*#L1 ME8AUF\4CHD[7\&^7/L)())#?L MJV;W4KG:RZII-M[HYN?U7S\H.U\K<$M- M#WDG`;0#GY;U('UD*F1Q)_O.8%?H`P]K>0SAMEE7(D[_H.5`KKZCI@Y9-J]T M>H?.\^H2+LGP'Q%J]F79Z1NA_/YH,+8YJG7O`%G[OY.U?8UF[T)]HP2_GL&( M-[Y3PCVK)OL6?G\1P=?MH)03&R=,\&.21B3O;UH]_"1LXV@(0&5.RZ0;Q]$R MA@J8M=X5CO,L(Y2!A'OV9AA,S>4EG1M[#LK/<[DLR.03/9;-E?E\'YNPOF)Y M>7]J+#=M.Y_!CS7Q*-NGCT!FE`-.I2)OQ`KJI<:%(I!D*QAKK?LJ1_O!Z_-[ MS5>Y_:^:4:I>S%-Y/:@U+K)[I#(]#W]N=J^F1\V?JAN_WYRBS-PMFV,YZLM9 M_F/]\$US:&K9_F'Y(XH8/U+G46^ORA_S+ZL?J_-8?GT"DHK@."<61FW.R3+" M4/U0-CM??,"X^(];Z2CCE^<@"_.TQO!HT!E&"9`E<,GFG^^4Q'ZRNOUE^:^R M7W^R?>Z,Y>.0%\:!K"G4V10EPB%>EQV?)YP^3!)LE&Y7&,U3C\ZRC#H'2UCV8XKD[0VA7;D_(A:A]9D^+K_ZJI*@V70*N\1!%`7H M.%#Y:>WE(GM[3!5@CD,NT8:V\W<3/'%=)?5&".<;">0MGZJA)/E+Y54BN[8]TZ M2#Q?O=S[8)!])W5F<#FC6"U0S[S*65[-2117F@*5?#&"*_,E^UU:YFW5($AM M3KUT*.465J08/Y+[9'F<1[?O5YE66,YFYT!VJW:]_$6DS2RU`VBX1S9Z9VBH6])''J"E>XU;Z*!.X71ND#!^-J;T$.7P>NS M/DO4]->TSRZ5`8L4IYS4LOO^K<%B'J"=QUNQ*:)$C*>58HLGU\%EB MW)ZSF")0TM3680(/;U"P9_?T8)%A>$+-RWEX[99?+0`69IX\=/V,CQP<%[!6 M"/'*O,LUN[/\WC0OWE9G%#J+L>)V^7@2EN7"38">`.ZV`%]A@/94J?:QE0Y$=>YV5Y=M,Y^+O2_2NB4TY1+5G>=&,=J M4!_*7G`-^58B5RJ7!F^U1XW./3/3PQ*GV:;,. M7%T:F'NA5!'3N7'0T3(S&C)&=#KOJ:C.7<]W4R($MP*J#%Z,B@\%]':6C@OO M`Z^"?I.*2;RD\[K_[CZKC(2M#?+TJKP[.]^Z`O8D1;*;)*E_2Y[7(-%=,-@Y@?T[Z+RG/8(V.;*W9!S^&1D5F(IZF#-6A8G! MX^IFB0;)1[-\EA0>%QYXM:P-+KF,F-V^L=;WQV`,+)0Q,EYS*;`T-LQ5?&,3 M\#BJR[03J+OV'Q).0."UHJM+/J?T67ESM_[67A0VW=C?6W>2!9%>.)$7BQI\ M$:$60CGTV)=0+?]^MS4+I121=PH M[MG=6[5&.5@0B;PG'%Y&21MSE(2H?XSQEY,_)>^$!.?JSR[ON?RSA)R")';. M,R*6[89.;>]48N>7U[\U8XQV0!?&P(4_XRC_1%6I6`I9=0/*WI1TD?6(N\H"+/3@)5DYG2`^0O7?F`T<)E@->5$#ED$OP-E7 MTCW0B^2L7:JB;3G647#++GP8RD_+IMA#\^^<;E!VA<+,VQO$ET^[3;@BI`BR M9A]N839A5SR]RXZ2.M<^@M=Q65@( M.R#QFK*H4/GUSE^[Z21N&C5D"PZ57]8MJH,_:;N/RQX2":6VA7=@[O'8_[\@ M0#F['4H#=%Y;V*U[EXZW89:3*1G8WL]G8K+G?.X;W:(&ZPS.)T[$PXW#;KI]\$E3GRQ82XA"P``,V$```T```!X;"]S M='EL97,N>&ULY%UM;^/&$?Y>H/^!X+5%`M261%&6Y%@.3K+9'G!U@YR+%FB* M@I(HFS%?5)*ZDQ/TOW=F^38KB>326FG3-D;.$J6=>>:9V=G9%](WWVY]3_OL M1+$;!A.]=]G5-2=8A$LW>)KH?WFT+D:Z%B=VL+2],'`F^JL3Z]_>_OI7-W'R MZCF?GATGT4!$$$_TYR197W+9\>WX,EP[`7RR"B/?3N!M]-2)UY%C+V-L MY'L=H]N]ZOBV&^BIA&M_(2+$MZ.7S?IB$?IK.W'GKN[W[][U_WGU]_\_7MG M^8\?OMK_[(>O]4ZNAL@$']3+O.S6BH6/4\F=S(+;FU48$$.&0!.R=?T2A%\" M"S^#8`#S\&NW-_%/VF?;@RL]A+<(O3#2$O`RV,>N!+;OI-^8V9X[CUS\VLKV M7>\UO6S@!188V?=\%]R$%SNIAO/JF2.:W*81PN!LZN,5:I,/)MEXL=XF^\<# M-G&Z!LVZCN&/T\6LJ+=+FJ[]N-CC\!A=A:^(GNAI/M$M"W)(K]M%6JG#3J1L M/.N"OK,INQJ&4BWC8G'?;ZBP;\FDLD&A]7YX=S8ZY2NKLBY+P^?J M`=CAY++H0M>MZ=]#"W_.$2=G'M!.XS$FE4OZK.N5N?'1]9U8>W"^:-^'OAT@ ML7108]_FQF0N\.2+Y]PO7WP166AH'2^2"A=6Z)Q>SW[-9JP>S^JAV=6]-;MG>@DR41050BUK-CR!T/OI M>"8?Z6P\EBW4L.!'LM#W`_R1+-2"_V;2.,U&1%,6R$*>EK@X?^Y>#L?C\:AW M-1J-QF:_9YJ,Y'D6T6ZP=+8.3JFET;2/8``(QOW1^,H`(%USQ%2=%4$?``P' M@]&@-S9,^)]E\M,CD,WI0%?M58)`D5<)`D5>9<-@1T+FSWH*K&8I[JL$@2*O M$@2*O#J4G(%AN4^Q5PD"15XE"!1YE17#$OLJK!(K]BI!H,BK!($BKTHK/K,, M/%;N58)`D5<)@G-[-9]6S>[O+;8,M5^95=?';"8'<\=Y&"UABRW?-^KA[#&] M=GOC.:L$9HF1^_2,OY-P#?_.PR2!#:G;FZ5K/X6![<'+3MXB_UW3$K;L8'=N MHB?/[N(%E'$3XQ1OJN)4&HI,9&*%;P[-[M`<&%?I)$J2:M]9NAM_W[I"]\%8 M`1J1VV;#"8=!H20+AW)5LH->R-PGV(*YFGE:L`'$1!X2@BUDV%BNT(O:2%J( MV4@:"-I(6HC:"%WG4.?*F5R&&]@MWG6P98VZW70Q5%1/O4`"_$#$'`9!VNSS MV=CD`*.-;=K:"OEEKV],#?QA%>L!2QM:[-O9T."`E0TM1&WDXR;W+B>\6$[` M]'P`R0[?W->/@[&3^[*TA'LSZ>X,10/@V@TCN:T[\.4J`50I!;FV1I/.QY@4 M2-EX#`9$GP)Z\G9RW2\3]\` M:U6-C,I&FKU>>Z\/&W_N1!8[CL-4L*NX;EV^F[)"I7S_WG.?`M]ABW5Z*N:[ M*$R<1<*."[']FBH\_0H\O4R0")YC])L5^H$G83Z.T0^+00>="+PHU0_!):Q? M9CS@P:@LJ,$%-*CK\,A$`%/^'`$X004"/,B5<0#AJ0(!3*5R!!"@)0*`4Q,5 MQ_2#'LEF$`.E2M!_*I608W(K.94GM+(J_8+^&BLM+OT>13/)MQ#H)U%!@P:@K9\CK5>5\9820I`L82D8@#=0Q(B\J2D:F$NL0$A28BE1#`#A*(!!']!2-OSV*0=$(3*-!T1!,(7!C\!G[!/4$ M-T(JP@!XE/2*LD[H<2/&&6D@$%1E2!(-AJH423&HRI&E*PQ5*9)`4)4AJ2=4 MI4B*056.)*Y0E2()!&!$28:DGE"5(BD&53FR=$5?58HD$%1E2.*)_HE39(\>3I[2F>.X`LVER)3:;QUSL[73K7G M,')_@DDFWD*W@,54)]+QELO$7=`K7R)[_>AL82J:[CMM5]5KO8`D7]_8#48> M826F4C_L6^A:&^72^3D"R_%$-%K.)O6-"_,[D<$O;C=&2",(7-Q1C0&YSC!( M#P%)701[KFJ:8)!4CH&Z"@9,L5QA`7.8?!JR66.L4N5(1K;@#9>Y`H9/5"=0 MCE,9=6ZD<-S+JM$^S_9/&_"<'#:@Y#QI2 M!M-`:E,!Z]ZE#R'E7A: M15G-'FI=D%4JIV3DLV\I@'`;K0Z1<"<\'4((O5\$0@PNH6E`I1?;>*SW_SOE M@9`4(_H$/9?2WI"1>>UOR+TRZYT6(\G1N--LW#1[H(BD)&":8<0@&/]=\U>9 MI?+9O7/$^N=)(T6\D[&G?=5.B"G07TYR4(_["-\;LOOY91DU\YY#NV@P9[9N0.!/[^@V*'3<,'1,$#+;N_U2ZT M]PL46LSI<%B?;UP/[BW&K3/<_5QL8KB%;II>S/:KZF05A3+.+*@LF%RWE564 MM`;NB!-Z0-!<7\(PX(C7@*6HB*`_@B/ M_X8GBVO`2\H0'\-84;414_0%GAXLTMJ(@=8I&C[^<,K21@RT3L7P217K)Q$Q M'X+UIO`0GTMQZ!81\=$-7IPE'SD\P[BC("+IP=DDD5W$']^E#$%B'O!>TT(& MGR+21WWF-\9F]><#W%J:DXC';D@RP.I?!/B?-PFAD=WP48Z[N*@A(N313>"1 M`'DGYG$`+"$1(1SW*D3L9!1!&7^UHP!["]=U=V*TPJ+R\!Q4_\MM>=\QXSW! M!^2S.Y*+^0#0NW16]L9+'HL/)WKY^D_L81L03-FWOG,_APD3,='+UQ_Q*2;0 MBV$)!=+-QQB>C`&_M4WD3O2?[Z?#\=V]95R,NM/1A=EW!A?CP?3N8F#.IG=W MUKAK=&?_!LKPKPEQQX\TS_*C,W`?RJO373R)H7/ M'ET`L&&+/S>B$Q=_[>#V/P```/__`P!02P,$%``&``@````A`/MBI6V4!@`` MIQL``!,```!X;"]T:&5M92]T:&5M93$N>&UL[%E/;]LV%+\/V'<@=&]M)[8; M!W6*V+&;K4T;Q&Z''FF9EEA3HD#227T;VN.``<.Z89UC1"SF67"72(6=L#/F-^-"0/E(<8E@HF MVE[5_+S*UM4*WDP7,;5B;6%=W_S2=>F"\73-\!3!*&=:Z]=;5W9R^@;`U#*N MU^MU>[66\/7.=K?;=/`&9/'-)7S_2JM9=_$&%#(: M3Y?0VJ']?DH]ATPXVRV%;P!\HYK"%RB(ACRZ-(L)C]6J6(OP?2[Z`-!`AA6- MD9HG9()]B.(NCD:"8LT`;Q)__/QY.1`R:"'1BR^?_/;LR8NO/OW]N\*1R5D1SB MB!4-?A.KL$S(P5SX15Q/*O!T0!A'O3&1LFS-;0'Z%IQ^`T.]*G7['IM'+E(H M.BVC>1-S7D3N\&DWQ%%2AAW0."QB/Y!3"%&,]KDJ@^]Q-T/T._@!QRO=?9<2 MQ]VG%X([-'!$6@2(GIF)$E]>)]R)W\&<33`Q509*NE.I(QK_7=EF%.JVY?"N M;+>];=C$RI)G]T2Q7H7[#Y;H'3R+]PEDQ?(6]:Y"OZO0WEM?H5?E\L77Y44I MABJM&Q+;:YO..UK9>$\H8P,U9^2F-+VWA`UHW(=!O-29#`P< M7""P68,$5Q]1%0Y"G$#?7O,TD4"FI`.)$B[AO&B&2VEK//3^RIXV&_H<8BN' MQ&J/C^WPNA[.CALY&2-58,ZT&:-U3>"LS-:OI$1!M]=A5M-"G9E;S8AFBJ+# M+5=9F]B(K5"MQ:FNP;<#N+DXKLZBO89=Y[$R]E M$;SP$E`[F8XL+B8GB]%1VVLUUAH>\G'2]B9P5(;'*`&O2]U,8A;`?9.OA`W[ M4Y/99/G"FZU,,3<):G#[8>V^I+!3!Q(AU0Z6H0T-,Y6&`(LU)RO_6@/,>E$* ME%2CLTFQO@'!\*])`79T74LF$^*KHK,+(]IV]C4MI7RFB!B$XR,T8C-Q@,'] M.E1!GS&5<.-A*H)^@>LY;6TSY1;G-.F*EV(&9\F_W4`BA;JI)6@8,[F3\ MN>]I!HT"W>04\\VI9/G>:W/@G^Y\;#*#4FX=-@U-9O]2!=(.SB"QLD.VF#2I*QIT]9) M6RW;K"^XT\WYGC"VENPL_CZGL?/FS&7GY.)%&CNUL&-K.[;2U.#9DRD*0Y/L M(&,<8[Z4%3]F\=%]25G:LP,],X^O5QP_+O50/NF',(&#H=($;8_H\##5MF"`ZD#WK MX*222A`#2U6'NE>,E"Y(M&$21=-0$-YASY"K2SAD57'*;B7="=893Z)82PSH MUPWO]<`FZ"5T@JB'77]%I>B!8LM;;IX=*4:"YO=U)Q79MI#W4YP2.G"[Q1F] MX%1)+2L3`%WHA9[GO`@7(3"MEB6'#*SM2+&JP#=QOLEPN%HZ?WYQMM='OY%N MY/Z3XN47WC$P&\ID"["5\L%"[TN[!<'A6?2=*\`WA4I6D5UKOLO]9\;KQD"U M,TC(YI67S[=,4S`4:(+$R:"R!0'P1(+;S@!#R)-[[WEIF@)/ID$VBR8QP-&6 M:7/'+25&=*>-%+\]*+:B1I+D0`+O`TF;O89D<6.`]L,R"9)[%V?3_ M6D*?E[/IEABR6BJY1]!ZH%SWQ#9RG`.S]2?]JS^0DXVYL4$N%-`::OJX2K-T M&3Y"(>@!LS['Q*>(S3EB$BU&3`@"1Y7@W+'*MZLWJ+/@U^JBD==EL/:8&49C M!LDI8O,62S9B3M2!;Y>KLV"KSC:(-7/M-V;CQF9`O&A+L^G;-Z?ON=F"H7^/ MN0!<=NW)99]F@`H/WX_UI-G^ET6,6KN^B MX-4I#!/+,)R^])S7Y@>%_P<(IFJV86VK$94[.P1BX!QW_7Q:)SE4R(Z8\0#F M0T]J]I6HFG<:M:R"T"B8P3:.0RSB.++-[>][;',-%>(%XGC.9&;.L<=O>UFA+==&J#K#211C MQ&NFX9.4KW>-"],R08HEJ(2]N!),9)L]+&JE:;+"GSO MDQYE)VZ_N*.7@FEE5&$CH"-!Z+WG(1D28)J,Q/ MM?O*Q:JTT.T4##E?H_PPYX9!H$`3=;P,IBH0`+]("C<9$`C=^_^=R&V9X6X_ M2@=Q-P$X6G)C%\)18L0VQBKY-X`2)^I,TCF2=$']<3^->IUT\/H$"PF*O,$Y MM70RUFJ'8&C@FZ:A;@23$3`[9UW(Y__.0(VK>7=%OA30!KJQG?1ZPS'90H3L MB)G>8_K=6\CL'I*<$03TG46"]6N1C\4Y<$M<&I]YO8'I/:9SBY@]0MQH@]"> MU^;`&0;N2W#IQ7/0%C"]*TS:TO8(<:,-2)[7YL#0_*OO]M)6*M.`>:3M$>)& M&PS^\]H*LZQ^JAP43);$*2S5$0^YV(N6/,CT6 MO#161/&<&?"O#Z+29[4B'2)7,/5\K#ZFLJA`8BMR8=YJ41(4Z?+KOI2*;7,8 M]RN=LO2L75_TY`N1*JGESHQ`+K1&^V.^#^]#4%JO,@$CP+0'BN]B\D"7"9V2 M<+VJ$_13\)/NG`?Z($^?E#-O^PW.>&I[!S)$`9V0KY3.^^A5N MC2&(K@$,HO\[AWF(,$K8ANF>GT,^U=/VEPHROF/'W/PM3U^XV!\,1)I!&C`; MR^SMD>L4I@%BC:(9JJ8R!PGX#0J!ZPG2R%ZM.Y&90TPF\]%L,9Y0P(,MU^9) MH"0)TJ,VLOC70K21LB)1(P+'DWT>+4;1W8S.YN]0F30J<&Q4:#342FB'56?L MD1FV7BEY"F"]@G%=,5S]=`G"U],"^4#V`>&8+&#B8J)A;E[6XU7X`ME/&V)C M"?AM">H2R9G`"00/K1'(S7`C"*,1G"]TMK$WNG$C+VZ?F+2$8P2R,-P(PK`D M.N.=MJK6F26F'6+F$LGO",<9B`QWAG!,8-3M3,S=N!M+=)TM7"+I$Q?OCC,H MA>'.$':=W;EQ-Y;H.KMWB:1/W'`V?X\SA%UGU%_@%IG5BW]*9U,_9?9YU_H- M8U!%PU.&L&?,JZN-1;J!J5\"?>2&-_QB#MX4$/:\72K+UH!%'&]>F21]Y(:W M^_=X0]CS=I&UWBSB>/,*)>DC%Q&G#"A\TX8GKJ8]=]YRVC2,8\^KEN0*<\L? M;KZ#)Y;:K;J[A5"O#C<-T_47>2637&%N^<-->K@_NZ5W_45^55#+./[\LKC" MW/*'6_5P?W9C=_SYE4'[FW_DE\85YI8_&&?7'S8[$UB3__-5Q[?<=1A=`M@J M@;X.F6X>/01;/T3FS=:X6"PFT:62;)W8ELTV(`57>Y[P/-=!*H_8@E%XM;W; M]I1-L]<^@.ZL8GO^)U-[4>H@YSMX=3Q:P"=!V?[.7AA9U>W-5AKHR^K3`S3O M'-J%\0C@G93F?('-2/MW8/T+``#__P,`4$L#!!0`!@`(````(0!1#&L0<`(` M`,H%```9````>&PO=V]R:W-H965T08;`5[9P;EXQ9T8'B-M$C#/BET49QAT?3,CL:X'4(4CW+T_2"*2X' M&AF6YC4^D> M`RDE2BQOVT$;ONW1]T-VSL43=SB\H%=2&&UUXQ*D8S'1EYX7;,&0:;VJ)3KP M92<&FHI>9KS7<+>'CT3V^G]>R/KCW(`+#:VR3=@J_6=A][6_A4& MLQ?1-Z$!GPVIH>&[WGW1^P\@V\YAMTLTY'TMZ\=KL`(+BC1)'M(0NL<$\$J4 M]).!!>$/X;Z7M>LJ6EPDY2PM,H23+5AW(STE)6)GG58_(BCS24TD^8$$[P>2 M+$_R>9F5%W]G83&C8/":.[Y>&;TG.#2H:4?N1S!;(K-W5F!]?N\,L_$Q5SXH MA"+:8C?NUT4^6[%[+*$X8#81,Z-DPN03@J'XE`&J_GL&/N@T@_G$'[+<1,PL M=/98L/@?01^$I3FR4^2+$\&(.3_"E!/BF66$'%O^<[$]N*)HYEJY>%*?J$3,/ZJ?:<:?BR"DP+;R#OK=$Z)W? MEPQCIK=QE3>XRGGHV?0!5VGD+7SBII6#)3TT&)HF,]0U<1GCP>DQS,16.URB M\-CA/Q-P9-,$P8W6[NG@UWWZ"Z]_`@``__\#`%!+`P04``8`"````"$`/@Q> M6PX#``"_"```&0```'AL+W=OR`"58!(]MIVG^_:QPH)FU3[27!]KDG M]]QSX\OBYJDJT2,5DO%ZB3UG@A&M4YZQ>K_$OW_=7G\?E]S078EZ'[RIB3MN-O%&7W%4L$ESY4#=*Y)]%SS MM7OM`M-JD3%0H,N.!,V7^-:;;R/LKA9M??XP>I2#9R0+?OPB6/:-U12*#39I M`W:!!W"THU+=,4V)47J0BE=_ M#<@[41D2_T0"$2<2SW?\6>B%T646UV34"DR((JN%X$<$30._*1NB6]";`W.G MS.31:WU+*FC4)+>:I>4"%1+L>5P%OK=P'Z&FZ0FS-I@8HQX3!39DTT%T!35O MTFV\Q(Q8MQU"VP>2>EU0K;&N`'Q_W;%.A@ZR9?BQG>+Z%8B-V)PCHJD-2!/TIA;3#3`2:TD]Q<1"07$=OW$)9. M2&1HZ/M&:O`20Q'[7HNO[>37!C)KF_7*]P;E;5MO8YV'T6PD/K'.O2B>CCO3 M!DS"X*7`EC`P:RA,_P,O=ZH.L@5ZX;A5#6;:*HSB47J;X>E5$(R.$W,[-@Y,[&G(,%?0.,$,E%!`P4G%"AH2```_8P``&0```'AL+W=O M7 MJS\W[_OM[NWC=7!S=WVU>7O:/6_?OGV\_I]_9?]XN+[:'Q[?GA]?=F^;C]=_ M;_;7__STW__UX=?N_8_]]\WF<$4:WO8?K[\?#C^BV]O]T_?-Z^/^9O=C\T8E M7W?OKX\'^N?[M]O]C_?-XW-=Z?7E-KR[&]Z^/F[?KK6&Z/T<';NO7[=/FV3W M]/-U\W;02MXW+X\'LG__??MCS]I>G\Y1]_KX_L?/'_]XVKW^(!5?MB_;P]^U MTNNKUZ>H_/:V>W_\\D+]_BOH/SZQ[OH?H/YU^_2^V^^^'FY(W:TV%/L\NAW= MDJ9/'YZWU`/E]JOWS=>/UY^#:#WH7]]^^E`[Z'^WFU][Y_>K_??=K_Q]^SS= MOFW(VQ0G%8$ON]T?2K1\5H@JWT+MK([`\OWJ>?/U\>?+8;W[56RVW[X?*-P# MZI'J6/3\=[+9/Y%'2>3QK_KGK^WSX3O]-KH) M'P;!8$CR5U\V^T.V53JOKYY^[@^[U_\S4D:7UA(:+3TR7Y?WAC>#^[M><(&2 MOE%"/XV2\";HW]5V=+1-5M8]H)^FVNB<:D-3C7ZRR6=W]][4I9^F;G#S,!CT MAP_WY_N,9F!M-_WD[G;Z>&3DZ:>1?[BY#^Y&/=5FAW\"&E,ZQ!2EWS'C\].%]]^N*UDB:8/L?CVK%#2*ED">RCFPSM8_-;)K22LMGI>;C M-76+YNR>EJ,_/X7A_8?;/VD)>3(R8Y0)?(F8)=1ZH=0F$J029!+D$A02E!)4 M$DPDF$HPDV`NP4*"I00K"=8.N*7P-#&B"?2?B)%2HV+$WATS<((F`L(27"61 M()4@DR"7H)"@E*"28"+!5(*9!',)%A(L)5A)L':`%Q!:.?X3`5%J:-[1XM(Q M:[10CWXT0@,1I4:D"1.0%$@&)`=2`"F!5$`F0*9`9D#F0!9`ED!60-8N\:)& M*[\7M?:S"J]H2KH.#CMUK$F/?C21",,'$8M&B*LE0%(@&9`<2`&D!%(!F0"9 M`ID!F0-9`%D"60%9N\2+!8WY"V*AI/U8:")B,1*Q:(2:6`!)@61`CKX7.%Y)^XXW)&A. M5S&0!$@*)`.2`RF`E$`JEW@=I3SN@HXJ:;^CFH0CV]&&V/D?#'K^_$^T4(^2 MPF:1"(:A+Y0V0KQ(9(UN)GE#'$6RM:)19(7"GL@VRD:(=5>-;B*>TU0RZWE- MITDW*@<^?-\^_3'>4;?H_-YRINA1.F22)*7%]V:M^..UZTY$B4&]0&=6=X'P M;FH%N"\9JLD1%;9BG;/=!2(DI15@S96GQG>3RF#<;++%'70ST_A#)SQT`&;= MX\`@6B";<1+VA%$Q2]$@;Z1PR%DI5I\:%-[7CNP'P[LP$*?IC&6\H2I'6&Z5 M=YA06"DVH63UQH3A,!CTQ<&E8IEC)OA.5UF*ZW0U-L/!#0W-$^[7Z8WG?HU" MBD+CV+`G1ELVHJA@]Z'`?#H!^(@T+&RNGHV)@`RG.6ZC2A ML%)L0NF;,.H/^W>B>Q77.F:![WV5;KC>/^%SG9UX/C?('_)]?VF,U3V86CM. M#/E&BCN*:*,D56?6]2AOF`IJ[Y$5#&JU?N>46=\US/U MLCQ4'X=</`0/X?U@ MZ$_7C&6.35>S8!A#.TTHT(22U>L%XSX(^_<]V"*U\O"8"7XLU+%?QB(8V./; MOW8_:%2>W#!U]N`%0R-O]#:HT_-&:NAX'E"F/BC0,X'#GUO4H;Y@*:N^1%0Q M:AF]*G]P/79B7IMTPQVF&HEK`3&28K6?40=)BCN8($H198AR1`6B$E&%:()H MBFB&:(YH@6B):(5H[2%_0*M,Q0V/LP6>B)3.<;PQ;!(A.U;B`%""*$64(
D8YHL)6M$:$GR/:,REPL\8Q(=US,:>9X!E(0: MD6?8J!119I"C*T=4V(JN&^0UDY7B%BM/E^\&=;)WW>`L[.=?-*F3LYQD&CD] MBHV4@Q*#Z**);4T195@Q1U38BJYWQ%5.::6XQ=^=DQKU:=(UC@S[PNHX-!5IT6^D MX,HGL5+LE-0@FD[J]K(W%+W-N$IG(IFSE!WTA46N1<+NTF_^_F8DVJ]8S;'V M?6^KL_X%WM:I@3>X->J[S85]F1G2X*RGP(G!W4A9;QOD;LIA7YSH,Z->'1B< M8`JIW!K!Z@N+W(K@\\8(%?*[&[&G5>W-VPGNNUQE'Z[+?V^UU3F,%PF-Q+@7 M)Y.8;H+J2)P8]XT4NRHU%=4VTO@XA+LD5N\.!WJ^TL_EK#:7Q4\O" M8J3LNI5R18LR1E9]CJA`5"*J/.2-2'5BN\`-M;A_FF9$:VK3YU!^PA"S%,VF M1@H]PU+.#F<033,5=?4)BC\L,A;PY[^-NM[A6+-]&JU@1(//,4F..I;B'>Y> M+@"GVO?=K?*,\T<=G8OJ"6N'Q=@@[TD4NMKUG1);*1Z;":(4488H1U0@*A%5 MB":(IHAFB.:(%HB6B%:(UA[RPW-9NM3#=,D@_Q9J`.'1%=U;*%N1(Y8BRA#E MB`I$):(*T031%-$,T1S1`M$2T0K1VD-^>%0NY9_OL7K[5XXPB03&HY]Q" M(4H0I8@R1#FB`E&)J$(T031%-$,T1[1`M$2T0K3VD!\6VNZ\L)R(A1(7>XA! M]DP0JP5.25F4($H198AR1`6B$E&%:()HBFB&:(YH@6B):(5H[2$_%I=EK&J= MDK'0B(X,O!#%1DJ=(IR=4FRQB9%2^Z&5DBE2:J58?88H1U0@*A%5!CG63RQR M[)+/5TRM+D=J*/HXLU)L_1S1`M$2T0K1VB!MO1]7E;(>6?K.OZ>AQ0["K9'C ML-A(.2@Q2.V<3FS%W4IJI=@[&:(<48&H1%09Y-@U032U%3M,G5DI-G6.:(%H MB6B%:&U06R!5/OG_#Z3)2MV#H49TX\D]BGL-6("EO1:!8#IK0"K*9"-1.+.KHQM;K:NS&S`MS8W&IFM$"TM!7;N[&R M`JQF[:GQ9[)*=MT!<&*W-+FQ&VF#O(QK(.Z"XIZ1HA]VRF+P&RDV/;45&66( MI4RO%=LT0S1$M$"T1K1"M/>0'4:7P%P119_SN[4%/(__& M9B`F2&RD3CS[8Z78,ZE!YJ8RN!%701E7H5-6,SI".3IREK*'L`)1:=MR=8E$ MNN**;HMP`S!A*6^CD79-K11W>&:-4),TN!'-S[F*VSQT>,%2ML-+1"O95J"> M,+/_B9FX9@W'FO9&%CU*?\G(JL7]P[1!_JWL0-[*(5HQ:6UJ?:LD?1)==,_7QFLD@L3R)N]R8*W;.UL1*L5=3@\SR=!_" M^L1UCLT9?:O'4G:Z%HA*VUC7^L05W19;QI%Q56>/IZS+VC6S1JCU:7@O/TB8 M,]+P9WHC>9J;<6Y(@L#EKL7.T0%0R.K$D:1]TMSAA79T=GEHI[O", MT9$.STUY=_,+UF([O$2T8G2DK?6IMORA]-OW=VH=$O<4!E&FQ8Z)$26(4D09 MHAQ1@:A$5"&:()HBFB&:(UH@6B):(5I[R`\+K0/>859=JY[SA0XUHV54-%(K MC'.N%(>QV%044O:3%=^\RZZT^GBE99"Z77&,$D_XQE:*!U2"*$64(V?;R-,LB;U%K*00E*I8@R1#FB M`E&)J$(T031%-$,T1[1`M$2T0K3VD!\6><]T(A9XH=0WR)XK8D0)HA11ABA' M5"`J$56()HBFB&:(YH@6B):(5HC6'O)C05N\M\">B(42%SF=1L[59]QOD%W4 MX%B3&*D3E_)6BI>^#%&.J$!4(JH,_#H7`G`6\3[;EE%VT-R9&][)= M2K2X8BGMI+[\%'U]RB)_V,H;G-];W?!B9V#N.=QD;RC3*B-TXB,,*\7S,&7M MYF'K!^&CC*NXMU@P37*6?%5?I;'["4IW-3ZT4-S_S MFW^0CSW.N4IG\PN6ZFQ^::6X^97??`A7B%SE6//^`)3W/B?63;SL&6CD/FMK M4>C^N%/U+]D,E+O9#@]S],,`-T4A10MJU(1HI?TL0JT9* M+RFNC=`KZTAN/YDI/[4AGF-1P6UU6E2RE%GK`V%Q=99%$];2Z:,I2W5:-.,6 M]888#D)ATIP%3FR(YSAI>99)*Y;23KJ7;^A1[YY683T:-CUN]>NE]?MH7S?O MWS;QYN5E?_6T^ZE>'3U4;PIJL'ZO];@_C-0M"RV,LB081>JKN2TE/7H9-F5E M;24AE=1/Z$AMO1Z5]-KJ]*F$+F];M/4'5%)/7J&-WL;]N;45,JS5+C*K3?YS M+_I,GFUI6EG;QOMD41LG2]L,'9-W6YU['ZWK1_5%Q\;!`_6@_LA"E-!=0:2R M=[25DD\J:0L4I?9D;EL)Y5]12HD`:J-D*5+Y$)909A/-6DLH#8E4IH%UQF3! MN-4"NM^)5-*/=>A.)U*W+&TE(RIIJT-7,)%*U;$.W<1$*F/'$GHD,E(/*;:5 M#*FD+6[T!",-C+82>LPL2NFI*-1&CXE%ZDDP+*%GNB+UV!:6T#-99$%;R9@L M&+=:0(^Q1NK91M1&CZZ2!6T]I0*2^[]K2#@V=ME%` M;VR+U$O9L$8UBM2KV;!@3(V,6QN)J41]#1CK)%2BOCG?5A)229L#Z+O55-+F M`/I>,96TM4-?Q8_4]XFQG?$H&K=V)QY%<6M!,HKH#8*HB5Z?%ZDWY&%)-HK4 M>_*P(!]%ZFUY5'#;K&OTYPM^/'[;S![?OVW?]EJDZ_:&*#;W/_$Z]E.WK;G?@?Z@&FC]]\>G?`@```/__ M`P!02P,$%``&``@````A`(S&031R`@``&P8``!D```!X;"]W;W)K&ULE%1=;YLP%'V?M/]@^;T82).N**1*5G6KM$K3M(]GQUS` M"L;(=IKVW^\:$Y0TV9:]`+Z<>\X]U]>>W[VHACR#L5*W.4VBF!)HA2YD6^7T MQ_>'JP^46,?;@C>ZA9R^@J5WB_?OYCMM-K8&<`096IO3VKDN8\R*&A2WD>Z@ MQ3^E-HH[7)J*V>E!(ELL>JU8:O&_3]DEQSL>?N%R?T M2@JCK2Y=A'0L%'KJ^9;=,F1:S`N)#GS;B8$RI\LD6\TH6\S[_OR4L+,'W\36 M>O?)R.*+;`&;C=OD-V"M]<9#'PL?PF1VDOW0;\!70PHH^;9QW_3N,\BJ=KC; M4S3D?67%ZSU8@0U%FBB=>B:A&RP`GT1)/QG8$/[2OW>R<'5.$4;68-V#]%24 MB*UU6OT*/Y.!(B2G0S*^A^3)+)K>Q)/DWR0L%-+[NN>.+^9&[PC."DK:COO) M2S(D/F\$'7CLTH-S>D,)UFJQ^<^+-)W,V3-V3`R85<#@<\0D(X*AZ*B,:I[!7]BWUI:Q"X%`F/2\S^1\9#\9.X)Z,U9\Z#*#K`\STO#1"+G?HP;WT:'&( MX)`>%'-]7@HKOES*@X^EA@@V]4#J#ZYFQU+^"$SB672#''^?'I]X+#M$CG8Q MG;UQ&`YC&%H%IH*/T#26"+WU!RW%,1RCXQVP3/VDO(U/LF5_-[#Q!Y[-CE?P MQ$TE6TL:*)$R[KV8<+K#PND.*\>3JAV>SOZSQDL8*TO M?@,``/__`P!02P,$%``&``@````A`#)Q1CR$$@``WF8``!@```!X;"]W;W)K MO'4=)7&-;*?3X]D? MVY?]P^[YXWGP;G9^MGV^WWU]>/[^\?Q__A7]X_WYV?[U[OGKW>/N>?OQ_*_M M_OR?G_[[OS[\VKW\MO^QW;Z>D<+S_N/YC]?7GZN+B_W]C^W3W?[=[N?VF:Y\ MV[T\W;W2/U^^7^Q_OFSOOO:%GAXOYK/9U<73W%^N]G= M__ZT?7[5(B_;Q[M7\G__X^'GGM6>[H^1>[I[^>WWG_^XWSW])(DO#X\/KW_U MHN=G3_>K]/OS[N7NRR.U^\]@>7?/VOT_0/[IX?YEM]]]>WU'M]3;%"<5@2^[W6_*-/VJ$!6^@-)1'X'FY>SK]MO=[X^OW>Y7LGWX_N.5 MPGU)+5(-6WW]:[/=WU./DLR[>>_&_>Z1'*#_GCT]J-2@'KG[L__[Z^'KZX^/ MY_/ENV`YNR+KLR_;_6OTH!3/S^Y_W[_NGOY/VP3*IT%C;C3HK]%87+V[O)XM M@A-$%D9D.8@$@8AX:B<_^Q;0W[]?^Y41H6%A1(ZL_<84I+]2._>?Q^N`(JT[ M7GKMR"H#[BKU/Z=52IVK*Z7VGM;.X)J+TO^<5BGUJ:[TV,Z]T#G:I_SF[O7N MTX>7W:\SFDJ"S`6Y"PH7E"ZH M7%"[H'%!ZX)N!"XH/$.,*)W_$S%2,BI&W+NW#"1HJ[6M6:$>O0I02G:<-''B=.W$:3`:X@0D M!!(!B8$D0%(@&9`<2`&D!%(!J8$T0%H@W9A8<:+5E14G__REK.U8:+*\&A8` M:R`;("&0"$@,)`&2`LF`Y$`*("60"D@-I`'2`NG&Q.IX6A9;'3\:(/X8J()V M#`S1FSVUQ%UKLJ2UW^BN\MX>(1MC-!]"%TX6NQF*6?[31LKRW^^TLK:=UF2< M.$`V0$(@$9`82`(D!9(!R8$40$H@%9`:2`.D!=*-B=7Q:D=J];S>7=$*Q1^" MOIP=`T:CS#'H0.JPU2AW&(USCLZ8II,G4+N2\0[Q@.MZ$T.+6I[,;WN%C^?C M_$&T010BBA#%B!)$*:(,48ZH0%0BJA#5B!I$+:+.0G8^J0W).!8JGZX6[Z[I M5GT@+'HK8X7%H'%&:70HHXS5.*,F"LYGP1L9I5;HXU8<<%TOZ"W7S1J?FCU, MFO.9NWE59SDTD]'B@U-Q@RA$%"&*$26(4D09HAQ1@:A$5"&J$36(6D2=A>PD M4XOV<7CTI'5,DNGEOA4ILP,8+3H"0!M$(:((48PH090BRA#EB`I$):(*48VH M0=0BZBQDAT6MW\=A.3!JE+ES"S%H/.`!;2AZ?4&Q"A%%B&)$":(4488H1U0@ M*A%5B&I$#:(646J'4BUYO_W`ZEW#E8@-;(".2!O(+75@FZHPZTMN'+V M`Z%Z=*!N;9(GD4&C&F-!(RTW=1+1$JOYS#F\3\6*DS43>4:Y(-&"9"U$2ZSF M,^^4*L6+Y$5"&J!7GD&[%B^1919R$[U&J#=T*H]7[0"K79(M**=`CB?.:, MZG5@"HXG\8E03UHYXS4T6O/W_<.XQ6)Q[216Q+717TJIJTS:"_JG)['B$1@:-+_N$_3J_57@)BA; M4$L\"2K2'JM$K-B!E!$-)Y%W(Y\=Y43.6MY>*,2*G2A9_LU>J-C"VPNU2(\: MX][J&[%B!UI&WE[HQ`DJ:.<9)?L)<^-B]G*6WTB5EQ]*M6/`H-99KK%ZT0N\B,M MU]5"K-B)4IR8[(.*BWBKK]G*VP>-6''UK50_\MOM@XX+3LQEZG3I^/LO+8$A MQ\SYE-7`]TXJK+F@=Q1OQ(H;&!IDYK*`[K5RF&JR3#N@QI%,-F[H8I'V6"5B MQ0ZDC+RC.&,WO4[DK.7MA4*LV(F2Y?5<-M$+%5MX':A%VM,+C5BQ`RTC;R]T MX@05M.1/<7=R/%HGR-K+N@=7QNQXG:' M!IFUWO5L[DR>$9>QTA^SSSCNK3]A+3E#2+E^*B_)[8[OC`MZG\V`D5E_'67[.5M_Y&K+C^ENOW=D+'!2I[E:]B$'A60I:&Z1.)V3$ M85R-ECV3.ROXT&CQS6N^N+Z!NY<6.G3W,M5YG4K8=:]3J>W4Q/8U8POOO23G MVKP^%6SE]:GD&O7][6:V#)SSU8HMO#[57)O7IX:MO#ZU;'7@EC?$CP:XG9WJ MW/B$[-3'S..CC;E&:O4VI.)\!DLK8T7+H,$*#ALV1HL>@,I$9&H4%*%5S$YX MY1,LF"+*$.5'R1=8L$14(:J/DF^P8(NHLY`=:LJW4T*MS)T;C$;6B<`\<":+ M-4TD?4'ZXPNUL?*F=VBT>&Y:W,R=15/$%MXA%Q_E4\)67I]2MO(.N>PHOW+6 M\O95P59>OTJV\OI5'>57S5I>OQJV\OK5ZD ML4$RI:QIZ:RLQJ\*(`H118AB1`FB%%&&*$=4("H158AJ1`VB%E%G(3L6E&M6 M+/[6<]"Y4G%"I!%MU?A&L#96:O?FFU9T07K"*5;SP)DT0J,U?@Z**$:4($H1 M98AR1`6B$E&%J$;4(&H1=0;I7K4"N:"A]^\'LE>Q`VG0.)"")$2X%#!6!YZ# MBA7G223RC&)!GAH3T1(K?`XJ5BR?B3RC7)!H01L+T1(K?`XJ5BQ?B3RC6I!H M08V-:(D5/@<5*Y;O1)Z0G3HTU*S4\>]OU,AT!CLC6ND-(QN?@[(5S=2#%31P M(U;L>H@H0A0+\L@G8L7R*:(,42[((U^(%MG)WMT:+[F'JZ'MQL[AR-FT1UT:' M(&\G5LQ6=FV.5C)MY?B4'O0I8QVO3SE;>7TJIJT`)Z#]O50P0/3DY%_/ZQK0E.0 MUL`J09?+]Y?.:RD16[RU/.Z/^N*C'$C$BJ>`E!&MG"3_X?3V*"=RUO+V0B%6 M[$3)\F_V0L46WEZH17K4&/=@K!$K=J!EY.V%[I`3]G2ICE5/F"Z5N9-Z&EG3 M90"/1M4G$E5![W#;B!6W.33(S(U7RQOG#>J(RU`%DAIN;\9LY:T_$2NN/^7Z M:5"(/&:>:9[7B5SD1UJNJX58L1,E.Z%O$-@)%9?QUE^SE;<3&K'B^ENNW]L) M'1=\RPD[\=1QWSCQ_M:V3'UHS\U'C9RIT#WKXX+>26`C5MP5H4%F*KP:?R1% M/T5E`^\<$(NR)Q42L>+Z4T;>.2`[RHFFE?- MVDJ[Z?7UJ6>O`?=&T;R(Y:>8])3F5N;/Z,L@^EX"[G;$B1]Z. MPV9AK,8+?T`16L6,O/()6XE\BBA#E#/RRA=L)?(EH@I1S<@KW["5R+>(.@O9 M\Q#=JTX)M3)W0JV1M=">PY.MA;;R3P,;8W5H:C):>L@%LV#A3!01ZWBG@?@H MGQ+6\@ZYE+6\0RYC+:]?.6MYIX*"M;Q^E:SE]:MB+:]?-6MY_6I8R^M7RUIO MQK!CG;=\LM)X22NZ$]*X-[?3V"#Z,RR3$&T0A8@B1#&B!%&**$.4(RH0E8@J M1#6B!E&+J+.0'0N*_"FQ4.9.+#12"^7AOC`/G!WV6GW4F@J2%4=L@RA$%"&* M$26(4D09HAQ1@:A$5"&J$36(6D2=A>SPT/"UPC/:X?HW%[34A$AI1.MP[T.I[KT*N%RBFK-8`VQLIQW5FVA&(EKH^U;-=/ M.QF@KQ"!0)B3@7$@`&U,0<=UYU->H5B)ZV,MVW5:TUHY-)J"CG]9?*E4G-32 MR`H&H(TIJ![6C6XOSJ.#4*RD16,MNT5J0W+\=GYI]B]RZ[IE1)TVJ&FODI@ MZ,!YX!X&<$$:8X,5!I"M[`'@IK:QXM2>>/>1+<;WDG%M=E`]2Z:^9_ZU^TE- MGOS."GK+F#_'?HGK)X.L8&LK]5:\KQ^,E2R\0M82%#&:"/9IRXU+7&X89"_2 MY^X;K6+%L^@&48@H0A0C2A"EB#)$.:("48FH0E0C:A"UB#H+V1FGECKN6/Q[ M7RQYJ5=-XQG5("=TSIM^:[&2T&FMT98K1*L(48PH090BRA#EB`I$):(*48VH M0=0BZBQDATZMV-S0S2_?$3[QB\'IB_K=!8Y!3N32TEA4Y0!$6C!$E MB%)$&:(<48&H1%0AJA$UB%I$ZN9R25?Z M21K*7/(/-KA7KE==_WWD+K]9=?V"WN4!>:PW@G"%_*+O-)MH2T!^T==J35Q9 MSJB5_5F9HT:KZY5:.V,9VH:MHLDK]*L4GR=[3+D\H71+73QE_WFQ^DSAQ:IO MJ863#:3V339/]?J4SM6JZV^O;J/G-ROUUC#6O%G,5B'MG?`*O32[2B>OT,NM MJW+R"KV$NFHGK]Q2Y]Y.=NZ:KJPGKVSHBMHNHV^T7Z4K4SU`VT&Z,MD'P=5* M?8/4A%I`*4&?M\,K]`5**_7U2'B%ONAHI;[&"*_0%Q)1/5-7Z*,(E!?]DY"+ M(4#TZR(_[[YOR[N7[P_/^[/'[3<:TK-^4?NB?Y]$_^/5+.&^[%[IAT7ZU=P/ M^AV9+7W/[$S-W=]VNU?^!SEU,?PRS:?_%P```/__`P!02P,$%``&``@````A M`#(T&(,%#P``V4X``!@```!X;"]W;W)K2:W6]"N/ MS]IW5^=CBN7NY73[N7S>?SOS>'\S^^_/M?GW[M]C\.CYO-\8P<7@Z?SQ^/ MQ]?.Y>5A_;AY7ATN=J^;%_KD8;=_7AWIO_OOEX?7_69UGQ9Z?KJL7UW=7CZO MMB_GF4-G?XK'[N%AN][T=NN?SYN78V:RWSRMCA3_X7'[>F"WY_4I=L^K_8^? MK_]9[YY?R>+;]FE[_#LU/3][7G>"[R^[_>K;$UWW7[7KU9J]T_^`_?-VO=\= M=@_'"[*[S`+%:VY?MB_)Z=[\&^^U]N'W94&M3GDP&ONUV/XPTN#>("E]":2_-P'1_=K]Y6/U\ M.LYWO_S-]OOCD=)]0U=D+JQS_W=OCGUSWS46]=5.[>:\D^:91T\^\ M9+UU2HVW>3D:.A\)M)T7HY]<';67X\IJU`FRG$B[GM0D-6Y*\TM>5^WZM$:I M<7O6Z#(_\UL:)^:]S^YI? M/G*I=1XLYI>\8-V=2_-Q-D1.R^5E-CS3T=Y;'5=?/NUWO\YH"J4:#Z\K,R'7 M.L:4QWG6CXJ1_];`IQ%O7+X:F\_GE"D:VP>:K?[\4FM>?;K\DV:8=:ZYJ]#8 MBBXKS'1B;'L:]#7P-!AHX&L0:##48*1!J$&DP5B#B093#68:S#58:!!KL-0@ M*8%+2G&19TKM/Y%G8V/RS!FZ8R")KZNDLH*+]#3H:^!I,-#`UR#08*C!2(-0 M@TB#L083#:8:S#28:[#0(-9@J4%2`E92:3K^)Y)J;&C\T\SH&+V9J$$_"M&- MRG0A*5(-I`_$`S(`X@,)@`R!C("$0"(@8R`3(%,@,R!S(`L@,9`ED*1,K.S3 MG=7*?O72C&=HHTZ3S,FYRTB#?A09K35K*J>%B(OU@/2!>$`&0'P@`9`AD!&0 M$$@$9`QD`F0*9`9D#F0!)`:R!)*4B953&H-63LWMN'YS42Q:3KXA&R,[W1EI MT(]2NO5D78B*=`/I`_&`#(#X0`(@0R`C("&0",@8R`3(%,@,R!S(`D@,9`DD M*1,KW;0FMM+M'L)&;>?!PI]<4M-.;D<9ML=SJ`ND! MZ0/Q@`R`^$`"($,@(R`AD`C(&,@$R!3(#,@D#\0#,@#B`PF`#(&,@(1`(B!C(!,@4R`S(',@"R`QD"60 MI$RL!-)3O)7`TF`\/F[7/^YV=#.D9Z:*Q#;H,39[N#4F=EXS0L_+/*5V"U*Z MN]ZHF;B7B1JT/5"Z!5_;TW6_$+&WEWNGNWUI1(-3:O,+HW)MMW9M02'BVH90 MV^B4VL+8 MY$9I\UN=RVRH_?^]*W6QNU>.2E?3%51J7^A@N:IA9T$]I_5%Q=?HL7VICS&B MAT_)J*[1%Z^2JMFT&S40%= M7^-4O$JJEEHZST3%]G.Q9[1`%'-!*VDMM7NV%!5[)>Q5T3/)R^J9%?,;[8/S M!%J+BT/N(/$0#00Y[7U1L'R`:(AH) ML>;15BL/]CMSIF8&$3U/2F=MJ:"ZK'IGHLV]6H5]GPO2(J9DKSJ# MEZO,P96H<,04]@Z5SS5*$`&C=MH5VVT8')FQN_H1NSC;()1+X2:.\*%WJK-[NQFP[8\JZ?;\+?F+UW.3M\V,`=J M>@SDR)KLV^K9I M3"?[YE5=3;1#%CAO-B-Q=O314%1V>;[:URSW_G0?';!>KU=9F4NH(R)BKWZB#Q$`T$.>Y]5$FJ`:,A(HA\)9HL![;R\VYC\A#-#C)WI>"Y2#4PT;`7MEMJ7UU?2V/$>E&[I!] MWKHMI:H1^S@O.60O^WZM8HK8*WLLK*L%TIA-G`%-V,09T)2]G`'-V(N>`61) MAH^%>7>QXX+'PKP'R<9\?%(02PZBR%1-92IA'SL`4=E#A&XES,V:A6=(6MZ+5"I`7&Y4*AD>@7DU0`-!#GL?5;)666`:,A()JB1((=] MR"JQCQ"-&8G]1)##?LHJL9\AFC,2^P6BF)%X+1$EC"JF5UH[6'WGG5NPD:L^ MDJ'K]"^\TQFD:_Z64D][0NHAZB/B(/T0"1CRA`-$0T0A0BBA"- M$4T031'-$,T1+1#%B):($@O9>:5IW,KK;RV'S*)'#>,N>< M651\0_#87L[D!HR<=WI?O$IQ-=7=.1`5USAD>ZEQQ,A98\A>UMJBJ=:*D:BX MQC&B":(IHAFB>8Y*&5H@BKF@]0#65!M?2U%QJ`E[X?F>6?S^`WW.N*@I)D.E M*^JF==$#G3,?O5SUSLFSJ/@B/;:7'C!@Y*S1%Z]RGU-/OX&HN,8AVTN-(T;. M&D/VLE1P\BPJKG$L]HPF@DK1ZT7;5+Q**CAY%A7;S\6>T0)1S`6M000GSZ)B MKX2]*GJFV]+RJV#Q`-$8T$.>Q#4;%]A&B,:"+(83\5%=O/$,T1+1#%B):($@O9-U%Z MK/I(MS%R-7-ER,R9TB%:ZNFW2\]-:4%+A=VF4''+]/."Y@I*]FIKTV-[*B\J M;3]@E3,(OUJE+BC@N+('U^OK5EO=`X?LXXQIQ"IG3&&U2L44<4S9%H.:D.8@BD3= M*.N$?>P`)$Q[P)B=X`_,L_G&L>SYW9G###.&K+,(.'AFU3OS+.Q+][D@/7C* M4(#SN%QE5M>BP@%3V#M4/MHV,F2!L_Z1.#OJ#\6+9XTH M1^^>6WJ)@_VGFD,LXZQ^QREE_R"K9((MR],Z!M!1TCH`\A`V=;^P&2?[Y67)_M\ M8UPRTZ430S/_F[O.VU-O3U3L$OL( MT9B1V$\$.>RGK!+[&:(Y([%?((H9B=<24<(H];+[B-FY+_>1WYLEL_W_\H%N M/4VCC\A#-&#DM/=992]6U'(PR%74E.8/(V^: M-WI5,F3%6[>G[%2.:W/&%++*&5/$JNR/%F#)G*7`O4J:L(&A`S<@:QS%62J&MU\TQ8\5:B[!%BSD!<(^2T0SEZZPX\ M>V:(IE*>)+NYZKW9%0KVI2![>8@&@AS#S6>5'$4%B(:,)/J1((=]R"JQCQ"- M&8G]1)##?LHJL9\AFC,2^P6BF)%X+1&9%RKEMT1J^ZSO9"](REZ9\KS9?]]T M-T]/A[/U[J=Y^1%]>?[+IP(7;V;ZFIX_*WY';VQ*UR2:U^E-3J;C*/ZUT?E* M`>$'=XT.O12@@E]WZ(OE%?RF0]]`KN"W'?H6:P5O=N@;D16\UJ8KJ(J(=N,[ M9G\V44@159>@TI-.OC(#V MK.F3JC)T$-(Q&],8-9UT=,PY1M4G=?JDJ@P=:.Q=I5^IWF>O)LO^<\S_JN+;[DBO%J.]#7J?$;U";D.O$KHR[U!XV.V. M_!]30?%2NB__`P``__\#`%!+`P04``8`"````"$`9PW#)R<*``#+,```&``` M`'AL+W=OW6CE?-L>GS3X])O?5W\FY M^N?#/_]Q]YZ>OI]?D^12(0W'\WWU]7)YZ]5JY^UK7VOGME&R>LD:'?:U1K_NUPV9WK$H-O=,U.M+GY]TV&:;;'X?D>)%*3LE^ M/MCFQ[>2,7C;K^[_,Z45BN';2]Z.::GS>.> M^OW+:VVVK#O[`NH/N^TI/:?/EQM25Y.&8I]O:[+&^UJ[>$N<]"_=\G[N?"YGW=-L=TS(VQ0G$8''-/TN1*,G@:AQ M#5J'6016I\I3\KSYL;_$Z?LXV;V\7BC<;>J1Z%COZ?S$T""/;'YEU_?=T^65/G5NVIUZTR/QRF-ROH0[H;):V?XX7]+#?Y20 M,"I7TE!*Z*J4-/TO*VDJ):U<2??&:]5]88?CV70WZP!=^=FMFVZ[W?*['7=+ M7[6DJVK9O:YA1S6D:][P"DMIRF66WN;-BEYR=-&C42&'XRA,]#HSXP-XI M1,;U3`Z'1Q^XZ96.]2B$TEX=E*MBZ7%(/.W::WW$WO7HPQ4^JLEYD$VKX>:R M>;@[I>\56JO(Q>>WC5CYO)[0Q1-*^BJ?8A_-,)H50LLWH>:^2MV@R7.F9>'G M@]>ZO:O]I*F\53+]$AE38L`28K()M4,;!#8(;3"RP=@&D0TF-IC:8&:#N0T6 M-EC:8&6#M0WB`JA1>/(8T6C^.V(DU(@8L7?[#'30&E9`6(*;#&T0V""TP<@& M8QM$-IC88&J#F0WF-EC88&F#E0W6-H@+P`@(K1%_1T"$&IIWM&HX9HT4:M(E M%VI;4":]=MV*1"W&S(9``2`AD!&0,)`(R`3(%,@,R![(` ML@2R`K(&$A>)$0L:\T8LQ+;3IO7OB]N.4&,&29*F,:?:GA6D7"@/$I``2`AD M!&0,)`(R`3(%,@,R![(`L@2R`K(&$A>)$21*3XP@N2>,D#9C(8D5"WN+R87R M6``)@(1`1D#&0"(@$R!3(#,@ M&S%P.UY(FXY7Q-..!S($$@`)B\0PD(Y:7S!02)L&*D*#,-_A.E86/U`RY*1< MQFLWS05VJ(3(T()0RQ0*E!!="D)6;A-*H08="0M"?J[)Z+XX.!K]%Y.DX8M* M0.7RNMM^[Z<$:)H#H9'%@ M>^VN'3\EY1[:K,L]MEG*'-S67`J5U)6C6R2VMG>\=K8%9*/[K_3MH]%=#+C, MCPWW2&0$/$?.@"LIO94$HGXB1HI&(:.2@(O\L-BE3\:J3"<-TR4R$D-$`:(0T0C1&%&$:()HBFB&:(YH@6B):(5HC2@VD#D?1698#,_5 M20>%*)MPVN%]A8II!Z(AH@!1B&B$:(PH0C1!-$4T0S1'M$"T1+1"M$84&\@, MBT@2BV'Y9-;(G)+T\>#OBX50K(=Z#QH@&B(*$(6(1HC&B")$$T131#-$7@&HAPLUE!S\X!$0DHUC=3(MW*' M0.DB*8Y^B&B$:(PH0C11J&#]5"/'UC'3N@I2OM7'N99BZQ>(EHA6B-:(8H6D M]69<18Y=C&MAZ?M"*JDR]>+4DZC@L($HN\MP'"C4IH=(9GV\=G0,MQ0U# M1"-$8T01HHE"!5.GB&:ZH(EHA6B-:(8H7*`BD.$/]_(.4QQ)BW M$C4:^<0:>#DJN`+.1DJJV-A8ZU+'"WH8=88 MBK0`:YYHS8RF&CD>-M.ZU,.LGLVU`&M>:,V,EAHY'K;2NLI[MM8"K#G6F@D9 M\UVDX,8P<>^IF;AY:F)DG#%\Z\P[8"F:\GIBPQ#14FQZP(B&F&[HVZ=E)24N M6LI6/V)=3B/&6HJ-B%A])QNZ7M._%?_,8]2$A9PV3+5VAZ4S+<4VS!DY';&X MRH@EZW(Z8J6EV(@UJWYRP.J[6>R;]997;UKS.^1F=-SZ6/F(I9PFC+44FQ"9 M)C2ZK;;?L6;`A)LY39BRE-.$F99B$^:6":U.R_>L.;[@9DX3EBSE-&&EI=B$ MM65"M]%LV7E3S,T^,L$<>F5EEV)AX:JR&6V$V9FBD.LP,I=$NVS&4LY).-12 M[(B`D7,E")64F(RN,:FL=QHQYB=V\ST_8N0T8G*5$5/6Y31BIJ78$W-6KY:C M5KW>;5G5K07+./VPU,H=WEII*39AS7)6!)5,:I0 MR6SDR-'!(4OIP1P@"AEI]2.-'.K'+*751X@FC+3ZJ48.]3.6TNKGB!:,M/JE M1@[U*Y;2ZM>(8D:9>C.NM"I]):Y"W,JU)!*KG)[3OC7B!Z):+39$FMI:RDZ& MADJJ4`L)N*%SJU-6T>5CY2/6Y#1AC"9$W%":X/EML==9&\V$VSEMF+(JIPTS MUJ5+0G-NJ-Q`[Q>V["/H@ILY35BR)J<)*]:E35ASP]P-8K.SCC`QM_O(!G/P MV37-3_(L+&2*7Y-H6%DE9RL+'F@I7B*'B`)$(:(1HC&B"-$$T131#-$$-8N9"<(\,CW_B5KR8>DM-+,DCV^W-EF_X0;_-2@X>[',M7C:FB MW!-54E)AWVG0'6J"=^CUY&_9@=UN0:\M9\/.Y@U25*:G27K*'M!O]N)F28-^ MJQ=G*Z']`+*T5(_?HWV) MDAEJ&](=4:,LN].E.V5MJ(#9$X4N;$-US)ZH=]&=6NX>>I7\;?.2S#>GE]WQ M7-DGSS0XZ]E/<"?Y,KK\*`L_WR6A;>"VUX MSJJ=CQ:A[]$J95E>'7?^S_\>/WWV/2Y(E9&"573GOU'N?]G_^(!0\9U_$J+>!`%/3[0D?,%J6L$O!]:41,!EGO.8]6IG.@2M)\WRN/Z6LK`'B*2]R M\:9`?:],-S^.%6O(4P%UOZ*8I#VVNIC`EWG:,,X.8@%P09OHM.9UL`X`:;_- M>*!>/N83TO?3,!2O_ M;YV02JK%4JD]$$'VVX9=/)@W>/.:R.U!&P#N` MGT-G7_8(XVWP`MU(.Y_[U@<^WWT&CP"R&5*"-,8IV=O3,TMGR2S;)5.Y;PUC MFO=$-)KH(S32&5H$?7[/?E)AZQ2/?);V"L%E7*%L.E[)H3MVH2]6QJDLAFH[ M"^SB**_(S@KP8];K?97..E5GT:EB.]5*IU);M8;)7.>443IG9QE/$Y;=S@G; M-RY/<<80>9U31NFL3\R M4*?M+#KM9SLM@M%/J@WQ(KE9KHK4B7N3SKQV,(/7F/GZ2)'T-M@ZD[:\4>A@ M,P1(;=(*I/;6+J%.>UKQ5FK4F[0R(^0@_I`DH4&3!C7H37J9#OU#-A4*XSGC MG.J0`H.>ZW4ZA$C*Z'B<2O]0,J/!,M"8;&?2B1VRA`Q=NK%'4SU2`)``#/I= M;R.'("&+(D5).*/,J2@IK$E_':J$#%FZ4>94C!0`L$7JU6'\;$86[<'SEF8J M/@IL4I1#]+"A/M>+4MX`/;H5>Y,^.X?682D8AK*O(8,;K#+*8.U,^GXZ=`X; MRG.#;2HW"@`2T`0@=N@<-N1&W8:S9JDBC3H[-=+JC!U"ARW2,Z.[4]E10)"( MSNH0//E^-9[IC>Y.M48!3+KK$#EL:(WL;I+,>$BK0*.YMO>@V"%RV"([\VY1 M%6DPV]Z&8H?@X0_ICO(VV#HITM?7H7+8)D7+Y8SGEXHTF&TO0K%#BN"0J"V2 MNG%BN`&N;Y0*TVE[D[Z_IB:U)\KVV%;2YDB_TJ+@7LK.\K2(X;PU6(>3[!V6 MVFW:H\U=>\(-AE_@A%F3(_V;-,>\XEY!#X`9JBXV[1FUO1"LAMSAG,D$G"W5 MUQ/\ET#AS*4>:0?&1'\!S,'P[\3^-P```/__`P!02P,$%``&``@````A`'-M M-R*!!@``PQP``!@```!X;"]W;W)K^?NU70YV%0FYO'1W MVL?%\:ER'1,_?_A1[YWO9=M5S6'ELKGG.N6A:-;58;MR__G[\VSI.EV?'];Y MOCF4*_=GV;D?7G[]Y?F]:;]UN[+L'1'AT*W<7=\?GQ:+KMB5==[-FV-Y$".; MIJWS7GQLMXONV);Y6DVJ]PO?\Z)%G5<'%R(\M;?$:#:;JB@_-<5;71YZ"-*6 M^[P7_+M==>Q.T>KBEG!UWGY[.\Z*ICZ*$*_5ONI_JJ"N4Q=/7[:'ILU?]V+= M/UB0%Z?8ZL,H?%T5;=,UFWXNPBV`Z'C-R2)9B$@OS^M*K$#*[K3E9N5^9$]9 MP-S%R[,2Z-^J?.^LOYUNU[S_UE;K/ZI#*=06>9(9>&V:;Q+Z92W_)28O1K,_ MJPS\V3KKN9&D(1?(?ZO=[M>YW*Y='\S#V.!-PY[7L^L^5#.DZQ5O7-_5_`%(K&H+X M.@@7[/6X/_>7(0NCZU$6P$@M\%/>YR_/;?/NB*H1S^R.N:Q!]B0BGU8&/(:U M7EJJ6*,,\E%&4;'$*CJ1G^\OR^7SXKN0M-"0%""QZPP0AA'9"2$S(=@-%,7" M*44N4GA>_!,C.0DS\F/\O/0,!".R,2(*!@CB**2S.4YSDV!1`I84RV0(JP1- M`1)8D!`CLBD$HB:"W$Y-@E>N6/>0I9A2`\A297G&HCB@><0`+^3^0!T1$Z5O M$Y.E=SVOQ^P=0LPHX\/M48G3"/F80!/3VN-6,7-&/$(:9%4VC"BU::QL!S9[3X MA]%SVQ=ED\GV?'>IJ5FD@Q`.J<9,;89)"*8I.[5%\XJ`T-?M#FQ5#FP%=NK] MTFAG"=$WT\.0]QGW/-,@,3'9J&\G)M$DLV03I@PP.K,A(WLX0^.A41W3(KYP M12_HY;9>@5FOUNO4[]7!Q">&ELF3G%@9L&:!V2:8%O&"*[3&)D!],F5VGQ?G M.-Q<,C0(9&0T,:D?*)"TSKI=!X M+S)KEX-@&J3;`$L\9C:<0F08D83QA63Z=UF`0N,&RSQ2W*D&377820@6CQC! M%?$DFHIG5J[%`Y`6+_0X/65F/D(DOG4BP>1(^[_MF.N/;8!YI@=HD@#2!A^% MH[VJHP#`#\+0;&;,\2XG\,=.P#QZ^-`@W48BC^X*/!Y;9R?,["XSD._!H]2: M':=5L]O]+!AM"C3,EF8Z)D;LX,:TCFV!>81!Z@-(UQX/Q@=+A&`!#XWZF.1= M[N"#.XBB&EZ-4"[ M_B4?\XE9W,AP;!K,HZZA0LMCAY';U)INT!`'*B&\>)"3[U?V0>XVDFH6Z8/, M-`C8+!JDM_'2U!D0Q,/<-Z6,\LR)@=Q($+X0$GW6U*/UEJ()`FA*1?7TE:OW M$^-636.6LJ-;Y^$;68(/8):DV%(.(*`01$%,VR$"\"`RQ8(I/F0F_(R9,&HF M&J15BKW1AD&`I6^=5S%%D8H'5)2S:#&2:DLY@+2*7A@2F3,$2)CU'0>F2$SE MQD2?,1=Z!DTY@(`BY\'HV(``+`XN;IF'_(6#=:`63H]]J09-;AF(CS$UXB[3QT)^QE7H5R:I!FG3((Z"!OV+ M7>8A1^'@!#BQIDGH7@B@2>&F($B]X"%34;/(/J;'TE2#0,60I#\;1DW;-[Z( M*3YD*^*B:-1J?/I^HD%34FH(?!%N&2=0A+LDN&JIRW9;9N5^WSE%\R;OB9CX M$G7X+]QAI>(.2UWX+(8!<85TS+?EU[S=5H?.V9<;,=6;QZ+'M'`)!1_ZYJBN M.EZ;7EP>J3]WXK*P%#&ULE)==;Z,X%(;O5]K_@+B?@/E*&B49-8'NCC0CK5;S<4W`25`!(^PT[;_? MG3 MRC2XB,LTSEE)M^8;Y>;GW9]_;&ZL?N872H4!"B7?FA1"BY@O6$5+ M^,^)U44LX+$^6[RJ:9PVDXK<\M2 M<=F:;K#PE[9+`#>.E(NG#"5-([ERP8I?$B)W*2GBW$5@QEV$.`MGY1,_F%:Q MY(H:@V$LXMVF9C<#J@;>R:L8:Y"L01F=N1`?N8[.ZT=6P2.*/*+*UER:!DSG MD)^7G>NX&^L%8IK6.E\0K;ZOWV>J M73["N/SVO7LY`-J='T=][V%,!)Z*A&-D(!*-B9Z(8L=5[6":O`\+L+6%DR"= M/1>N,UCD7C)>C_%5&X=)(IPD(AVA^(2%]-,VSR=.VIH0S"Y;KC-PL9=,(&O3 M]HCM#HNO3Y#`]_Q@.0A6V$?%00P.DT0X240Z0O$7J/[F91(G356L9'0^)XEPDHATA.(3-KU^'N?Y MQ$G#?`ZRM9>,SJU#]S4:;66I&Q[OL M'=)MLPKBK'";'51^J"+>T@O(8">.5&2%^^S[?JZZQ0YA=MD2V4_TSQ)GW,E( M2)?0NXX&":>12(NH+K&5Z+F92^6<.[7\N(C'P2KFLO#D0FXL#0?+W!!I="UVPN`3XR) M]@%?T%UY=_\!``#__P,`4$L#!!0`!@`(````(0!$`BW+30X```Y3```9```` M>&PO=V]R:W-H965T9UO7_8OC[=#O[['_>WV>#B>%J]/JQ>]J^;V\&? MF^/@][M__^O3C_WAZ_%YLSE=4`VOQ]O!\^GT-A\.C^OGS6YUO-R_;5YIR^/^ ML%N=Z)^'I^'Q[;!9/52%=B]#^^IJ.MRMMJ\#6G/JM+!Q6X] M#YY>]X?5EQ?ZW']8X]5:U5W]`ZK?;=>'_7'_>+JDZH:RH_B9;X8W0ZKI[M/# MECZ!V.T7A\WC[>"S-2_'UF!X]ZG:0?_;;GX<6_]_<7S>__`.VX=X^[JAO4UY M$AGXLM]_%:'!@R`J/(32;I6!_'#QL'E[K3@T:(^L_JC^_M@^G)YO!R,J_65S/+E; M4=7@8OWM>-KO_B\W5I^D*6S7A>FO*CR]G%Q?C2QJJZ_@J"XX;@I:T\O99#*> MSJ[[2]+6JK_T][PFIW5!.O#K@C_;Y$U=DOZ>UZ1%V90[5^^@GVW44KM(_,^9 MS=)>EKT^KNTV'_XX(&##KL MCF\K,?Q8U/!:;X_R]PYR.;U'+9U'-[8`^"1W)1SHWO]_-KC\-O]/I MM*Y#[C'$,B,6*D*<.Z+6)0>'@\O!X^!S"#B$'"(.,8>$0\HAXY!S*#B4+1A2 M=IH4T2']*U(DJA$I4GOW7H'.F/@.0"`^ M2``2@D0@,4@"DH)D(#E(`5*VQ4@:#=5&TKHOVVH\$]%5;M1.O90@!4C9%B,7-',Q9.1@_X=+Z+-'5^+O&40,Z<%R!+$`7%!/!`?)``)02*0&"0!24$RD!RD M`"G;8NQXFO">L>-%M+GCI=@W^HAO1`]-UF1D7B:6,FA$-RW-^&5-V?CE-$%J M_')!/!`?)``)I;1Z'372ZA#O==Q4I(/L*9LR)DV0ZG4*DH'D(`5(*47VVD@B MW2T:26R-8*?G[?KK_9[V,DVN.\ZJ$=VJR!L848F96RFMO;0`64H94>6M1+)= MXC1!:I>X(!Z(#Q*`A%):78Q`XJ943Q>3)DAU,07)0'*0`J24TI$U<EIM9.X,?WLHX:V=7]JWUEL=/6T0%J-[FZ9D6>II[&?%V7N%FF MQMA1$^@`57.H:U84:>II+-9UU8VQ3Y;H`%5SJFM6E&GJ:2S7=75_LD('J)I+ M73.1<7);XJZXO4#1<1;3$I@ZC:MP=CS(^VJ+KK[-26I/V1Y8J((TRC11.'!W M1XW-X=VIH^SKZD":C&V66U<%&!<`?CQZW8VQCOO=4:Q+@6I1=LF>7+$[EU`% M]'8IZFZ,=2GNCF)=2E2+LDO6UF?LQ51&]?ZY)Y[(H%A#..7;G>0`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`5*(%"'%2`E2BI0AY4@% M4FF0D3EQ9P:9F]!<\,R\5?689UQ-[!M==C%=Z*@F;T@.DHOD(?E(`5*(%"'% M2`E2BI0AY4@%4FF0F3=*T2_)FZB'Y4T2RQN;WB_$#9T8*?54;8GD(+E('I*/ M%""%2!%2C)0@I4@94HY4()4&F7D[;_F0OO"`]$AB%S(VB5W4!=L7,B0'R47R MD'RD`"E$BI!BI`0I15BGJ MC7"0/R4<*D$*D""E&2I!2I`PI1RJ02H/,U-%M M/J3N0W,0L6#`QT1)YIAXS;[=7]0%C3&Q*:@S!^1B00_)1PJ00J0(*49*D%*D M#"E'*I!*@\S,B76:]DG7_W6@.!=Y>B2U[JH6=52+ED@.DHOD(?E(`5*(%"'% M2`E2BI0AY4@%4FF0F8OS%FQL7+"I:4PWNGJZ?LV^+5WH*'5>+)$<)!?)0_*1 M`J00*4**D1*D%"E#RI$*I-(@,SUB^:!]JGSX1HN6M^`LDL0&.7Z+7!CX\)E8UF3?#-;$QD7]]J:.:S"$Y2"Z2A^0C!4@A4H04 M(R5(*5*&E",52*5!9N9^T2*&>%:3S0AK8GGCBX8Z2N<-UC4EB7(SRD'RD`"E$BI!BI`0I M1X9)'3>*LUGF;\75&':62M$1RD%PD#\E'"I!" MI`@I1DJ04J0,*4FA;S5^U32QJLI<\ZB)I8XO)NHHE:+]?Z;>/W7>$H_<&E8OIOL?G0]%Y<^J@*VS&C+K'/+#6VI?EK.RXRO MZ%5GU9.BL*5Y"1K?,J(MM$S3U0.;ME2_EH4R(]HRZBPSIBW5!`?*3&A+-2## MEBEMJ5X.P;?85(:^9^SHFTUEZ"NNKBVT1^DKE*XMM$=IA;YK"^U16ASNV#*B M/4J+CQU;+"I#S\1U;+&I##UUU;6%]C4]U].UA?8U/5+2M87V-3VQT+6%]C5] M(XY;Z(UWGSOKHN:[6Z>*NNH9S3_388X-W(O\=SGUJ*M#]Y3'SC12%CN3:%$2 MZ4G>CI8M2B(]1(I;XMF\Z/2;>=&5II(JZG+ZN?=<_*(;6Z#?9L_%SZ]Q"_V0 M>BY^*XU;Z%?/<_'#9MQR/YO?=[6_F,T77;ZF5#5C/\F9.;P!`#V=S>@\` M>C2;T]L`R(?-V49O(WQ;/6V2U>%I^WJ\>-D\TG!U5;WJY2#?9RC_<=J_T56> MWDVX/]'["*O_?:;W3F[HQ2)7XCG=Q_W^I/XA&FC>9'GW%P```/__`P!02P,$ M%``&``@````A`)QFZ8!B`@``M@4``!D```!X;"]W;W)K&ULE%39CILP%'VOU'^P_#X8R#9!249)H[0CM5)5=7EVS`6L8(QL9YF_ M[S40E)FDFO0%;'-\SKD;LZ>3*LD!C)6ZFM,H""F!2NA45OF<_OJY>7BDQ#I> MI;S4%0H;)S6CA7)XQ948#B-M`U5/@ETT9QAUN3 M,UL;X&ES294L#L,Q4UQ6M&5(S#T<.LND@+46>P65:TD,E-RA?UO(VI[9E+B' M3G&SV]0YK[3AVQ+C/D5#+L[:*7DEAM-69"Y". MM4:O8YZR*4.FQ2R5&(%/.S&0S>DR2E8CRA:S)C^_)1SMQ9K80A\_&YE^E15@ MLK%,O@!;K7<>^ISZ([S,KFYOF@)\-R2%C.]+]T,?OX#,"X?5'F%`/JXD?5F# M%9A0I`GBQH;0)1K`)U'2=P8FA)^:]U&FKL#58Q`-PS&BR1:LVTC/2(G86Z?5 MGP[C/?4<<<>![XYC,`Y&DW`0O4_"6C]->&ON^&)F])%@RZ"DK;EOP"A!XMOQ MH`F/77KPG$XH0:\6:W!8Q--PQ@Z8.-%A5BT&GSTFZA$,17ME5+M?V8.]LL^' MM[)J#RYEXMLR@_^1\6#,!-:D=W\=80L:7F!&MZ41JW#Y)E,R^L_X!C4_,$.`D:P`B3R/7WQ>GP/VK+^_YYGRABN:DF*C(LU0%5PDY)`6IXWZZV?P;:DJM(Z+0YR1 M`F_4#TS5[]O??UM?2?5*SQC7"B@4=*.>Z[IT=)TF9YS'5",E+N"7(ZGRN(:O MU4FG987C0S,HSW33,.9Z'J>%RA6/".7Q]7KI?R6D+P$B7V:I?5'(ZHJ>>+\.!6DBO<9Y/V.9G'2:3=?1O)Y MFE2$DF.M@9S.)SK.>:6O=%#:K@\I9,!L5RI\W*@OR(E6JKY=-_[\D^(K[?VM MT#.YAE5Z^",M,)@-R\068$_(*T-_'%@(!NNCT4&S`']5R@$?XTM6_TVN$4Y/ MYQI6VX:$6%[.X:-:<\U> M&!8"7-EC6@/%=;Q=5^2J0!_",M(R9EV-'-!EQ6)!R?&EO97/9]4#9<-$ M7IC*1H7L8#B%BG_;6L9RK;]!F28ML^,,?/:8U9!QQSIH2'@=P>J6W=KO9+M` M(`;";LC$C:..88T%SMSL@4+IV_.XASH7&,Q/08/W!,#KACPQ(`O!@(Q M$/+`,$-KZ&;TB+D[/L@0GDS]#%G[S#Y]UG9UP@9!FPU/)%LM+`-0VP_ M3L`,;RJ"SYZ4\*5$("5"*1%Q@N>"EJNEL5K>VW=@([RKGK>1P:*-"\%&SJP: M&U>:8)#+?YVR4$KX4B*0$J&4B#BQ;/+XI*'A'?:\=PP6O1-?>YR9<,>5$IZ4 M\#G!,T/&$NI+"MF.YH-DBT4]@A[#@S92(]4_%3(O]2D;(X!>U+#::[Y\PR'=PR;:T,#^$A(W7UA-[C].V#['P```/__ M`P!02P,$%``&``@````A`(H_%E0?"```V"0``!D```!X;"]W;W)K&ULK)I9<^(X$,??MVJ_`\7[`K8Y74FVPF$N<]8>SPPXP36` M*>Q,9K[]MBRW;'4;);.[+R'\^*N[I6X="#_\_OU\JGP+;G$871ZK5JU1K027 M?70(+Z^/U3__\'[K5BMQLKL<=J?H$CQ6?P1Q]?>G7W]Y>(]N7^-C$"05L'") M'ZO')+FZ]7J\/P;G75R+KL$%/GF);N==`F]OK_7X>@MVA[31^52W&XUV_;P+ M+U5IP;U]QD;T\A+N@V&T?SL'ET0:N06G70+QQ\?P&J.U\_XSYLZ[V]>WZV_[ MZ'P%$U_"4YC\2(U6*^>].WV]1+?=EQ/T^[O5W.W1=OJ&F3^'^UL41R])#B1Z)A[^#$,XCV,*)BIV6D8^^@$`<#?RCD4I0$CLON>OKZ'A^3X6'7:M5:G MX5@@KWP)XL0+A@) MU'$,,_3;D]-H/]2_P:S:9YH^UUBZ8H`*4??"[)""$04>!6,*)A1,*9A1,*?` MIV!!P9*"%05K"C84;`N@#NE1.8*"_C]R),R('.'H]A'D2;-)0E"!3884C"CP M*!A3,*%@2L&,@CD%/@4+"I84K"A84["A8%L`6D)@F?@_$B+,P+R#I;0P:SIZ M"OI2Y,"+$K5TR4!)5)H8&3'B,3)F9,+(E)$9(W-&?$86C"P963&R9F3#R+9( MM*S!6JUEK7S[QA5-J-/DX*#V)7&*Z;+;=`E3(FPV9&3$B,?(F)$)(U-&9HS, M&?$963"R9&3%R)J1#2/;(M%R`8.HY4)N.S5QDC&G1334TR*)TU;KVH"1(2,C M1CQ&QHQ,&)DR,F-DSHC/R(*1)2,K1M:,;!C9%HF6`SBR:#DP#[Q0ZP.?$7E, M%=OU@)$A(R-&/$;&C$P8F3(R8V3.B,_(@I$E(RM&UHQL&-D6B3;P<$SZB8$7 M:GW@);%[><4KDF\25LO1MXFA%#EP3E8[B477KY$2X?KE,3)F9,+(E)&9)(6H MYXH4`J)1^\I0+K+;Y)RR4"*,>LG(BI$U(QM&MI+(J+4DPEE92V)A!4N.X?YK M/X)1AA-=R:QRX(`LC\W"B)Y;20JC-&!D*(D#Q@N))$,R4B(<$H^1,2,31J:, MS"0IA#AGQ%>M#"$NE`A#7#*R8F3-R(:1K20E68/OE?\]:\*(GC5);#N?D8H4 M!H#6]E"*'#O]PF0W+#)C1^IS'"!/F44R5L3@:*(,B6]FX(@4RU1]CF9GRBR2 MN2(&1[XRE#DB/5JHS]'L4IE%LE+$X&BM#)7W:*,^1[-;91:(-I/%S8%6%"53 M%NX[<,ZFQ.6CJMIDTRZJ%` M6^UI`8[+G9'`)^4J$M(4/D6U+Y"B?]E+CODCNI&38QNI^CRNC>SU7H?H'NN[+W;8=T?XEMC/Y7J#+Z7^;.(^Y">*35Z?:,66(7VAI/<95J;Z8*%4*NSN"!OV MTN%NMHEA+_OUTADQ1BM&]Y-ZGB*3['LGU[%/>YVC$Z-W/5>A]@>:S MQKG9=(^R4V,;I?HM]CBGG>]_$"EE=\' MNZJ0DQ.A1'8S_T8@?BL"%2##Q!JB2OZ.*&Y51AQYB'+SXQP9S$]0E9N?Q5U8<5GY(*_RZDS; MP#)4W,"L-CE5#J!%6A!P>7#_4#-$E;[2DUUCE*FRDW[;LH@S#P7&97V,SHPA M35!E#&F*'K.3/CM5S%!@#&F.SHPA^:@RAK1`C]GFU[0LLOC#&M M466,:8,>94R])KVU$L\LI"O"O9!D[%-%Z[\2WC+ MA6MHSOV."U=N);SKPJ4.Y]N."U<[G`][+MR5<#[IN7"UP;G?<^$F@O-USX6+ M`\[[';=?YG?0<>%ZCNN''15QF#YTJN MN]=@L;N]AI>X<@I>H`@:Z0\G-_EDBGR31%?8D>#IDBB!)TK2?X_P!%$`&TJC M!G7W$D4)OA$.U#-)3_\```#__P,`4$L#!!0`!@`(````(0"!F34$?`(``"\& M```9````>&PO=V]R:W-H965TK#]^6.VU>;(U M@"/(T-J-%O4@U+XWC&%)ZU)Z5$ MB>RA:K7AVP9]OR377+QQ]XL3>B6%T5:7+D(Z%A(]];QD2X9,ZU4AT8$O.S%0 MYG239+QM=Y_-K+X*EO`8N,Q^0/8:OWDH0^%#^%F=K+[ MOC^`;X844/)=X[[K_1>05>WPM*=HR/O*BM<[L`(+BC11.O5,0C>8`#Z)DKXS ML"#\I7_O9>'JG*;7T3R)EY,YLFS!NGOI*2D1.^NT^AU`R4`52-*!!-\#R606 M3>?Q)$'-?Y"PD%#O[XX[OEX9O2?8,RAI.^X[,,F0^+PA=.*Q&P_.Z9P2S-7B M(3ROT\5LQ9ZQQR?9IK\OV/@#Y[7C%3QR4\G6D@9*I(Q[+R9,?%@X MW6'F.'#:X:3VGS5>S(!=&4=8O%)K][9`839>]>L_````__\#`%!+`P04``8` M"````"$`-+WV@D03``")90``&0```'AL+W=O?F;?>T??UX&5S=7%YL7A^W M7YY>OWV\_+]_9?^XO;S8O3^\?GEXWKYN/E[^O=E=_O/3__[/AU_;MS]VWS>; M]PO2\+K[>/G]_?U'='V]>_R^>7G876U_;%ZIY.OV[>7AG?[Y]NUZ]^-M\_!E M7^GE^3J\N1E>OSP\O5[6&J*W4W1LOWY]>MPDV\>?+YO7]UK)V^;YX9WZO_O^ M]&/'VEX>3U'W\O#VQ\\?_WC_]XKO;QX>8S*;Z_;MX?/SS3N MOX+^PR/KWO\#U+\\/;YM=]NO[U>D[KKN*([Y[OKNFC1]^O#EB49@S'[QMOGZ M\?(^B-:#P>7UIP][`_W[:?-KY_Q^L?N^_96_/7V9/KUNR-KD)^.!S]OM'T:T M_&(05;Z&VMG>`\NWBR^;KP\_G]_7VU_%YNG;]W=R]X!&9`86??D[V>P>R:*D MYBK<=^-Q^TP=H/]?O#R9J4$6>?CKXV6/&G[Z\OZ=?AM>#48WO8#$+SYO=N_9 MDU%Y>?'X<_>^??E/+1283C5*^E8)_;1*PJN@?S,T*CJJ4>F^;?IIJ]V=4FUH MJ]%/[O+)/1W9NO33U@VN;@>#_O!V=/IP:>WL^TT_>;B=X[RS\O33RM]>C8*; MNYYIL\,^`X&Y-M:C3BY?_ZH`_:R^>5LPYLY67="W/8[8V$' M!N+!WMGS-6`/FE].''_X].%M^^N"=C=:&[L?#V:O#"*CD)=@ M[=EF41Y:D[2.C)9[H^;C)0V+EMN.-I(_/_5NP@_7?]+B?[0R8Y0)?(F8)+C!G&-Y( M^X:WI+Y"FS,Z!I(`28%D0'(@!9`22.42;Z!T%SECH$;:'VA-PKOFN(P;(CMQ M,%#;=5(+]>CRVVS7P5`=JVDCQ)M$UNAFDC?$4:1;*QI%(A3VU*VJ;(18=]7H M)N(9C2Z`GM'JV^"5N>J_?W]Z_&.\I5'1-:5EZ^S1K:^^"QHEOBUKXMH22%*3 M7K"_/(8W@3)LVI3S*#+0D0,IFEKF2DI:E2?*IIRU5JX.SS84`'FV:;$!A8QL M!"/M&\$2FK#-S`A[JC^Q%:).-$(XQQHA[G1:DW"T-UX_&-Z$@;HD9%;$FYAZ M/N6-YH[FBT:(FR_]YH?#8-"_\\_%ZDCSGJ5-Z.B9VDS#<'!%L[#;Z/N*OM4M M"FG2-A8->VIRQ5S1E4*[BQ2//&7UM_6T#89!/U!7@HRKT6'8=`&4YRS5V85" MI+@+I=^%N_ZP?Z.&5W&M0SWPK4\]\*Q_Q.9&7-G<(G^J]_T9$0=6JGNNBQ0/ M.+6(9SM-]ELUX(Q%NF>[Z.YP3"%2W(.2U=?K+1C_LS(V>ISBX4(L5=*%47>L/AZ%:-K^)JA[K@^\+$#ZXOCDS_.MR@((Z[-#8I M*_)#V&]0+*C3PK:BZ$JYHJ",D:C/!76H+UA*=)6(*D9[];YER'Z>9?;;\M"D M9L^X'9@$G)ZE%OG[A3K`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` M+?->W4QB*W5LWEOU,CU36]%LE(V-0T@*LGIW.K1X`M077-%?C^")NB(OOBN] MK"M6X[=_R!4FXCACKZD#%&^OJ1'M<#QC8\J9&C>83:^Q4\O&8J7DF$BYHJ", MD:C/$16(2D25A_P9:2[[9YC!Q@;2SS&=\"TGG,J#Q2Q%/NRRC-4EJS2U%^2F1X%B>(4D09HAQ1@:A$5"&:()HBFB&: M(UH@6B):(5I[R'>DB8%.7S=TP=TO$F?=6-3S]@H=T\0B)>ZI=5%%1BE*98AR M1`6B$E&%:()HBFB&:(YH@6B):(5H[2'?/>=%=SV,[BSRTXD#M?G$(L6^2!"E MB#)$.:("48FH0C1!-$4T0S1'M$"T1+1"M/:0[QX3";JKQ[D'==]"S5ZF,A06 M.;G#&%&"*$64(6(+XRX MGUHSNYE!,$26(4D09HAQ1@:A$5"&:()HBFB&:(UH@6B):(5I[R/>%"37= M)7+$%S98=0\8&ZQ*NB4VNYFYG]*5Q;GRR%UE?U=*K)0Y_$1*Q[JI2/'6ER'* M$16(2D251=155C\1Y/1+/^TT%5V.U%"-<292K'Z.:(%HB6B%:&U1W7O?KSKJ M=K:^TQ-NM-G!TJN18[#82CDHL#& MYJ*9T0+14BJV#V,E`JQF[:GQ5[()X]T)<&2'KJ-^-X/0LXA6;K,8PX%*ZL4L MY<>IRK>)2''74T09HAQ1@:A$5"&:")(!0?YC*E+->[:BM^_B"FZDV#*IK6BS7L&5RNEEK-@-(T.M M.&GU@4KRQ%RQ M>WL0*39TRLAFME5:S99Z:2TP<\XZ)&%7("H9T>QV]CGEV*JM19Q7K*MSN%.1 MXN'.&+4.=][6.`QWP3IDN$M$*T:M+:V/M>1/(I/K.7U[ZAMQ-8EJI+8G]2%* MS!4[5VLB4FS5U"+^2"J$_8GK'%HS=7J6I62Y%HA*::QS'EDCN"VVS",KU3GB M*79B)ITP^]-PI#\1FG,=M_V6J=2TS[9<UL2.#9G+;)&"T0EHR-;4FV# M[A8GK*MSP%.1X@'/&!T8\-R6=S>_8"TRX"6B%:,#;:V/M>5/I=_.WYE]2.]0 M-:)(BPT36RD')8A21!FB'%&!J$14(9H@FB*:(9HC6B!:(EHA6GO(=POM`]YI M84+24[YB95:T]DJ-S`YS^,R.;44E)1^1^=W3*:TZ8C[[PZ]^D^N2KM'75/P+ MS-A*F6QG,P"X.]6:2(:G7B+5&*6(,D0YH@)1B:A"-$$T131#-$>T0+1$M$*T M]I#O2)W#ZHY\^YBLLLBDR1KGA`/]H;%(L2\21"FB#%&.J$!4(JH031!-$2[IR,S=<13F(WJU\C9BF-$":(4488H1U0@*A%5B":(IHAF MB.:(%HB6B%:(UA[RW4+W`V]W/N(+(Z[N\A;)!3'N`TH0I8@R1#FB`E&)J$(T M031%-$,T1[1`M$2T0K3VD.\+DV@Y(ZZR>1DG[=.OD9/#C@7)I@;WT\1*'?ET M1:1XZ\L0Y8@*1"6BRB*G]Q-!';V?BBY'"CY=$2GN_1S1`M$2T0K1VJ*6I/Q` M)UU^*RF_U^(O/8L<@\6($HN.?+HB4FR=#%&.J$!4(JHLV?5)0BP)HKT.#\W(:>W&UL&V:P_T,9B@!S#X]%7,].FR; MZRKN[.U2*LV9LE0=B`_N5'EFR[N#_IRU=/:H:)=2+98L5?0Y5^EL?L%2 MG".M0O64K4KQ"M M&>W5^W[5*;8C?FTR:3S-QO1FZ+VKW?,PP`/12E%RH-EGP!<)Z_*/!+5KI"Q5 M[ZQW^OC);/FQ`_&4'A7<5F>/2I:R>WV@>ER=U*,):^FTT92E.GLTXQ;K`S$< MA*I+8J3E25U:L51MI)%^Z9EYQ;B92`?=5L_;^BWB]$#XTRAML7U_>'T3WI)QFK"JAE&]DLI9M)4,JV7_``'5&5++_ M5H@JN0^&T7T=F:@2>@](9%YET=).0-KH+0IM);=4LO^(1FF[[]U$]Y1';ZE# M)>8K"&TE]`YWBC+;2D(JV0=%\_^*2;-GUJ:7C6$)I!%+6 M5D*Q7I12T(%U*#"+3.R%)11%1290PA(*>:@';25CZL&XM0>42XI,@@&U4?XH M,AF=EA(:JR*3%L`2ROI$)CN`)?0<;62>;&TK&5))V_2GQU[)G6TE M]&QB9!X_1&WT;&%4MI;0@X"1>=8/Z]"#?-2#MI(Q]6# MF7K0-E)Z6I9*VNK0X\F1>8P5M=%3RI%YFA5+Z)4/D?G>.I;0FQ\B\UZ'MA*: M;W2;;RL)J:1ML=$7X:FDK1UZ441DONW>HHVJU&9%Z:@=KHM1)4TC9Z>JT"E;2-GEXI0"5M8Z2W<$3F50+8 MSG@4C=M&$X^BN(TG-)G;K)7<1O1&4]2?C2)ZKRGR?!31VTV)7S?;(OTAC!\/ MWS:SA[=O3Z^[B^?-5SH&;_;O#'RK_Y1&_8]W^R:PS]MW^A,8=#6GE_S3GSS9 MT+M[;\PK-;]NM^_\#]-`\T=4/OV_`````/__`P!02P,$%``&``@````A`/3W M3A5Y#@``%TL``!D```!X;"]W;W)K&ULK)Q=<^*X M$H;O3]7Y#Q3WF\1\!'!-LC7ARP8;;#`^UPPA$VI"2`$SL_OO3\M6NZUN4$AV M;R:3)Z]>M=62+$N8+W_^M7VI_%KO#YO=ZUW5N;JI5M:OJ]WCYO7[7761#/YH M5RN'X_+UUW?5?]>'ZI_WO_W/U]^[_8_#L_K];$"#J^'N^KS\?CF7E\? M5L_K[?)PM7M;O\)?GG;[[?((O^Z_7Q_>]NOE8U9H^W)=N[FYO=XN-Z_5W,'= M7^*Q>WK:K-:]W>KG=OUZS$WVZY?E$>(_/&_>#NBV75UBMUWN?_Q\^V.UV[Z! MQ;?-R^;X=V9:K6Q7KO_]=;=??GN!Z_[+:2Q7Z)W](NRWF]5^=]@]':_`[CH/ M5%YSY[IS#4[W7QXW<`6JV2O[]=-=]:OCIK56]?K^2]9`Z6;]^U#Z?^7PO/L] MW&\>@\WK&EH;\J0R\&VW^Z&D_J-"4/A:E!YD&8CVE_>^K""%@6;JUI3.:UV+Q``_%O9;E37@!99_I7]_+UY/#[? M5>N-JUJ[Z31O05_YMCX]5LW=2= M#YC4M0G\U";.5;O9;-RV6Y='`LKL>N"G-FE]_')NM4FK,/E$)##"LDC@IXX$ M6L?2AAVMAY]:7VI"2SD'^DR>0FK]3X3K8/.K_^@`ZEX^D_KK?"K(9I;>\KB\_[+?_:[`=`U1'-Z6:O)WW!HX MXYR21U+,,N)945&"1'@=]#@8<##GP./`Y&'$PYB#@(.1@ MPL&4@XB#F(,9!W,.$@X6'*0E8"059N]_(ZG*!L8_S.*ET=LVT_B0B^KPHQ`U M34FWD!2I%J0OR$"0H2">(+X@(T'&@@2"A(),!)D*$@D2"S(39"Y((LA"D+1, MC.S#[=?(_NEE(,[02ITE&9/SD)-Z.>U.J\YR6HBP6$^0OB`#08:">(+X@HP$ M&0L2"!(*,A%D*D@D2"S(3)"Y((D@"T'2,C%R"LDP7E703&]. MZK?%7-T5I"=(7Y"!($-!/$%\04:"C`4)!`D%F0@R%202)!9D)LAD)TA=D(,A0$$\07Y"1(&-!`D%"02:" M3`6)!(D%F0DR%R019"%(6B9&`F$Y:R2P-!B/SYO5CX==_K!\(K%U6`/G*V-E M8N8U)[#8QBFU6Q"ZMSI--A/WW>*VH:7U.85 M1N7:;LW:_$*$M8U$;>-+:@NT$2Q>2]?&5B!A(<+:)H),!8D$B069Y:24D;D@ MB2YE-G_';)!%(<(04VV4-;_1N>"Y\Y]W+F5B=JZ3F1*;?:UG-2ABY<:EDU;75T,@B`1;[1>(<*@^X(,!!D6 MQ&+M%2*T]@49"3(NB,4Z*$1H'0HR$61:$(MU5(C0.A9D)LA1F#]%([751]MOLIM7%@H9*]!%289OTT1X>D4KV;-H:8$%8=).* MVP]190W".ZUB%^1C7.UL)^RV?=M@-XH1^EAC&J/*&E-P6L5B"C$FM3+Y=>^P MF^L$3:P!35%E#2@ZK6(!Q110*2UMML28H9<9%U/-445KY810R;[)@EA@$$6F M''8;2M''#(!F.7/$0,-\9,0H.1LQ&L&BE#IKFP75=;3*/JN2BD:,+@ACOF3/ M.L-`%U2[VZ22(^:2(#P9A(^HDW7%3D<,CMS87OT87:QM$-"E8!N$&M6-@K=L MUIA004L;3"\*(B(5!A$C,A+!@YA=%,0N#5TV&)I@`7/#>[L M$6Z(*FL0'JDP"!^#R&<7I]YJL0!&6,@:P!A5U@`"5#6*1@XUJEM[V80*6AIY MBBIK$!&IL!5BC6I&*F17UUW$VA)S:9](M,`:S[9[BH7.U69V=K4%6^[L:B.@ M=JL.V2N7;P2HLU8^V6MD3/8=]FC2Q8+&?,5GXQZIL.'[B(SLM\5DGP=AGVV' MZ&4-PB,5!N%K!)^+4.N.UDV-3;0C%%AO-F-RMO31@%18?X@HG_;8@]CDHLJG MZ&&]^(A46'F,R,B`[/J79&".7N597O>:V^SY,#Z,GO_. M-*_D;#V3HQI-2EWUN0%0`;*DLDGF9U9 M?&!VS+?1C15"CLP5PBV;OKKJV%+U)F-[1\Z.VIX>$/JZ("Q[L(,-)!I>9.]1 MP7+6V,.&CU[Y;:ESTVC08T2VTABACW5HC-''>LD!>IGW:Q93B%[Y8V&-K4\F M:&(-:(HFUH`B]+(&%*,73&VTXI./A3J?9ESBL;#H&YCBY*(@%AA$D2F'92I% M'S,`4IE#1!TQV(9(LGN#:?.],S[U`2D^O>;(F%X+5&I`.2`*%39-7]N7O`82 M#0E9[#U4T>FC+]$($4U08T(6^P!59!]*-$%$]E-"%OL(560?2S1#1/9SB1)$ MY+60*$5T8GI5)PCEOO/.+3@_<(#NB7E]<'+4R#YP MKOHTHU(1ZDG4EV@@T5`B3R)?HI%$8XD"B4*))A)-)8HDBB6:2327*)%H(5%J M(#.OL-8W\OJI4V-'N;!TYZA\M*=5[ZU]\H+OG!QK+U#AQ#%`^]+Q'B+KG=XC MK](LVV)W9Y]46.,([:G&,2)KC0%Z&6N+%ELKAJ3"&B<2326*)(HEFFE4RM!< MH@0+&@]@+;;QM2`5AIJBESS(4\_N_[S/92YFG].H=$5=0J7(K#4&Z&6HQ,$RJ;#&"=DCFA(J M1<];-2*ODDH<+I,*[6=DCV@N48(%C4$D#IA)A5XI>IWHF>!E]$S[ZD4]Z[%I M3R/SE+G#]G&Z6!#N?_34P-NO1RH,O2_10*(A(8N]1RJT]R4:230F9+$/2(7V MH403B::$+/81J=`^EF@FT5RB1**%1*F!C)NHNJ-]I-LH.9NYK+U4DDENXVVIU557Q**FL\T6D5BR>F>$I) M[]"C>Y:5&7J9<;$US!Q5U#420B5[#+GQ)5 MO^4#1B/8%R@-&):M+A9\9Y[57K0OW<>"L!8E>W$>IU7J?D(J/A2&Z&4-PB,5 MSF<^VN=G$?"I#'8;&:'`6O^8G"U1!N2%]8<:O7/R3`4M]M.+@HA(A4'$B(Q, MB#.)BX*8HQWS)T]-8@//2BRX#8_/CC" M,M;ZQZBRUA^@BC;(0HW>.9"F@J6FXM/`%%76(")2829BC[Y67M@35R37T?J@5&Z5+R-+F/5)AP;Y$ M`XF&A"SV'JHH5%^B$2**?DS(8A^@BNQ#B2:(R'Y*R&(?H8KL8XEFB,A^+E&" MB+P6$J6(,B^SCZC]_7(?^=PLF9\2E'>3:QH9ZP1Q*H#I75[J?ZWI5Z#3[D5.#B2V&^9J]Z,?X`7Q:3 M+/(OL//IQB?_T@.W M_LD(>E"F?[(,'&RX:J-9Q@8G%ZXZESCQ%W#S3Y:!0PM7;2++,D'+C4^U9])R MX4TQJ4_:+KR^(WD*B3G%@[8+[RU)?=1VXU.\UW+A!4&I[[5=>+=+\D'+A3>\ M)/=:+KSZ=X*W77AK2_)1RX5WMX!?%WT:OI;H;?E]'2[WWS>OA\K+^@F&STWV MF:%]_L5&^2]'_<&(;[LC?!\1[-3!-Y3`%U"MX6W8FRM8Q#[M=D?\1550?*75 M_?\!``#__P,`4$L#!!0`!@`(````(0"HPB^[U@0``/@3```9````>&PO=V]R M:W-H965T6.`E:P!$FF]U_W_'8`6P@D)=5&(_GFYN_\7K]_3//G`]6BI07&Y?, M?-=A1<+W:7'2(YL3P6,WYF!:P<>)G'%7R61T^<2Q;O<5.>>=3W%UX>IX6K+$3E M%!O\<$@3]L*32\Z*2ADI6197X+\XI6=QLY8G4\SE'X&$V]IEE9? M:-1U\B3Z<2QX&;]E$//D9AL_.N;S-"FYX(=J!N8\Y6@WYI6W\L#2=KU/ M(0*9=J=DAXV[(]%S,'>][1H3]&_*KJ+UVQ$G?OVU3/>_IP6#;$.=9`7>.'^7 MJC_V4@2;O<[N5ZS`GZ6S9X?XDE5_\>MO+#V>*BCW'"*2@47[KQ&+)4E,B0>77E6 M@C8,[8<)'H&1RI`BR'/C/0UKPPI:*84MG7FM840(*M,CE,H(78>H)="`O$M>C!#V'D?4^XR,;7$Q%ST8T+O=>(D M\QFX?1]5[C-1M<1$7?:C2FJV3\]R)8_O"*S<:,)JB0G[U`^[ZH'UZ6PY"BLW MFK!:8L*N^F$)=%P[W/N916T$:[5IX->FU9G16A,.#0$?'T"7VF:H:`!$QKEI M.62<&V*Q$!ZB1=!3#?L'`TQ,>@@J6/H3PNP2%-J"8IOY':!C8E'42)A= M7D(#@!;@[<6X'E@L-+UIJ-QIMNM-9`8UP/84M-KM>C\HU$:T=J$:1M?7%6ES MXT[@/VHQT@BZYAQUD927M&-9+P**K^\V%VE:LFKG,\C8.F>6U:`I' MT'P^X=X2R)T6LA:9]1T80?`^T:UO"+Z/!-SE*K34*:X]#=1CAGHQR%EY9+^P M+!-.PB_RH>()_M6OI?H1A3Y%.^@E:%][):"P@I/!7B'1CO;NB':K/CGQHQV, ML1X,$H`I?(:Q,:@$P=M$9R6$%7Q!\.HE>'TT(X&3M`N#X6N%0O M-^JCXF?((;R^\`I>7/#G"5[8&,Q;O&4=.*]N'^"N5[_9;?\'``#__P,`4$L# M!!0`!@`(````(0"LVA;7O0D``.HM```9````>&PO=V]R:W-H965T^O5Z^G^-3[MTEKR%I^AY#FYG'89_'EYJ:=OEWCWE!N=CG6_T0CJI]WA M7)4>>I=K?"3/SX=]/$SVWT_Q.9-.+O%QET'\Z>OA+45OI_TU[DZ[R[?O;W_L MD],;N'@\'`_9K]QIM7+:]R8OY^2R>SQ"NW]ZK=T>?>=_,/>GP_Z2I,ES5@-W M=1DH;_--_:8.GNYOGP[0`M'ME4O\?%=]\'I;OUFMW]_F'?3?0_R>&M\KZ6OR M/KH4U M@W2WH46B8;VG7\,XW4./@IN:WQ:>]LD1`H#_*Z>#&!K0([N?=U4?*CX\9:]W MU690:W<:30_DE<ISO)4=^-,H1/-&QIP==_Y58/ID7C4&/,RE^()]=%WG>IA-\05-K^U>3*FG<^J*MRZG33X+A[ML=W][ M2=XKL+1!=M*WG5@HO9[PA?-/#HIB1GXT(6$F"B\/PLU=%=H!3'O7_3 MNJW_@)F_5YH^UWBV8H`*,[2,PDD82@@HT&5(04A!1,*)@3,&$@BD% M,PKF%"PH6%*PHF!-P8:"K0&LA,#R\CL2(MS`O(,5QY@U;3L%?2EJPD,#)D)&0D M,HD5(&PGOA"@4-L!*@+^BZ6S*)#X8&B%TBA!RLX$2P0/0$-%N4;[U``B5F:C^QWW0(?N[2!G`JE#JU6H] M]*/5^I)60D]@,X7:;J8D?DLO"P4IKUWN.)5('C7%H`X9B0I'L,9;,8M#CQ7T M/TI9[L5N#")S*'OM+DD:JMR#&560#",+=#2C"MIJJ,CLB93JNO$L3H*L=[QV MONCG`_JOY.VC`6VD.G=#ND?NG,UD*Q4@,WXZ@E&E'QXA1Q&B?"S9"1<[Q-]Q M?)([3;(5U.M"/C;[XF@,H]RY%]2:8@/"4.P%#3I[ M"Q4:#K4AHI"CB*,11V..)AQ-.9IQ-.=HP=&2HQ5':XXV'&TM9&=.[#%IYM2J MXGYFB#L?\M!0R-Q,$- MR+XPU"I2N1 M[QOSMD!&5_!Y*U5-7][E-SPRZ$/Q6P&,&A!@7T4*&96--')4-M:^\A\.&AY) MS$0+L+*I]HQHII&CLKGVI2HC+5MH`7I>:L^(5AHY*EMK7^4MVV@!>MYJSX#L M^2X.GN8P^>29*L^I\%Q`WWU/(5B[C9TH.?L-4`4IUBH^1)2O;N$^1$,HT88! MO0-1*G)H)&D8H2]G$&.MPC9.T'TG'[I>,[@1_^S-]A1%UG.)-G&FO1OMH:JY M5F$,"T3.CEA>%<0*?3D[8JU5&,0&W;LZ8HNBCSK"&H`B95\8@+G2@.T!#Z\E"^WVH5=CD$-UW\]PW&RVOT20#*T(SY\W`"%7.$,9:A2%,[!#\ M;JL==,@,F**9,X09JIPAS+4*0UB0$%J=5N"1.;Y$,V<(*U0Y0UAK%8:P(2%T M_6:+[INV:/91"/;0@Q"LH?>/]CIBW)&]#B)[2:3WH:AR3L*A5F%'A(B<*T&D M5*)'],))!_P(?3F#&&L5!C%!Y`QB>E40,_3E#&*N51C$`MVKY:C5:'1;Y`9S MB1IG/ZRT:E4GUQ>HDH_ MWT..(D3Z(GRDD:/_QJC2[B<<31%I]S.-'.[GJ-+N%QPM$6GW*XT<[M>HTNXW M'&T1\9M=>.?-7F\^R2N_]B M^FB%S:^51^C)&<*8AS!!0QF"%[3%LXX\:*9HYXQAAJZ<,N+&NZRD"27E-BTH MR6<#\0;O@3Z4^P*#LCJ@\C+]0[/W((`D?,GCA%\A(X#T($ M925]B*!?&@%N)J!DK+VP%U83]R97PSFM'.-G&(:-_!>[BWQ75_Z1J5_N'I,,WK&%+3^\2`CO5,?P M^VE#_(;RG"09_@%5UXNWM.__!@``__\#`%!+`P04``8`"````"$`OU*]0]8/ M```T50``&0```'AL+W=OG6L7B]^KG?[S?;]?N!<#@<7Z_?5]FGS_NU^\._?_7_=#B[V MA^7[T_)U^[Z^'_RYW@]^>_CG/^Y^;7??]R_K]>$"'-[W]X.7P^%C=G6U7[VL MWY;[R^W'^AT^>=[NWI8'^.?NV]7^8[=>/C6-WEZOW.%P5K/HV_MVM_SZ"L?]AS->KM"[^0>S?]NL=MO]]OEP"797,E!^ MS-.KZ14X/=P];>`(Q+!?[-;/]X,OSJP>CP97#W?-`/UGL_ZU[_S_Q?YE^RO8 M;9[2S?L:1AOR)#+P=;O]+J31DT#0^(JU]IL,E+N+I_7S\L?KH=[^"M>;;R\' M2/"O:C:^'+O7-[=-WY:&8-L$#7]50^?Z\O;Z>CRYO;%W.5$MH?S/B72J MFL%?U6QZ>>,,IZ,CW3F0SR92IS.^IPR-@T,J_N>\+G%4'3C6G%\K!\N-MM?UW`/`%5MO]8BEG'F3G@A<4L2Z$M[\^J M&\I:N'P1-O<#.`HHW#V_(D;`1.<+1?430 M29J1$%1@DX4)/!/X)@A,$)H@,D%L@L0$J0DR$^0F*$Q0FJ`R0=T!6D)@@O@[ M$B)LX+R#Z;,]:T;#H9Z"1RD:P9]6=*U+YJVD31,C'B,^(P$C(2,1(S$C"2,I M(QDC.2,%(R4C%2-UEVA9@UF:9O ML/`:)!KJ:9%D-&FGO#DC"T8\1GQ&`D9"1B)&8D821E)&,D9R1@I&2D8J1NHN MT7(`ZQ@M!_:!%VI]X!612U9Q)9\SLF#$8\1G)&`D9"1B)&8D821E)&,D9Z1@ MI&2D8J3N$FW@806E#;Q*\)IS6-2D:P>*ES9HSN=53Z[6B-FNM M-Y*@)1TCLT;"UHA$[G"L]Q:U(O2.6V\D24O(B!U;VAJ1R!T:ZZ&L%:%WWGHC M*5I"1JRWLC4BD3N; M67=XH\U7&:>D MIU3N;7.W/AJ-;HQ"\M$'5FJ?5U*`*FM,8;_*B"DZ&E.,/M:8$E198TK[549, M&<;4S8PS,::<'+VL<16HLL95]JN,N*J3XJK1:RRN_'K-0A#GU*R0&S4KT5@[ MYELCSKFC&MKG(U+A^>?K4!/"2#D`42(X+0G>S/S M,89I#2)!+^LHI*3"4SF7]8Q"C@KK*!1D;4E#22H,H$)D'86:@H"&^C43ZE^K,W%[[D[$8[Z+ MTV_/'>%B7$HETJ>X*7L\HAI:SZ\%VM/FBZ>06NO=#%UC\O2Q#73P>6$'J++V M'Y(*QSW"_N'$('OS_(ZQH36(!%76(%)281`9!B$7O'P0AQH8]DYS8K3MCDI.;>]HD)Y';>#=;17/Q\`%J$5`G,^858X$JFC`] MCGQ$9!\0LMB'J"+[B*,8$=DGA"SV*:K(/N,H1T3V!2&+?8DJLJ\XJA$U]OJD M(C8#S\BKVCND[A[%8V=Q\2(T5T@\8*8SCN=5>>DSN;&"]Y077KSFY?8U18KR4)]F:-*465-:8,>Y37M^EP[!A[I3DJ MK#$5V)LUIA)5UI@J5!VYY+7Y8Y<\".*JL4^Y`TCCF*.DI/L4]XPXRCGJ#C)ON0-*XYJ#>D3 M$532.:D6<3=SP!5MZ\NTKU.DQ(&3I,20O4O%'G:3"THG)'E%" MB+S8DYR4O$C%'W>2"NUSLD=4$"(OUF-)7J3BCSQ)A?8UV0/2YP"Q=7GZ_0WD MA=6(0K!(;9<"_+DG-M0O-NS\5UZ=S3EJB$?C:K'S>4:JU48I750?81=>9%_;".//095* M/'1H"X+E8M&O,E>02H7/0:>CB5$R/OI8]T@"5%EC"OM51DS1T9AB]+'&E*#* M&E/:KS)BRC`FZ_95CE[6N`I46>,J^U5&7-5)<=7HQ;=?Q-;7.34KY,8E3"+M MKL=AST&;?J#AD>E)V7>G)XG4+EE'(245!I&AO;Q)Z!F%'!7642C(NG,PYL9822H,H$)D'87Z M6!#Z='G>CJYXRF"6GD3:=,D?C6)#Z^FV(!4>LZ>0FALGXZGQE68?VT")4FF8 MHQF@RMI_2"KL/\+^K7-.C`VM022HL@:1D@J#R#`(^=R`#T*.;:S]%ZBR]E^2 M"ONOL'_K(-38\+,@],(3VWW=Z_1?NRU3V[G=R[=$QE1H[O6YJJ%U$EB0"H?" M4TA-A1/XW:/^W3Q+ M5)%]Q5&-J+'7\PK%?4Y>A=Q86TDTIOOW.5R-A$K?V MZ61J[@3Y2B$>RW[>6X`^UIA"]++&%*&7^F(FOR&)T<<:4X(^UIA2]++&E*&7 MC.GZYGIL?#4U1Q]K3`7Z6&,JT1ZZ+J@YZBA,FL'.*4\B-XE0(+F=M M;?`G6ZY26;?*%ZCJ+OQ50T(^5P6(K/8AJL@KXBCF*$%DM4]11?891SE'!2*K M?8DJLJ\XJC6DS4,CN!2>D>I&KJ=:(6VA[;(G6TIU9&I">VMY>^@E3SEGZ(R, MRUE,N1B]K7`EZ6>-*TUKAR]++&5:"7 M-:X2O:QQ5>CU:0YK]/DL)KV,H3>MC.6R'5_XSTF%N5APY''D]=)#%[%:LV MJ8(-#O&SF-XUN%)T3[AN;]H0C,W;$)'4LW\^T+CH9:J0>`;?'K/K&+?HV_7>=]5$0:\;3"V$LY,;A2M3=[%.J M(YM]J**B\CCR$?$M`]B&TD/_2V=EXV(H=9)5!YZ2>` M6=K*"TN[YXN3J#BMM"U+IF:^^GW[`8=\[!4NXO[:3+9$6K);9!T'I:*WOWC* M'O:FL;9]1)UDRQ?_R;>DO:UWW];S]>OK_F*U_2%>Z@?3Y,-=B^4;!^%>:2:6 M^^#*/G'ADV;WDGTR@D^:&R?C$YA]9V)NY6YPF9[YO9_`.P^_]/8"@?7&!6'U MZ;^,9E_@.L:[?A31]O$QO&RQCU_/ZN8T,P[N"PS5%QATW@-\-6\FOI36]XDS M\V!RXY_`=[)F4>\G\-VI6=;["7S'"?KIWLZJ M/@[?;X4Z:9:;5VU(\,[*C^6W=;;U\]0_L/F730[^=9+^8^#.K6_ M;@_PMLKF+'^!MY.NX;4_0_%VK>?M]H#_@)"NVO>=/OP/``#__P,`4$L#!!0` M!@`(````(0#5W)8^-`$``$`"```1``@!9&]C4')O<',O8V]R92YX;6P@H@0! M**```0`````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````````````"4D=%*PS`4AN\% MWZ'DODVS#9'09J"R*P>"$\6[F)QMP28-.=%N;V_6=76B-UZ&_\^7[YQ4\YUM MLD\(:%I7$U:4)`.G6FW M0C2`62(YY,K79!NCYY2BVH*56*2&2^&Z#5;&=`P;ZJ5ZEQN@D[*\HA:BU#)* M>@#F?B22`:G5B/0?H>D!6E%HP(*+2%G!Z'X=F+'9=5W337B/Y,_JRO'_L1\V-.^Q*`1&'_302XS*M*VHK^S2JO>CJL`,H+.TGO\:'=*GJ>W=ZL%$9.237/&&^&(%V$/@7<7)&/`%$[_WSS\47````__\#`%!+`P04``8`"````"$`CKL* MOFD#``#C"0``$``(`61O8U!R;W!S+V%P<"YX;6P@H@0!**```0`````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````"<5M%NVSH,?1^P?PC\OCIMA[NA<#RD M:8H6V-:@27L?!55F&MW*DB?21K.O'V6OJ;,H*>[>;(FD#@\/*65?GDLS:,"C M=G:4'!\-DP%8Y0IM'T?)W>+RP^=D@"1M(8VS,$K6@,F7_/V[;.9=!9XTX(!# M6!PE*Z+J+$U1K:"4>,3;EG>6SI>2^-<_IFZYU`HNG*I+L)2>#(?_I/!,8`LH M/E2;@$D7\:RAOPU:.!7PX?UB73'@/!M7E=%*$F>9?]/*.W1+&DR?%9@L[6]F MC&X.JO::UODP2_N_V5Q)`Q,.G"^E0(.T$L5!6M#3"TQ7^+: M=M76KH]\D\/$<:$M0B'.I9%6@9COI/FFL6"X8-^(/R=)$#2&PBW%#0M5TO]R MF4A4`^HA55R\*\+LNHRW<@\=4ABAEXSID3B)I=VP:06MC1 M_4O6EKB7I@;Q#236ODLQ:LM<3?C`@OCL"/ENN)?]%K>?DU-/*F8('@9C^ MJ+F8>^R82'C42HR-80TKCAOJ/W'&R(>HRRT8=BE"V5@A"R\M2A7Z<$O=F[+/ MZP>$'S7S*J9-*&`TZ.$:'$=]=HL@%H&0^`F]6APRVU.20RX1K@^;'Z(\GNIY MC=H"ZRW*4Y2=H%WIUZ%=QL5_=2=#P>TL`F]1EQG+BOM>&K,6%]K4I!ONZ&YV MZKC.(C48%X4.:6]^KU;I-98P(>^;` M2MI'%K.V8HJD^<9BR6[BO'5*OQN9OI!0U&5O4[9.>US*TEG1BD;<\L#Q#2,+ M=;FLJ8ZZ=+8W56!5C+G7FC";+X"DYLMNTVGA\NE&.=-2EZTYBKLPGLEM6-@S M!-LS6%UL/'$EW_38C<$#I]P"]S./KJ5W)>?SAZJCP':LML;-2=1G_[P))$== M=F;.[QJVHKSNNVS=IG_;W8WPG+GOWFSY\<>CX>F07RJ]M2Q]?9WEOP```/__`P!02P$" M+0`4``8`"````"$`J?HP#^8!``#,%P``$P``````````````````````6T-O M;G1E;G1?5'EP97-=+GAM;%!+`0(M`!0`!@`(````(0"U53`C]0```$P"```+ M`````````````````!\$``!?&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`,Q=JA<7`P``C@D``!D````````````` M````714``'AL+W=O&PO=V]R:W-H965T M&UL4$L!`BT` M%``&``@````A`,JK["X/!```/A```!D`````````````````DA\``'AL+W=O M'8'4#``#1 M"P``&0````````````````#8(P``>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`$K0 M^[-9!@``[2```!D`````````````````#BL``'AL+W=O,0``>&PO=V]R:W-H965TV>@,``"L,```9`````````````````+PV``!X;"]W;W)K&UL4$L!`BT`%``&``@````A`*C8[$6D!```3Q0``!D` M````````````````;3H``'AL+W=O&PO M=V]R:W-H965T&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`-3[ MJAG+1@``$OL``!0`````````````````\%T``'AL+W-H87)E9%-T&UL4$L!`BT`%``&``@````A`-Y1G>XA"P``,V$```T````````````````` M[:0``'AL+W-T>6QE&PO=&AE;64O=&AE;64Q+GAM;%!+`0(M`!0` M!@`(````(0"U%?I$I0(``)\&```9`````````````````/ZV``!X;"]W;W)K M&UL4$L!`BT`%``&``@````A`-SSA1UA`@``-08` M`!D`````````````````VKD``'AL+W=O[LMV)$#``!3#```&`````````````````!RO``` M>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`%$,:Q!P M`@``R@4``!D`````````````````.<```'AL+W=O6PX#``"_"```&0`````````````` M``#@P@``>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`(S&031R`@``&P8``!D````` M````````````1MD``'AL+W=O9@``&`````````````````#OVP``>&PO=V]R M:W-H965T&UL4$L!`BT`%``&``@````A`#(T&(,%#P``V4X` M`!@`````````````````J>X``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`'-M-R*!!@``PQP``!@````````````````` MM0P!`'AL+W=O&UL4$L!`BT`%``&``@````A`$0"+&PO=V]R:W-H M965T&UL4$L! M`BT`%``&``@````A`(H_%E0?"```V"0``!D`````````````````'RT!`'AL M+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`/3W3A5Y#@``%TL``!D`````````````````HTL!`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`+]2O4/6#P``-%4` M`!D`````````````````5&D!`'AL+W=O0$` M9&]C4')O<',O8V]R92YX;6Q02P$"+0`4``8`"````"$`CKL*OFD#``#C"0`` M$`````````````````#,>P$`9&]C4')O<',O87!P+GAM;%!+!08`````+@`N +`'0,``!K@`$````` ` end XML 12 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8

Condensed Statements of Operations and Comprehensive Loss (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended 9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Revenues:

Total revenues $ 6,118 $ 2,809 $ 14,115 $ 9,462

Operating expenses:

Research and development 7,106 5,248 21,710 14,735

General and administrative 1,917 1,093 5,545 2,998

Total operating expenses 9,023 6,341 27,255 17,733

Loss from operations (2,905) (3,532) (13,140) (8,271)

Other income (expense):

Interest and other income 72 20 207 74

Interest expense (7) (110) (25) (294)

Loss on extinguishment of debt (1,738) (1,738)

Gain (loss) from changes in valuation of convertible note payable 671 (331) (3,787) (331)

Loss before income taxes (2,169) (5,691) (16,745) (10,560)

Income tax benefit (5) (6) (4) (28)

Net loss (2,164) (5,685) (16,741) (10,532)

Other comprehensive loss:

Unrealized gain on short-term investments, net 37 10 8 44

Comprehensive loss (2,127) (5,675) (16,733) (10,488)

Net loss per share:

Basic $ (0.05) $ (15.98) $ (0.45) $ (41.03)

Diluted $ (0.07) $ (15.98) $ (0.45) $ (41.03)

Weighted average shares used to compute net loss per share:

Basic 40,154,812 355,735 37,367,368 256,682

Diluted 41,555,660 355,735 37,367,368 256,682

Strategic Alliances and Collaborations

Revenues:

Total revenues $ 6,118 $ 2,809 $ 14,115 $ 9,462

X

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=16317811

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_EarningsPerShareBasicAndDilutedAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 50

-Section 40

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6850294&loc=d3e12317-112629

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 50

-Section 40

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6850294&loc=d3e12355-112629

+ Details

Name: us-gaap_GainsLossesOnExtinguishmentOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 10

-Article 5

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).

+ References

No definition available.

+ Details

Name: us-gaap_InterestAndOtherIncome

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of the cost of borrowed funds accounted for as interest expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.9)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 9

-Article 9

+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate amount of gains or losses resulting from nonoperating activities (for example, interest and dividend revenue, property, plant and equipment impairment loss, and so forth).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 9

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7,9)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_NonoperatingGainsLosses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e637-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=28358780&loc=SL7669646-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_RevenuesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 13 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8

Convertible Notes Payable
9 Months Ended

Sep. 30, 2013

Convertible Notes Payable

5. Convertible Notes Payable

2012 Amendment of the 2010 GSK Note

In July 2012, we amended and restated our 2010 GSK Note. In October 2012, in conjunction with our initial public offering, we issued the Post-IPO GSK Note in the principal amount of $5.4 million, which was equivalent to the original principal amount of $5.0 million plus accrued but unpaid interest of approximately $0.4 million. The amended and restated 2010 GSK Note was then simultaneously cancelled and our obligations thereunder terminated. The Post-IPO GSK Note has a maturity date of October 9, 2015. At GSK’s option, the Post-IPO GSK Note may be converted into shares of our common stock at any time prior to the maturity at a conversion price per share equal to the initial public offering price of $4.00, subject to complying with certain threshold ownership percentage limitations set forth in the Post-IPO GSK Note. At September 30, 2013, the fair value of the Post-IPO GSK Note is $13.9 million and is classified as “Convertible note payable, at fair value” on the condensed balance sheet.

X

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20,22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 14 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 15 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8

Net Loss Per Share - Additional Information (Detail) (USD $)
In Millions, except Per Share data, unless otherwise specified

Sep. 30, 2013

Schedule Of Earnings Per Share Basic And Diluted [Line Items]

Convertible notes payable $ 5.4

Conversion price per share of convertible notes payable $ 4.00

X

- Details

Name: rgls_ScheduleOfEarningsPerShareBasicAndDilutedLineItems

Namespace Prefix: rgls_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_ConvertibleLongTermNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The price per share of the conversion feature embedded in the debt instrument.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 20

-Section 50

-Paragraph 5

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6928298&loc=SL6031898-161870

+ Details

Name: us-gaap_DebtInstrumentConvertibleConversionPrice1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

XML 16 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8

Fair Value Measurements (Tables)
9 Months Ended

Sep. 30, 2013

Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis

The following table presents our fair value hierarchy for assets and liabilities measured at fair value on a recurring basis at September 30, 2013 and December 31, 2012 (in thousands):

 Fair value as of September 30, 2013

 Total Level 1 Level 2 Level 3

Assets:


Cash equivalents
 $ 33,377 $ 33,377 $ — $ —

Corporate debt securities
 68,617 — 68,617 —

Commercial paper
 999 — 999 —

Certificates of deposit
 13,770 — 13,770 —

Debt securities of U.S. government-sponsored agencies
 7,027 — 7,027 —









 $ 123,790 $ 33,377 $ 90,413 $ —

Liabilities:


Convertible notes payable
 $ 13,921 $ — $ — $ 13,921

 Fair value as of December 31, 2012

 Total Level 1 Level 2 Level 3

Assets:


Cash equivalents
 $ 39,363 $ 39,363 $ — $ —

Corporate debt securities
 44,856 — 44,856 —

Commercial paper
 6,492 — 6,492 —

Certificates of deposit
 6,200 — 6,200 —









 $ 96,911 $ 39,363 $ 57,548 $ —

Liabilities:


Convertible notes payable
 $ 10,134 $ — $ — $ 10,134

Changes in Estimated Fair Value of Convertible Notes Payable

Changes in the estimated fair value of convertible notes payable from December 31, 2012 through September 30, 2013 are as follows (in thousands):

 Fair Value Measurements
Using Significant
Unobservable Inputs
(Level 3)

Balance at December 31, 2012
 $ 10,134

Change in estimated fair value of convertible notes payable
 3,787



Balance at September 30, 2013
 $ 13,921



X

- Definition

Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19279-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19190-110258

+ Details

Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 17 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8

Changes in Estimated Fair Value of Convertible Notes Payable (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Change in estimated fair value of convertible notes payable $ 671 $ (331) $ (3,787) $ (331)

Fair Value, Inputs, Level 3

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Beginning Balance 10,134

Change in estimated fair value of convertible notes payable 3,787

Ending Balance $ 13,921 $ 13,921

X

- Definition

Fair value of obligations measured on a recurring basis.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate amount of gains or losses resulting from nonoperating activities (for example, interest and dividend revenue, property, plant and equipment impairment loss, and so forth).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 9

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7,9)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_NonoperatingGainsLosses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 18 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8

Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $)
In Thousands, unless otherwise specified

Sep. 30, 2013

Dec. 31, 2012

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Assets measured at fair value on a recurring basis $ 123,790 $ 96,911

Convertible Notes Payable

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Liabilities measured at fair value on a recurring basis 13,921 10,134

Cash Equivalents

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Assets measured at fair value on a recurring basis 33,377 39,363

Corporate Debt Securities

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Assets measured at fair value on a recurring basis 68,617 44,856

Commercial Paper

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Assets measured at fair value on a recurring basis 999 6,492

Certificates of Deposit

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Assets measured at fair value on a recurring basis 13,770 6,200

US Government-Sponsored Agencies Debt Securities

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Assets measured at fair value on a recurring basis 7,027

Fair Value, Inputs, Level 1

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Assets measured at fair value on a recurring basis 33,377 39,363

Fair Value, Inputs, Level 1 | Cash Equivalents

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Assets measured at fair value on a recurring basis 33,377 39,363

Fair Value, Inputs, Level 2

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Assets measured at fair value on a recurring basis 90,413 57,548

Fair Value, Inputs, Level 2 | Corporate Debt Securities

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Assets measured at fair value on a recurring basis 68,617 44,856

Fair Value, Inputs, Level 2 | Commercial Paper

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Assets measured at fair value on a recurring basis 999 6,492

Fair Value, Inputs, Level 2 | Certificates of Deposit

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Assets measured at fair value on a recurring basis 13,770 6,200

Fair Value, Inputs, Level 2 | US Government-Sponsored Agencies Debt Securities

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Assets measured at fair value on a recurring basis 7,027

Fair Value, Inputs, Level 3 | Convertible Notes Payable

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Liabilities measured at fair value on a recurring basis $ 13,921 $ 10,134

X

- Definition

This element represents the aggregate of the assets reported on the balance sheet at period end measured at fair value on a recurring basis by the entity. This element is intended to be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements.

+ References

No definition available.

+ Details

Name: us-gaap_AssetsFairValueDisclosureRecurring

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Aggregation of the liabilities reported on the balance sheet measured at fair value on a recurring basis by the entity.

+ References

No definition available.

+ Details

Name: us-gaap_LiabilitiesFairValueDisclosureRecurring

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 19 R34.htm IDEA: XBRL DOCUMENT v2.4.0.8

Revenue from Strategic Alliance (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Revenue from External Customer [Line Items]

Total revenues $ 6,118 $ 2,809 $ 14,115 $ 9,462

Strategic Alliances and Collaborations

Revenue from External Customer [Line Items]

Total revenues 6,118 2,809 14,115 9,462

Strategic Alliances and Collaborations | Sanofi

Revenue from External Customer [Line Items]

Total revenues 5,422 2,500 10,828 7,530

Strategic Alliances and Collaborations | GSK

Revenue from External Customer [Line Items]

Total revenues 144 186 1,634 1,809

Strategic Alliances and Collaborations | Astra Zeneca

Revenue from External Customer [Line Items]

Total revenues 465 94 1,394 94

Strategic Alliances and Collaborations | Biogen Idec

Revenue from External Customer [Line Items]

Total revenues $ 87 $ 29 $ 259 $ 29

X

- Details

Name: us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 20 R31.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stock Option Activity (Detail) (USD $)
In Thousands, except Per Share data, unless otherwise specified
9 Months Ended

Sep. 30, 2013

Number of options

Options outstanding at December 31, 2012 4,720

Granted 361

Exercised (720)

Canceled/forfeited/expired (201)

Options outstanding at September 30, 2013 4,160

Weighted average exercise price

Options outstanding at December 31, 2012 $ 2.11

Granted $ 7.91

Exercised $ 0.80

Canceled/forfeited/expired $ 3.44

Options outstanding at September 30, 2013 $ 2.78

X

- Definition

For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)-(4)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average price of options that were either forfeited or expired.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)-(4)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Net number of share options (or share units) granted during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of options outstanding, including both vested and non-vested options.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average price at which option holders acquired shares when converting their stock options into shares.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of share options (or share units) exercised during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 21 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8

Summary of Short-Term Investments (Detail) (USD $)
In Thousands, unless otherwise specified
9 Months Ended 12 Months Ended

Sep. 30, 2013

Dec. 31, 2012

Investment [Line Items]

Amortized cost $ 90,443 $ 57,590

Unrealized Gains 20 7

Unrealized Losses (50) (49)

Estimated fair value 90,413 57,548

Corporate Debt Securities

Investment [Line Items]

Maturity 2 or less 2 or less

Amortized cost 68,649 44,898

Unrealized Gains 18 7

Unrealized Losses (50) (49)

Estimated fair value 68,617 44,856

Commercial Paper

Investment [Line Items]

Maturity 1 or less 2 or less

Amortized cost 999 6,492

Estimated fair value 999 6,492

Certificates of Deposit

Investment [Line Items]

Maturity 2 or less 1 or less

Amortized cost 13,770 6,200

Estimated fair value 13,770 6,200

US Government-Sponsored Agencies Debt Securities

Investment [Line Items]

Maturity 1 or less

Amortized cost 7,025

Unrealized Gains 2

Estimated fair value $ 7,027

X

- Details

Name: invest_InvestmentLineItems

Namespace Prefix: invest_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Maturity Period Of Short Term Investments

+ References

No definition available.

+ Details

Name: rgls_MaturityPeriodOfShortTermInvestments

Namespace Prefix: rgls_

Data Type: us-types:durationStringItemType

Balance Type: na

Period Type: duration

X

- Definition

This item represents the cost of Investments which are intended to be sold in the short term (usually less than one year or the normal operating cycle, whichever is longer) including trading securities, available-for-sale securities, held-to-maturity securities, and other short-term investments not otherwise listed in the existing taxonomy.

+ References

No definition available.

+ Details

Name: rgls_ShortTermInvestmentsAmortizedCost

Namespace Prefix: rgls_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Investments which are intended to be sold in the short term (usually less than one year or the normal operating cycle, whichever is longer) including trading securities, available-for-sale securities, held-to-maturity securities, and other short-term investments not otherwise listed in the existing taxonomy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.2)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Subparagraph g

-Article 7

+ Details

Name: us-gaap_ShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The increase (decrease), resulting in a gain, in the difference between the fair value and the carrying value, or in the comparative fair values, of securities held at each balance sheet date, that was included in earnings for the period.

+ References

No definition available.

+ Details

Name: us-gaap_UnrealizedGainOnSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease), resulting in a loss, in the difference between the fair value and the carrying value, or in the comparative fair values, of securities held at each balance sheet date, that was included in earnings for the period.

+ References

No definition available.

+ Details

Name: us-gaap_UnrealizedLossOnSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 22 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8

Basis of Presentation and Summary of Significant Accounting Policies
9 Months Ended

Sep. 30, 2013

Basis of Presentation and Summary of Significant Accounting Policies

1. Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management’s opinion, the accompanying financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results for the interim periods presented.

Interim financial results are not necessarily indicative of results anticipated for the full year. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and footnotes included in the Annual Report on Form 10-K for the year ended December 31, 2012 for Regulus Therapeutics Inc. (“we,” “us,” “our,” or the “Company”), from which the balance sheet information herein for the year ended December 31, 2012 was derived.

On September 7, 2012, our board of directors approved a one-for-two reverse stock split of our common stock. The accompanying condensed financial statements and notes to the condensed financial statements give retroactive effect to the reverse split for all periods presented. No further splits (or reverse splits) of our common stock have been contemplated as of September 30, 2013.

In October 2012, we completed an initial public offering and concurrent private placement of 18,980,982 shares of common stock at an offering price of $4.00 per share. In addition, principal and interest of $10.8 million from convertible notes outstanding were automatically converted upon the closing of the initial public offering into an aggregate of 2,703,269 shares of our common stock. We raised a total of $70.0 million in net proceeds from our initial public offering and concurrent private placement, after deducting underwriter discounts, commissions and other offering expenses.

In July 2013, we completed a public offering of 5,175,000 shares of common stock at an offering price of $9.50 per share. The shares were registered pursuant to a registration statement on Form S-1. We raised a total of $45.8 million in net proceeds, after deducting underwriting discounts, commissions and other offering expenses.

Use of Estimates

Our financial statements are prepared in accordance with GAAP. The preparation of our financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions.

Revenue Recognition

As of September 30, 2013, we have ongoing strategic alliance agreements and collaborations with GlaxoSmithKline plc (“GSK”), Sanofi, AstraZeneca AB (“AstraZeneca”) and Biogen Idec MA Inc. (“Biogen Idec”). Our revenues generally consist of upfront payments for licenses or options to obtain licenses in the future, research and development funding and milestone payments. We recognize revenues when all four of the following criteria are met: (1) persuasive evidence that an arrangement exists; (2) delivery of the products and/or services has occurred; (3) the selling price is fixed or determinable; and (4) collectability is reasonably assured.

For these multiple element arrangements, deliverables under our agreements are accounted for as separate units of accounting provided that (i) a delivered item has value to the customer on a stand-alone basis; and (ii) if the agreement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item is considered probable and substantially in the control of the vendor. The allocation of consideration amongst the units of accounting under our strategic alliance agreements and collaborations are derived using a “best estimate of selling price” if vendor specific objective evidence and third-party evidence of fair value is not available.

Milestones

We recognize revenue from milestone payments when earned, provided that (i) the milestone event is substantive in that it can only be achieved based in whole or in part on either our performance or on the occurrence of a specific outcome resulting from our performance and its achievability was not reasonably assured at the inception of the agreement; (ii) we do not have ongoing performance obligations related to the achievement of the milestone; and (iii) it would result in the receipt of additional payments. A milestone payment is considered substantive if all of the following conditions are met: (i) the milestone payment is non-refundable; (ii) achievement of the milestone was not reasonably assured at the inception of the arrangement; (iii) substantive effort is involved to achieve the milestone; and (iv) the amount of the milestone payments appears reasonable in relation to the effort expended, the other milestones in the arrangement and the related risk associated with the achievement of the milestone. Any amounts received under the agreements in advance of performance, if deemed substantive, are recorded as deferred revenue and recognized as revenue as we complete our performance obligations.

Generally, the milestone events contained in our strategic alliance agreements and collaborations coincide with the progression of our product candidates from target selection, to clinical candidate selection, to clinical trial, to regulatory approval and then to commercialization. The process of successfully discovering a new development candidate, having it approved and ultimately sold for a profit is highly uncertain. As such, the milestone payments we may earn from our partners involve a significant degree of risk to achieve. Therefore, as a product candidate progresses through the stages of its life-cycle, the value of the product candidate generally increases.

Deferred Revenue

Amounts received prior to satisfying the above revenue recognition criteria are recorded as deferred revenue in the accompanying condensed balance sheets. Amounts not expected to be recognized within the next 12 months are classified as non-current deferred revenue.

Stock-Based Compensation

We account for stock-based compensation expense related to stock options granted to employees and members of our board of directors by estimating the fair value of each stock option on the date of grant using the Black-Scholes model. We recognize stock-based compensation expense using the accelerated multiple-option approach. Under the accelerated multiple-option approach (also known as the graded-vesting method), we recognize compensation expense over the requisite service period for each separately vesting tranche of the award as though the award was in substance multiple awards, resulting in accelerated expense recognition over the vesting period.

We account for stock options granted to non-employees other than members of our board of directors, which primarily consist of members of our scientific advisory board, using the fair value approach. Stock options granted to non-employees are subject to periodic revaluation over their vesting terms.

Fair Value Option

Applicable accounting guidance permits entities to choose, at specified election dates, to measure specified items at fair value if the decision about the election is: 1) applied instrument by instrument, 2) irrevocable, and 3) applied to an entire instrument.

In July 2012, we amended and restated our $5.0 million convertible promissory note originally issued in February 2010 to GSK (“2010 GSK Note”), which was accounted for as a debt extinguishment of the original note. We elected to measure the 2010 GSK Note under the fair value option. Upon initial measurement, the difference between the carrying value of the original note and the fair value of the 2010 GSK Note was recorded as a loss on extinguishment of debt to non-operating earnings. Thereafter, any change to the fair value of the 2010 GSK Note is recorded as a gain (loss) from valuation of convertible note payable to non-operating earnings.

Recent Accounting Pronouncements

In February 2013, the FASB issued Accounting Standards Update No. 2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income (“ASU 2013-02”). This update will require companies to present information about amounts reclassified out of accumulated other comprehensive income and their corresponding effect on net income in one place and reference the amounts to the related footnote disclosures. Current accounting standards present this information in different places throughout the financial statements. ASU 2013-02 was effective for us for the nine months ended September 30, 2013. The adoption of ASU 2013-02 had no impact on our financial condition, results of operations, or cash flows.

In July 2013, the FASB issued Accounting Standards Update No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (“ASU 2013-11”). This update provides explicit guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. This guidance is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013, with an option for early adoption. We intend to adopt this guidance in 2014, and do not believe the adoption of this standard will have a material impact on our financial condition, results of operations or related financial statement disclosures.

X

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28200181&loc=SL6228881-111685

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 720

-SubTopic 15

-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 852

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2122150

+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 23 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8

Investments
9 Months Ended

Sep. 30, 2013

Investments

3. Investments

We invest our excess cash in commercial paper and debt instruments of financial institutions, corporations, U.S. government-sponsored agencies, and the U.S. Treasury. For investments in debt securities with unrealized losses, we do not intend to sell these investments, nor is it more than likely that we will be required to do so, prior to the recovery of their amortized cost basis, which may be their maturity. As of September 30, 2013, our short-term investments had a weighted average maturity of less than two years.

The following tables summarize our short-term investments (dollars in thousands):

 Maturity
(in years) Amortized
cost Unrealized Estimated
fair value

 Gains Losses

As of September 30, 2013


Corporate debt securities
 2 or less $ 68,649 $ 18 $ (50 ) $ 68,617

Commercial paper
 1 or less 999 — — 999

Certificates of deposit
 2 or less 13,770 — — 13,770

Debt securities of U.S. government-sponsored agencies
 1 or less 7,025 2 — 7,027







Total
 $ 90,443 $ 20 $ (50 ) $ 90,413







 Maturity
(in years) Amortized
cost Unrealized Estimated
fair value

 Gains Losses

As of December 31, 2012


Corporate debt securities
 2 or less $ 44,898 $ 7 $ (49 ) $ 44,856

Commercial paper
 2 or less 6,492 — — 6,492

Certificates of deposit
 1 or less 6,200 — — 6,200







Total
 $ 57,590 $ 7 $ (49 ) $ 57,548







X

- Definition

The entire disclosure for investments in certain debt and equity securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27290-111563

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27357-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-Glossary Debt Security

-URI http://asc.fasb.org/extlink&oid=6509901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6379141&loc=d3e15032-111544

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27232-111563

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 320

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27161-111563

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27405-111563

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-Glossary Equity Security

-URI http://asc.fasb.org/extlink&oid=6511694

+ Details

Name: us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 24 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stockholders' Equity
9 Months Ended

Sep. 30, 2013

Stockholders' Equity

6. Stockholders’ Equity

Shares Reserved for Future Issuance

The following shares of common stock are reserved for future issuance at September 30, 2013:

 September 30,
2013 December 31,
2012

Common stock options outstanding
 4,160,215 4,661,549

Common stock options available for future grant
 2,161,410 946,403

Employee Stock Purchase Plan
 460,283 150,000

Convertible note payable
 1,400,848 1,366,787





Total common shares reserved for future issuance
 8,182,756 7,124,739





The following table summarizes our stock option activity under all stock option plans for the nine months ended September 30, 2013 (in thousands):

 Number of
options Weighted
average
exercise
price

Options outstanding at December 31, 2012
 4,720 $ 2.11

Granted
 361 $ 7.91

Exercised
 (720 ) $ 0.80

Canceled/forfeited/expired
 (201 ) $ 3.44



Options outstanding at September 30, 2013
 4,160 $ 2.78

Stock-Based Compensation

The following table summarizes the weighted average assumptions we used in our Black-Scholes calculations:

 Three months ended
September 30, Nine months ended
September 30,

 2013 2012 2013 2012

Employee Stock Options:


Risk-free interest rate
 1.7 % * 1.4 % 1.1 %

Expected dividend yield
 0.0 % * 0.0 % 0.0 %

Expected volatility
 72.7 % * 67.8 % 71.0 %

Expected term (years)
 6.1 * 6.1 6.1

* No stock options were granted during the three months ended September 30, 2012.

The following table summarizes the allocation of our stock compensation expense (in thousands):

 Three months ended
September 30, Nine months ended
September 30,

 2013 2012 2013 2012

Research and development
 $ 594 $ 278 $ 1,664 $ 461

General and administrative
 384 136 860 271









Total
 $ 978 $ 414 $ 2,524 $ 732

X

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8

Fair Value Measurements
9 Months Ended

Sep. 30, 2013

Fair Value Measurements

4. Fair Value Measurements

We have certain financial assets and liabilities recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.

Applicable accounting guidance defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants as of the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact. The guidance provides an established hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs that reflect our assumptions about the factors that market participants would use in valuing the asset or liability. The guidance prioritizes the inputs used in measuring the fair value into the following hierarchy:

• Level 1 includes financial instruments for which quoted market prices for identical instruments are available in active markets.

• Level 2 includes financial instruments for which there are inputs other than quoted prices included within Level 1 that are observable for the instrument such as quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets with insufficient volume or infrequent transactions (less active markets) or model-driven valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

• Level 3 includes financial instruments for which fair value is derived from valuation techniques in which one or more significant inputs are unobservable, including management’s own assumptions.

The following table presents our fair value hierarchy for assets and liabilities measured at fair value on a recurring basis at September 30, 2013 and December 31, 2012 (in thousands):

 Fair value as of September 30, 2013

 Total Level 1 Level 2 Level 3

Assets:


Cash equivalents
 $ 33,377 $ 33,377 $ — $ —

Corporate debt securities
 68,617 — 68,617 —

Commercial paper
 999 — 999 —

Certificates of deposit
 13,770 — 13,770 —

Debt securities of U.S. government-sponsored agencies
 7,027 — 7,027 —









 $ 123,790 $ 33,377 $ 90,413 $ —

Liabilities:


Convertible notes payable
 $ 13,921 $ — $ — $ 13,921

 Fair value as of December 31, 2012

 Total Level 1 Level 2 Level 3

Assets:


Cash equivalents
 $ 39,363 $ 39,363 $ — $ —

Corporate debt securities
 44,856 — 44,856 —

Commercial paper
 6,492 — 6,492 —

Certificates of deposit
 6,200 — 6,200 —









 $ 96,911 $ 39,363 $ 57,548 $ —

Liabilities:


Convertible notes payable
 $ 10,134 $ — $ — $ 10,134

Changes in the estimated fair value of convertible notes payable from December 31, 2012 through September 30, 2013 are as follows (in thousands):

 Fair Value Measurements
Using Significant
Unobservable Inputs
(Level 3)

Balance at December 31, 2012
 $ 10,134

Change in estimated fair value of convertible notes payable
 3,787



Balance at September 30, 2013
 $ 13,921



We obtain pricing information from quoted market prices or quotes from brokers/dealers. We generally determine the fair value of our investment securities using standard observable inputs, including reported trades, broker/dealer quotes, bids and/or offers.

In July 2012, we amended and restated the 2010 GSK Note, which resulted in a debt extinguishment for accounting purposes. Concurrently with the debt extinguishment, we elected the fair value option for the 2010 GSK Note. The amended and restated 2010 GSK Note provided for a rollover of the 2010 GSK Note into a new promissory note effective as of the closing date of a qualifying initial public offering (“Post-IPO GSK Note”). We used a third party valuation firm to value the Post-IPO GSK Note at September 30, 2013 and recorded a gain from the change in valuation of the Post-IPO GSK Note of $0.7 million for the three months ended September 30, 2013 and a loss of $3.8 million for the nine months ended September 30, 2013 on the condensed statements of operations and comprehensive loss for the respective periods. The gain from the change in valuation of the Post-IPO GSK Note for the three months ended September 30, 2013 was principally driven by a reduction in our stock price to $9.43 as of September 30, 2013, compared to $9.81 as of June 30, 2013.

The third-party valuation firm used an income approach in the form of a convertible bond valuation model to value the Post-IPO GSK Note. The convertible bond model considered the debt and option characteristics of the Post-IPO GSK Note. The key inputs to the model as of September 30, 2013 were stock price, volatility (65%), risk-free rate (0.32%), and credit spread (8.5%). The volatility inputs were based on historical and implied volatility of peer companies. Peer companies were materially consistent with those used previously in our 409A analyses and in previous valuations of this instrument. The risk-free rate inputs were based on the yield of U.S. Treasury Strips as of each date. The credit spread inputs were based on a creditworthiness analysis of the Company and market rates for comparable straight debt instruments.

X

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=28364263&loc=d3e13537-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=28364263&loc=d3e13433-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=28364263&loc=d3e13504-108611

+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8

Fair Value Measurements - Additional Information (Detail) (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended 9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Jun. 30, 2013

Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]

Gain (Loss) from valuation of convertible notes payable $ 671 $ (331) $ (3,787) $ (331)

Stock price $ 9.43 $ 9.43 $ 9.81

Fair value assumption, volatility rate 65.00%

Fair value assumption, risk free rate 0.32%

Fair value assumption, credit spread 8.50%

X

- Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Risk-free interest rate assumption used in valuing an instrument.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average expected volatility of stock price.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsWeightedAverageVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Risk associated with risk of default, credit spread risk and downgrade risk, expressed as a percentage, used as an input to measure fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (bbb)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueInputsEntityCreditRisk

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate amount of gains or losses resulting from nonoperating activities (for example, interest and dividend revenue, property, plant and equipment impairment loss, and so forth).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 9

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7,9)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_NonoperatingGainsLosses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Price of a single share of a number of saleable stocks of a company.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19207-110258

+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

XML 27 R32.htm IDEA: XBRL DOCUMENT v2.4.0.8

Assumptions Used to Estimate Fair Value of Stock Options Using Black-Scholes Option Pricing Model (Detail) (Common stock options)
3 Months Ended 9 Months Ended

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Common stock options

Employee Stock Options:

Risk-free interest rate 1.70% 1.40% 1.10%

Expected dividend yield 0.00% 0.00% 0.00%

Expected volatility 72.70% 67.80% 71.00%

Expected term (years) 6 years 1 month 6 days 6 years 1 month 6 days 6 years 1 month 6 days

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.D.2)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section D

-Subsection 2

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The risk-free interest rate assumption that is used in valuing an option on its own shares.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iv)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

XML 28 R37.htm IDEA: XBRL DOCUMENT v2.4.0.8

Subsequent Events - Additional Information (Detail) (Biogen Idec, USD $)
In Millions, unless otherwise specified
9 Months Ended 1 Months Ended

Sep. 30, 2013

Oct. 31, 2013

Subsequent Event

Subsequent Event [Line Items]

Payment received pursuant to the terms of collaboration and license agreement $ 0.8 $ 0.1

X

- Definition

Cash received from collaborators during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_ProceedsFromCollaborators

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_SubsequentEventLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

EXCEL 29 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\U8S%E-C-A-%\T,3DU7S1E-#A?83DY,%\U,F9E M9C0W8F(V.3DB#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I% M>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/D-O;G9E6%B;&4\+W@Z3F%M93X-"B`@("`\>#I7 M;W)K#I%>&-E;%=O#I%>&-E;%=O5]4#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D)A M#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O5]486)L97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I%>&-E;%=O5]O9E]!9&IU#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O5]O9E]3:&]R=%1E#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O M#I%>&-E;%=O#I%>&-E M;%=O#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/D%S#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/E-T;V-K0F%S961?0V]M<&5N#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/E)E=F5N=65?9G)O;5]3=')A M=&5G:6-?06QL:6%N8SPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-T#I7;W)K#I7;W)K#I7;W)K#I3='EL97-H965T($A2968] M,T0B5V]R:W-H965T&-E;"!84"!O3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\U8S%E-C-A-%\T,3DU7S1E-#A?83DY,%\U,F9E M9C0W8F(V.3D-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-6,Q938S M831?-#$Y-5\T930X7V$Y.3!?-3)F968T-V)B-CDY+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R2!);F9O'0^)SQS<&%N/CPO'0^)S$P+5$\'0^)V9A;'-E/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N M/CPO'0^)S(P,3,\ M'0^)U)'3%,\2!#96YT3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)S`P,#$U,#4U M,3(\2!&:6QE3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)U-M86QL M97(@4F5P;W)T:6YG($-O;7!A;GD\3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\U8S%E-C-A-%\T,3DU7S1E-#A?83DY,%\U,F9E9C0W8F(V M.3D-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-6,Q938S831?-#$Y M-5\T930X7V$Y.3!?-3)F968T-V)B-CDY+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)SQS<&%N/CPO M'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO M3PO=&0^#0H@("`@("`@(#QT9"!C;&%S3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\U8S%E-C-A-%\T,3DU7S1E-#A?83DY,%\U,F9E9C0W M8F(V.3D-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-6,Q938S831? M-#$Y-5\T930X7V$Y.3!?-3)F968T-V)B-CDY+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R MF5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XR,#`L,#`P+#`P,#QS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPOF5D(&=A:6X@;VX@'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPOF%T:6]N(&5X<&5N'1I;F=U:7-H;65N="!O9B!D M96)T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%SF%T:6]N(&]F('!R96UI=6T@;VX@ M:6YV97-T;65N=',L(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO6%B M;&4\+W1D/@T*("`@("`@("`\=&0@8VQA6UE;G1S(&]N(&]T:&5R(&QO;F2!F:6YA;F-I;F<@86-T:79I=&EE'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!A;F0@97%U:7!M96YT+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA M'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\U8S%E-C-A-%\T,3DU7S1E-#A?83DY,%\U,F9E9C0W8F(V.3D-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-6,Q938S831?-#$Y-5\T930X7V$Y M.3!?-3)F968T-V)B-CDY+U=O'0O:'1M;#L@8VAA2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG M(%!O;&EC:65S/&)R/CPO2!O9B!3:6=N M:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM0D]4 M5$]-.B`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`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G M/@T*($EN($]C=&]B97(@,C`Q,BP@=V4@8V]M<&QE=&5D(&%N(&EN:71I86P@ M<'5B;&EC(&]F9F5R:6YG(&%N9`T*(&-O;F-U2!C;VYV97)T960@=7!O;B!T:&4@8VQO6QE/3-$)TU! M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E. M1$5.5#H@-"4G/@T*($EN($IU;'D@,C`Q,RP@=V4@8V]M<&QE=&5D(&$@<'5B M;&EC(&]F9F5R:6YG(&]F(#4L,36QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0 M.B`Q.'!T)SX-"B`\8CY5'!E;G-E6EN9R!N;W1E2!U;'1I;6%T96QY(&1I9F9E6QE/3-$)TU! M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$ M14Y4.B`T)2<^#0H@07,@;V8@4V5P=&5M8F5R)B-X03`[,S`L(#(P,3,L('=E M(&AA=F4@;VYG;VEN9R!S=')A=&5G:6,@86QL:6%N8V4-"B!A9W)E96UE;G1S M(&%N9"!C;VQL86)O#(P,40[*2!A;F0@0FEO9V5N M($ED96,@34$@26YC+B`H)B-X,C`Q0SM":6]G96X-"B!)9&5C)B-X,C`Q1#LI M+B!/=7(@$$P.W!E&ES=',[#0H@*#(I)B-X03`[ M9&5L:79E2!I6QE/3-$ M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4 M+4E.1$5.5#H@-"4G/@T*($9OF4@$$P.W1H92!M:6QE6UE;G1S+B!!(&UI;&5S=&]N92!P87EM96YT(&ES(&-O;G-I M9&5R960@$$P.W1H92!M:6QE2!A$$P.W1H92!A;6]U M;G0@;V8@=&AE(&UI;&5S=&]N92!P87EM96YT#L@34%21TE.+51/4#H@,3)P>"<^#0H@)B-X03`[/"]P/@T*(#QP('-T M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`P<'0[ M(%1%6%0M24Y$14Y4.B`T)2<^#0H@1V5N97)A;&QY+"!T:&4@;6EL97-T;VYE M(&5V96YT6UE;G1S('=E(&UA M>0T*(&5AF5D#0H@=VET M:&EN('1H92!N97AT(#$R(&UO;G1H6QE/3-$ M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\ M8CY3=&]C:RU"87-E9"!#;VUP96YS871I;VX\+V(^/"]P/@T*(#QP('-T>6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1% M6%0M24Y$14Y4.B`T)2<^#0H@5V4@86-C;W5N="!F;W(@'!E;G-E(&]V97(@=&AE(')E M<75I'!E;G-E(')E8V]G;FET:6]N(&]V97(- M"B!T:&4@=F5S=&EN9R!P97)I;V0N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=) M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5. M5#H@-"4G/@T*(%=E(&%C8V]U;G0@9F]R('-T;V-K(&]P=&EO;G,@9W)A;G1E M9"!T;R!N;VXM96UP;&]Y965S(&]T:&5R('1H86X-"B!M96UB97)S(&]F(&]U M2!C;VYS:7-T M(&]F#0H@;65M8F5R2!B;V%R M9"P@=7-I;F<@=&AE(&9A:7(@=F%L=64-"B!A<'!R;V%C:"X@4W1O8VL@;W!T M:6]N6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!- M05)'24XM5$]0.B`Q.'!T)SX-"B`\8CY&86ER(%9A;'5E($]P=&EO;CPO8CX\ M+W`^#0H@/'`@6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!4 M15A4+4E.1$5.5#H@-"4G/@T*($EN($IU;'D@,C`Q,BP@=V4@86UE;F1E9"!A M;F0@2`R M,#$P('1O($=32PT*("@F(W@R,#%#.S(P,3`@1U-+($YO=&4F(W@R,#%$.RDL M('=H:6-H('=A6EN9R!V86QU92!O9B!T:&4@;W)I M9VEN86P@;F]T92!A;F0@=&AE#0H@9F%I6QE/3-$ M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\ M8CY296-E;G0@06-C;W5N=&EN9R!02`R,#$S+"!T M:&4@1D%30B!I#(P,40[*2X@5&AI$$P.S,P+"`R M,#$S+B!4:&4@861O<'1I;VX@;V8@05-5(#(P,3,M,#(@:&%D(&YO#0H@:6UP M86-T(&]N(&]U2`R,#$S+"!T:&4@1D%30B!I&ES=',\+VD^("@F(W@R,#%#.T%352`R,#$S+3$Q)B-X,C`Q M1#LI+@T*(%1H:7,@=7!D871E('!R;W9I9&5S(&5X<&QI8VET(&=U:61A;F-E M(&]N('1H92!F:6YA;F-I86P@69O&ES=',N(%1H:7,@ M9W5I9&%N8V4@:7,@969F96-T:79E('!R;W-P96-T:79E;'D@9F]R(&9I7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2!I;G-T$$P.S,P+"`R,#$S('1O('1H92!N=6UE$$P.S,P+"`R,#$S("AI;B!T:&]U6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P6QE/3-$)T9/3E0M4TE:13H@ M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XH,BPQ-C0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE6%B;&4\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C8W,3PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M+W1R/@T*(#QT"<^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q M,G!T.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE2!D:6QU=&EV92!S96-U$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI M9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P M,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L M:6=N/3-$8V5N=&5R/CQB/DYI;F4F(WA!,#MM;VYT:',F(WA!,#ME;F1E9#PO M8CX\8G(@+SX-"B`\8CY397!T96UB97(F(WA!,#LS,"P\+V(^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V M86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED M)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XF(W@R,#$T M.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XQ,RPV.3DL.3DY/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C,L,#0Q+#`S,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XR+#@T-2PV-S4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C(L.#(S+#0V,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T* M(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,L M.#6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$V+#4R,RPT M-C(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)TU!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($EN($]C=&]B97(@,C`Q,BP@86QL(&-O M;G9E6%B;&4-"B!O=71S=&%N M9&EN9R!W:71H(&$@<')I;F-I<&%L(&)A;&%N8V4@;V8@)#4N-"!M:6QL:6]N M('1H870@=V%S#0H@8V]N=F5R=&EB;&4@:6YT;R!C;VUM;VX@3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\U8S%E-C-A-%\T,3DU7S1E-#A?83DY,%\U,F9E M9C0W8F(V.3D-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-6,Q938S M831?-#$Y-5\T930X7V$Y.3!?-3)F968T-V)B-CDY+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R6QE/3-$)TU!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1% M3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM M0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@5V4@:6YV97-T(&]U M&-E2X@1F]R(&EN=F5S=&UE;G1S(&EN(&1E M8G0@2!T:&%T('=E('=I;&P@8F4@2X@07,@;V8@4V5P=&5M8F5R)B-X03`[,S`L(#(P,3,L(&]U6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N M/3-$8F]T=&]M(')O=W-P86X],T0R(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N M=&5R/CQB/DUA='5R:71Y/"]B/CQB$$P.WEE87)S M*3PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@$$P.R8C>$$P M.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@F5D/"]B/CQB$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C M,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V M(&%L:6=N/3-$8V5N=&5R/CQB/E5N$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(')O=W-P86X] M,T0R(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/D5S=&EM871E9#PO M8CX\8G(@+SX-"B`\8CYF86ER)B-X03`[=F%L=64\+V(^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(')O=W-P86X],T0R/B8C>$$P.SPO=&0^#0H@/"]T M$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED M)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(F(WA! M,#MO$$P.VQE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C8X+#8T.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@U,#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C8X+#8Q-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C$@;W(@;&5S6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z M(#$P<'0G/@T*($-E$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C$S+##(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$S+#$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ(&]R(&QE$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$"<^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T M6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P M<'0G/@T*(%1O=&%L/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C(P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@U,#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z M(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$ M)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S M='EL93TS1"=-05)'24XM5$]0.B`Q,G!X.R!-05)'24XM0D]45$]-.B`P<'@[ M($9/3E0M4TE:13H@,7!X)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE M/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@ M65A6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P M.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.S,Q+"`R M,#$R/"]B/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4 M+5-)6D4Z(#$P<'0G/@T*($-O$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR)B-X03`[;W(F(WA!,#ML M97-S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`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`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0T+#@U M-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C(@;W(@;&5S#(P M,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C8L-#DR/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@ M/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C$@;W(@;&5S#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C8L,C`P/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T M>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XU-RPU.3`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH-#D\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C4W+#4T.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\U8S%E-C-A-%\T,3DU7S1E-#A?83DY,%\U,F9E9C0W8F(V.3D-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-6,Q938S831?-#$Y-5\T930X M7V$Y.3!?-3)F968T-V)B-CDY+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R6QE/3-$)TU! M4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE: M13H@,3!P="<^#0H@5V4@:&%V92!C97)T86EN(&9I;F%N8VEA;"!A6QE/3-$)TU!4D=)3BU43U`Z(#$R M<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T* M($%P<&QI8V%B;&4@86-C;W5N=&EN9R!G=6ED86YC92!D969I;F5S(&9A:7(@ M=F%L=64@87,@=&AE(&5X8VAA;F=E#0H@<')I8V4@=&AA="!W;W5L9"!B92!R M96-E:79E9"!F;W(@86X@87-S970@;W(@<&%I9"!T;R!T&ET('!R:6-E*2!I;B!T:&4@<')I;F-I<&%L(&]R M(&UO$$P.V%B;&4@=&\-"B!TF5S('1H92!U2X@5&AE(&=U:61A;F-E('!R:6]R:71I>F5S('1H92!I M;G!U=',@=7-E9"!I;B!M96%S=7)I;F<-"B!T:&4@9F%I$$P.SPO<#X-"B`\=&%B;&4@6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@34%21TE.+4)/5%1/33H@ M,'!T.R!&3TY4+5-)6D4Z(#9P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S M='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)O$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1'1O<"!W:61T:#TS1#(E(&%L:6=N/3-$;&5F=#XF(W@R,#(R M.SPO=&0^#0H@/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1'1O<"!A;&EG;CTS1&QE9G0^3&5V96P@,B!I M;F-L=61E2P-"B!O8G-E6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@34%21TE.+4)/5%1/33H@,'!T M.R!&3TY4+5-)6D4Z(#9P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL M93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)O$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1'1O<"!W:61T:#TS1#(E(&%L:6=N/3-$;&5F=#XF(W@R,#(R.SPO M=&0^#0H@/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1'1O<"!A;&EG;CTS1&QE9G0^3&5V96P@,R!I;F-L M=61E#(P,3D[$$P.S,P+"`R,#$S(&%N9"!$96-E;6)E$$P M.S,Q+"`R,#$R("AI;@T*('1H;W5S86YD6QE/3-$ M)TU!4D=)3BU43U`Z(#!P=#L@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-) M6D4Z(#$R<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE M$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C M,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q M-"!A;&EG;CTS1&-E;G1E$$P.S,P+`T*(#(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@ M8V]L$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T M=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/DQE=F5L)B-X03`[ M,3PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V M86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P M<'0G/@T*($%S$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T6QE/3-$)U1% M6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!-05)'24XM3$5&5#H@,V5M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($-A$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XF(W@R,#$T.R8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C8X+#8Q-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XF(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV."PV,3<\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($-O;6UE$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XY.3D\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C$S+#$$P.SPO M=&0^#0H@/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!&3TY4 M+5-)6D4Z(#$P<'0G/@T*($1E8G0@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$$$P.SPO M=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS,RPS-S<\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T M>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M+W1R/@T*(#QT$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$S+#DR,3PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XF(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XF(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XQ,RPY,C$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P M(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q-"!A;&EG M;CTS1&-E;G1E6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L M$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,Y+#,V,SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C0T+#@U-CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XF(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X M03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8L-#DR/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8L-#DR/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C8L,C`P/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8L,C`P/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF M(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CDV+#DQ,3PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T M>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XS.2PS-C,\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P M,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE: M13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C$P+#$S-#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE: M13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XF(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE: M13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XF(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE: M13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XQ,"PQ,S0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)TU!4D=)3BU43U`Z(#$R<'@[($U!4D=)3BU" M3U143TTZ(#!P>#L@1D].5"U325I%.B`Q<'@G/@T*("8C>$$P.SPO<#X-"B`\ M<"!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[($9/3E0M1D%-24Q9.B!4:6UE M$$P.S,Q+"`R,#$R('1H6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/@T*(#QB M/D9A:7(F(WA!,#M686QU928C>$$P.TUE87-U$$P M.S,Q+"`R,#$R/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$P+#$S-#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X M03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6%B;&4\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+#"<^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T* M(#QT$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$S+#DR,3PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X M03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO M='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!T M.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE2!W:71H('1H92!D M96)T(&5X=&EN9W5I2!N;W1E(&5F9F5C=&EV92!A6EN9PT*(&EN:71I86P@<'5B;&EC(&]F9F5R:6YG("@F M(W@R,#%#.U!O2!V86QU871I;VX@9FER;2!T;R!V86QU92!T:&4@4&]S M="U)4$\@1U-+($YO=&4@870-"B!397!T96UB97(F(WA!,#LS,"P@,C`Q,R!A M;F0@$$P.S,P+"`R,#$S(&]N M('1H92!C;VYD96YS960-"B!S=&%T96UE;G1S(&]F(&]P97)A=&EO;G,@86YD M(&-O;7!R96AE;G-I=F4@;&]S$$P.S,P+"`R,#$S('=A2!A(')E9'5C=&EO;B!I;B!O=7(@$$P.S,P+`T*(#(P,3,N/"]P M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4 M.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/ M5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%1H92!T:&ER9"UP87)T M>2!V86QU871I;VX@9FER;2!U$$P.S,P+"`R,#$S('=E0T* M(&]F('!E97(@8V]M<&%N:65S+B!0965R(&-O;7!A;FEE6EE;&0@;V8@52Y3+B!42!3=')I<',@87,@;V8@96%C:"!D871E+B!4:&4@8W)E9&ET#0H@7-I'10 M87)T7S5C,64V,V$T7S0Q.35?-&4T.%]A.3DP7S4R9F5F-#=B8C8Y.0T*0V]N M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\U8S%E-C-A-%\T,3DU7S1E-#A? M83DY,%\U,F9E9C0W8F(V.3DO5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQAF4Z,3!P M=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B`\8CXU+B!#;VYV M97)T:6)L92!.;W1E3I4:6UE'0M:6YD96YT.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM M97,@3F5W(%)O;6%N)SX-"B!);B!*=6QY(#(P,3(L('=E(&%M96YD960@86YD M(')E2`D,"XT#0H@;6EL;&EO;BX@5&AE M(&%M96YD960@86YD(')E2!C86YC96QL960@86YD(&]U2!T:6UE('!R:6]R('1O('1H92!M871U2!A="!A#0H@8V]N=F5R$$P M.S,P+"`R,#$S+"!T:&4@9F%I#(P,4,[0V]N=F5R=&EB;&4-"B!N;W1E('!A>6%B;&4L(&%T(&9A:7(@ M=F%L=64F(W@R,#%$.R!O;B!T:&4@8V]N9&5N3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\U8S%E-C-A-%\T,3DU7S1E-#A?83DY,%\U,F9E9C0W8F(V M.3D-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-6,Q938S831?-#$Y M-5\T930X7V$Y.3!?-3)F968T-V)B-CDY+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R6QE/3-$)TU!4D=) M3BU43U`Z(#$R<'@[($U!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q M<'@G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P M,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L M:6=N/3-$8V5N=&5R/CQB/E-E<'1E;6)E$$P.S,P+#PO8CX\8G(@+SX- M"B`\8CXR,#$S/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C0L,38P+#(Q-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XT+#8V,2PU-#D\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$ M)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($-O M;6UO;B!S=&]C:R!O<'1I;VYS(&%V86EL86)L92!F;W(@9G5T=7)E(&=R86YT M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CDT-BPT,#,\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P M.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$ M)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($5M M<&QO>65E(%-T;V-K(%!U$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XT-C`L,C@S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C$U,"PP,#`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G M/@T*($-O;G9E$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C$L-#`P+#@T.#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XQ+#,V-BPW.#<\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@ M/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@ M/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C@L,3@R+#6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S M='EL93TS1"=-05)'24XM5$]0.B`Q,G!T.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P M="<^#0H@5&AE(&9O;&QO=VEN9R!T86)L92!S=6UM87)I>F5S(&]U$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^ M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L&5R8VES93PO8CX\8G(@+SX-"B`\8CYP$$P.S,Q+"`R,#$R/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(N,3$\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5& M5#H@,V5M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($=R86YT960\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XS-C$\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!&3TY4+5-) M6D4Z(#$P<'0G/@T*($5X97)C:7-E9#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/B@W,C`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@R,#$\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)TU! M4D=)3BU43U`Z(#!P=#L@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z M(#$R<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P M,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L M:6=N/3-$8V5N=&5R/CQB/E1H$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P M86X],T0V(&%L:6=N/3-$8V5N=&5R/CQB/DYI;F4F(WA!,#MM;VYT:',F(WA! M,#ME;F1E9#QB$$P.S,P+#PO8CX\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+C<\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/BH\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+C$\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE'!E M8W1E9"!D:79I9&5N9"!Y:65L9#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C`N,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/"]T6QE/3-$)U1% M6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!-05)'24XM3$5&5#H@,V5M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($5X<&5C M=&5D('9O;&%T:6QI='D\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XW,BXW/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#XE)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XJ/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`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`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$6QE/3-$)T)/4D1% M4BU#3TQ,05!313H@8V]L;&%P$$P.S,P+"`R,#$R+CPO=&0^#0H@/"]T6QE/3-$)TU!4D=)3BU43U`Z(#$R<'0[($9/ M3E0M1D%-24Q9.B!4:6UE6QE M/3-$)TU!4D=)3BU43U`Z(#!P=#L@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4 M+5-)6D4Z(#$R<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X] M,T0V(&%L:6=N/3-$8V5N=&5R/CQB/E1H$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R/CQB/DYI;F4F(WA!,#MM;VYT M:',F(WA!,#ME;F1E9#QB$$P.S,P+#PO8CX\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R M/@T*(#QT6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L-C8T/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT-C$\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO M=&0^#0H@/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4 M+5-)6D4Z(#$P<'0G/@T*($=E;F5R86P@86YD(&%D;6EN:7-T$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$S-CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XX-C`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/CDW.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT,30\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP M="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$'1087)T M7S5C,64V,V$T7S0Q.35?-&4T.%]A.3DP7S4R9F5F-#=B8C8Y.0T*0V]N=&5N M="U,;V-A=&EO;CH@9FEL93HO+R]#.B\U8S%E-C-A-%\T,3DU7S1E-#A?83DY M,%\U,F9E9C0W8F(V.3DO5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)VUA3I4:6UE3I4:6UE$$P.SPO<#X-"B`\=&%B;&4@8V5L M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#DR)2!B;W)D M97(],T0P('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313I#3TQ,05!313L@9F]N M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z,3!P="<@86QI M9VX],T1C96YT97(^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#6QE/3-$)V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.CAP="<^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P M86X],T0V(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O6QE/3-$)V)O$$P.S,P+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\+W1R/@T*(#QT3I4:6UE M$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$ M,B!A;&EG;CTS1&-E;G1E6QE/3-$)V)O$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E6QE/3-$)V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.C$P<'0G/@T*(#QT9"!V86QI M9VX],T1T;W`^#0H@/'`@F4Z,3!P=#L@9F]N="UF86UI M;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!386YO9FD\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C(L-3`P/"]T9#X-"B`\=&0@;F]W6QE/3-$)V9O;G0M9F%M:6QY M.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.C$P<'0G/@T*(#QT9"!V86QI M9VX],T1T;W`^#0H@/'`@F4Z,3!P=#L@9F]N="UF86UI M;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!'4TL\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XQ-#0\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA M;CL@9F]N="US:7IE.C$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@ MF4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O M;6%N)SX-"B!!$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C0V-3PO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XY-#PO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#,Y M-#PO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XY-#PO=&0^ M#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT3I4:6UE6QE/3-$)VUA$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XX-SPO=&0^#0H@/'1D(&YO=W)A<#TS M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XR.3PO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A M<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XR-3D\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M$$P.R8C>$$P.SPO=&0^#0H@/"]TF4Z,7!X.SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B M;W)D97(M=&]P.C$N,#!P>"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O M$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)V)O$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@"!S;VQI9"`C M,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X- M"B`\+W1R/@T*(#QT6QE/3-$)VUA6QE/3-$9F]N="US M:7IE.CAP=#XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XV+#$Q.#PO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$9F]N="US:7IE.CAP=#XF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#@P.3PO=&0^ M#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE M/3-$9F]N="US:7IE.CAP=#XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XQ-"PQ,34\+W1D/@T*(#QT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1&9O;G0M$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$9F]N="US:7IE.C%P>#MM87)G:6XM=&]P.C$X<'@[;6%R9VEN M+6)O='1O;3HP<'@^#0H@)B-X03`[/"]P/@T*(#QP('-T>6QE/3-$)VUA'0M:6YD96YT.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!);B!*=6QY(#(P,3(L('=E M(&%M96YD960@86YD(')E3I4:6UE&-L=7-I M=F4@2`R,#$S+"!W92!R96-E:79E9"!A;@T*('5P9G)O;G0@<&%Y;65N="!O M9B`D,BXU(&UI;&QI;VXL(&]F('=H:6-H("0Q+C(U(&UI;&QI;VX@:7,-"B!C M2!3 M86YO9FD@=&\@=7,@=6YD97(@86YY#0H@9G5T=7)E(&-O+61E=F5L;W!M96YT M(&%N9"!C;VUM97)C:6%L:7IA=&EO;B!A9W)E96UE;G0@=V4@96YT97(-"B!P M=7)S=6%N="!T;R!T:&4@;W!T:6]N(&%G6UE;G0L("0Q+C(U(&UI;&QI M;VXL('=I;&P@8F4@FEN9R!T:&4@6UE;G0@;V8@)#(U+C`@;6EL;&EO;@T* M(')A=&%B;'D@9G)O;2!*=6YE(#(P,3,@=6YT:6P@=&AE(&5X<&ER871I;VX@ M;V8@=&AE(&]P=&EO;B!P97)I;V0@:6X-"B!$96-E;6)E6UE;G1S#0H@ M=6YD97(@;W5R('-T$$P.V9O2!A6UE;G1S('=I;&P@8F4@2P@86YD('=H96X@8V]L;&5C=&%B:6QI='D@:7,-"B!R96%S;VYA M8FQY(&%S'!I$$P.VUI;&QI;VX@=7!O;B!T:&4@ M9FEL:6YG(&]F(&%N#0H@26YV97-T:6=A=&EO;F%L($YE=R!$#(P,40[*2!F;W(@=&AE#0H@6%L=&EE6QE/3-$ M)VUA3I4:6UEF4@ M;F]V96P@;6EC'!A;F1E9"!T:&4@#(P,4,[2$-6)B-X,C`Q1#LI('1O(&1IF4@;6EC'1E M;F0@=&AE('1A2!UF%T:6]N('!E2!E:6=H="!Y96%R M$$P.S,P+"`R,#$S+"!D969E2!U$$P.U1H:7,@86UE;F1M96YT M(')E;6]V960@86YY(&9U2!O M8FQI9V%T:6]NF5D("0Q+C$@ M;6EL;&EO;B!I;B!D969E6UE;G0@9G)O;2!T:&4@1F5B'!A;F1E9"!O=7(-"B!A9W)E96UE;G0@=VET:"!' M4TL@=&\@:6YC;'5D92!P;W1E;G1I86P@/&D^;6EC6QE/3-$9F]N="US:7IE.C%P>#MM87)G:6XM=&]P.C$X M<'@[;6%R9VEN+6)O='1O;3HP<'@^#0H@)B-X03`[/"]P/@T*(#QP('-T>6QE M/3-$)VUA'0M:6YD96YT.C0E.R!F;VYT M+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!. M;W1W:71H$$P.VUI;&QI;VX@ M9F]R#0H@2!M:6QE$$P.VUI;&QI;VX@9F]R#0H@8V]M;65R8VEA;&EZ871I;VX@;6EL97-T;VYE M2!P0T*(&-O;6UEF5S('5N M9&5R('1H:7,@86QL:6%N8V4N/"]P/@T*(#QP('-T>6QE/3-$)VUA'0M:6YD96YT.C0E.R!F M;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX- M"B!792!H879E(&5V86QU871E9"!T:&4@$$P.V9O2!A="!T:&4@9&%T92!T:&4@86=R965M M96YT('=A6UE;G1S(&)E:6YG(&1U92!T;R!U2!A6UE;G1S('=I;&P@8F4@ M2P@86YD('=H M96X-"B!C;VQL96-T86)I;&ET>2!I$$P.VUI;&QI;VX@=7!O;B!T:&4@6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE0T*(&1E=F5L;W!E M9"!A;F0@8V]M;65R8VEA;&EZ960@=&AR;W5G:"!P6QE/3-$)VUA'0M:6YD96YT.C0E.R!F;VYT+7-I>F4Z,3!P=#L@ M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!792!H879E(&5V86QU M871E9"!T:&4@$$P.V9O2!A="!T:&4@9&%T92!T:&4@86=R965M96YT('=A6UE;G1S(&)E:6YG(&1U92!T;R!U2!A6UE;G1S('=I;&P@8F4@2P@86YD('=H96X-"B!C;VQL96-T86)I M;&ET>2!I6QE/3-$)VUA3I4:6UE M'0M:6YD96YT.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM M97,@3F5W(%)O;6%N)SX-"B!);B!!=6=UF4@;&5A9"!C;VUP;W5N9',@9&5S:6=N871E9"!B M>0T*($%S=')A6F5N96-A(&EN('1H92!C;W5R'1E;F1S('5N=&EL('1H92!F;W5R=&@@86YN:79EF%T:6]N(&]F(&%L;&EA;F-E('!R M;V1U8W0@8V%N9&ED871E3I4:6UE6UE;G0@;V8-"B`D,RXP(&UI;&QI;VX@:6X@3V-T M;V)EFEN9R!R979E;G5E#0H@65A2!D979E;&]P960@86YD(&-O M;6UEF5D('1H6UE;G1S('5P('1O M#0H@)#0Y."XP)B-X03`[;6EL;&EO;BP@:6YC;'5D:6YG('5P('1O("0U+C`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`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`\8CY" M:6]G96X@261E8SPO8CX\+W`^#0H@/'`@#(P,4,[35,F(W@R,#%$ M.RDN(%5N9&5R('1H92!T97)M2UF&-L=7-I=F4@;&EC96YS92!T;R!O=7(@8F%C:V=R;W5N M9`T*(&EN=&5L;&5C='5A;"!P2D@9F]R('1H92!P=7)P;W-E(&]F M(&-O;6UEFEN9R!P6UE;G0@;V8@)#`N.`T*(&UI M;&QI;VXN(%=E(&%R92!A;'-O(&5L:6=I8FQE('1O(')E8V5I=F4@6UE;G0@;V8@)#`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`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'0^)SQD:78^#0H@/'`@'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA'0^)SQD:78^#0H@/'`@#(P,4,[1T%!4"8C>#(P,40[*2!F;W(@:6YT97)I;2!F M:6YA;F-I86P@:6YF;W)M871I;VX-"B!A;F0@=&AE(&EN$$P.U,M6"X\+V9O M;G0^($%C8V]R9&EN9VQY+"!T:&5Y#0H@9&\@;F]T(&EN8VQU9&4@86QL(&]F M('1H92!I;F9O2!F;W(@82!F86ER('!R97-E;G1A M=&EO;B!O9B!T:&4@#(P,40[("8C>#(P,4,[;W5R M+"8C>#(P,40[(&]R('1H90T*("8C>#(P,4,[0V]M<&%N>28C>#(P,40[*2P@ M9G)O;2!W:&EC:"!T:&4@8F%L86YC92!S:&5E="!I;F9O6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!- M05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*($EN($]C=&]B M97(@,C`Q,BP@=V4@8V]M<&QE=&5D(&%N(&EN:71I86P@<'5B;&EC(&]F9F5R M:6YG(&%N9`T*(&-O;F-U2!C;VYV97)T960@=7!O;B!T:&4@8VQO6QE/3-$)TU!4D=)3BU"3U143TTZ M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T* M($EN($IU;'D@,C`Q,RP@=V4@8V]M<&QE=&5D(&$@<'5B;&EC(&]F9F5R:6YG M(&]F(#4L,3'0^ M)SQD:78^#0H@/'`@6QE/3-$)VUA3I4:6UE M6QE/3-$)VUA3I4:6UE$$P M.S,P+"`R,#$S+"!W92!H879E(&]N9V]I;F<@#(P,4,[1U-+)B-X,C`Q1#LI+"!386YO9FDL M($%S=')A6F5N96-A($%"#0H@*"8C>#(P,4,[07-T#(P,4,[0FEO9V5N#0H@ M261E8R8C>#(P,40[*2X@3W5R(')E=F5N=65S(&=E;F5R86QL>2!C;VYS:7-T M(&]F('5P9G)O;G0@<&%Y;65N=',-"B!F;W(@;&EC96YS97,@;W(@;W!T:6]N M6UE M;G1S+B!792!R96-O9VYI>F4-"B!R979E;G5E$$P.V1E;&EV97)Y(&]F('1H92!P$$P.W1H92!S96QL:6YG M('!R:6-E(&ES(&9I>&5D(&]R(&1E=&5R;6EN86)L93L@86YD#0H@*#0I)B-X M03`[8V]L;&5C=&%B:6QI='D@:7,@2!A$$P.VEF('1H92!A9W)E M96UE;G0@:6YC;'5D97,@80T*(&=E;F5R86P@#(P,40[(&EF('9E;F1O6QE/3-$)VUA3I4:6UE6QE/3-$ M)VUA3I4:6UE6UE;G1S('=H96X@96%R;F5D+"!P$$P.W=E(&1O(&YO="!H879E#0H@ M;VYG;VEN9R!P97)F;W)M86YC92!O8FQI9V%T:6]N$$P.VET('=O=6QD(')E6UE;G0@:7,@8V]N6UE;G0@:7,@;F]N+7)E9G5N9&%B;&4[("AI:2DF(WA!,#MA8VAI979E;65N M="!O9B!T:&4@;6EL97-T;VYE#0H@=V%S(&YO="!R96%S;VYA8FQY(&%S$$P.SPO<#X-"B`\<"!S='EL93TS1"=M M87)G:6XM=&]P.C!P=#L@;6%R9VEN+6)O='1O;3HP<'0[('1E>'0M:6YD96YT M.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O M;6%N)SX-"B!'96YE2!A<'!R;W9A;"!A;F0@ M=&AE;B!T;PT*(&-O;6UEF%T:6]N+B!4:&4@<')O8V5S2!S M;VQD(&9O2!U;F-E2!I;F-R96%S97,N/"]P/@T*(#PO9&EV/CQS<&%N M/CPO'0^ M)SQD:78^#0H@/'`@6EN9PT*(&-O;F1E;G-E9"!B86QA;F-E('-H965T'0^)SQD:78^#0H@/'`@'0M:6YD96YT.C0E.R!F;VYT+7-I>F4Z,3!P M=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!792!A8V-O=6YT M(&9O65EF4@3I4:6UE2!C;VYS:7-T(&]F#0H@;65M8F5R2!B;V%R9"P@=7-I;F<@=&AE(&9A:7(@=F%L=64-"B!A<'!R;V%C M:"X@4W1O8VL@;W!T:6]N6QE/3-$)VUA3I4:6UE'0M:6YD M96YT.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W M(%)O;6%N)SX-"B!!<'!L:6-A8FQE(&%C8V]U;G1I;F<@9W5I9&%N8V4@<&5R M;6ET6QE/3-$)VUA'0M:6YD96YT.C0E.R!F;VYT+7-I>F4Z M,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!);B!*=6QY M(#(P,3(L('=E(&%M96YD960@86YD(')E2!I M'1I;F=U:7-H;65N="!O9B!T:&4@;W)I9VEN86P@;F]T M92X@5V4@96QE8W1E9"!T;R!M96%S=7)E('1H92`R,#$P#0H@1U-+($YO=&4@ M=6YD97(@=&AE(&9A:7(@=F%L=64@;W!T:6]N+B!5<&]N(&EN:71I86P@;65A M6%B;&4@=&\@;F]N+6]P97)A=&EN9PT*(&5AF4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N M)SX-"B`\8CY296-E;G0@06-C;W5N=&EN9R!0$$P.S(P,3,M,#(L(#QI/D-O;7!R96AE;G-I=F4@26YC;VUE("A4 M;W!I8R`R,C`I.B!297!O#(P,4,[05-5(#(P,3,M,#(F(W@R,#%$.RDN(%1H:7,@ M=7!D871E('=I;&P@6QE/3-$ M)VUA'0M:6YD M96YT.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W M(%)O;6%N)SX-"B!);B!*=6QY(#(P,3,L('1H92!&05-"(&ESF5D(%1A>"!"96YE9FET M#0H@5VAE;B!A($YE="!/<&5R871I;F<@3&]S69O"!##(P,4,[05-5(#(P,3,M,3$F(W@R,#%$.RDN M#0H@5&AIF5D('1A>"!B96YE9FET('=H96X@82!N970@;W!E69O2!F;W(@9FES8V%L('EE M87)S+`T*(&%N9"!I;G1E$$P.S$U+"`R,#$S+"!W M:71H(&%N(&]P=&EO;B!F;W(@96%R;'D@861O<'1I;VXN(%=E#0H@:6YT96YD M('1O(&%D;W!T('1H:7,@9W5I9&%N8V4@:6X@,C`Q-"P@86YD(&1O(&YO="!B M96QI979E('1H90T*(&%D;W!T:6]N(&]F('1H:7,@3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U8S%E-C-A M-%\T,3DU7S1E-#A?83DY,%\U,F9E9C0W8F(V.3D-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO-6,Q938S831?-#$Y-5\T930X7V$Y.3!?-3)F968T M-V)B-CDY+U=O'0O:'1M;#L@8VAA'0^)SQD:78^#0H@/'`@$$P.S,P+"`R,#$S("AI;B!T:&]U6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P6QE/3-$)T9/ M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XH,BPQ-C0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6%B;&4\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8W,3PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[ M/"]T9#X-"B`\+W1R/@T*(#QT"<^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T* M(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\2!D:6QU=&EV92!S96-U$$P.R8C>$$P.SPO M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O M;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R/CQB/DYI;F4F(WA!,#MM;VYT:',F M(WA!,#ME;F1E9#PO8CX\8G(@+SX-"B`\8CY397!T96UB97(F(WA!,#LS,"P\ M+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/"]T$$P.R8C>$$P M.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C M>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P M.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XF(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XQ,RPV.3DL.3DY/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T* M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C,L,#0Q+#`S,SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XR+#@T-2PV-S4\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L.#(S+#0V,SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF M(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@ M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C,L.#6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C$V+#4R,RPT-C(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M$$P.R8C>$$P.SPO=&0^#0H@/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A6QE M/3-$)TU!4D=)3BU43U`Z(#$R<'0[($9/3E0M1D%-24Q9.B!4:6UEF4@;W5R('-H;W)T+71E M6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B M;W1T;VT@65A6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UE$$P.V]R M)B-X03`[;&5S$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/CDY.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T* M("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/CDY.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R M/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XR(&]R(&QE$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$@;W(@;&5S#(P,30[)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T* M(#QT6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XY,"PT-#,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@.'!T M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XY,"PT M,3,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE M/3-$)TU!4D=)3BU43U`Z(#$R<'@[($U!4D=)3BU"3U143TTZ(#!P>#L@1D]. M5"U325I%.B`Q<'@G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L M:6=N/3-$8F]T=&]M(')O=W-P86X],T0R(&-O;'-P86X],T0R(&%L:6=N/3-$ M8V5N=&5R/CQB/D%M;W)T:7IE9#PO8CX\8G(@+SX-"B`\8CYC;W-T/"]B/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!R;W=S<&%N/3-$,CXF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@ M8V]L$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T M=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/DQO$$P.SPO=&0^#0H@/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-) M6D4Z(#$P<'0G/@T*(#QB/D%S(&]F($1E8V5M8F5R)B-X03`[,S$L(#(P,3(\ M+V(^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(F(WA!,#MO$$P.VQE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0T+#@Y.#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C8L-#DR/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$ M)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($-E M$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C8L,C`P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C4W+#4Y,#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XW/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@T.3PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE M/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\ M+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)TU!4D=)3BU43U`Z(#$R<'0[($9/3E0M1D%- M24Q9.B!4:6UE2!F;W(@87-S971S#0H@86YD(&QI M86)I;&ET:65S(&UE87-U6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/E1O=&%L M/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!&3TY4+5-) M6D4Z(#$P<'0G/@T*($-O$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV."PV,3<\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CDY M.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XF(W@R,#$T M.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XQ,RPW-S`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE: M13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C$R,RPW.3`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CDP+#0Q,SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XF(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\ M+W1R/@T*(#QT6QE/3-$)U1%6%0M M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!- M05)'24XM3$5&5#H@,V5M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($-O;G9E6%B;&4\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,RPY,C$\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T M;VT@8V]L$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$ M8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/DQE=F5L)B-X M03`[,3PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED M)R!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z M(#$P<'0G/@T*($%S$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T6QE/3-$ M)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!-05)'24XM3$5&5#H@,V5M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($-A M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XF(W@R,#$T.R8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C0T+#@U-CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XF(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT-"PX-38\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)U1%6%0M24Y$14Y4 M.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM M3$5&5#H@,V5M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($-O;6UE$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV+#0Y,CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XF(W@R,#$T.R8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV M+#0Y,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XF(W@R M,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT M$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV+#(P,#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XF(W@R,#$T.R8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV+#(P,#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XF(W@R,#$T.R8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT M6QE/3-$)T9/3E0M4TE:13H@.'!T M)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XY-BPY,3$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C4W+#4T.#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XF(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\+W1R/@T* M(#QT6QE/3-$)U1%6%0M24Y$14Y4 M.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM M3$5&5#H@,V5M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($-O;G9E6%B;&4\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,"PQ,S0\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$'0^)SQD:78^#0H@/'`@6QE/3-$)TU! M4D=)3BU43U`Z(#!P=#L@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z M(#$R<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@$$P.SPO=&0^#0H@/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-) M6D4Z(#$P<'0G/@T*($)A;&%N8V4@870@1&5C96UB97(F(WA!,#LS,2P@,C`Q M,CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,"PQ,S0\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P M.SPO=&0^#0H@/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!& M3TY4+5-)6D4Z(#$P<'0G/@T*($-H86YG92!I;B!E$$P.R8C>$$P.SPO=&0^#0H@ M/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-) M6D4Z(#$P<'0G/@T*($)A;&%N8V4@870@4V5P=&5M8F5R)B-X03`[,S`L(#(P M,3,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T M>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,RPY,C$\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^ M#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\U8S%E-C-A-%\T,3DU7S1E-#A?83DY,%\U,F9E9C0W8F(V M.3D-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-6,Q938S831?-#$Y M-5\T930X7V$Y.3!?-3)F968T-V)B-CDY+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R3I4:6UE M$$P.S,P+"`R,#$S.CPO<#X-"B`\<"!S='EL93TS1&9O M;G0M$$P.SPO<#X-"B`\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP M861D:6YG/3-$,"!W:61T:#TS1#6QE/3-$)T)/ M4D1%4BU#3TQ,05!313I#3TQ,05!313L@9F]N="UF86UI;'DZ5&EM97,@3F5W M(%)O;6%N.R!F;VYT+7-I>F4Z,3!P="<@86QI9VX],T1C96YT97(^#0H@/'1R M/@T*(#QT9"!W:61T:#TS1#6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA M;CL@9F]N="US:7IE.CAP="<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$ M8V5N=&5R('-T>6QE/3-$)V)O$$P.S,P+#PO8CX\8G(@+SX-"B`\ M8CXR,#$S/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N M=&5R('-T>6QE/3-$)V)O$$P.SPO=&0^#0H@ M/"]TF4Z,3!P="<^#0H@/'1D M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P M96T[('1E>'0M:6YD96YT.BTQ+C`P96T[(&9O;G0M3I4:6UE6QE/3-$)VUA M$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#$V,2PT,3`\+W1D M/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)VUA M$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C0V,"PR.#,\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R M87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$6QE M/3-$)VUA$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"=B;W)D97(M=&]P.C$N,#!P>"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)V)O$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)V)O$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO=&0^#0H@/"]T MF4Z,3!P="<^#0H@/'1D('9A M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[ M('1E>'0M:6YD96YT.BTQ+C`P96T[(&9O;G0M3I4:6UE$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$ M9F]N="US:7IE.C%P>#L^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O6QE/3-$)V)O$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B M;W)D97(M=&]P.C,N,#!P>"!D;W5B;&4@(S`P,#`P,"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B M;W)D97(M=&]P.C,N,#!P>"!D;W5B;&4@(S`P,#`P,"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B M;W1T;VT@8V]L&5R8VES M93PO8CX\8G(@+SX-"B`\8CYP$$P.S,Q M+"`R,#$R/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(N,3$\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^ M#0H@/"]T6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!&3TY4+5-) M6D4Z(#$P<'0G/@T*($=R86YT960\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XS-C$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$$P M.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$ M)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!-05)'24XM3$5&5#H@,V5M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($5X M97)C:7-E9#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@W,C`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/B@R,#$\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W6QE/3-$ M)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T* M(#QT$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B`\8CY3 M=&]C:RU"87-E9"!#;VUP96YS871I;VX\+V(^/"]P/@T*(#QP('-T>6QE/3-$ M)VUAF5S('1H92!W96EG:'1E9"!A=F5R86=E M(&%S6QE/3-$9F]N="US:7IE.C$R<'0[ M;6%R9VEN+71O<#HP<'0[;6%R9VEN+6)O='1O;3HP<'0^#0H@)B-X03`[/"]P M/@T*(#QT86)L92!C96QL3I4:6UE$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@8V]L$$P.S,P+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$-B!A;&EG;CTS1&-E M;G1E$$P.SPO=&0^#0H@/"]T$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@8V]L$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E6QE/3-$)V)O M$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@8V]L6QE/3-$)VUA$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/"]TF4Z,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O M<#X-"B`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HS+C`P96T[('1E>'0M:6YD M96YT.BTQ+C`P96T[(&9O;G0M3I4:6UE M$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)VUA6EE;&0\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XP M+C`\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M M/B4F(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/BH\+W1D/@T*(#QT9"!N;W=R M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$6QE/3-$)V9O M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.C$P<'0G/@T* M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@F4Z,3!P=#L@ M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!%>'!E8W1E9"!V;VQA M=&EL:71Y/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XV-RXX/"]T9#X-"B`\=&0@;F]W3I4:6UE6QE M/3-$)VUA$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8N,3PO=&0^#0H@/'1D(&YO M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/'`@F4Z M,3)P=#MM87)G:6XM=&]P.C!P=#MM87)G:6XM8F]T=&]M.C!P=#X-"B`F(WA! M,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313I#3TQ, M05!313L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z M,3!P="<@8F]R9&5R/3-$,"!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<] M,T0P('=I9'1H/3-$,3`P)3X-"B`\='(^#0H@/'1D('=I9'1H/3-$,B4@=F%L M:6=N/3-$=&]P(&%L:6=N/3-$;&5F=#XJ/"]T9#X-"B`\=&0@86QI9VX],T1L M969T('9A;&EG;CTS1'1O<#Y.;R!S=&]C:R!O<'1I;VYS('=E$$P.S,P+"`R,#$R+CPO=&0^#0H@/"]TF4Z,3!P=#L@9F]N M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!4:&4@9F]L;&]W:6YG('1A M8FQE('-U;6UA6QE/3-$9F]N="US:7IE.C$R<'0[;6%R9VEN+71O<#HP<'0[;6%R9VEN M+6)O='1O;3HP<'0^#0H@)B-X03`[/"]P/@T*(#QT86)L92!C96QL3I4:6UEF4Z.'!T)SX-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L$$P.S,P+#PO8CX\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!C;VQS<&%N/3-$-B!A;&EG;CTS1&-E;G1E$$P.SPO=&0^#0H@ M/"]TF4Z.'!T)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A M;&EG;CTS1&-E;G1E6QE/3-$)V)O$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L M6QE/3-$)VUA$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)V9O;G0M9F%M M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.C$P<'0G/@T*(#QT9"!V M86QI9VX],T1T;W`^#0H@/'`@F4Z,3!P=#L@9F]N="UF M86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!'96YE$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,S8\+W1D/@T* M(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"=B;W)D97(M=&]P.C$N,#!P>"!S;VQI9"`C,#`P,#`P)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)V)O$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)V)O$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D M97(M=&]P.C$N,#!P>"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C M0T-%149&('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@ M9F]N="US:7IE.C$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N M)SX-"B!4;W1A;#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@F4Z.'!T/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CDW.#PO=&0^#0H@/'1D(&YO M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$9F]N="US M:7IE.CAP=#XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XT,30\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1&9O;G0M$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1&9O;G0M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQD:78^#0H@/'`@F4Z,3!P=#L@9F]N="UF M86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!4:&4@9F]L;&]W:6YG('1A8FQE M('-U;6UAF4Z,3)P=#MM87)G:6XM=&]P.C!P=#MM M87)G:6XM8F]T=&]M.C!P=#X-"B`F(WA!,#L\+W`^#0H@/'1A8FQE(&-E;&QS M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Y,B4@8F]R9&5R M/3-$,"!S='EL93TS1"="3U)$15(M0T],3$%04T4Z0T],3$%04T4[(&9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.C$P<'0G(&%L:6=N M/3-$8V5N=&5R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N M/3-$-B!A;&EG;CTS1&-E;G1E$$P.VUO;G1H$$P.V5N9&5D/"]B/CQB$$P.S,P+#PO M8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$-B!A;&EG;CTS1&-E;G1E$$P.SPO M=&0^#0H@/"]TF4Z.'!T)SX-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N M/3-$,B!A;&EG;CTS1&-E;G1E6QE/3-$)V)O$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@8V]L6QE/3-$)VUA$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)VUA$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XQ+#8S-#PO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ M+#@P.3PO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)VUA$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XT-C4\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C M>$$P.SPO=&0^#0H@/"]TF4Z,3!P="<^#0H@/'1D('9A;&EG M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E M>'0M:6YD96YT.BTQ+C`P96T[(&9O;G0M3I4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$6QE/3-$ M9F]N="US:7IE.C%P>#L^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"=B;W)D97(M=&]P.C$N,#!P>"!S;VQI9"`C,#`P,#`P)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)V)O$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)V)O$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO=&0^#0H@ M/"]TF4Z,3!P="<^#0H@/'1D M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P M96T[('1E>'0M:6YD96YT.BTQ+C`P96T[(&9O;G0M3I4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1&9O;G0M$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1&9O;G0M$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CDL M-#8R/"]T9#X-"B`\=&0@;F]W'1087)T7S5C M,64V,V$T7S0Q.35?-&4T.%]A.3DP7S4R9F5F-#=B8C8Y.0T*0V]N=&5N="U, M;V-A=&EO;CH@9FEL93HO+R]#.B\U8S%E-C-A-%\T,3DU7S1E-#A?83DY,%\U M,F9E9C0W8F(V.3DO5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQAF%T:6]N($%N9"!3=6UM87)Y($]F(%-I9VYI9FEC86YT($%C M8V]U;G1I;F<@4&]L:6-I97,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A&-L=61E9"!F'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO&-L=61E M9"!F'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&-E<'0@4&5R(%-H87)E(&1A=&$L('5N M;&5S3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\U8S%E-C-A-%\T,3DU7S1E-#A?83DY,%\U,F9E M9C0W8F(V.3D-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-6,Q938S M831?-#$Y-5\T930X7V$Y.3!?-3)F968T-V)B-CDY+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R2!O9B!3:&]R="U497)M($EN=F5S=&UE;G1S("A$971A:6PI M("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE'0^)SQS<&%N M/CPOF5D($=A:6YS/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XR,#QS<&%N/CPO'0^)SQS<&%N/CPOF5D($=A:6YS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XQ.#QS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPOF5D(&-O'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6%B;&4\+W1D/@T*("`@ M("`@("`\=&0@8VQA'0^)SQS<&%N/CPO7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6%B;&4\+W1D/@T*("`@ M("`@("`\=&0@8VQA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\U8S%E-C-A-%\T,3DU7S1E-#A?83DY,%\U,F9E9C0W8F(V.3D-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-6,Q938S831?-#$Y-5\T930X7V$Y M.3!?-3)F968T-V)B-CDY+U=O'0O:'1M;#L@8VAA&-E<'0@4&5R(%-H87)E(&1A M=&$L('5N;&5S'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A6%B;&4@+2!!9&1I=&EO;F%L($EN9F]R;6%T:6]N M("A$971A:6PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@ M/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`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`@("`\=&%B;&4@8VQA&5R8VES960\+W1D/@T*("`@("`@("`\=&0@8VQA'!I&5R8VES92!P'0^)SQS<&%N/CPO'!I'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'!E8W1E9"!D:79I9&5N M9"!Y:65L9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S'!E8W1E9"!V;VQA=&EL:71Y/"]T9#X-"B`@("`@("`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`@ M("`\=&%B;&4@8VQA2!!;&QI86YC93QB2!!;&QI M86YC93QB2!! M;&QI86YC93QB3QBF%T:6]N/&)R/DEM;75N;RU) M;F9L86UM871O2!!;&QI86YC93QB2!!;&QI86YC93QB&EM=6T\8G(^26UM=6YO+4EN9FQA;6UA M=&]R>2!!;&QI86YC93QB&EM=6T\8G(^2$-6($%L;&EA;F-E/&)R M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S&EM=6T\8G(^/"]T:#X-"B`@("`@("`@ M/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`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`@("`@("`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`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS M<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)T%U9W5S="`R,#$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`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`@/&AE860^#0H@("`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ilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 161 166 1 false 54 0 false 5 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.regulusrx.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information true false R2.htm 103 - Statement - Condensed Balance Sheets Sheet http://www.regulusrx.com/taxonomy/role/StatementOfFinancialPositionClassified Condensed Balance Sheets false false R3.htm 104 - Statement - Condensed Balance Sheets (Parenthetical) Sheet http://www.regulusrx.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Condensed Balance Sheets (Parenthetical) false false R4.htm 105 - Statement - Condensed Statements of Operations and Comprehensive Loss Sheet http://www.regulusrx.com/taxonomy/role/StatementOfIncomeAlternative Condensed Statements of Operations and Comprehensive Loss false false R5.htm 106 - Statement - Condensed Statements of Cash Flows Sheet http://www.regulusrx.com/taxonomy/role/StatementOfCashFlowsIndirect Condensed Statements of Cash Flows false false R6.htm 107 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Sheet http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Basis of Presentation and Summary of Significant Accounting Policies false false R7.htm 108 - Disclosure - Net Loss Per Share Sheet http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock Net Loss Per Share false false R8.htm 109 - Disclosure - Investments Sheet http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock Investments false false R9.htm 110 - Disclosure - Fair Value Measurements Sheet http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock Fair Value Measurements false false R10.htm 111 - Disclosure - Convertible Notes Payable Notes http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock Convertible Notes Payable false false R11.htm 112 - Disclosure - Stockholders' Equity Sheet http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock Stockholders' Equity false false R12.htm 113 - Disclosure - Strategic Alliances and Collaborations Sheet http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock Strategic Alliances and Collaborations false false R13.htm 114 - Disclosure - Related Party Transactions Sheet http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock Related Party Transactions false false R14.htm 115 - Disclosure - Subsequent Events Sheet http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock Subsequent Events false false R15.htm 116 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) Sheet http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlockPolicies Basis of Presentation and Summary of Significant Accounting Policies (Policies) false false R16.htm 117 - Disclosure - Net Loss Per Share (Tables) Sheet http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables Net Loss Per Share (Tables) false false R17.htm 118 - Disclosure - Investments (Tables) Sheet http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables Investments (Tables) false false R18.htm 119 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables Fair Value Measurements (Tables) false false R19.htm 120 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables Stockholders' Equity (Tables) false false R20.htm 121 - Disclosure - Strategic Alliances and Collaborations (Tables) Sheet http://www.regulusrx.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables Strategic Alliances and Collaborations (Tables) false false R21.htm 122 - Disclosure - Business, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.regulusrx.com/taxonomy/role/DisclosureBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation Business, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail) false false R22.htm 123 - Disclosure - Summary of Adjustment for Net Loss for Diluted Net Loss per Share Calculation (Detail) Sheet http://www.regulusrx.com/taxonomy/role/DisclosureSummaryOfAdjustmentForNetLossForDilutedNetLossPerShareCalculation Summary of Adjustment for Net Loss for Diluted Net Loss per Share Calculation (Detail) false false R23.htm 124 - Disclosure - Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Detail) Sheet http://www.regulusrx.com/taxonomy/role/DisclosurePotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShare Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Detail) false false R24.htm 125 - Disclosure - Net Loss Per Share - Additional Information (Detail) Sheet http://www.regulusrx.com/taxonomy/role/DisclosureNetLossPerShareAdditionalInformation Net Loss Per Share - Additional Information (Detail) false false R25.htm 126 - Disclosure - Summary of Short-Term Investments (Detail) Sheet http://www.regulusrx.com/taxonomy/role/DisclosureSummaryOfShortTermInvestments Summary of Short-Term Investments (Detail) false false R26.htm 127 - Disclosure - Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) Sheet http://www.regulusrx.com/taxonomy/role/DisclosureFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) false false R27.htm 128 - Disclosure - Changes in Estimated Fair Value of Convertible Notes Payable (Detail) Notes http://www.regulusrx.com/taxonomy/role/DisclosureChangesInEstimatedFairValueOfConvertibleNotesPayable Changes in Estimated Fair Value of Convertible Notes Payable (Detail) false false R28.htm 129 - Disclosure - Fair Value Measurements - Additional Information (Detail) Sheet http://www.regulusrx.com/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformation Fair Value Measurements - Additional Information (Detail) false false R29.htm 130 - Disclosure - Convertible Notes Payable - Additional Information (Detail) Notes http://www.regulusrx.com/taxonomy/role/DisclosureConvertibleNotesPayableAdditionalInformation Convertible Notes Payable - Additional Information (Detail) false false R30.htm 131 - Disclosure - Common Stock Reserved for Future Issuance (Detail) Sheet http://www.regulusrx.com/taxonomy/role/DisclosureCommonStockReservedForFutureIssuance Common Stock Reserved for Future Issuance (Detail) false false R31.htm 132 - Disclosure - Stock Option Activity (Detail) Sheet http://www.regulusrx.com/taxonomy/role/DisclosureStockOptionActivity Stock Option Activity (Detail) false false R32.htm 133 - Disclosure - Assumptions Used to Estimate Fair Value of Stock Options Using Black-Scholes Option Pricing Model (Detail) Sheet http://www.regulusrx.com/taxonomy/role/DisclosureAssumptionsUsedToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModel Assumptions Used to Estimate Fair Value of Stock Options Using Black-Scholes Option Pricing Model (Detail) false false R33.htm 134 - Disclosure - Stock-Based Compensation (Detail) Sheet http://www.regulusrx.com/taxonomy/role/DisclosureStockBasedCompensation Stock-Based Compensation (Detail) false false R34.htm 135 - Disclosure - Revenue from Strategic Alliance (Detail) Sheet http://www.regulusrx.com/taxonomy/role/DisclosureRevenueFromStrategicAlliance Revenue from Strategic Alliance (Detail) false false R35.htm 136 - Disclosure - Strategic Alliances and Collaborations - Additional Information (Detail) Sheet http://www.regulusrx.com/taxonomy/role/DisclosureStrategicAlliancesAndCollaborationsAdditionalInformation Strategic Alliances and Collaborations - Additional Information (Detail) false false R36.htm 137 - Disclosure - Related Party Transactions - Additional Information (Detail) Sheet http://www.regulusrx.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation Related Party Transactions - Additional Information (Detail) false false R37.htm 138 - Disclosure - Subsequent Events - Additional Information (Detail) Sheet http://www.regulusrx.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation Subsequent Events - Additional Information (Detail) false false All Reports Book All Reports Element rgls_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable had a mix of decimals attribute values: -5 -4. Element us-gaap_CommonStockValue had a mix of decimals attribute values: -5 -3. Element us-gaap_ProceedsFromIssuanceOfCommonStock had a mix of decimals attribute values: -5 -3. Element us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber had a mix of decimals attribute values: -3 0. 'Monetary' elements on report '122 - Disclosure - Business, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail)' had a mix of different decimal attribute values. 'Monetary' elements on report '130 - Disclosure - Convertible Notes Payable - Additional Information (Detail)' had a mix of different decimal attribute values. 'Monetary' elements on report '136 - Disclosure - Strategic Alliances and Collaborations - Additional Information (Detail)' had a mix of different decimal attribute values. Process Flow-Through: 103 - Statement - Condensed Balance Sheets Process Flow-Through: Removing column 'Sep. 30, 2012' Process Flow-Through: Removing column 'Dec. 31, 2011' Process Flow-Through: 104 - Statement - Condensed Balance Sheets (Parenthetical) Process Flow-Through: 105 - Statement - Condensed Statements of Operations and Comprehensive Loss Process Flow-Through: 106 - Statement - Condensed Statements of Cash Flows rgls-20130930.xml rgls-20130930.xsd rgls-20130930_cal.xml rgls-20130930_def.xml rgls-20130930_lab.xml rgls-20130930_pre.xml true true XML 31 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8

Condensed Balance Sheets (Parenthetical) (USD $)

Sep. 30, 2013

Dec. 31, 2012

Common stock, par value $ 0.001 $ 0.001

Common stock, shares authorized 200,000,000 200,000,000

Common stock, shares issued 41,774,442 35,831,808

Common stock, shares outstanding 41,774,442 35,831,808

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 32 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8

Subsequent Events
9 Months Ended

Sep. 30, 2013

Subsequent Events

9. Subsequent Events

In October 2013, we received a payment of $0.1 million from Biogen Idec for work performed pursuant to the terms of our collaboration and license agreement based on our research to discover microRNAs as biomarkers for MS.

X

- Definition

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

+ References

No definition available.

+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8

Condensed Statements of Cash Flows (USD $)
In Thousands, unless otherwise specified
9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Operating activities

Net loss $ (16,741) $ (10,532)

Adjustments to reconcile net loss to net cash used in operating activities

Depreciation and amortization expense 996 741

Loss on extinguishment of debt 1,738

Loss from valuation of convertible note payable 3,787 331

Stock-based compensation 2,524 732

Amortization of premium on investments, net 1,018 311

Gain on investments (6)

Change in operating assets and liabilities:

Contracts and other receivables (95) (3,000)

Prepaid and other assets (512) 56

Accounts payable 829 148

Accrued liabilities 851 73

Accrued compensation (120) 302

Deferred revenue (11,615) (527)

Deferred rent and other liabilities 68 55

Net cash used in operating activities (19,016) (9,572)

Investing activities

Purchases of short-term investments (50,390) (9,287)

Maturities and sales of short-term investments 16,520 24,550

Purchases of property and equipment (608) (724)

Acquisition of intangibles (46) (185)

Net cash (used in) provided by investing activities (34,524) 14,354

Financing activities

Proceeds from issuance of common stock, net 46,562 102

Proceeds from issuance of convertible notes payable 5,000

Principal payments on other long-term obligations (84) (326)

Costs paid in connection with initial public offering (1,307)

Net cash provided by financing activities 46,478 3,469

Net (decrease) increase in cash and cash equivalents (7,062) 8,251

Cash and cash equivalents at beginning of period 40,552 9,175

Cash and cash equivalents at end of period 33,490 17,426

Supplemental disclosure of cash flow information

Interest paid 32

Income taxes paid 1 207

Supplemental disclosure of non-cash investing and financing activities

Amounts accrued for property and equipment, net 57

Amounts accrued for patent expenditures, net $ 10

X

- Definition

The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Future cash outflow to pay for purchases of fixed assets that have occurred.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_CapitalExpendituresIncurredButNotYetPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

This item represents the net total realized and unrealized gain (loss) included in earnings for the period as a result of selling or holding marketable securities categorized as trading, available-for-sale, or held-to-maturity, including the unrealized holding gain (loss) of held-to-maturity securities transferred to the trading security category and the cumulative unrealized gain (loss) which was included in other comprehensive income (a separate component of shareholders' equity) for available-for-sale securities transferred to trading securities during the period. Additionally, this item would include any gains (losses) realized during the period from the sale of investments accounted for under the cost method of accounting and losses recognized for other than temporary impairments (OTTI) of the subject investments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7(c),9(a))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27405-111563

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (c)-(e)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27357-111563

+ Details

Name: us-gaap_GainLossOnInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 50

-Section 40

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6850294&loc=d3e12317-112629

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 50

-Section 40

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6850294&loc=d3e12355-112629

+ Details

Name: us-gaap_GainsLossesOnExtinguishmentOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (f)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_IncomeTaxesPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeferredLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of cash paid for interest during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NoncashInvestingAndFinancingItemsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate amount of gains or losses resulting from nonoperating activities (for example, interest and dividend revenue, property, plant and equipment impairment loss, and so forth).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 9

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7,9)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_NonoperatingGainsLosses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow for cost incurred directly with the issuance of an equity security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585

+ Details

Name: us-gaap_PaymentsOfStockIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquireIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquireShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.

+ References

No definition available.

+ Details

Name: us-gaap_ProceedsFromIssuanceOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3179-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4K

-URI http://asc.fasb.org/extlink&oid=31814832&loc=SL4591552-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-Subparagraph (a),(c)

-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4J

-URI http://asc.fasb.org/extlink&oid=31814832&loc=SL4591551-111686

+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow attributable to repayments of borrowings not otherwise defined in the taxonomy (with maturities initially due after one year or beyond the operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_RepaymentsOfOtherLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 34 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8

Condensed Balance Sheets (USD $)
In Thousands, unless otherwise specified

Sep. 30, 2013

Dec. 31, 2012

Current assets:

Cash and cash equivalents $ 33,490 $ 40,552

Short-term investments 90,413 57,548

Contracts and other receivables 95

Prepaid and other current assets 1,288 829

Total current assets 125,286 98,929

Property and equipment, net 3,981 3,310

Intangibles, net 1,145 1,154

Other assets 178 125

Total assets 130,590 103,518

Current liabilities:

Accounts payable 1,140 311

Accrued liabilities 1,705 658

Accrued compensation 1,228 1,348

Current portion of deferred revenue 9,454 10,451

Total current liabilities 13,527 12,768

Convertible notes payable, at fair value 13,921 10,134

Deferred revenue, less current portion 7,138 17,756

Other long-term liabilities 1,558 767

Total liabilities 36,144 41,425

Stockholders' equity:

Common stock, $0.001 par value; 200,000,000 shares authorized, 41,774,442 and 35,831,808 shares issued and outstanding at September 30, 2013 (unaudited) and December 31, 2012, respectively 42 36

Additional paid-in capital 171,608 122,528

Accumulated other comprehensive loss (44) (52)

Accumulated deficit (77,160) (60,419)

Total stockholders' equity 94,446 62,093

Total liabilities and stockholders' equity $ 130,590 $ 103,518

X

- Definition

Amount due from customers, clients, or other third-parties, or arising from transactions not separately disclosed, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.

+ References

No definition available.

+ Details

Name: us-gaap_AccountsAndOtherReceivablesNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=28358780&loc=SL7669686-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e637-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e681-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Convertible Security

-URI http://asc.fasb.org/extlink&oid=6509036

+ Details

Name: us-gaap_ConvertibleDebtFairValueDisclosures

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph ((a)(1),(b))

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 17

-Article 5

+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 24

-Article 5

+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Investments which are intended to be sold in the short term (usually less than one year or the normal operating cycle, whichever is longer) including trading securities, available-for-sale securities, held-to-maturity securities, and other short-term investments not otherwise listed in the existing taxonomy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.2)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Subparagraph g

-Article 7

+ Details

Name: us-gaap_ShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 35 R29.htm IDEA: XBRL DOCUMENT v2.4.0.8

Convertible Notes Payable - Additional Information (Detail) (USD $)
1 Months Ended

Sep. 30, 2013

Dec. 31, 2012

Oct. 30, 2012

Jul. 31, 2012

Oct. 31, 2012

October 2012

Oct. 31, 2012

October 2012

Convertible Debt

GSK

Debt Instrument [Line Items]

Convertible notes issued $ 5,400,000

Outstanding principal amount 10,800,000 5,000,000 5,000,000

Accrued interest on convertible notes 400,000

Conversion rate Oct. 09, 2015

Conversion price per shares $ 4.00 $ 4.00

Convertible note payable, at fair value $ 13,921,000 $ 10,134,000

X

- Definition

Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Convertible Security

-URI http://asc.fasb.org/extlink&oid=6509036

+ Details

Name: us-gaap_ConvertibleDebtFairValueDisclosures

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.16)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16(a))

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 16

-Article 9

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20, 22

-Article 5

+ Details

Name: us-gaap_ConvertibleNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The price per share of the conversion feature embedded in the debt instrument.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 20

-Section 50

-Paragraph 5

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6928298&loc=SL6031898-161870

+ Details

Name: us-gaap_DebtInstrumentConvertibleConversionPrice1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(2))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentMaturityDate

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The after-tax amount of interest recognized in the period associated with any convertible debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

+ Details

Name: us-gaap_InterestOnConvertibleDebtNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The fair value of notes issued in noncash investing and financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_NotesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 36 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8

Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Detail)
3 Months Ended 9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Potentially dilutive securities not included in calculation of diluted net loss per share 3,041,033 16,545,674 3,875,462 16,523,462

Convertible Preferred Stock

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Potentially dilutive securities not included in calculation of diluted net loss per share 13,699,999 13,699,999

Common stock options

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Potentially dilutive securities not included in calculation of diluted net loss per share 3,041,033 2,845,675 2,474,614 2,823,463

Convertible Notes Payable

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Potentially dilutive securities not included in calculation of diluted net loss per share 1,400,848

X

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 37 R35.htm IDEA: XBRL DOCUMENT v2.4.0.8

Strategic Alliances and Collaborations - Additional Information (Detail) (USD $)
1 Months Ended 9 Months Ended 9 Months Ended 9 Months Ended 1 Months Ended 1 Months Ended 9 Months Ended 1 Months Ended 9 Months Ended 9 Months Ended

Jul. 31, 2013

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

GSK

Sep. 30, 2013

GSK

Immuno-Inflammatory Alliance

Sep. 30, 2013

GSK

HCV Alliance

Sep. 30, 2013

GSK

Preclinical

Immuno-Inflammatory Alliance

Sep. 30, 2013

GSK

Preclinical

HCV Alliance

Sep. 30, 2013

GSK

Clinical

Immuno-Inflammatory Alliance

Sep. 30, 2013

GSK

Clinical

HCV Alliance

Sep. 30, 2013

GSK

Regulatory

Immuno-Inflammatory Alliance

Sep. 30, 2013

GSK

Regulatory

HCV Alliance

Sep. 30, 2013

GSK

Commercialization

Immuno-Inflammatory Alliance

Sep. 30, 2013

GSK

Fourth Micro RNA Targets

Immuno-Inflammatory Alliance

Sep. 30, 2013

GSK

Development Candidate

Immuno-Inflammatory Alliance

Sep. 30, 2013

GSK

Phase One Clinical Trial

Immuno-Inflammatory Alliance

Sep. 30, 2013

GSK

Phase One Clinical Trial

HCV Alliance

Sep. 30, 2013

GSK

Phase Two Clinical Trial

Immuno-Inflammatory Alliance

Sep. 30, 2013

GSK

Phase Two Clinical Trial

HCV Alliance

Sep. 30, 2013

GSK

Proof-of-Concept Trial

Immuno-Inflammatory Alliance

Sep. 30, 2013

GSK

Proof-of-Concept Trial

HCV Alliance

Sep. 30, 2013

GSK

Commercialization Milestones

HCV Alliance

Sep. 30, 2013

GSK

Development Commercialization And License Agreement

Sep. 30, 2013

GSK

Minimum

Immuno-Inflammatory Alliance

Sep. 30, 2013

GSK

Minimum

HCV Alliance

Sep. 30, 2013

GSK

Maximum

Immuno-Inflammatory Alliance

Sep. 30, 2013

GSK

Maximum

HCV Alliance

Jun. 30, 2013

Sanofi

Sep. 30, 2013

Sanofi

HCV Alliance

Sep. 30, 2013

Sanofi

Preclinical

HCV Alliance

Sep. 30, 2013

Sanofi

Clinical

HCV Alliance

Jul. 31, 2013

Sanofi

Development Commercialization And License Agreement

Jul. 31, 2013

Sanofi

Research and Development

Sep. 30, 2013

Sanofi

Minimum

HCV Alliance

Sep. 30, 2013

Sanofi

Maximum

HCV Alliance

Oct. 31, 2012

Astra Zeneca

Sep. 30, 2013

Astra Zeneca

Agreement

Sep. 30, 2013

Astra Zeneca

Preclinical

Sep. 30, 2013

Astra Zeneca

Clinical

Sep. 30, 2013

Astra Zeneca

Commercialization

Sep. 30, 2013

Astra Zeneca

Minimum

Sep. 30, 2013

Astra Zeneca

Maximum

Sep. 30, 2013

Biogen Idec

Sep. 30, 2013

Biogen Idec

Research Tax Credit Carryforward

Sep. 30, 2013

Biogen Idec

Identification Of Micro Rna Biomarker

Sep. 30, 2013

Biogen Idec

Validation Of Micro Rna Biomarker

Sep. 30, 2013

Biogen Idec

Longitudinal Study Of Patient Samples On Ms Therapy

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Option expiry date 2013-12

Option extension period 30 days

Initial upfront option payment $ 2,500,000 $ 25,000,000 $ 3,000,000 $ 800,000

Upfront payment creditable against future accounts receivables 1,250,000

Upfront payment non-creditable portion recognized 1,250,000

Deferred revenue 3,700,000 10,100,000 4,300,000

Revenue through milestone payments 432,500,000 144,500,000 15,500,000 5,500,000 87,000,000 29,000,000 150,000,000 50,000,000 180,000,000 500,000 5,000,000 4,000,000 4,000,000 5,000,000 5,000,000 20,000,000 20,000,000 60,000,000 165,000,000 15,000,000 33,000,000 498,000,000 5,000,000 123,000,000 370,000,000 1,300,000 250,000 500,000 500,000

Royalties based on percentage of net sales 10.00% 10.00% 20.00% 20.00% 8.00% 12.00% 10.00% 20.00%

Deferred revenue recognition period 8 years

Acceleration of remaining amortization of upfront payment 1,100,000

Number of collaborative areas granted 3

Collaboration and license agreement date August 2012 August 2012

Expected term of research and development plan 4 years

Common stock issue 42,000 36,000 25,000,000

Common stock issued 41,774,442 35,831,808 6,250,000

Price per share $ 9.50 $ 4.00

Number of days during which AstraZeneca could not sell, transfer, make any short sale of, or grant any option for the sale of any common stock 365 days

Restricting common stock valuation measurement period 1 year

Revenue recognition period 2 years

Issued promissory note $ 5,000,000

Conversion to common stock 1,256,232

Conversion rate $ 4.00

X

- Definition

Collaboration and License Agreement Entered Date

+ References

No definition available.

+ Details

Name: rgls_CollaborationAndLicenseAgreementEnteredDate

Namespace Prefix: rgls_

Data Type: us-types:dateStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Collaborative Areas Granted

+ References

No definition available.

+ Details

Name: rgls_CollaborativeAreasGranted

Namespace Prefix: rgls_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition

Common Stock Transaction Restriction Period

+ References

No definition available.

+ Details

Name: rgls_CommonStockTransactionRestrictionPeriod

Namespace Prefix: rgls_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Deferred Revenue Recognition Period

+ References

No definition available.

+ Details

Name: rgls_DeferredRevenueRecognitionPeriod

Namespace Prefix: rgls_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Expected Terms Of Option Agreement

+ References

No definition available.

+ Details

Name: rgls_ExpectedTermsOfOptionAgreement

Namespace Prefix: rgls_

Data Type: xbrli:gYearMonthItemType

Balance Type: na

Period Type: duration

X

- Definition

Fair Value Inputs Period

+ References

No definition available.

+ Details

Name: rgls_FairValueInputsPeriod

Namespace Prefix: rgls_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Option To Extend Maturity Date

+ References

No definition available.

+ Details

Name: rgls_OptionToExtendMaturityDate

Namespace Prefix: rgls_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Research and Development Plan, Expected Term

+ References

No definition available.

+ Details

Name: rgls_ResearchAndDevelopmentPlanExpectedTerm

Namespace Prefix: rgls_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Revenue Recognition, Milestone Method, Expected Milestone Receivable

+ References

No definition available.

+ Details

Name: rgls_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable

Namespace Prefix: rgls_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Revenue Recognition, Period

+ References

No definition available.

+ Details

Name: rgls_RevenueRecognitionPeriod

Namespace Prefix: rgls_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Definition

Royalty Percentage Based On Net Sales

+ References

No definition available.

+ Details

Name: rgls_RoyaltyPercentageBasedOnNetSales

Namespace Prefix: rgls_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_AdjustmentForAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The current portion of prepayments received from customers for goods or services to be provided in the future.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CustomerAdvancesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_DebtConversionConvertedInstrumentSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The price per share of the conversion feature embedded in the debt instrument.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 20

-Section 50

-Paragraph 5

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6928298&loc=SL6031898-161870

+ Details

Name: us-gaap_DebtInstrumentConvertibleConversionPrice1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

+ Details

Name: us-gaap_DeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount per share or per unit assigned to the consideration received of equity securities issued for development stage entities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 215

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6472370&loc=d3e38297-110927

+ Details

Name: us-gaap_EquityIssuancePerShareAmount

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Cash received from collaborators during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_ProceedsFromCollaborators

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. For cash flows, this element primarily pertains to amortization of deferred credits on long-term arrangements. As a noncash item, it is deducted from net income when calculating cash provided by or used in operations using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

-Subsection 1

+ Details

Name: us-gaap_RecognitionOfDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 38 R36.htm IDEA: XBRL DOCUMENT v2.4.0.8

Related Party Transactions - Additional Information (Detail) (Alnylam, USD $)
In Millions, unless otherwise specified
3 Months Ended 9 Months Ended

Sep. 30, 2013

Sep. 30, 2013

Alnylam

Related Party Transaction [Line Items]

Service agreement $ 0.1 $ 0.5

X

- Definition

Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

+ Details

Name: us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_RelatedPartyTransactionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 39 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8

Related Party Transactions
9 Months Ended

Sep. 30, 2013

Related Party Transactions

8. Related Party Transactions

We have entered into several agreements with related parties in the ordinary course of business to license intellectual property and to procure administrative and research and development support services. These agreements include a Services Agreement with our founding companies Isis Pharmaceuticals, Inc. (“Isis”) and Alnylam Pharmaceuticals, Inc. (“Alnylam”). Total costs incurred from services provided from Alnylam under the Services Agreement were $0.1 million and $0.5 million for the three and nine months ended September 30, 2013, respectively. Activities under the Services Agreement for the nine months ended September 30, 2012 were immaterial.

In August, 2013, we entered into an amendment to the Amended and Restated License and Collaboration Agreement with Isis and Alnylam dated January 1, 2009, as amended in June 2010 and October 2011 (as amended, the “Amendment”). Under the terms of the Amendment, the parties agreed to our use of certain Alnylam-controlled intellectual property concerning the use and manufacture of GalNAc conjugates (“GalNAc Process Technology”) on a non-exclusive basis. We will generally not be permitted to sublicense or otherwise transfer the GalNAc Process Technology and other Alnylam licensed intellectual property rights relating to GalNAc conjugate technology without the prior written consent of Alnylam, subject to certain limited exceptions for sublicenses to third party collaboration partners. There were no financial terms related to this Amendment.

X

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph b

-Article 3A

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 40 R30.htm IDEA: XBRL DOCUMENT v2.4.0.8

Common Stock Reserved for Future Issuance (Detail)

Sep. 30, 2013

Dec. 31, 2012

Equity [Line Items]

Common stock options outstanding 4,160,000 4,720,000

Total common shares reserved for future issuance 8,182,756 7,124,739

Common Stock

Equity [Line Items]

Common stock options outstanding 4,160,215 4,661,549

Common stock shares available for future grant 2,161,410 946,403

Employee Stock Purchase Plan

Equity [Line Items]

Common stock shares available for future grant 460,283 150,000

Convertible Notes Payable

Equity [Line Items]

Total common shares reserved for future issuance 1,400,848 1,366,787

X

- Details

Name: rgls_EquityLineItems

Namespace Prefix: rgls_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Aggregate number of common shares reserved for future issuance.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of options outstanding, including both vested and non-vested options.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 41 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8

Net Loss Per Share (Tables)
9 Months Ended

Sep. 30, 2013

Summary of Adjustment for Net Loss for Diluted Net Loss per Share Calculation

The following table summarizes the adjustment to net loss for the diluted net loss per share calculation for the three months ended September 30, 2013 (in thousands):

Net loss
 $ (2,164 )

Less: gain from change in valuation of note payable
 671



Net loss used to compute diluted net loss per share
 $ (2,835 )



Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share

Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common equivalent shares):

 Three months ended
September 30, Nine months ended
September 30,

 2013 2012 2013 2012

Convertible preferred stock outstanding
 — 13,699,999 — 13,699,999

Common stock options
 3,041,033 2,845,675 2,474,614 2,823,463

Convertible note payable
 — — 1,400,848 —









Total
 3,041,033 16,545,674 3,875,462 16,523,462

X

- Definition

Net Income Loss Available To Common Stockholders Basic And Diluted [Table Text Block]

+ References

No definition available.

+ Details

Name: rgls_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedTableTextBlock

Namespace Prefix: rgls_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8

Strategic Alliances and Collaborations
9 Months Ended

Sep. 30, 2013

Strategic Alliances and Collaborations

7. Strategic Alliances and Collaborations

The following table summarizes the amounts included in our revenues which resulted from our strategic alliances and collaborations (in thousands):

 Three months ended
September 30, Nine months ended
September 30,

 2013 2012 2013 2012

Sanofi
 $ 5,422 $ 2,500 $ 10,828 $ 7,530

GSK
 144 186 1,634 1,809

AstraZeneca
 465 94 1,394 94

Biogen Idec
 87 29 259 29









Total
 $ 6,118 $ 2,809 $ 14,115 $ 9,462

Sanofi

In July 2012, we amended and restated our collaboration and license agreement with Sanofi to expand the potential therapeutic applications of the microRNA alliance targets to be developed under such agreement. The modification made to the agreement was considered a material modification, which required the application of the new authoritative guidance adopted by us in January 2011 for multiple element arrangements. We determined that the elements within the strategic alliance agreement with Sanofi should be treated as a single unit of accounting because the delivered elements did not have stand-alone value to Sanofi. The following elements were delivered as part of the strategic alliance with Sanofi: (1) a license for up to four microRNA targets; and (2) a research license under our technology alliance.

In June 2013, the original research term expired, upon which we and Sanofi entered into an option agreement pursuant to which we granted Sanofi an exclusive right to negotiate the co-development and commercialization of certain of our unencumbered microRNA programs and we were granted the exclusive right to negotiate with Sanofi for co-development and commercialization of certain miR-21 anti-miRs in oncology and Alport’s Syndrome. These options expire in December 2013, subject to a 30-day extension in certain circumstances. In July 2013, we received an upfront payment of $2.5 million, of which $1.25 million is creditable against future amounts payable by Sanofi to us under any future co-development and commercialization agreement we enter pursuant to the option agreement. The non-creditable portion of this payment, $1.25 million, will be recognized as revenue over the option period from the effective date of the option agreement in June 2013 until the expiration of the option period in December 2013. Revenue associated with the creditable portion of this option payment will be deferred until the option period expires, or is re-evaluated in connection with a creditable transaction. In addition, we agreed to continue specified research on the miR-21 programs during the option period. As a result of the expiration of the original research term and subsequent option agreement, we re-evaluated our estimated period of performance and are now amortizing the remaining deferred revenue of $10.1 million associated with the initial upfront payment of $25.0 million ratably from June 2013 until the expiration of the option period in December 2013.

We have evaluated the remaining contingent event-based payments under our strategic alliance agreement with Sanofi and determined that the preclinical payments meet the definition of a substantive milestone because they are related to events: (i) that can be achieved based in whole or in part on our performance or on the occurrence of a specific outcome resulting from our performance, (ii) for which there was substantive uncertainty at the date the agreement was entered into that the event would be achieved, and (iii) that would result in additional payments being due to us. Accordingly, revenue for these achievements will be recognized in its entirety in the period when the milestone is achieved and collectability is reasonably assured. Other contingent event-based payments under the strategic alliance agreement for which payment is contingent upon the results of Sanofi’s performance will not be accounted for using the milestone method. Such payments will be recognized as revenue over the remaining estimated period of performance, if any, and when collectability is reasonably assured. As of the expiration of the research term in June 2013, Sanofi no longer has rights to select additional microRNA targets. As such, we can earn a preclinical milestone of $15.0 million upon the filing of an Investigational New Drug application (“IND”) for the selected microRNA target. We can also receive milestone payments of up to $33.0 million for clinical milestones and up to $165.0 million for regulatory and commercial milestones. In addition, we are entitled to receive royalties based on a percentage of net sales which will range from 8 to 12%, depending upon the volume of sales.

GSK

In April 2008, we entered into a strategic alliance with GSK to discover, develop and commercialize novel microRNA-targeted therapeutics to treat inflammatory diseases (the “immuno-inflammatory alliance”). In February 2010, we and GSK expanded the strategic alliance to include hepatitis C virus infection (“HCV”) to discover, develop and commercialize microRNA therapeutics targeting miR-122 for the treatment of HCV (the “HCV alliance”). In June 2012, we amended our product development and commercialization agreement with GSK to extend the target selection period for the fourth collaboration target under the agreement. The modification made to the agreement was considered a material modification, which required the application of the new authoritative guidance adopted by us in January 2011 for multiple element arrangements. We determined that the elements within the strategic alliance should be treated as a single unit of accounting because the delivered elements, the opt-in licenses for microRNA product candidates, did not have stand-alone value to GSK. As a result of the extension of the target selection period, we extended the amortization period for the remaining deferred revenue to approximately eight years, which represented our new estimated performance period under the amended agreement. As of September 30, 2013, deferred revenue associated with the product development and commercialization agreement was $3.7 million.

In June 2013, the product development and commercialization agreement with GSK was amended to state that RG-101, and other formulations thereof, will be developed by us independently of our alliance with GSK for the treatment of chronic HCV infection. This amendment removed any further milestone or royalty obligations owed by GSK to us as it relates to RG-101. Concurrent with the amendment, we accelerated the remaining unamortized $1.1 million in deferred revenue associated with the upfront payment from the February 2010 amendment that expanded our agreement with GSK to include potential microRNA therapeutics for the treatment of HCV, which represents that our estimated performance period under the amended agreement is complete.

HCV Alliance

Notwithstanding the foregoing, GSK has retained its interest in the miR-122 program in HCV, and miR-122 remains a collaboration target under the alliance. If the HCV program is successful, we could receive contractual milestone payments up to $144.5 million, including up to $5.5 million for preclinical milestones, up to $29.0 million for clinical milestones, up to $50.0 million for regulatory milestones and up to $60.0 million for commercialization milestones. In addition, we will receive tiered royalties which can increase up to the low end of the 10 to 20% range on sales from any product that GSK successfully commercializes under this alliance.

We have evaluated the remaining contingent event-based payments under our strategic alliance agreement with GSK and determined that the preclinical and clinical payments meet the definition of a substantive milestone because they are related to events: (i) that can be achieved based in whole or in part on our performance or on the occurrence of a specific outcome resulting from our performance, (ii) for which there was substantive uncertainty at the date the agreement was entered into that the event would be achieved, and (iii) that would result in additional payments being due to us. Accordingly, revenue for these achievements will be recognized in its entirety in the period when the milestone is achieved and collectability is reasonably assured. Other contingent event-based payments under the strategic alliance agreement for which payment is contingent upon the results of GSK’s performance will not be accounted for using the milestone method. Such payments will be recognized as revenue over the remaining estimated period of performance, if any, and when collectability is reasonably assured. We can earn a preclinical milestone of $5.5 million upon the selection of a development candidate. We can also earn the following clinical milestones: $4.0 million for initiation of a Phase 1 clinical trial; $5.0 million for the initiation of a Phase 2 clinical trial; and $20.0 million if GSK chooses to opt-in to the program following the completion of a proof-of-concept trial.

Immuno-Inflammatory Alliance

The immuno-inflammatory alliance with GSK includes contractual milestones. If all the product candidates are successfully developed and commercialized through pre-agreed sales targets we could receive milestone payments up to $432.5 million, including up to $15.5 million for preclinical milestones, up to $87.0 million for clinical milestones, up to $150.0 million for regulatory milestones and up to $180.0 million for commercialization milestones. We are also entitled to receive tiered royalties as a percentage of annual sales which can increase up to the low end of the 10 to 20% range.

We have evaluated the remaining contingent event-based payments under our strategic alliance agreement with GSK and determined that the preclinical and clinical payments meet the definition of a substantive milestone because they are related to events: (i) that can be achieved based in whole or in part on our performance or on the occurrence of a specific outcome resulting from our performance, (ii) for which there was substantive uncertainty at the date the agreement was entered into that the event would be achieved, and (iii) that would result in additional payments being due to us. Accordingly, revenue for these achievements will be recognized in its entirety in the period when the milestone is achieved and collectability is reasonably assured. Other contingent event-based payments under the strategic alliance agreement for which payment is contingent upon the results of GSK’s performance will not be accounted for using the milestone method. Such payments will be recognized as revenue over the remaining estimated period of performance, if any, and when collectability is reasonably assured. We can earn the following preclinical milestones: $0.5 million upon the selection of a fourth microRNA target and $5.0 million upon the selection of a development candidate for each of the selected three targets. We can also earn the following clinical milestones for each of the selected three targets: $4.0 million for the initiation of a Phase 1 clinical trial; $5.0 million for the initiation of a Phase 2 clinical trial; and $20.0 million if GSK chooses to opt-in to the program following the completion of a proof-of-concept trial.

AstraZeneca

In August 2012, we entered into a collaboration and license agreement with AstraZeneca. Under the terms of the agreement, we have agreed to collaborate with AstraZeneca to identify, research and develop compounds targeting three microRNA alliance targets primarily in the fields of cardiovascular diseases, metabolic diseases and oncology. Pursuant to the agreement, we granted AstraZeneca an exclusive, worldwide license to thereafter develop, manufacture and commercialize lead compounds designated by AstraZeneca in the course of the collaboration activities against the alliance targets for all human therapeutic uses. Under the terms of the agreement we are required to use commercially reasonable efforts to perform all research, development and manufacturing activities described in the research plan, at our cost, until the acceptance of an IND or the end of the research term, which extends until the fourth anniversary of the date of the agreement, and may be extended only by mutual written agreement of us and AstraZeneca. Following the earlier to occur of the acceptance of an IND in a major market or the end of the research term, AstraZeneca will assume all costs, responsibilities and obligations for further development, manufacture and commercialization of alliance product candidates.

Under the terms of the agreement, we received an upfront payment of $3.0 million in October 2012. We determined the elements within the strategic alliance agreement should be treated as a single unit of accounting because the delivered element, the license, does not have stand-alone value. As a result, we are recognizing revenue related to the upfront payment on a straight-line basis over our estimated period of performance, which is four years based on the expected term of the research and development plan. If all three targets are successfully developed and commercialized through pre-agreed sales targets, we could receive milestone payments up to $498.0 million, including up to $5.0 million for preclinical milestones, up to $123.0 million for clinical milestones, and up to $370.0 million for commercialization milestones. In addition, we are entitled to receive royalties based on a percentage of net sales which will range from the mid-single digits to the low end of 10 to 20%, depending upon the product and the volume of sales, which royalties may be reduced in certain, limited circumstances.

We have evaluated the contingent event-based payments under our strategic alliance agreement with AstraZeneca and determined that the preclinical payments meet the definition of substantive milestones because they are related to events: (i) that can be achieved based in whole or in part on our performance or on the occurrence of a specific outcome resulting from our performance, (ii) for which there was substantive uncertainty at the date the agreement was entered into that the event would be achieved, and (iii) that would result in additional payments being due to us. Accordingly, revenue for these achievements will be recognized in its entirety in the period when the milestone is achieved and collectability is reasonably assured. Other contingent event-based payments under the strategic alliance agreement for which payment is contingent upon the results of AstraZeneca’s performance will not be accounted for using the milestone method. Such payments will be recognized as revenue over the remaining estimated period of performance, if any, and when collectability is reasonably assured.

Concurrently with the collaboration and license agreement, we entered into a Common Stock Purchase Agreement (“CSPA”) with AstraZeneca, pursuant to which we agreed to sell to AstraZeneca an aggregate of $25.0 million of our common stock in a private placement concurrently with our initial public offering, at a price per share equal to the initial public offering price. In October 2012, in accordance with the CSPA, we sold AstraZeneca 6,250,000 shares of our common stock at a price per share of $4.00. Further, the CSPA stipulated that AstraZeneca could not sell, transfer, make any short sale of, or grant any option for the sale of any common stock for a 365-day period following the effective date of our initial public offering. Accounting guidance for multiple element arrangements contains a presumption that separate contracts negotiated and/or entered into at or near the same time with the same entity were negotiated as a package and should be evaluated as a single agreement. We valued the discount applied to the shares of common stock due to the one-year restriction. Based upon restricted stock studies of similar duration and a Black-Scholes valuation to measure the lack of marketability discount, $4.3 million was attributed to the collaboration and license agreement. We continue to recognize the $4.3 million into revenue ratably over the estimated period of performance of the collaboration.

Biogen Idec

In August 2012, we entered into a collaboration and license agreement with Biogen Idec pursuant to which we and Biogen Idec have agreed to collaborate on microRNA biomarkers for multiple sclerosis (“MS”). Under the terms of the agreement, we granted Biogen Idec an exclusive, royalty free, worldwide license to our interest in the collaboration intellectual property for the purpose of commercializing non-microRNA products for the treatment, diagnosis and prevention of MS and non-MS diseases and disorders. We also granted Biogen Idec an exclusive, royalty-free, worldwide license, with the right to sublicense, to our interest in the collaboration intellectual property (and a non-exclusive license to our background intellectual property) for the purpose of commercializing products for the diagnosis of MS. We also granted Biogen Idec a right of first negotiation on certain commercial transactions relating to microRNA products which utilize intellectual property developed during the collaboration. Pursuant to the terms of the agreement, in August 2012 we received an upfront payment of $0.8 million. We are also eligible to receive research milestone payments up to an aggregate of $1.3 million. We considered the elements within the collaboration and license agreement as a single unit of accounting because the delivered element, the license, does not have stand-alone value. As a result, we are recognizing revenue relating to the upfront payment of $0.8 million on a straight-line basis over our estimated period of performance, which is approximately two years based on the expected term of the research and development plan.

In June 2013, we amended the collaboration and license agreement with Biogen Idec to provide for revised terms with respect to phase 1 of the research plan under the Biogen Idec agreement and revised payment provisions relating to the phase 1 milestones. The Biogen Idec amendment does not modify the maximum dollar amount we were originally eligible to receive in connection with phase 1 milestones under the Biogen Idec agreement, or our estimated period of performance.

We have evaluated the contingent event-based payments under our collaboration and license agreement with Biogen Idec and determined that the research payments meet the definition of substantive milestones because they are related to events: (i) that can be achieved based in whole or in part on our performance or on the occurrence of a specific outcome resulting from our performance, (ii) for which there was substantive uncertainty at the date the agreement was entered into that the event would be achieved, and (iii) that would result in additional payments being due to us. Accordingly, revenue for these achievements will be recognized in its entirety in the period when the milestone is achieved and collectability is reasonably assured. We can earn the following research milestones: $0.25 million for identification of a microRNA biomarker; $0.5 million for validation of the microRNA biomarker in a second independent sample set; and $0.5 million upon the refinement of the microRNA biomarker signature from a longitudinal study of patient samples on MS therapy.

Concurrently with the collaboration and license agreement, we entered into a note purchase agreement with Biogen Idec, pursuant to which we issued Biogen Idec a convertible promissory note in the principal amount of $5.0 million. The $5.0 million note plus accrued interest converted into 1,256,232 shares of our common stock upon the closing of our initial public offering in October 2012 at a conversion price of $4.00 per share.

X

- Definition

The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 808

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434

+ Details

Name: us-gaap_CollaborativeArrangementDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8

Net Loss Per Share
9 Months Ended

Sep. 30, 2013

Net Loss Per Share

2. Net Loss Per Share

Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted average number of common stock equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of convertible preferred stock, options outstanding under our stock option plan and convertible notes payable. Applicable accounting guidance provides that a contract that is reported as an asset or liability for accounting purposes may require an adjustment to the numerator of the diluted earnings per share calculation for any changes in income or loss that would result if the contract had been reported as an equity instrument for accounting purposes during the period. Securities are assumed to be converted at the beginning of the period, and the resulting common shares are included in the denominator of the diluted earnings per share calculation for the entire period presented. Adding back the gain from the change in valuation of the convertible note payable for the three months ended September 30, 2013 to the numerator and adding the number of shares to be issued upon conversion of the convertible note payable into the denominator of the diluted earnings per share calculation resulted in an increase to the loss per share for the period. The convertible note payable was anti-dilutive for the nine months ended September 30, 2013.

The following table summarizes the adjustment to net loss for the diluted net loss per share calculation for the three months ended September 30, 2013 (in thousands):

Net loss
 $ (2,164 )

Less: gain from change in valuation of note payable
 671



Net loss used to compute diluted net loss per share
 $ (2,835 )



Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common equivalent shares):

 Three months ended
September 30, Nine months ended
September 30,

 2013 2012 2013 2012

Convertible preferred stock outstanding
 — 13,699,999 — 13,699,999

Common stock options
 3,041,033 2,845,675 2,474,614 2,823,463

Convertible note payable
 — — 1,400,848 —









Total
 3,041,033 16,545,674 3,875,462 16,523,462

In October 2012, all convertible preferred stock converted into common stock in conjunction with our initial public offering. As of September 30, 2013 we had a convertible note payable outstanding with a principal balance of $5.4 million that was convertible into common shares at $4.00 per share, at the option of the note holder.

X

- Definition

The entire disclosure for earnings per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 44 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } ZIP 45 0001193125-13-440494-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-13-440494-xbrl.zip M4$L#!!0````(`#4P;D,?T9H,0:D``#B3!P`1`!P`D:6A_$P'"6Q^MQ[5%GO/[_\^[_]_!\(&>?G1C^)8S4:J4?CMX$:J33,E7$< MZQ8#!3\.)G9&AI);/SFGG\UR`$VC-L\'Q\='O[X\>-`#6_"%"7Q M*(K5P2"Y.S00FC_C;]/N'1F&=4"@BTL_G2>3>'ADL*6OO%2%.5QN#*$C1P8Q M,448(TPN,3LBXL@4_UB^.AD_IM'-;6[\:?!GN-CD2+G,(CZ"' MT8R>WO3*(_WKZ)GK@95_:OX6U^LO2M?_H,75V+;MP^+7^:51EC""Q7.=F5ZQ MN'<6U=T9+L6'OWW[>C&X577HS*E.:JIO):)*E#X6^Z`:F389NAO#O-RK&7A^./VQ=&E4>ZDUO32:7YKEX[0>J?Y%=P.7NS$`K<[3Q_HV MLQ]K>C^8I"D8[[IVLU]U0U)NJ!X&M_6-]"\U3XKB>Y7E]4VFO]4TBB=W]5HX MS--#+9%#N$*ET6#1`,SOY39)C"KM)GFZ5MWM0_BU!X9J&(6ICHZR0J'/U7>C ML)LC?=?/O2RZ&X^T=A??A>D@34:JF846+6Y3]?US3^LLFFOFP4,VW,"`F_N& MPRFLF<4=>0E((LVCZY$Z27*5G86/(?QM#)(X5P_YN>Z@2D979[YDF-HF0IAB M$_T5#)U<75SVK\PKK2JFH/@*S&H21],V,W]Q]>M%OV<,U2"Z"[5E(MXSHB'\ M/+PB%N6<65<>P5[@$1%VS*32#V MU76NXVE:!-*E)M,_=6@\`^U7>`/0P/R5P(P*^2"XH)354W`U5NE5=ANF$/J7 MV"`K9%!!7$J$A;!#0.*.[2/'!$9$/W#`!GQ/]/D5,TURQ7I?V,$R%XUA[DH! M&G+Q@CHT9P!OJO-]]5V!+Q^>JWL53UX+E4X-&J!B8@-48G&+7PENVQ9[$("< MR`*IL"Y-@5<05X!51'R),L3\/'. M\%XG'9E7Q++\C9?$ M%WDR^.=%88BGD[S(RB%3?RT/&#Q1R=NMFO;Q2;#JSAWL4$XI^._`!)QP?]L! MQXZIZW'J@MYC#IZNP`ZG_\_YU$ M]^$(9)PYN1>FZ2.`_ULX>K4E$YU5-(I:=!6?+X4,K`"QO@?_$S9&TB$44;)/45]`:&).WT92B#X@ MMFSN@WHS/P"PQ)I:,8,$9SE&U79]+3XO'$=Y.)I>.Q\N!TD:3/))JG3C8J:@ M'>06P=3R^@'J]WT&=AUX2#)PW9;M8.Z;+CS$`^20G4@LB>!6+>YFD&H7_*#WWH(8.*%AX MH_P'E0ZB;$-ON0WC@:S7;9#'<0@SB)PFSXR^P0'#K6DX[K31!_B`CD0 MLN(P=T_+SF1Q,KF[5ND.M+?&:6.?,VPRBH@=`,U4`LV<6)IUTY?$MYF-%S2# MRRHG&EL'O;6`O0T5;!2PZ31@,]H@8%>]G#/);Y,T^K_..6EM4J:Y.I)8V_^U M0,_"]#2]R$.PH2)^GZFT:-N"0-]"`#AK$V(RK@6_#M,+TGY#=KUC<8M&,7EM M7ET99YTD\6##P=3FR6=#J-CN?1&8RN?&B4_]+\/\&H77T2C*H\T'B[O'!Z+$ ME!-1`KC:\S(R9S"8W$U&6J%/\UN5:F>>JEOPY]&].HX',);\FF39BLY$$+*JOTBCHHB#(>1#LSA MZ"R,AL?Q+"GM'E@B]0@2TI$RW#7]7]%V_;YC/A'678'JJ1W,S*I6UW2^#+!0 M]R51=]DA$Q-`,L@?NP>0ZO00(FMYKF.UYV5D MYRH/HU@-_3"-(=YF2\X,HE4TB#HH2@JB1$)4QP@O0WDVF^BN>5I:L)P]ETJL MB[;IY)W$%*;=K,FK+JB^_VO?HGQ-XIM+E=Z]X6U*<["KKQ$:SL/I%X9L_.WK99!ZY#4`0'AE9-T"MF2Q>DJ6>80W"*"VN MZD?98)1DD[2+8L,ZT:$VP>O4FE MYLB99=.`<`?9W/41$US"7Y:#`M_#?<_W*9X]GHS#.05NTR8_UG#*0UCUI"PBXMBP[[N<0U$FY>ZBP6>N7I]W=_0OJ-A(+ MD!ME%7P;O)R^N$W27&>,Q\7R12WE#LH3LBC;A"Y4WNNL=KUJBFH<1D/_0;_U M47///=6"SH:>8H9,RHI%O@BDSC`[B['PM)Q(J\8\2WCT0M):03MW\)U^J>,E M69L`;0;"@>$)$I*8$$KT"(T20&GU>>#;G`C'OM++IK6%@LZRJA#P$9.=XJ:%_E(AJN]@U]GJ+B7<*FZRC+LC\L9$F'2GN(M5C;9M=TG: M;:`F3Z@[(VN;V#M%7<0F2UI8=$O:N\=-"MRL6_(6IL`[Q,DYI-L6K4 MK&Y\^-I)UG:8@$]<<`&?A.1\I[S0=\(+AKXVL8L-F5C8!9U2T74FEC1$L!V^ MG""SC9/O@9>-1]^-F*"SA+0ZY]!-'MKR(%1[D/?!RJ:C]48\L*?1.NZ\G0`3 M;>D'F\U0O@=>-A[@-V*"S^:Q5N8UNDE$6PK"9U/W&]-2S)/,LE;X*;F)BT7. MWZ*1RO(D5M]4?IL4;[`&N1HNOGY:1K$Y6U1P8(MQ6\[3=TD$D4V4:#5]#R0A MTO(PZF,L$,-N']F8F4@$KLL\(BQ+]!>3@L4;R<4LT5O0=X-$!II'RV.@*\DI M9O1!4HOA)G%]E5(F'0;I$D,NIWJ+&O61;;D44<(E([['L72F<5WGP'*QI>LC MD@J4$FLSS63PCVMZ'`6,6(B97H!(^0Q[S`H$Y6*JF70QL/Q`-')`S=?I M)C"XV;$E(`R/8DTE-L$Y/,@QP)1*3/X*`64X@_-Z:Z'FK24>GX@$CEC>QIH\MDDB/7!QD02 M\FR\_8%FHRC_0=548M.V^7["_#PD4?JQ.6W3]*U9?D_LWQ.GNXWS;+;%9 M!OKA.*6"VFP_>LI*EO\[H72W:LK+;^2V1FD+BSO:62^HM]AV>K%@.\OB-`VK M.\=?2\/BRJ6#7;ZI4+<8GL:+1FZ81=GI]2BZ*9:[;[[!:\H-_&-OMM26<&SC M/HPU/*E/NG=]&TEF.\@CTF,.]R#/=:'R0CV,6,BYB^;&/LH M8ZI]3)+,:624;)G&G=3\6#OKT6Q;F]X-YYG81=@KEG<*%SG2TJ5]_(`1B)2V M?-I':*W4+&I2`F1+V]+>/+G3'*JNFC!?R=IH(]IV#EYL%>-B?<_+9S'NV?QW M/9_'YP9ORW;"SYE*H^3-YCZ=G=MDM?9\:?$9^?M:J-,^[OYH,`QCYV9E)3>L M735=`*S/<\:B?(C?!J>#;<=SDQ7,6ZP,08IJ39"+4BS-^O,)]E>M:5/DS7:[ M:YT6F#!![2Z>R[#%:DVK/.ZL6M/B#($#7"UO]WNKUM1$>S>MUC2GF0E2#LD[ M/A1C>^6-=NW5.E?>:!,C?`L!W2IOM&MQBT9!;.?EC9X5\C8.?R1%>2,L!+>> M&V_LK+Y1&P!U?2/(/.ZWOE$+L(OZ1KQ\V'VGZANU(?KB]$O6@?I&;0A< M%L6<.-E7?:,V!*KW4F)<5>KVRANU(4<3QA%6^4UA:]6-6L!'BZD\/9^PU^I& M;2#5U8TLD^'R*2![J6[4AG'J!T]^L.,\'59TE:GG-L`I$.%U6!^>7>U?MI01QWT3O`_1IF'I&DQY&-L4^E0DW!G6FG"MNQJN:VBIWTT9LU1O?>65R83_E;MH(-;TO7/#*+,(^RMVT@!6;PBY\E<5L MTB5IMP&;+,'NC+0W/4:V*>SIJC@F*Z^I]B[NW>,F!6Y;;BSOEE;5M%3^I$C' MX%)+2-'%939O6=K14E$.4BPWM"P89MNMK?3H2#6.MIG6*_^8Q^= M5C\I@B/FU02P#;YW->.TC6(@C>:?YF?=5//GO6]2K"5B&UL6&])"WP"^0] MT+)Q,9`F1+"GT0ROJS3=-2;:4I!Y,9!.\]*.+]6#_$X[TG8\AJ9A]8U#-X]) MJ'*SXV,2%D?:KJQYZ/`Q";4<;>-(@";:Q/4+`5''6(>.27ABJ"U.\!8X&:KH MZ#(-]93'Q>/==?**Y11$T*5ME2LH/`<[E%.]/][Z<__+UXN?#E>X\]=*/\RA_/%M)>/>*:;XM=A8RY7/_ MEU^__GIA7/Z7?^Z<^;]>'GL7QO&)=S!%4-?5)R`.C,Z'>H0>C,)7*-D+"`CW MI208(Q?;>GLN>!WI]C'BW#:9:^L-P##XT6G^=]`[->UHJ2M5JH-HI%(OS-5- MDKYB]=06F89!ZP58"73#.%=C/3L,5JEG0,+X<9GI4D^?8/23P:0`!\H?COZN MPC2`;UX1';9#>7&>'*;3#J_ITVJG+Q_'VU/OACTM@A+Z:[FGNB.KW9ON;O;C M81]H;[N?9,HH,FU$S7)O2_VJ:K0'%Z3AZ#@>JH?_5OO1:>B[]B'(UV+S;;]IJ[$B-Q1'(A%02,=.UD.O:/O*EPWW"/$&P?46+G1?( M/&!+1>%K451FV@>W:C@9J=/O#NCB,!I-\NA>7>A4H<@CIDL5U3!(DSOM?R=Y MD7F>?J_>^Q*(<4?)X)];$Z[`IG2U<#GQ'<1(WT0R@&2HSZ3C8-(?>Y]<\Y_.3Y!EZ=G1P8FX_R3<>G_=HF.3_K^ MR>61P?[XR0A.3RY1X'P[_OKW(^,RNE.9<:)^&.?)71A_,F8W<$\O+T^_'1FF MOD71XN+X'S[<$[[HS1Y\EN2@61&$K4=CSJ21+:@TXB0WHGC*)_QAY+=@R>%H MH'=/`*=&\AUN4C2$WV.5&Y"W90:HB5&HB7&M!N$D4T:>&,/$R!+C1S(9#>%K M`S*-",T?"3?15X>9\3T9C9(?F?$G>-B@>,EHJ,7BMNE-LS\?:;X.QR^15P!_ MB0SR1,9/X=WXTQ\>'//3ROWSXER3V3/A\/A_/./:)C??N[9Y(\](X315/RY M-P!*5-I;[F:Z_&$X;\3E'XNK"ECYL'S-_>QNUTF>)W>+!Y'U3;;U_;\>O?QH MO+U'O_H1AV7%2>>:WEB=Y9(5U7:A>&[9OE[H=*7%\VW+ECDW]C],CP\P\!A< M1S**AKT59L!TP>K@"^L9L[K6?U_>IDH]=0,\4WZ;/7V&L8D:%GV[GG-\G1J' MU;M2=<+B@XB>+WP>._K$*G=L](4F="'TQU7P1, M?F^`_R7A/7N16:IX`P@2R!7_X'F^'P1K'$N>C)=_6>3%I2$$PNJNX2#BJQ]` M@Z?K5X<02WL?C7$ZVWP,C]7CJN3_VWO3YK:1)&'X>T?X/R`?O;YXH#(HHAM$.``H&3-KW\SLPHG08JD>(`4-G:W+0DH M5&;E77ED.6I+)O5>R>+%1)C01(C=J?+O`T$8.^\#_*?'T)G_XRW_[SYA.CH^ M5+UE=CJM3J?SVB!O*.$TE+`?R5D?.4G1#"$8>0[OV0E%O:48:DO1]==&\UK+ M-MHMTVJ_/L`-RVB9JO'Z`+^D$,-B)O&W5VHJ^Q`AI\K+6* M6H:B@):P7QO@IR6$M?)3B*/Y]PW"<$?`=%GJBB@&759E(8SO(H11<3;;RLN# M?G![VFGPU^"OP=^YX.^RW._;(':\W8Q.^,LDP.R#)83^_R[\$24L/KKQE-YTJ%%'A?+"7-O44D.;SM ML72WB*6%CSWB8"LQ0X3@*\Y\'@;?W1D@!W#WHW)E9`M<2;?3%6@LH)"V"IOS MX=7(G2V\V/%9L(A@P1&V6T%FL`)_#8_:N%*4EA0M[OZ7C8@Z8$MS#ULXX=(CK8 M-G;7A;>#1Q\^/W7G^&%,9'#NF>2Y,S<6!Q*Q&%@MA-<%N>;Q`PMPA@&D5F=2 M(=IUCMB)XX:HO18L$1O)4K!,QA21]*.J7W52DD4J@5^./">*W(F+=!-)V?'U M?\Z)2U@H'QMN(9:SSV8O#7Z6`I&$'*"$B9`;'`\ID\Z5L?AJV<9?4H@K%-9^ M>Q11SY+HX];C_U8FXN]O^A05I>AFL?/M?N$M#Q-8&C@('NOH:?^VPL!4!\/K M;E_N*B:6AR@]N:OW+=G6K:'6!>#UCG5R6R$9C9K#QYY,A#THWRY)QK52X1$% M^`.(`_\^0"F%A8,QNP?YY@#O"VYT[D/&>+,[%`64(W\7A$(\D6#[U7.^!S<@ MLZ;_]%P?V-\;P8OO\D*B(/('/[]O23>.'TS<%NP3OOK_F,]&CM3ME=_+_;7P M/NVEYP;WS)<^`B=)OW?!:AA=%=_F#Z`E`H\4WK^2/H/."/D!1A(\Q4*JG@`" MCERNB!?S28@^RYPS203K@"0&Z3Q"B07H#9/[?Q3VP1T)]_2O0EQ/J'U:"_4T M<\+1%#$*6Q_#E[V`^C/#(WR2%_Y^E@PE3;]Z)?W)X&VBL/_@@:2;?@3]CB<% MNT(MSF4Z+[R@2F+0<\###I5DS%C\`7&KOL\(`31.M'!PA)'$'ER@-=!C\914 M)[R3R@N)?0>$1$A3[[3D"@54'8\I-([;`M`)P.KYI=U.5&D^T[* MCR(RNP2_2>1UXVY#!FSBPW^P(.DA_71Q:RE^@.9P-T#``/Z,>B\*(D2<%:!Q M(\[28_H5X.&.2H`X*8&MAL"(PBDW-4GB,/"2%8'9QD$H#&_@K5&N8BI9F?\* MK'YPLF.QCZ5CR,XS$[1XLD+4/B-H\=3A=0!M+"TB$A=(S#EA=X?^`_P?>0[X MZ0);%8PO.!P.EA3-P0J9T$8"LEL+T@#W$4_=<"P#=0%[I7^`U7/FI$L%9@A+ MTNMM0Y;;LU(FIS<=ZQS5QQ'.2_!$?DN@7&85\IZ+==`5/ANW4L8E)[;,NN30 MI`O@LC&>14K5#\+'A?=PS)/C$P=[Y$TYHZG+'LCNCGA-X".X).C-XK_QN)'9 MF8L.H9!!!78+$PM>2'9!%4Y*49@TC(/Q4/.AT",Y1#`C!^37(@\#J9ZVE(AR M]&"Q;#&3YTA@7**C7\&]LA&;"W8LBIN?2^((3)UQ0.NAQ4-XX#9/`:B<(QSR M*7>)(!+HR@5=N%/.<9\*P(($C$65)$=`(EY"G#8^C[D`<=(A5<"FFV'!U2P$#9W MQ48!AA_'+"4<5![P1A0)/A-2G)OIJ`[&+@;L(BZ58P"&.Y[[']H^ MMZ_@67`8R&Z*%B/\YV3!2]JC4?!`$3?0,#Y[A"7R'E2ZNQ:*=WP*A"__M(AS MH@82$=4H\(39S+$Q<4F:3,$4A;\N?!&FNT(/&G8Q+1]9IJ@I-`F+H++.J3;0 MG1C42^03ZD076`-T(O8!'C,\1;)YD>$)'8*_"0D@=0-T&"FRNG18Z9DRC-6& MP>(^D1$1A@X)=:A+/7?"Y-'3"(-P9,7FXWY+JV86.9G!(Y1YK((AET-PST:$ MRCW54Y)]8+F8U"&OGLWF_P.:GNX.Z+1@7HI/"8@:+PS*1E*G5J-!J(LC%6=*;%&X2 MH?N:<,VRP*L4VD,B!B*Y]2=`OX60#I<%AWJ;#0ZXQQ(JF M$\D_UAY!^;RV;QUAK6E+L*K-@'ZZ)@JO\]-':!VQLC'&JBRQ#:GRU"7RF_
DB5+M7U;2I<=\K"%E>NQ24PXP,3J?#A#3GZY@S_` M+W"7?<0#)^__N!&!+&5UMEN&5IW064K@/&!9UK%@U5IM17DEL*I*R]:J:_4N M#UBKU=8/?+`OM(!J)J,P[>38`NK%^>=&=2U#C#8+G1\!E612*4"+=_6,<\7M5'''UK7$-/KD] MA30X;'#8X/`<<7CI#O#^&L`LW]NNI+1M>U#L&-\U6ZIZFEAV[5&C'3YT=*ZH M40T@F]-$5FJ/F\[*/BX',FV7^KALD,1N'R&)_27)J;F;WNQV_"SZBA2R1^G/ MHC[W32Z;GB?,U&?-DKAHUQG#F;!'SHKWY'!82.:DBJQH10=5F M,W<4!H0C^O'KIVY6Y,>S[*E@^`XW(;+8TX(-3#C/=L:SXF?!F)+'"8:9,TZJ M(XLP.(4*(6K*@=6_7N'U5II_^^^%&Z:]47+@)-#X@'1G$4^#D%I1/##I?N&. M>;W6.)@C@N^>I`7F^L(B_^WX"R>D$U$IMWYMG2N5-">EO:(H5>Q$/,X+RT71 MS')JF@2`SW+-3=(F M/"DP2%W(RDCF+4`4-@WB77R2ZE_!\90W)+K*8.D[K^G/D=A\@77RO.%/L@2\ M?H^-,N`]L0R\R;`!%]73\[IF>-YG]T&,]5RBM%C.E:V\^4%DN)=J89`RDEXQ MHKD-`.N/%IC\2#R[3M10@8@SX]GS`"M17[)78K&E7<**V3[SPA!)K+CGE3N& M-9(]S]ROLJ;RR9#P;RHZ"_P1D1&]W_5PKK(@0=$"Z.;)'X?!C(E>0T"%26\% M?H:XR("-*`%4G'NNTXXCZ8H\YL4XWT%D4\D3MHP26QJY(:`/V7?$HJN\`N%M M,-*R.:J1+35^H.8^VE4[;0B%O^"$\*-ZI:6_EUPL@! MD59'B.XX*#\SI;-(ZOT='Z$0KVR$_)PP9)R:88$\T1*#E*B:JQ8L\\QMF,9= M)\<)\C=*4-`J0@HX@W^@F*TN^\-:+2%2Q7?GO'L.KS3C=9.BV#SI&56U2:%< M$E:74&A[@HB!*`H*J_BA'+6\H19B^I7T-2U*7*JQE"J1P%'`%WZ3E<DV5F4(*BB)MSI)O?LBDPWA!U71+FZ:R-R>I61:X+6!; M:.H5$A=)%.M'P<`@UBF=:(O+S@(B4,`E?0O&">Z*U:FT+!8Q@[6.B)CA&?TG M`2!D,V`T_&FI-!595U6NU(1RW_Q0>?Q)>Z]*SF]?*;G7`0]4T4RDO!MIPBH% M479ZA?JGZ`24'4H1KYS$[JD;#%:LRKQK0*XS3D5SBV?,-=$')[$"WX@.![Q` MD:5EI6FYY8RQ6#0%F;B\UE!T'"A4PV>%FCG;[HF()U?3S^MNE^KA'2J*Y*;Y M9AT2E@J:D\8(*/LV;HU0V1@!&P\6Z^Y1'W/%0WWZR.C/U\:GQ:N\P1TABY=W M%GNQ4"/#O-F38IXWD\OH%/8:4K^F!"?6NX<=8;.^0L!@9JYP!$:F\D1?W MP?,VTYMB2PY"$KHJ=^7^0+Q?3!$9,P:^'75VO%ED&XDV5.R9:$!DK)?=U%D` MK)H6MTCQ7);P_N:'2LQWHTH-E.`FIW:*AD+270S0(8&S=@^;QJY&9.^2[\U+ MV'.D^HQ1+=RG7$WX(R-)0:7?3EY@%400J1_0'QG+)+9B>L83EYKTH("@3F7^ M`^*3]T0`%D)1/0@7]P4?O=#D[..G0?8CMD833/0FJ=2'@WD>-O+)$2+'BX+$ M'J[J#A+QUFB(Q1]U/5.-W%E(I';6_(*7W\^YF_&C:K9+K^2;!13,V]P:E?9/ M2,:N&WM_)/31]+HH94$QI9<'C0!X2\2$3*0K\S)-PEE)3$ZXG**`<&W M)YXSFW$2@P]0;P/I'>>0/".YL]G"#^3"\\D^"QQ&#N0UNPN3F)@`/JPP(,;4DAM(KR"`J/_5_]?14:'92H1]N:' M$LH29)4P1)A#X8/N@:II.6/(EF^14$`AD`GNT=:,>?@7N.WKK[*J MJ-P0IB9A=&$0SA9>OOUZ,&GE8DS)_5#"]]P@@0]Z3UE3IV5UFI!@09"/IF$` M]AD*]#<_9&KF*J."6XQX.>E\`2!@T4+I29J@(,WW->--.+F]]51HGA<\\@T+ M<8T][R-LR<0=<-+-'!7H?_0#G[O)<1:/27?`3;W1"!@Q7(Y+4-Q!,"#\[42\LJ1#'#58$O,BW"36E)AP(L"+?R!2X4VE^=\XWZ`"K#*&TB!> MS#O=\KL^Z2/7B(B[=.THUYZ-N\+"-$B<,.JAZXSB1=Z-RT5*N/NH&L95>\DU M;I%H0KZAIKG\T7;%@\0@^5!AYC"V,H]3ZSSOH[;2SRA5OCJ/V.0K=%WY:[HP*7X,MRJRGS;#G_H[>>-&L3>\"3\H)';*F2F#(@N>`/ MFO(WBEVCAXM3,LCW)4&'HCU1>"1&D.#RW??*WD06Z$)549L[X>.&L!%)Q?AU M/HLA3Y1D.&P'LS8/9;P[6Y[>U73";#J0RG+UI,#N) MTU:$LS<-9K^I;-&;A;,W"V:_^:$RG+U=,%N05CZB5'[S(*:E$,07Y*0_J-6J63A7%`BCZ9!$''_0@05TDRYQ';)=;"DA!PR M=]-=P%/!1(;_!0+&#M7\TR?L9O^1QR0_YF.2]3-A,6*V+GJ:Z"A:/TR:YP'*R2)G@QD^2B2GZ4W.Q7[KU6+)8 M#5W;U&)5VUG&T&:6JFVM8ICU[ZDKK=;G;%9ZVU[Y]GJC]4]^!X,B!C5MQ54, MMUQS=BOO:5RXB7%\GY-`_CIF1\NV,4(;([0Q0ALCM#%"GS=""_8@V4=5VND# MSA_-U-@J,S2]9'L^SX!;I2#\$KZ(Y5YJ-33!*AR!BV9&?D'"B$1BE M89J+@>8S2$_8/H[633,TZ)),E`U<25]*^>QE?"05#GFX\R49\%@0>N-'')"2 MU+GPI4!23GC.O,!%"VC&7TS0.0E910**QYQQ#E_@S;CW-"=9ND-W)+^#=*0< M[#[-<3G&Y$X$3J(MI`04:M\1XI'F2*/QK5DX`&B1J%[QPV- M0@K?W'-\&A;,;;]1$,&Q9AG5>/\WCY.A10#[QT\#28C,G#^0HVP$/[DFX_?U M46X]KJ[0]<",A,C)9ECFBA'R;"JN4?@"88@M[^5_,^'#"OT"E;H"*/%&238)& MP8R(C-`=D6"88S(+V1`N9\`W/Q3N=9$"DVO@W,$O,4SEA4^V MB>#-%PI5%`N@/YU/B733.?:D)I;K'BN3;]#H6.?[;53DR*EG;2).\FV>]""$ M(G!TP))YCM6Y-(4DFE8F4[B%BY\3]BV)DL(8O264^2(K$%-?9!H>3!-%>:)Q MQ85VE3W,V1S'QJ*S1_DS6>ZG<,&^SX41A\G"Y0SB\D!>%$>Y.!3@/:??R@&H MC<)/W,"N#$!E]Z?/QI\H0MNQ*\(UK:H;TY67D6LC4=*/JK8JK;<0J6OE[SYU M:_,H4CG>Y^^4V/M&3*/=+K&7>Z]CF3,+ZGSWWN7ZK11A2J-+N1S@S%=)!!@7 M=O%R3G":I)'N6J@/8+S%2)1_\<`"VC^>.W.1/HN%BB>7B=7QK,W<=LZ]ST>Q MBA;;)M&LYP)8*PJ"HJ8B*+%QWC0506=?$93WBU]56=#)I6*6L0B[RDJ(5SG\ M2[YJ*5+0!P4);]S$./40_-P117VZ*7D4B@#Z-U^ZA73[-S\LB=%69Z+D+COW\,R]<(*H\G59IXN6!".^ZPAW3?=?%#MR'VA(I>>,^-Y'2ZC" M=Y-RV_D"G`N:/3Z9T'1/<@(=/K$@J,Q_,TFB0V;%$VKQ$O`)+C!S_F*4J@7&?\A-'`GSA(&- M*?)!?Q-UQER>\4B33I1K]Y;-+T<_%MW`W MDK*%-S\\7YB0S+[EXTY!O,TX%$+W1PST*GX^N3".LEX5)+)_PHAM@:'((?;! MM$^<*6>&=Y&SW-'3K\C(?.(-,O)KTDZ'B]R,LF1>L"0OG,# M(M)@&.)U`S+BNB?H#2><"#RWE/&\4P=G=97V\@W-B* M6@,LJ'+N?4(8'M"<6"[QL'Z_$9(1/P$_%(+V\`.U/!4Y(GC[5HTM"LR4\243 MOI:QUA\QX4CPI,U2"H=U!V(Q/L0H_YD\&0+I?0:JLE^.[L$@QPKMY?/=-N6`R?@PJPKWK@[W%:\\L MW'MRI[)8AIAK:KDAU21^8%Y2X*U=&#R@%.79@`]N)/#"B9(N?40/M7F:JU". MCR."Y`OQ.*? MA0%?G=\7(NI)M*$)> M^OWF35(`_71Z.;GG&"_H+?()>&QWM:#,0K><@U(GV04J7?(#X'S!BHI)K8&F MG<%#F.I/'TMS">9@B(_<.6:!<_7(JXR4S$Q&K5O(1^2[!2>(9Q&$"PX(=ZO$ M1Q/8U);6-EN:KE5&2ND&$"-3*6F-O"`2#:_6A!-SJ1-O?N#F/T5;^<>I50<>8?^MDY/K!N%HT^*6_)NJ>WP&DV--7Z]L?-X!O`\HUC\RTH MP1'8%%Y$L\[=,3PX_J:9>KMMF-^ZMF+T.EU+5NR^(1M*SY1[O_:)&A!_GHAGZ;WH\R). M*]=?CH1EH&5]9ZB-M[_HEF["_]J*HF2P;PE6$24(/4C"V'\Q` MP$8D%.@6YS-O7=SEN6]/MYA*EQ+4[F@JX<'L=OMZV])DPQHJLJ%:/=GN=@Q9 M'6JJ>:U>7YNV^DV%%W]!)A`\4!:GOW>__OKQDWS[^WGWS](2OK&S:GT2#JH@B.2Q:I\3!<"&1-/T3I`5ZFZK0T7(#H8-2B! M@D4$YQJ]_[!:Q>1Q0@`^![26FY"SNLV%P`#_1N_SU\'PJ]S__-MOW2\WL`BI MEGG$GCN`,K(E/E_H'V^!0$;,\Z*Y,P)\IS_/T4X3/S^ZXWCZC[>6^;=T5,:( M%%5AOD]A?M`X?:GSMXTGL*7OK'YE7[\_V:=73;3;^/3LE6.5=I[KM_G0DGA< M(L2$ML54*DF=QWQ.U=)D%*14(#*?%-(R%:4W&URN9IL()L4+CKM0^JE\&R)Z MOI=N0O8^_W"#-PZ-G40)/8\3AZNIYQ]DWS'6&VWP))E.^T7RB]E!"+/RL++J M3:T:/'8[_+^W\L=/@^&GVP^2K.*(L8W4V6_#:W@A>WY9F0F5CBY]:N^`19KT M\S\W"6H^AT/F*ZN47#:LN M+JX=-_P79GYUHXC%4=ZP[#;QK"M M=` MF^L0,_!U$S4U=Z.Y MK[!L/QX\N'BJYYH]-WN^N#N#:(J]%%S8`CJP1V?F70/I>DNWK(W>/=R5;@/L M`8#-:J^-G3_?H&$3-%RDP;)6V`7AG+<,&+,[;*@R6H04@#N^"?/"<+UIMTSU M["3"2Z&^--'04$%-J>#2C;ZL!\3.S+Y6`4OTR"(@')4[ID_.D>GV6HI6N,MO7(1V1!!'21DDXA^P`]N3S$- M_AK\-?@[%_R=QB??^!R]XU4]['BWIFK@)W7.H-SA)-@YX6US_9'345J&2$EM MD%-[,[.6COBZE+I75'I))3/M?`V,!XZKW7P2H[XDU)KK$H-@.-L,4O ME2S674[M:B7JK8YVFJXQ]4=.+<.*#=HN%&W'8,6R_"Y^9DJ]^?[Q5C57JXG< M,[E2N%4O-(5H6Y<)5E8UO_DAZZUWMY4*/Z17J8ID3G9;;(J64TL4';A:+M&*SX@O&$>Q@G6)I46#GOL!N&CG_/L#]9U'O*GOGB M/.'ONH]..!;C$&EN??31_\)"-QC_294Z;-P%`>[_ MY4:!H:G6MS]N!M_F+/P6XFBTA_WNT.C)G:[>E0W% MTN5>WQK*RD!3K[NZ:7=[O6_J-^WM+SCJ/8?TXV&F>"3I&6]PM'_XP5W$P@<\ MX8_^?`%H`BR/X"W:[?YG2!J6-5"'NB*K75V5#75HR!VSH\IFSU!,U;@>ZJ:Z MU0Q)9:\C)/M3/)U(8RG8;"X MGZZ?%!EB914N1N,L(YP-V4R&I"&/]@Z3(:TU`P^7Q'(R17"/DPH/9'1?:"F; M^,`=_AME6;8+DFK9CT*HS=+$][L$T7>A]%-YJ3\B'-5Z`U^CQ``_WN"5G'24 M2#QN\)UW5)4DZ>^+C[[TSO32HT<]QW-\4/).O$9X[N;`O<#B/!LK\!Q\]G7' MSQ4OZMVM=>[1B>*EJ0UZR[(/W,:KR5^X[/O/LY#C:RS MUH'5QL$")/FQF'OW+V['W1N$9@[AK!?#`5_!'/47#)\%TQAJ'=F^ME6YHQM]?0!>_D`UGO7M9TYX[_HR"*X/JHW. MJO@%/^(/Y+\B,\N1^Q_V09IP\=\)\)*`GH[%3?FATJG. M[^C!0.6$LW"$N(+5XML^,2_SQ+W2MB8P,W M&GD!LEFT_R"7>:WV0"T/9--63=DPE([<-;JZW#.O#=/N:$.SW]LJR,4Y86]1 MKM17-:XDZN5#*)%6^]//QYJ(+PI6!7+!WG;\)Y.F#A#]"#P`!ZAKXOI`G%CW MY%`@6W+\L>1E(C1'^C'Y$;`&]R0>I^YHRA>[8\PO$23WW=';E(#U]#PQ%U:9 MNBQTPM'TB;-6!&QW!ROD>`IX!?DUBF%G3CB.0`*$Q35F.70ODWHU'6B'17-W M/O?<$84['Q2>%_D\4*/T^(@<.UIA3K#Z>`N(?@X4W%@*" MBS1$@N/S0T,,SQV7A$@<.GX$?"LYL$)RCD_2.WB6?7=CONC[!+_P$QS^'$X? MEI@%42PYXP?'CYU[%BPP;`H"^B_X`'Z-SB/Y7+8RK`1K4_C1>^*?=T8H/F"[ M\2,01K;*W`&O$S^'TH_WN\)%<\5D&I=[=X8B$GTHAY'OY[ M"13Q-4(&]\S/#CZ8_ZO=)IQ`.LE M4+9H(^_NI%O88'KX\S!X<('4$23RTF%A%Y3#.,<,B'"7 MXF32(N+\P-&$2V=4@WM!,&?.=W<&:H/3$+R!N,V%W,12N-N9ZQAA6N6-\KX]3D`;.@^-Z^/&)(\GD*X42/P`#T"&ZJMI>I$"'C9SU&P1/,2>_B;H`0!4$`;3FP<11[R$!X MNY"C!7!2%^&(15>PQA\5R"CO.603#U2W!&_AAA8S?M>$-L4BIG-!23>*@[`` MY#8@XLGD@%PB(S!J0$8G1[F*7-*]I*+&]9$X\7=T*8+?3"EOCSTO$`.D)T`M@+?`5 MA*;>QNEK*/%B*5';AA)!="%I90(YP-^@E/43*N7D22O0LN/$`$T(/[$.\IHL ML7*RKTK18C1%/1T5%Z9'(]"CGA,6-KE$Y2WQ8F+/E5A&6KV.6(`VSE&QF$Q` M<^"V'@(/'I3(2)B@CL9?YFRO2'KGL2@2>TDML.@]M_/&S)/'(?R%*QV'OP+? MY/B-LJN]G/9#;93A"M:!OZ/.!^).G&QN@($9B,JU1<\$81C<4:\94,A/K>(B M.<7<2(-&&J320-]&&N0-FRBE1C+O4N)&&XB-IKX+G)(C],!GG"%`#JPD^KQE MW!(;0Y,)SM?A^4=9AE_G9Q!&CW[>(-P387.'=6_^Z6W!^N.T/@]91+A%DS:' MU:)7PL,$Y+L4`P7"C4L#!?D6C'$[)0=MV;=X.++XF]>>=2T?: MY/'\XVU'VR&/Q[2VS^-9D_JSK]\WG\Y_>H]Y4RMSLU9]HDFIVKIU>[4X>_-# M=DU;GQ2F\S^=IG=[$>*F=WNVAZ9W>XU$3[7]^>SR_E]2)[MY]N M#&T#[$&!K67-YT6BX2(-EM?1N]VT6Z9Z=A+AI5!?FFAHJ*"F5'#I1M^Y=VSO M=#H-U;]NV=>0P!D)OAJ;A!?2HUW56Y;5].=^Y4*QH8+SDHMUD8*#HCN,@O"/ MJYLKZ3YX8*&/>3IR-`_\**`885XI?3 M_:'!7X._!G_GB[_3^.0;GZ-7_P8I&OA)G=/X2?7'S@EOF^N/G([2,M1FVL>9 MF)FU=,2;\15[>*Z!L8'QU'NO@U5VQ)N25S?0X@AM],X6.;4,*S9HNU"TG:*C M9?$S4YI\\(^WJKE:3>2>R97"K7JA*43;NDRPLJKYS0]95^Z[K53X(;V*\S^< MIDJP"'%3)9CMH:D2K)&HJ8'?T%0)-GMN]GS>8+VBVC([6<,#KEH,-$9RI M&*RQJ7@AU8-F2U.:LK%7+Q\;(JB3?&QJ9`[XP>UII\%?@[\&?^>"OV,XX!N? MFE?[!*N.V>JH3:YC[2Y6ZH^!H&B_OI^H%].)$5QP+R MJ8(1CNAK!O31K#U[AP%]UIJY3;O!*?G+]1QIC^OQ+[\34 MU??%1U]Z=77I3GS/\1Q_Q'#>Z6KAN9L=_0+%?S;*^!Q[1 MB>*E-\QZR[(/W$VIN4:^[&NHLY#C:RSUH'5QL$")/FQ MF'OW+V['W=L,HR]PI/&W/?JT?X+ZO(L=4*WST$7_"K3L)`A!Q[J!S]W5?R\" M5+@S)_R+Q?089B^&_/=1XM3>A<%?+(Q^&C/'@_]>XAXWE/TIB!`3]S M?4:>0MT!&&- MD,V#$/<:A\Z8P1_YIL2>Q(;AM^XXPK'W/P$0P62"N]W,9S[T87STI?]>>$\9 M#:%9VY(>06`"8L;83-T?`Y2`#X(24`E/*-*O-_^4/@%L\.C4'4T)$]'"PV?@ M8!U>F,2^QX"EA1M-"/6TE`0>(;LY)`LD%CC881YPT5V!O/>Y@$<)>`5N;`_9(43T0 ML/[(G7.Q&<+6?.GN"0F?C1$4N`?N9)_D,?@P%$C!#/@ESGPOS.: M)N%:U&JP"/%XWEV\`SK*+34+QLQ;S8OBB#F1+"W#7X9?1R"Q0B$427`B(7*! M""L`.84.",W0!7=V%*UD0_Z5O]B3T':X+7B0^`\_Q$]M+4G!+O*$TI(>`@\` M]=SX"99Y9[;_]KXEP3[^DB=(JU3'^DZYTC7\/7$/@.&"3@867.:-TWDHMR$%(9^DFSATYY$X M+X9$B?I&$!$A&(481W$E)AWQV"/8-U.0EE$D0'(3ZB&]C2A[(AB%M192J0G* M(\[S(E(?.NB4$&62DDO`K3"$?AJ[#_CCWW]:1/*]X\P_8-B5@JT#-T+UN0`I M>@N&0<\#,OL%7I/^GCQZ@Y0W#3Q@AFCX[P6<.))U]E[Z&AYJ##]\99-_O&6! M]^W+T#94O:/(LJJKBOQ_%+"$OMW<#KYIEOX-25OIZ,HWY:WDCO_QUAU_TTR] MW3;,;T.[?6U>6UVYKUP/9:-C]^6>.51EU1HJO:YA]`W3_*;"B[\@<`*VM4+- MWNL=4AH)-J^D/'8RDZ'SL\1150H1/RM^S<-L]`:$%:SRE:'I+DM"7>\"B-?@6^78H(S4+U"^N&E69@'84(@(/4+()X)2FQXK;;' M&\W:7*M9YB[7:MKVUVKM0]^JG?#3S87>,VW3JGFO*%JJKM32B.'>;M-JCJC* M&["-\%2WKI7!'4BM!I&CC=3?1[1ZQ4?*'$M%NJK;6L$S7%/"-$62U5,UJ6?DHW^PQ5RR7E MN#48W*]ZV29+\$`W:N(>:C&;.:'['[Q;2Y-/1(J7@RDTF`6P\,(\L-"Y9\\_R+YCN^QH@RH(7WZ[96FGOL38\(T=*V>TJT-WFSN_*.VZ7C._XH6<$%'G1,FZ M>9JF@L>B8^NJSNW.WKS4@S]W":I^!\?M MG!L'["6!\R06\E9(V@4U.WN&UH$S.':*QQ^H:(ARS>0>585AM1?S(RI=HYUE M$:&3%N`L71=@Q/]1!,TD$1.3G`B>$`S^B&4X5+TG2O9ZG@-@WHRF@0?OCQQO MM/!XB=XKCOUWM!UB_^8.L7_S=+'_U_GI-0T(#_Z)YC+DK;DVW'^+-?S9'OBM M9?8S75_2PUFT?I-*IH-?C9P6:Y]=ZF>=Z MZ3YVJ8I%N-P[#DIYH7]YDN?.<:?GN.?:[/2R+A.^IIUI7!2'+.(M7X[/OR\M M2KG:N1SE;T>)YKX0OO]O5^CV="@G.-"=;U#.XD#5JYUOOM;"=PD&Q_K[^SEO M%SEVL:NC/^8ML\Y.8"E7.\?ASX*^7YW`NO0#/11\EV5/I>(IZU%X=J+)TAIC MZK)DDVE=[7S)>18G:JFUEDYG8$YA>W7IW1-SPNC]V4DLFVS"BO1V^95/0:D9&O5HON>U M%M)X$?*9`5MW?M>N]G/?U@7#RZ-<=I+$ON._65/'^Z)< M'FM-C]HCI)8TG][DTWL<#+KJ$RL;*S?I#4TN3Y/+\WJ(O78Y'R<'N,GJN72` MF_R>K?)[<&J'$XZF-!-FC+.G@SD.>EDRC0\=2-BQO*/=.7`A7FT@U0Y=QU(; M2-66:;Z64S4.W=#@_*[?UHFK7_G`4#XU<#QS?1=G5>%\OJ,+K)<&!'7[[&C\ MQ3DQ^FDZ9)X09/M$Y9@G!%FSFA'6Z;MET?C*:^,;_#7X:_!76_Q=NK=+GZ=DP[=ND*?WFP\L;3 MDHM#EM-YS-VLIT;2I+;+VVW\*\UF_8H#K'<>MKSP7?[6'+;S5AJSD3MSO(CB MMJ5!S*;6[O7M?E?N:HHI&XK2D>$CAJP/E%[7M+6!V1OR0Z]/L;*R5.@#H^JZ@:PBZ8E?!7KWYTFSMT92-%Q[[/.D[T13_ M#VD&J!?G>'?]\E6RP9B`41#%EX>S#9.+_O!#!G]>0M3! M,QE.32##*`8##AZ.7LY>:IW#YW\\JOC'GV^RFDA_BV( M(G;RD3*7'C3-5%:$2?S/M=?-3N*5]0=J]MSL^:5BYN#/758Z4#$YP'V,Y+& M[`ZT"1NA5^(*G7!.V4!:MD"0DZP>BZ*-%JQ1_LB.X7;3;IG&@0?#U@98];7D M1XTMR9@SUY;C);E8)0.D<)_5+` M.YVSDM//[&.'%991DMW-@"-D'&JK9T4E-CAS-`S\*0IPO=<_\T3E&B%ZMMV&U%*W]VH`^<.II_0!NU$%"ZZ<, M*]6L>NYDS[U@SV6]=]D50PW^&OS5&G]U`*)V6+NLF-%Y5/6=\KF:5UIUE)9A MZ">Q\.J/'.T,YGF?!#%'OEK>"B%'9A[UP,S3^`RGM]ET,`;&P>+.8\LY8;`IUOUF4^5:PWRW75N1&BV[\UJ*/P^?9%KJ^VD,EL&9VSRL)NZIA.0B M@[6`HGYXVWX^YXLG+CX_N!/G/%Z'C'W$/%%8Y$#S.HU=AU:J-+12T;7U$SNK MP"@"WW,B-_H\^0)_!3PY^!:B$$B$KDW\N#L:!0L_=OW[+^!*8D^W_0^N5'J& MIBL]4^YKO9YLF`!TS["OY6M]H*O6H&M:VO6F@RO7#:+E=JMG7#:/=,LF!,YO-'?$YVPN?&PD9_KTVKA&)YGTJ,;3T77 M/^:ST/&\)_PSSJH9TW.<4F@!%SXPQPF?[[+8?/_G7[O=+]G/@Y_?2Y,@A*\` M?;JSW+Y<'WX_(P3#:HX_EF(`S/6C.%R,B+:E.)"NX1D)*8V>Z(:Q._(8_`+/ MJ&Q@__E?'V^'\LV7;A\PGK-8O[+[A<=/,I52-_+_O2K8W%*7D`"P>4\MW,H3 M[&H M$!%BU"$NA5?^=^$3:W`V)6H0ZZU8I4B:@H['?,0ND[J^OP!PO[(YZ%,)EDVX M[9^P2@($[E]B/KZV.I>?GB8^6T0(*[`>6P!"(L+OZ*HH(AY9*R\AI/S?%M'J MOP6+L/A'OL4W/Q2>ZG/V*,B@EC0)@YGT.'5''&]WCD?R+IHR%I=D$6R?`8:V M0\"C$X':#X$NZD+7G_VJ&6,6WV^+AC'?!4XXIJP)D%BC.`B!8N;S,'A`88^" MQV3'UC%Y"*N44 M"A*?'^@S;]PC_X4L#@-G1+S()A,4>>G[Z6YIGR2S@!>719#T*0`V#>&ED#\+ MVBP(RPM$[ZM`S?0IMY-`P!/[.VA!P!)K)KS5A$1`ZWR&8X$),B%,8'[(SOQ!7F+[VI M*E>V-',]#R4E\3UL]`'SA+#E`2>T8!$#.?FH[P'HD"AV`>X2R(`1&3WB%4## M8AYP<3GR@DAH3J[9\KA!;DF`@-T$")5S?Q^R>T0+O**U+$5O:68GAXLEYH%5 M_@3"=ERD?`?(.7;(Y/C1`F<@A0F$D\\0Y\&(,2!G@A'7$EM"9;M\8&N/JR4Y M$T`AB+`Q6E]DX2V`!0FU*IH$MU\HVLKJ8-HYVC]Q)MK#U7W/W&!PLO MKC[:91_^)6YGT8']Q&(,`7P!M03FZ+CW]`<@X*/_&1#MX.M=U`"\8_G+_7TKZ_[`[6' M?KSU]A=9[2BJ"325H6=SH(K(P![M?1)->$[]1$A])+<)2>:&Z.UC%"W86-T# M0CC]YG'Q\=/U$C(&?4WIV:HM7_>'NFPH_8YL#X<:\*]ZK2AMU;:5'@]JJ%K; MU/)1C>T@*F)CZ(0^("OZPD)Z:O^!BXZNJWI?&;C-5%)*+K"NXXT6W'ZZ>P*I!&R!X@D5;?H">=3XFT>&EUDH!H%8P&F6_`7: M67GS0@COG)J?I-X"-P-;Y$7!$ZFGRZ6O\-8S><^RX..5-'"]12Q9+0(GV2^V(P!U&,!"=C.9?66_Q@" MA0HS)*5#V\HL*;"B037P^`"]"DX%CTH6-DGJALP3OCY_!DT//[,C2^;9W'G" M>.Z5U)V#_3VB7E59]$FZ7[@\7#7G\C,B+*!>)L8/'70%\&<7HR'HW7*S'+\8 M17`,F&OM.G4KB.?1N&AX1C@:>%Y)-$'(S`7\U MY@0B,2&;`=2:.IX]^3;TYF+"";T>Z03@B$1XH#\$"#Y'+3,P5R MZHRY`Y)`B8`0G+CK^$G$TVC+],4*(,>+,*$43D57Y+ND8T!PYPY&G`$H`/N. MY6QC)^;>-%@OOI_9QCD>2P)['`#N#.8YE-BF&)?`P!OS`R!C@=EM\]1X".PD\+WBD4^6=]Q:SF1.Z_\'SQ#A>0;2DFB)#7'(R%5JG M@OP+=,CQM#X@(;TCW@L6$=!?]/[#9H@CH)]#A#8OUS1472K6IA^A:>_0CM"V MMV]':-6^15W-DS@_"5;8Z4I\N^RLTZ2K:2W5-';-TUJ;L799-8"_L2CZD%/C MJ0HO*O"\CJD]S;RX4,A2=Z6/S>Y#RXN=TG00UW$;(V-5'MV MWUU%V/K.0_UV5Q%GR-^O**/N)$[.%]"N/MX^>4]2ZK?EIHGF$FG2!(2\YT(! ME#5>SAT;.0ON88X#$)PB,'+'BJXB!D`H8"$\KH@\&Q%SR$);PI=^S8Y.1]O! MT6GOX.A<)0F^YG"-;2W].JF MJHUS=32G^-[!FQB&*9WHS8PSRPDCW68#+'9`O'N#FA$\L M16KNV/>K+I>36^/L1GDGA^U%!:(OC,5EJ!:RS;:+=/:.6Q[OH`; MEM$RU9VO-,\7<%O36X9YRNG"%V8>OOPNM[$"&GS4%!]JRU`4T!)G-]_BO`GA MTFX\+R>CH<%?@[\&?^>+O\MRO\^D>>A9^^=GA"C5;+7)H3^-7WM&F-);MM4& M/_@TXX#."%%(4A0Q..HHF'KDD2WUI,#&'95EAR(`FE6C8673FU(U8U7CG%RK MA'(+@"NI^WSW#FPC@)5WSLH2)GB_T&$"O^KDNE8D[6>P?+]]9:35^[SBSXG> M%(LBJ62K5#<7EUMDM))J/%%@F58DTL:F@3=FX2:5^RN+JHNUUS>(7EZ5/:`* MPB]4VL6KM>F/GWED>O@=![=%O.G1WJO1*RKSU6';4!5#E[7.=5VW- ME#M=71G:VK!C=-1OZC?][2^6IA2J\K>'J8B3KXPJ?[\X8?QT&SI^Y/!.9@,W MPN8ABT-4J"MZ=V!9?4V^UI6V;-AJ%Z"U-'F@=&U5L]M#:V@]6Z$^<\)[UY?! MEOI`O"E^Y@*&_PIEH!RY_V$?U.SGB0.4^_2AQ.]Y>XPNO^TK2:!&(MQ(>>00 M%69WY)6YF+G]F2OVA\B47>P:%']`@;3#?O]DO*4/7>8+>2)%V`@(&\W4:E'7>2P4]H(Y$Q$/'Z'Q=@LHM)-D#;81(-:UGC8IPU; M<,W#`/@8$$/ELBC$L(''`A-9QS,05;PUR`.COV,EJQ..IO3#&+;G!7.J'(P6 M5+*P5$6(^Z M<35J"T]NSJAAE?>$5=:YUB7I_JIVER]_W;RH4^-0N;.9@QWN'&]-.6R.P;B" M/PR'@7+O+NX74=S*&O(4N`VK[`'D<;[(OCOCJ.7-`KXR:H\SEGX3C(3GT,>T MZ;M`='`HT3.1;8[^8)$QK?#?CK\`1LT01\WY0T:"V2ZH8G_FQC&'-R+[C`X:R]2Q)=&CBV4`J$$F`HEK]I/K M9)2(`K'>*AR1&8Z+D(0G5`5+"(%S2[^0M!&A`P-[(92PN5),;5:QM8CHAB8^ MWT*0_E/O`)-, ML[Z/FB1KH,=I+5%YRP&//OK<2/M3]%+I\E8JB87V MA;IS[;4QU#>@DV_+EJBV9)H9[6&_.S1Z:'F"(:I88(CVK:&L##3UNJN;=K>' M79&,M[_H5X:1,T-/B:OBL77]V$U*:[*>(,/OO([G&C1LGXKO:/W/D[+OT)UA MNY&CM:%2S($]L.R!;-G*M6Q<&X;M#V>Y8?5/OF@--T[_I:/GKM@4OY-I0 M[070$LFG;8N+W&X1H))SM`1>ZNZL#ICS[6]3F)6KYUI1*Y;\8RTVRZC?ON++ M:F]?\:6?KO;I=7[Z"!5?*^O95EWN;$B5IZYLV;ST*`&,LV8B`-0K14EJ!9*; MM*4`R*857[GZI#,H[SH*ZC:L\3HRYBZ5Z)=*6K8\N?38:E?NPZ M+[%3?;-?NG8]8#+EL2#5K.J4T\N#5&V9*UJK71ZLAEG="FQOD+[0&*J9N/J5 M1Z1%(];\[=O1!=:+$V[LLZ/Q%Z?.Z.9K`]DVJP=A7S#(VHKNAL<1:5R>S+__ MO($/=P1DEH6CL&@I((OF[/"H>7[OWNKUI@ M.7RXMX3E'3V+SHG\Q=HCQEA1Y/[J$:.UVEJ#FDK46'IUMO^!;-JMYK#O.8&A MF"?Q1X1?B&)W1IEF^TINZ'6L#DY3E_7^L",;EF[)G8%NRFK;O%9ZU_K0LH=; M)3?8!\B,_H.G\J70TT%DD>43)D-_7H0KIK6&;.WTG)9 MU*+!KOY"K)E,-$S'%(W3/+9D\"--2\(4/KX:/9E;$#&P$BR>6UD8A4OSK:ZD MKH>9*/VQ\SY,^Q01/A$+L1J3@82XM#JRB M3.(8,)BEI$\6F`S6PB<7N?G6]+3'OTQ=F[$()IV$E-_6FQ_*1[!)LF"1L8M, M_SF\=T`^$>83TT,9,ID?FAD9\GUPEF;U+$'K*>0K-4O=?5-=GHZKIL]"U3 M[O74OJPI/?VZ8PY5K?-\/<4!)IPNB0[UB@;JT2#9/,;HI&XH4^H)_Y:;N2EE M0S??8,=N/G=S$YFS9X#,"G@J@3G-WE9.D\6DM`([KYWHGA<%Z:SH5"I62\\_ MKFZN\J@#3P1TW'YZ%4U9[`/ED` MP3PQ)TQ*H-9RZIL?\H<839/1`B%SQI4EI$0-8KT5JQ1)LSSZH.O[J(J_DN&2 MSGD&;OLGZFL!!.Y?U!4-``^EG"955/G@T\1G8#QA\K\SI\JJB/!;+JQZ9*V\ MA"A4JRRBU7\#4Z3XQW0R7?ZI/F>/@@QJ<8OB<>J..-Z2XM=HREA4ES-`?3LW)\O+"Z"V+J&;U$56Q$H;S:BMN\Z]ZX1_X+ M61P&#I6R24S8X719#T*0`V#:DVAYX%;49%+X4%HO=5H&;Z ME!M^(.`=,>3UN>KMFI#(4IU[<3:]OZI"/9N9F[@"8`T\8$D2H&`DQL9/)-5N M=6P%_D_+!MD7,(ATLFJ0?;&PG#0DIJG'I`BS*G:^$](RX"G0FZJ2FT7/A[$M M#?%BB7G>4`%PZ%"IN@/D'#MDDQO2NT<5I)LYZI=(%FT MU/DJ;W[@Q7!`#F!^4:GI?!%&"X=7F#KB#R)*D0JZ5"??R.IJVC#:.7HOT<;: M<\7=;WRP&`LY_M':%4[:+O&J(_IG3="J"5IM%;0Z*O-\Y:!X#>,;U/QF M?0^#1]$D(_#O`Z0-DIP@04=HY;G(48CWK-\$UWZY4F71/^-7S_D>W,S@G__T ML*W!W$,]7@QGW/RSY$G<.'XP<5NP3_CJ_V/@'#I2MU=^+_?78C0$]])S`^`, MZ>.8C0`M%1X2?P#5%SQ2>/^*Y$O*BUF41KCVB+O%'$@1M3PORXV$-Y<6<6,1 M^SP-L01WHOQ;_%4XAPGI)YT^!"7G>WU,1'<._#WH'R#ZP&?I5ZF^/DSN8(1) M39M^G`+P:(]/4``($ZQ-(S%G]`W*JY09&@8D%U4B4_PS8;*$&Y M8(-ELPIE$%*`D`AIZIV6>WW,/'B5!R9YO7R`RI'(Y"?`3=K%8XJ6_(@W^*!5 M]-PJ^&;$@-Q2$\`%2\S]C@((]2T6NH-H`Y/S9R'.WAFYUY$<00AS")Q$=;&D;SFCC"(M1D*/;">).9Q#.>P#1I"(!9A3IJ)<$&<9\60)7%$ M$2D!)$=F50)P@R^V7'0U*E/A!T/+!J?EF74T:Z[R1T$I%;+)B.=VG@82#@%5\T:WA( M/UW<6HH?(+R0Q\,HZB!Z<%$O#+\$C1OEPG"(ASLJXN7T%"WN$!@Q[S(99\G; M;R0K`L>-`QY_*I8JD+9ZZB(Y( M"W*BG%+4Y@Z]MT1MXJ<+O%6(^L#A<+`D[&2#UPIXMM3/HB`2N&GBAF.9-ZM( M_P"K4_R2TXD;B;8?SH/C>HC?TZEH%__]>R)*N67KUD8SY^5Y(LVYU;,L_;F0 M!\WA8T^:A(/?_%#!PTAQV0)DG^&AI.3](`PR>,^-I9'C$RL#R>/D`2YGKG=>R'E!'DY*6A@I`"LT"6QS@90Z MW/FUD-R0;?B6$L&.<4&,(6?2G=O7*-^39GD@7-@\'T1/F>GGDEP"PT?<2:#] M0WC@%E`!*'!J[P7C%1JMI.A*`C3"W]! M!&8P&I)J_^XR593D6>Z$,88SR5^PY,R!P.>K1ZE!L(9^\("SCV';GY"AG<(5 M<1&;R]@HK+-\=,\?7*8/R6`HHC)/T6PRP:"[B_;60^`]\#,2.RINY6=A>KUS M'TI0\9$SKS.;`@;R0D@"!FXIH*29_3A=@->75I$RGN_Z>K1A1G*X.9 M.H`)I85N]!?B*0"?#G].KBK(GUN-;Z`7_RGU0HFZ2%GD6J85&L@!S3TDJC-' M_"TDHS$^5B"O%I(.80%=;AZC'21B(7^*5>3_' M<9O,!$0C9WPGL5H1[`1CQICLRNP M*3#"FSV-AE3U(S'VJZ-?A?P&.0#3C=^/B-*L&'5Y:*.@IIASGKF;@T[GP0Q1XPI+F MV)BX)%>F8)UZ&-40#;ZHK2SL8EH^LDQE4QP$XT>@MG-*3K3U2B05:L=8 MX2F2&8RL3^@0G"X:@<'>&.]GMWQ8Z9E2/YTP">WP:\Q['B9'K>JY$R:/GD8> MX]OGMEO1@RL<:N89`Q6A]#MEW))LN$$B<$0,IF;67;WD?.>Q_!Q0=39Z2 MCGW`H@^9_1=F@23D@[SOOE;:)JHD%^,KW/L5;FC1G!#;0XV,>FHDS)J[G%&* M]B4*"[&VS[['($23;I6XI9$'J@DHEV\*S8,D+IAL,`M4G#A21[U^9&4'K)Q%FMP!)L&H>[`JQ)^82/;EBF%&D<#TRFSY MVAH6N7M*W,>$3G,^'CS+0"85QA4FEO^8.YPH,O#[PC_%O_0\!V"Y&:%'$0$5 M@7->#&KEH7VSHN-7MASF47GH;@.(221%YGM!D8G2'?:8;\RYYHWT>>F=XT6! MB';[2-7X)H`"C"<_,)[L`T;S-!B_I\AIMOO\?K/K'0D5DS#I_KUP(V#H)"0F M+M#IH#D^1>"&O)KD8]@6#_XN']"PK MM$26"TCO&4]9RB+#R^]'(Q>$'SFZ8%"[$9HXM&8K1[@9(Q7H]&:S[:/8S=J- MODD2P>"+(&=A42<].OP8?BFA(VP5>F(A?(V@_XMD"&]L63/IVYW//3##*"B8 MQ>KN%RZ_5^1M;+%1<\POW="^G09!1)WZT6I+V7 M7%#$#P&!U2(%H&>O\M0*!(@\NNS-FO!X+N&`)]0D39Q%VW3>.!IY[\=V+JC>NSZW9FDT`$K#:W878N]HWA8:&P3?_+-\#45_@M]+ MGV"9TD46EQ,HA)<"\AA6OXM))R!!@1:8YKWV9#NT.5*)=-#\=!*JP0?Q\^@M MB@WD.HSGE?.<.TQ_S(,LXTBLDK:A1@>)KEDI1'?'XD?,NZ*(MQ.&9)L67(+" M%A-G#4-W!:,@V6.VPT=R^S.[U9&\`!TXOQ(9B*5$XF'K9FY\,-&85;@_E(&! M=(R4/IIBY"2)NSRW&[>\F7O>;/L=;NH]=]%R,G2RMV]Z26LF8/D!B^;T)`!XA9^Z:?@*HOE MX`*R`G(B=1+1T@_9%$P;C!)^]"GV_.XVF(.^U#3E_0>1KLO3E7)N&Z`Q\VT^ M+WB[[]%H,5MP>_LS61&%Y0D:_$#FB98NL6_^D,062Y?0M]BU>T$P\1[J(A%% M6,%\5@/0G,BT+.;+DWK(A?JR?0>+)**)Q(E"Z=&^2Q23R1T\Q3J7)8+,'=?>(XYQ1NE MYRT`)VN4@KP9_+"+1)3%?"]IZ"/1F]7IW.`$9P="DHI#B0A!P;W(TNYS4QH0 M&<^-A1`7A.-T;$_A2SAGB-JXNW"R'*G%S)TT1)_8Z]R^G(N[1;`FL`+"B3") M8.(%C_5,#GPI'ZMJCH^_E&HCP&;YP\]%EV^=[U*/^6SB(HW\21D1`$,,9F:B M1GY#Q=-'[0:G^D@VN2/=N&`Q."&]CP\0:C'PA[_HAPS.H?".-*0DB&#2`LA?LVK*=*_ MHQ(:(H$&?-]+T4`_CC@2\F^0[D8T",&5[MW-LQ#`F(U&(4Z:`+L[O(0C:HE; MF*22*`\0]UE<4EXQ[SD.HENZ8+<917>L`JJYA*<,JH< M*1G44F3V-S]LP>YX%JGHK))D!3FZ01'GO@LU5_7(KYYHD!^Z]:_$V.IF&7VW M:&#MOPBTD!P^>Z*0(4L7?8LHN[DJ1@%!'HQ$-6'4M._?K'V_V=F^?;]YND;V MK_/3>YP=.^OQ:H:]KWGVN7\V,W=C\9H$W3_N9LFU;]]*&DSY>X M7Q2.U[*M??#^P*=Z[AQW>HY[KLU.3]N[7M_WJ`TW^DN>8$I@6I6/&1O'Y]\7 M]O=6KZS*%S?HA?BW0^]V'_#]?[M"MZ=#.<&![MSU\RP.5+W:N2']6OCJ9G#L M6V`-DVS2L4L58F/IR67>^.P$EG*U\PR&LZ#O5R>P+OU`#P7?9=E3J7AZ"/#> M`:L*STXT65IC3%V6;#*MJYW[[I_%B5KJL:33I9I3F+\MO:.4B/=G)[',W8WI MXVV[D5S-R9X0T&>&.1P\&6*_60VY=(ER5D4YZR*9>*\H?RL(WNKT!\S%R`OD MY*10^JYAP?Q32P+]4U"J'J+V@DD-SG@A.O9AMDN,%\=)#>1SF:#:U=;'O&YF MQSX2JHK)6A]]+`^BQ*Z/_H#=Q5U__+L3_L5H6\-_+\`\OL&&UE3O`G_L\^KG MV]#!X^Q2+[I#]NZWS,ZU9IBJK+75KFRHBB9W!H8MV\..I?1-I3T8]C;MW9\F MS6^8\;HN:7;I5ES'GJHI,NDDLSNJ=:FY*U/D][C+/S%Z_$`=71>AQ+Y3%3UF M$/-.V$FQO31WL-\F;TQV%^>J@:AO^J30;SZ*W7@A\I%'03@/TNQDWO`>2]!\ M?%?&//(HX,7`SCWS1]0`,>ET04_?AE2@\G1%[;'<#)&4WHU[B5(J?,.KDBGS M%?@8\UXQ9Q77S!JZ9-F=V/E(--S*K8OYISY^*L)>`+.`*FP<[-OV%Z:K4GN< M1Y&,?\>R-O2P('PA"EJ\GAN%0I!T<`ER;=#<$//?PYBV-PH`\]0=*RD3PI:' M=XP_"&O,G!B!>[K:I%T?%1I.86V93,(<4+`2)I<[RREYR0=P<0\/GX#%1M1D M4#Z?0)[+_MX;55;D%D991M.?6N826NGTNH7:ZK+KFTY?VZ57!Q8WYY=2) M6T763Z2)2%Z1U"2=9Y1+OTR7=N;CI+ M+F:P<=I,?GL7A,%NHI.?1R$J[J,T`*>_DAMJ^U0ZMV7<\IZ@OD5O.&RNW=H)CDMQ+^1LW5JN?!BAA"& M=OFVH'I3JR+_!9==5C'&OY%[]-OP&E[(GE\36'C6(UP3:W@%:8?-GIL]GVU* MZG;"JBZBJ2^B?:PT,+]VN[)=N>\Y.9JO8#^,< M)?1+`>]TSDI./[./'5981DEV-X/-6@ZUU;.BDIKCXU)XY<(L>FQRB`WH8]XB M?LSF0>3&9Z<;M->J&U2]95D[VWR->C@+E#7JX9S8Y=(=B4$Q]H-J8V7B5YKV M=78:Y=5Z&U9+T=JO#6CMM0'IM-!V-@'"SN/'8L\V/W+];3ZFTPV&#P-)[#)>%MT^80Y8'W%76N MWXLF?4Z#K-YN4^:Z=%A[^'WSZ=?RZ;,OWVK*7,\)@TV9:U/FVI2YGD).GNK= MILRU*7,]QRRB3&51!M'R8$]=Y9W42@?15+DV>V[V7*^=7M;]9E/E6L-\MQUO M:PRC97=>2_'G@3/9:@/GN]WKENMX:7;E6>?9'KJRUD,EM&YZRR ML)LZII/02NIT7U!_O!SY?F$K MA!R9=XP#WYTU3L3IC;A+JI9H,-A@L/88K`44]VA]<*_680=NYDC)L M2!P=Q#-WJ:%QZDFT'WWI\R@.[E@HIID^TNA4YCY@ET!ISDD#K^9^5*Y4:>9Z M'M"'-`F#F=1S@WOFXR)`P](D"*7'(/Q+`N*&?\_@_?DBC!8.O"YFLN+<4+KF MPU&B5*1X)Z;4PB(X?]8#:O(C)CGW(2,ZQ2FML!!\$5\!?F%..)K2U%<0$-C9 M4.#.17AF[B@,"*WTX]=/W4AR(NG.!;2`_`DCVN3O-\OC52NF/*\BXR*UE_CB MTP*SI<5DZ.CS(HYB@`ND&C":.]J#%%F6&K*^Q"!=6S%ZG:XE*W8?&$3IF7*O MUQG*0[O;'FI&W]+4SC?X`,@-W=)-^%\;=$@&^U9`;2F6GQ$\UT$X86X,%N+\?!_`.7PN(7W/SY0**K.,I^ M[=S[)1'\E6$MB91A2"JB:!-QG-NCN6*+B%#9]<>PY`>4SSML&23Q-;L+%T[X M)$0QBLSK[DU/8(&/Y#)8NE==@/<_[E[\XO#S M^ROI=NI&TH)@XL.^Q:1O6!(6G#L^MK8%\3]'7>#C7''4-<0?$F@3V)XC]AWF M]QW0OE'+Y'8>T,Y'!<2X'#%B&+J+?P[A4_.`!!XLP"83-HI1(_DL3AYW03_Y M3)I[SHB_&[()"QD0&1UBLB6N!F&1D/$=3((@]@-,:4_-W>A*ZB_@DP";DYUW ME)ZW`!P6B1%5>?AQ-+L[H0_'?"\X5SP,%O=3A!]WD@Z,A_=AS9@SP964.Q#I M$50FAQ(1@AISP14G+N"[`.<,J'F*P[X94/QXW2R\*QHJ[HP#$FU$.KDOX7!T M/X!U7#A9CE14\]E4^Q&B'=]LH>Y?>#&W'L#"2&;;P[9&3C2%-29>\+AN<'I> MTF@'9>/_7GC[8F%5S;'P%W[T3H)*QY>P8'84W/LTUO[6^2[UF,\F+I+'GT#2 M8,%]`BK]S!$&'\4B.JGOA.$3'"CJG!8\;&%7/L/0^#!W<,.&3?YZ"AX"/W"W?L(-,$?I%:,UJ% M->;+:%CDT1##KN\X&J1'C@1DU2!!`BSA(1I&)31$`@WXOI>B@7X<<23DWT#J M)S0(F97NWWA-GK8K6C.T/+&=1[!((/>!M1 M$(`MS)\$B(!8?3Q#9Q*3V;MV6XD5#RL@8@3?X8=A&=A"PHI7TI](C<15%QX3QUXTI&PLCG$ M8RSP.?+LQIR.9Y%*S2HA5A"A&]CWVYI-FYBYW(`#HPVT'RP$A_[%RM M/UFB8(D](MHP=S='N0VC="*?-*$^X!5Z%I;@M`\,`Z:]^!.;S;W@B<$'D6=F MQ*"IRWL7(&=@FBM8-.!UAZA#[YXDQJO_D;E)[#E@=SQ@83\^RQQP>.F+"3<+ MZ4A"E(P:^CYHZ62!'NC^O^2;T33P8".S8,P\Y'8S/>"(F`.0@[V>`7*:,S"Y]Y(GY?>@>N%RO\O/WCTT4_'-P$4 M,"EDC"#BYV<,A.#X?1*6$+O/[Y?D,-\QA@-H$;(9(Q?0$['P`<-W7+(*.8CX M9','M^<]P?O)QV)`XVC*N"P#($C7T;[0A,K]#BTDD(W1X@[%W0@%80(E?R)* MI!@N"T_F\9'1$X'#3Y0',O`+R6;XCD]OSU2Q217A^X$O9\3/3>MXZN#Y/,L% M<+Q3%TYE#DK0"6$S*"LC4*ZL$'!=G_.!&`3A,M&8K1[,9#Q5( M]&:S[8-PQ]/]7[3T8Z11?AKPQ9#AHDYZ:L)+2$D((UP;A9>V5R!%#70-`/X+ MX?N=.:CT4',=UM\?]#6UI_=5N6M?H_(QK^5.M]V13=MNJY9RK0_4T^L=1(M$ M>)$X,NNC<+IS-'.I<5O.LTN-+2"QF0MF#YY[++Q+2. M'\7A@@=CG\AD3'X&8_.]Y(*O^A`06-Q.U+-7T:ST":"0%=X\O5C+N6D::1=G MQIU9[KV363DF1Y4T3X#7_,*=0`-`HKSS+A MTQ(N01*"`)*^8_$C8]Q:(=\)"3XU;):VF$1=T#$HF$#)'K,=(CI0@89T9(@) MXJ??\LB2G-B9Y,N*0SYTG$@SE32(XR38WT"H;*X6B+A%!Z.@VZ(XHV@;^ M$.P@?D+M@]>W>&D[)VSN]1[TF1"\-K0M&]6,,>C#_[,ZJFQW-5W6S6%O:%]? M]PZIQ1+O.G14L#>\O5&UM[_(NF5;!<)!HOJ MB";K[2]%VC@4]$4<\S7AURSZXKC[N+;:.^/H[;>_%*^N2ILN28DPF+@Q11!K M"`P(`5DU+:,(4+;G9R3>S30(XULPP7+9*[4$L_/VE[8">U@O[JK`J:)/Q,PU MJ*=^@-;H`FCZ3??\0P M)GRMEF)`%_31KB#X@V"AB.Z^,W=CQQNB\S_FE[NP)E[TC'N+&*R(_V%Q;>4$ MB-!V4\@$2+R%3@74\0PN/4%>-HB"NV/PS]AUH9?#HT>&NKY320#8;YGK# MK@S'TOG243;7.8RNC@IECRH,AZJB&9=]#6 ML$IP5VV^G/L7UYM]U7:E6U;8=Q$D.-R0T2T([YG/[T4F6`^0'#KHZ9F[F$4U ME\HDNA2U&'S8#;SGN#PQ67YSG3O7.[Y%O2EWFZ"H[&>XNP*6Y\`?BHN[K_R* MONY8,)`P2J[%-D"5K!3F@S+T@'"ZXYGKNU&,JO&!"?.UCE(!A`(\7A3SSX"Q M)/?Z3C3]PC/(QKVG/R(V_NA?\\0@_[Z+&5>U)0"M@WH>_,ZR3-P0IDU2D>H( M-W"_UM:,#9+ER[&3:(IE8O`?#-L_.!YE:5'PM?\K7!0A`VIIX2!16UJ[7>V?)#M?BJ2/&!LG,:?-U5KQ6EK=IV4DC7YF6FA<#Z*A!6 MW(,(5(@$Y3H>)2EFHR(^O+3[3>TQ$5>KHU#BEKEJJL]Y6R58-G`XPT7];3#] M[2]V>^GRZUE8JOW+&IM:Z%!KY2,N['K3",(7D:)0Q]/4X#2USH9A`P'(:I'\ M,<*JU1'[/,&^Y8'/DP9K"+?61D.R73(LG@6E"/F`S4/8"]E=\&^/B13$O(-: M1^"!@SN=8K1L$U!*T0;/"[#Y\+C:#CT%8VN]GMU3^[K<[RMMV=#;JMSK*]=R MNVWW.\I@J%\;;7Z/LV1,;P;-1JX4#S[4WY7":UW=*"-B+Z9T=HH.U4 MLZVMME6W!))C*[SWHF+,LOO@N!YJD=L@)UBG@3=F841E\8A\UUL`,][2UBF*3RFYE%":_0D<+8GJ^:61XXVP ML#>I=Z.&$].0)>6JO%@5UEA3KBJ]XV5WB\CQQ]'[#YNUZ""@GT.$-B_W!J]J MSE.;N=ZFO<-8;]O>?JRW5?M1SS5OAOI)L,).K:7P+W5O^ZBU5-/8Z-UM.S]> MUBR-WU@4?:#4R">HFLLI%JS^Z[JPA;;Q]?19PA?[_*SI3[]-]R'N'-:,K&"X\E MG='0[PX?V/@Z"*\7F!.=1-\.Y`$:NMWO&*8FJW:W!YZQ;6!'1.H.:74'NF7H MP_8V!;FK:E]W**\L^GJ\X1HO?$-DBRIR]-I"@3/>&X6PAI6B`G%8OKK&75OC MG^7V//_^<[&H-/TY!3)CX.=L%``9+TJ8%LD302P#@E)O2N7BE`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`W>;6!555: MMG9V%U<[`FNUVGIS1;N%C/KUYI]'%U`OOI0TJDON:DS.+P;9/LU%PDFOGDW] M]9USRU:.?15R8597%P.E_X_Y;.27;=MYA3RNOSZ@#PWQ95EE/3>X M9[[T<7@<-+=X`I M%7*&M4`LCE-9*7VN.FT#//`UW[; MI:5ND52ZW\F6WRS%MBW]NZV:AM8Y7&=<55%T'`G\W*A+PD;2#Y;/WA"-8/6E8V*;S9O<_$.9X4&\_'N:8]$S`[P;8BWCV&/1L*99Z MN),UDOG)FY/S$0^6P[X;7"\25%S]!D^.1T]COIASSUOU?_8_L1C[D[\$/M!V M&L"GJF;GF]7N=$SCNV6U+& MB)>N;.@Z:%RSVY757K^G#W7#OAYHJ'%)A"E7BIU8&<^`>4*,V)KY$HQHIMK7 MU3[0AZI@`W;3EF'%OMRS!AU#5_6>INL<(VW$B*J<&T9,6&HKC!AVUX`E#;G7 MUBW9L/6AW#%[NJQK;=O0AOVV:G?/"B.`#SCE[7``_^DI_;9\;6@FCM,"^NBT MKV5C:*A]P[RV]+;%+5.SOC@P57C@J))#0ZHP""-:_3%R#,E!&"$:T4',9..,A<7YHD^\4)XZ?;T/$C9Y0;"T3C47*_COYTXVG^E9=@R;2T M[[;2T2QSIT&%G6&GK]C`,`/3!!H9#!6Y=SULRUW3[%FF=MT%W"!^M&Q68=[C M?Q'8QQP8!:C2`,[O8)X")QUN?%02'K'-(JIV&2!U)(S`+XP##M32$",T/%Z<"^'P(6=#)_1=_Q[G M3)-`ZU*SA!6/8`W`.0Q\:U8OP='Q@%QCS;.""R@?P4X7L]SXZ=Z8Y^BD*9E'PC[U>BHP/_=\Q^\ MV^:#&%!6]X7VW5`+QN(7\W_4W\U!";D'@?4(-#UP<4*L/ZXW16LD3_+&P,&1 M49H2'/C!G&'_(_\>+V\BO)I[D6'5!JO_._ZGLYM1K+75CCI0AG+?QK&PO6%' MMHU.5^YK8%MUVWVE?RT"SB",=6AU;0#,MN4>G"I.-%+:IC+4S;:1 M`O;%_A\1`7MNM\43'?Y[`>(ZZ;FV+[/M>=_G&]#:MV4S;CD0"`QA]A6U)ZM] M%1P$U>K)71N0TNX.KPT-B+QC]SD60"085_FS70?;ZJ'/_;2S61"^@)VW=/^6 MZ7K3""C=%.A*B:Y70I2CZ^SW8.)V0^9$O^*4!/9B@EZ"NGL/MADR61[F996K MZ`"AV1D@L9O89:_-0^"FV54TNZ=HUK664KPNZ'TE%#E(4Q'_T0>+/=H/VR90 M[DRP:#JH"=M6;K%P6.E0MEQL]BO8NJ$[VI\L>C%08&I^`&)*0D,R\<>#%YDG:X'=G`Q!D787]Z!`_@(8NE+TG):M`F,]I&*,9,UA59^' M50!2A/9/AFG.;-Q]`'/ZGGU:8'.\SQ/Q+.]Z^SD;T;4'+"Q#O6N6,'S`P#BK M:=K%3+4M@2KY2BSN.]$4Q`%Z4^/>TQ_@@GWT/R?^1A5[:ZFR[HY[`WMZ^O^0.UA&JX%A-!I6T6$;`[3B0.J&]/, MSB%42FQ4S;:F&Z9VT`#J"BI<(K]]B=*],I:^#6-5@U2R%W@0([H-NB-P=4(& MQ`CD%S_A@*<85!$Z0'-\I(YLA?+5THJ75IM#M/=@S(O!WI`,5'!395U7MP^^ M?(ZG+$26"=D4+`S@*CZ].4LB_J_`&XL5RHGBW="-X$\#^-&_YS8W2+#/DUOG M>RVQ!#+7*-+&H<`O(IFO";]FT1?'W;.)LA_&T=N81EZ,WI6VO>173-P845)' M<-#,4I6VKI5=!['G9V3>2[/ACP9FY^TO':T4=-T(FBH"1<1P#0I*UE\`40O# M(_"C'IL$(#5Y-*LEH)`Y^112LLZ M(!:*Z,Y)X\\^+`$/+MQHB@<#UB^[JR?2B*G^1R+.,'^Z8"?L$$B#S`O MAG/9@/'_?O2_A&P.9YM<<8A40[`+R3CH`FG7\SB)(4F&%438#M"5SWF>T@0] M]%O@WZ/Z.+IDVI2N+61:LW3X:X`HPEMA_M7:BK5)>1EV41"O@:)D\2<^0:;N MZ@@FQD=LS2JZ-!5[?\:2`^GM^/*^<2NHJ@V-Y$%.,'4D=##A+:/2XBCN?2GZ66_^5=N5 M+EAAWZ4@Y@A.F>X[Q>8PE9Q(YH,R](!N MNN.9Z[LT5`]T_PZ50,>2"1ACZG1*#N1Z,#:Z\[D&]]L?U?[.1P-1KQMF9Y,K MGPJ0-DG3K"/8P/M620M4;WXI_#X"Q'P.L3Q0_$"V4$1Y9V5[2)A)XZTR=X\6 M5D#/6RE'YW<"K^2[X%O^&/^#MQ@/CH=:@\>BRZ*EEH@!L\_6VD55N0U0*WR; MI.JTCE(0^$&U+%VO]FR2G:^X01!_[H'4G+CUC!."EI-+%8`KMK^I=2,B.74D M8#)SV]K2QT9'27[\QY;"91J1ZW&9@OZIEJGVD>K-%-6^ZW@ MUO.YPC4\32K^6^+;]8"LSC5,`LF?)[ELS3K"K;51-R]=%*X'9!.X:QLN-9/F M#<]"O!PL';!Y"'L@>PW^[3&1H+AKW<;1#`V,LA3-C$U`.70/AI>#OTG7!;H? M*=O@NW1<6.&L$!%_?TOS"@#%!F;.&`5,)6O22+FA".T5`>@U;V`4HAJK,:H M`X6EESM0K(%BM93#MC=)-SXTU0//8R,>T:)L@[C^N1.8=JP9[?9J.;@ED/N] M+3UB"U_JM;CA]>EA1>`1&_,0T.7[I7HTYJG$R.$;\QA8BF"8+\?(RTG_:'UY M2"IN2/K[!>N(;7GH8*VV7N[7=4P@#]Z5AS>,A3^?#,@C=.41B2XG!/'@/7EX M0^-:MN19PL_AN\AP+65C$42N8N@26O)4(E-5VAW],,C4A1Q4=;.#__-Z>O*4 M,'W0'AI&TI-';7KRG`+[U)/'4@_=P:3^/7G6H7TWU#8]>4Y"T2?OR8,QT'X` M;GX8P0O\7S%&B*(X7.#:O*H.@Z9;W3X#^A"/JI*,3&BW00/JAF)LW^%/M0>& MH0U5V51[@,LV]NPU!JK<`0?WVK04T^AEG11P>HQF=O*!T&T@+%%FDC0.*,S5 M0?$W/K%'^M,65F@9*X9E8?\B%9!S&*QH21,?).".G2LUW0RT0W2^V0P)NY2I M;XX2=3^-;UYX#;0U)I[I/+$Y_"#N+66S6Y*E>R%JX9`7YYB$3O(F;>"P+0IT MQ2QV=^)1@Q)X.J"J`P)4-HP^@(=M57H`DMR[5J[!D>MW^M=]M(2)XG%5.>TX ML7Z[.;CX7VZ#X?<8Y&42']VNE<9A8%*Q2XR2-(E9O<]RGE&\B_16$$4>>MU MPU2!,`T-E!;\1[?L[P".KAM[:$:F6UI/URQ35KN:+1O=SE#N*D"YUN"Z"VIX MV+<&[:PMNU&BV3Q\RYHM$_([GF0)#SG(=X-#0SAHII':EN%32DE156^X.J?@ M<]S^LZ(6-OK:-,N M8QIFA'XQ_B<=E[C)E@]L?ZA<,ED(YM861U?I&7V[8\AMQ8+3[1NZ;`_,MCP8 M=(?7O8YA7`_!#B,V5:WB1=P)K8T5(._4!F:Y?O959#>"22V`T1.Y)$HNRT M\D"9#2EB?UA(E;QB:7CC:IBFM8=N=UI[H`T`5EGMMQ7``LX[-+2NK&O7G6Z[ M8_4[MIWUDMT-"?L88*F;)E?QVH;R<#FF,QP:EMH?7,L`U%`VK*XI@][OR@"S M.FP/=*6M&3Q*64R8/>8$UN.!"=QM=%;`>;29JT5PGYF3O!%@^AY&GQ@*XSRU:/2=X0L+V0\PN;BW:T(_?;Y$E^ MLMJ^ZN2F5!RCM^@I0%6?!_6XK457(6%_#1`UZBP*+Y336E_46?3(N1";HVGW M3!+13--HF]9AIQ$=J)GF44A)WX:4-NFE^>(.DAN(D?W`?LX-)(^')&NIBO>8 M_2-/W)[O>&C6J:]51RW%OL^O.=_Q4+:/WGS;IXP>#3X,#VV6VKN79E['.S>; M2+UT%7"<5EY'`Y*ZX93[`#W;R>NE#9R.!EX'[RJ/U;_I>)1)=>UFJ2O9FNY- M>VM'ZW4ZQ?WZH;S0NZ31P-2//M+Z9>*GP]=*^)XQ$IMII8:H"Y2:>) M'7L.'`^R=*S4[ZQK6X M+[35CEAV#S%]+]T2I+ MB<4WI/N]0G7$PE)^K.5[^Z/">/"Z4L[+=KF[]-%`/$)5J7;`JM*-(#QX4:E6 MUZ+29?0OF=1D'^[LN4^GFU5#;[;99&J-S?G>OFR!J9RE!F31@8:N*?M@2 M_H->O1Z8EG0L=E#;AJWN;9#AGBY?UPJ2_4"/EZ]FJ1/16=V]'@-'../%>MUW MK\=`,]Z]:FJI1_G1[EX+]PO=!\?UL,GH;9"KBIC"F;(PVK_Y\PP"._:@UQV" MF%=5$/C&0-?DSD#IR\..!?\=@NS'(CSTI&3-UM=RX)+W#[%M>P1P,.Q.M6#_`YV+7L,RFQS^;S4 MPO1(U[)'`!&O93NJ=<)KV2,`:;[]I:-HQQT!<#PBQ6O9I6D_![^6/09D2KDH MX@27LB^!<[,;+(H'[^6V9H^7LD;D,'SGN4.W#R"'*_COYTXVG^E9V1H:JFI7VWE8YF;7);NUQWV1EV^HJM M#.6!:5I@L0\5N7>-#5],LV>9VG47$+&R[O*%4!]1#ASQ7IO(1K=?GJUQ'(0< M_EZ;MW+H["-]Y86BXVCWVB0E-Q8=>X3JB/?:_%@-[3!=H3>"\>#WVL3+JG'( M6]^U(![A7ILWWC#+`P^.".+!+[;IV>$ MT%*P&&S!%0X?_8S?BMV)RT(I&DUAU_]X.XWC^8>??GI\?+R*V.CJ/GCXJ?_Q MGP`]?*BMM-O8A#-[+5LJ8O?4?//OW^]";^Q^8-_GGCMRX]\97H-+8W>&EQ&! M_X^WJ;)#9-P^S5GWNQN]_27-1A$SI>FJB3?&Y&O\_:?*I7_Y^T_)MP64/Q7` M_/N<;DQS.XW!ZZ5&C-155+%D184UTM^F#\(YY![KR+J"2X]S#_W]I]SB?_]) MG-4+#RYO?M3SX%YFI?2>JA=HR&!#([U61$'M66[PCH/=NZ.NY[G8'%`<)OVQ MYP;WS/\(0OB9`]R8`%%H?)[D1&WN:U^I"QW=ORSM*FT1W%`2]VC/C)*Z>)?V M_YC/1DY#2G4A)1'_.3-2^C7ZJR&A^I`0A4G/C(1N'#^8N-T'_$K4$-.IB:E> MY-._C7>*#\NO=\#_29G*[7 M=:3Y7(=:'NF*?(BH]Y3_2]ZO\/PGSYF]JF,LY._4\AA3GKP9,=\!^!O5N3K3 M[-`G>)[8J2ZPK26U'R6HFAO%\R44XQHHP'I`5M$V(P;MZ,301-B/&6&O)1DT M$?8S=%O/A9*:"'M#2GLAI2;"WI#0?AILG1D)O;H(>[V)J5[DTYSG;N?91-@O M\4";"/OE'&D3FKVD\ZQ7:+8&V%D[,JZ6Y)X-F5M.5^X'X1S'G-)L\RS4=E@" M5S(0RS,\PMF,A2/7\;XX@)Q7>71\QNKY'1W>9DQ<+&&.<$[0 M/(C<`RN7>AU@[;3+R=&S\7SL6A'[*8+\-XN[B/U[@8[30R5WE1XXZ'TZ'.(F M-\;PV&$)9X/Q\F=&.`>)HE4[X+DH#'9>#)U1?!M\8>$D"&?704BMS*+>4T9I MM,'<`IDJ=O_#O41__)L[0A>P7FD=UG')4#/;9KLAPX.28?5:KXC:ZF5+U`8[ M6F)+O(Z+W9>9QQNI<>W@:CP],]70+9"?;4O7C7J=62+"?@O\^YB%,XP?E"32 MYU$(8+ZK:,1KAE8\TN:*7%`14L]' M'YA\D5V!563]X6/[^F1#N!6$JW!]:O)(_FNQUUYH!9F;Z7GS8!%I)1$W_$K- ML"P+Q(W:;M,<&B!8^V[IAF)8 M-3TT3,T5O?.'_U[`QOJ>$^59+B>H/P7Q@2\13GZ`FF44;[*;CC5[C;$>[@9O MZ>2:ZHH35E?4E!KJS,<765Y10SIHZBO.,VGQ/$CILN-P#2T=CY9>??BHH:$] MT-"E1WD::CH\-=6+?IH#W?%`FR*+BSS1ILKB@LZT*;.XJ`.M5_9*+="C%SH^ MO8H(S`MO(CU<-+1V/EB[5Z6MHZ)@TU%PD M-]3T4FJJ%_TT![KC@387R1=YHLU%\B6=:3,1YT+.L:U@&8NIP@.-WS>[K:N&_ATD.RQ50Y))C:@BGA'-7M;*AS<^K45*MFK3!64N=_]?_5D./%D2.&-QIR/$V_K(8P"X0) MIGMS#[`)D8"/UQ!)8^K55+@TYUI`<&U.O5J;>JR1,,9O`4JR:&7>; M-+C_X^;7X(&%/E4!S0,_"D(V'@(JPGGH1BPZVM2)&I]L,SCD_(^P&1QRID?7 M#`XYUP-LZE\OZD#K5?]:`_0HQ3E'IJUV:EU0<#,-POAVJ:'R44L!7!_."Y[6 ME7=))677--]W' M2:F7<%*:HJDB]G%F'-:-(A;G6I^_+"#2\/@+*.>5TOBE+.XG!4M8,7SVW3JFF4.;W\HE.IG/%6Z!)U08>B6W5+ MJMWB4-"2#?P+.Y(:W\9L="07>PG2I$#5^UQJZY.?+*_IE.=18UOLQ,E*)SB5 MDR>L'!-FM7XPJX>&N>D\O]E!I$E01SN(RRYT/)^3:*H)#U2^=;XDT-1(O88S M;^KB]ET7=PZG7__4UIIEDQ[Q:)H.CFCDSJ/:]L:7IN>X*3. M(5.FAODJ1SPIWFY:M_2.T7BT=6E(LJ[%]I>I$[';QZ#ON;X[).G9MMXV&UU[ M#J+O.EB$\?1W=Q0&7WWGU@GOV>$*2X]/B(;6;HR^LR!$2@_Z[+/+3`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````(`#4P;D/IN]@S20X` M``.Q```5`!P`&UL550)``.6K812EJV$4G5X M"P`!!"4.```$.0$``.U=;6_C-A+^7J#_0><"AQYPCO.R;6^#30O'25H#F[5A M>XOBOA2,1-OLTJ1+2D[<7W]#O5BR+_U^ZZ< M:^M=XJ.>P$'/#F"ZMB[/+Z[:%Q?MB\O)Q;OKRQ^NSW_X;[(T7ZX%FO M+LY>I-/Z477X07"*1WAJ^1BNW?42W[0D62PI;H6?S06>WK3$C$I?\N?OK\Y5 M_6_NN.TM,`.JSCUSB;ONLRD7"Q]URU+M?A[UM^`+//.H)\6+KS]NJ(T=5;23 MV5KG6*PCJ/G[V`6%4WT,I@^$P0@11(=<$M5%CR(IR91@ISCTG.V^)8DA$O@5 M@U"@<7>.76(C6CZM/ABV!>Y2%PL&P[_"1_'8;ZUTP#TDYP^4/\L^<^%.L%CTV0H' M>BA+T>O4ADMD\("(^!51#_]"P!46]GP-LZ8K)78EF)B/!#T1ZJO-(T:JO--U M-U4&;*2T2H"U\2W4,81+Q5&B?'ISQ&88EIQ[Z1)0(.S$W4Y['`9%N.2)8IA5 M6`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`Y9A)L?Y`T MI,[803<&TPEZT7,JU(H1IIM-S"$B?C+$DKB(ZAAI2AM![H>3.J#!E^9P'=#V MK3(F4*I$,A6AP_^4<[M"U-_2=GM(B#4$ZWY(IT&?KZX15O'I;":!W6)FL&Y. MR%5PF19':^$?KFF"T1V>8M!H)SS+RYX"FL(UP/V),[L(]$1Y$^COP8WF:QP= MO.5><0_7,\&FKYS=F5+MP$;"XGC_HC+UP*[\S+GS3*AN<P+41.-]US#4V$.6)[VL,=0)">:#GE[!!/ZAP$MP M8>]?5)8,CN*^/+Y;GIIF&/$E>`7K(54Y\,Q14W"I(G6P@UHJ&55,C`,Q%!P:)+;*)CDJ.B"3[I*=&I##*2G-\81/6G@B_V8KZH,ZX+MRPN`+)_4?*[\_.6]8S5 M74#_;_AK*0@7P.6F==FR/`G@^#((>>O*+GOBQV2_/P6R^?S#F/0/IT!:XR+$ M+/_3-)8[2VR2;,Z=B9C\Q0F13U\P8JZ7)\0UYX9]3/[JA,CG\C]CZN^:0STE MVDT23PO/-CPO&C3$!WCFVMZ+B9_.`&?LIL5T&^1X':";%0C'?!OD>^7="]), MZB3K!CE?KV&=5FI#_K)!2[5^RRQMO=X]BHY7J?.7G;#S.9!KK_\I*9=)'=:7`@I2NKAHG-^I]!E:6:NE@. MV/V+>O3((W(>R%C%G1H>A^L988,9%HB"`]YU%H01Z0;9UN$NB8[+@5IFTA@B MFZINM/>X>H[*`R$/ECB\\7V+IUR$*@3:@R6,@D!@>&`&BW4?YHD?2D)-F#J` M;]9G,%>PU(UHE3V:DR#@#(?Q%D9YJCW_TY4VE,+BBRW:U`NPZ9-6T@J;Q)T] MVW9+F4`*)C=6=PW.[3)&4,+*%TP^-DO86QU>36DCR1T1D'"0=9CWRQE%>U`G MTDH:2YY)<24^,X$1)7]AYQ?P8D-%4"@'+'&O5A#U3,V=I][Z&F)P1IT#3DME MW9E)$9%8O8T&!O,.(G3*_:/N;)N57<<,"W]S0:>HFZ^-QE,YW.-D8+5CE1MY MJ%.06>RP4.?_5^O,/0R`?:' M>L&%&SZLJ![^EYMTU*'`"^(MY.%;&Z]LK#XWOH.X$W00`E:)[W#P?]WI5Y$F MS-SDA4C<)OXHP+]I,#1@'A.CH^&6JZJI([Y@Z^"P.J:7_?M@LH3#J"WE[K., MY'7]$56!-NK%G*)LM=>02JM;+U:ACU>8 M452O'FST^92YB64T40^.X7V6:`!2[[7D9INK,4,'S\KY&0J^(N`/WZ[5STKT M69AUQ6;A;VKH1[9``S7B%S@31_!+:Z!&_#9!UFOYI37P=\I!H=<+T#IX[3[X M09;HIW1Z7&KM1F85DQPFO&M#>*3V);^9Y:>D;J`6_`H\U MY*MKZ!40&V/'WS"/9H3ZT;1-@K^.T<%Z]6&3$3YF5#"-?XPH?D2N.OQ?A[__ M@^U@N\C7'C>?YAW1HB$)3(F;D9.5*&`F$6>Y64:"JYR=1X8.^17'79HZ(:GLY+,TZ2;X<>(XL)C&$KEJ4`K"D1J2&=?&$GG7?(ED M[!*E2>1`W*5Y.^.T17-,N-#(9S=*5J6,+0K-C?;3UJ?#&U*:2^_-%$O&/N[. M--O$I(U\1NXX^OF2)!J95'6<8`HE*9^`"Y-3+(>3CL]/P'O)*0S=3DLCWY0] M3A2O3:33W-`Y:;71)'%I+MR\EO3;T"4ZI@LK*S&OGF6]D"VDO&:^3-[JJDHM&7U]RW>>N;&?%3Q+>> M)`Q+"8XMD8,IK#92_>IH&!B.E7C%>C`=DQDC4V*KS97`R*J;ZYP26UUGW[RK M9_Q'2F-B&^A=YP\O<+L>N`!=\"\53/OQ@B(7OW_=B8*8)##DTXQ)$ MZ=K'2E8X?D'@$U>W`:GG8/\=PPT8Y82G\3)-9@=.O34F=5O:,+C-*^*_$#!; MPIZO08<#[P_F:<(4/8*1@O).-WYX?,!&2G'48Q/^-#?-I3=7OZ`-H>&]=,E" M+;TQU&GB]73_=YDC7ZXN\@_EZRM%+=58(\":8MV<(JNKO&(%JL#%@^?"=]&! MF6F,/KJ!OUZ'GL+:-"28]]["1R25+S/AT41*S*,$;"BDICY%]I>Q/8>F9/#Y M4!!UC/G('6SH6=`=*>_OKAE&%3J^_JF>/A& M0BWG?!AM#9%PUQ.!8*3M^H(=>T\2_^FI1P56-;/XOG&?\,V[OYO;UG(@9HB% MN[*P&DAPTYW(HT\Z^(E'@^/*,?<)P+NE*L'GQ/E%<4S=>$;O5$=>M()8$?[X'U!+`P04````"``U,&Y#^)1]\_`N M``!Q>@,`%0`<`')G;',M,C`Q,S`Y,S!?9&5F+GAM;%54"0`#EJV$4I:MA%)U M>`L``00E#@``!#D!``#M?6MOXSB6Z/<%]C_D9H&+OV?W24"3:UI0LN4G)%?>OOZ0D6P^3%"E3/I2B!78ZE?!QSB%UWN?P MY_]Z708G:X2)'X6_G%Z\>W]Z@D(W\OQP_LOIUZ>SR=/5W=WI?_WGO_[+S__K M[.SD\?'D.@I#%`1H<_(/%P4(.S$Z>79>HS!:;DZNT
]_/&,S3A[?/;XKX?B_3YZB MD-#1RY43;DXF07#RR&:1DT=$$%XC[UV^:)#C>T(I&I)?3DLHOK[@X%V$Y^=T MFX_GVX&G__HO)]G@3Z_$KTSX_G$[_.+\'U\^/[D+M'3._)#$3NA6)K+%>%,O M?OKII_/TK^71%`XOW@TO@_7C>?;';#3Q/Y%TS\^1F])4`9T3X0CVK[/ML#/V M*WHH9Q\OWKT2[_0_V88_XRA`CVAVDD+\*=ZLT"^GQ%^N`G2:_VZ!T>R74SP/ M2'I.[W_Z^)[-_[?KR$V6**2$\6["V(\W=^$LPLL4ZM,3MN[7Q[L*^!C-DR`A M^#6];7%^=<_9T'/I:N>'POI(9_[^%-/KR?:8SF[]D)ZG[P0/$4D_FJO`(<2? M^!@U.(0-!:/%RCV72@R(939$W+I$)],9P^8LE+Z MS;'SG83>4[)<.G@SG3WY\Y`>M>N$\<1U*<./J51ZB`+?]1&9>%YZ(9S@L`_^ M"$`9I-P.C(GWSX3$[*QN(WR/XL\1(?2G:S](8N3EOWA`^&E!/Y,K)W"3X&`* M';ZY04H\1#'=GW*&8)/N2[^I)^0FF-(?D?LHIE])=U.FX2.[59ARFY1#'8*P43@, MTN=JX81S1$7.#8E]>H&05VP[NXKHH>#8?PD0_:H0>7`VSDMPT*?;:K\N[D-. MY_3"&?].-78Q>99\\AG'3FL?H_@MEU'X%$?NMZTE2#^BVR2F?[LC)$D-M8/P M4EC?)'=E.TU7J;KC4B%&;9^#>"IG.8/04F:5+-/5R5>"O.=H^P67/N`2"'00 MXU>!XWZCMC3=GV2_?\!4;0OG7R(/!8=@VP4XIL_VDGEAF!\#A>1P59"_HD&8 M']$:A0FZQ='R*69.IKGO3H+`/_2[DJYKE.:UQ9EHO8J"P'F)<$HM\YR^]9Y& MSRU@@I1:Y_'F&3OT9KC=(*NWD5$]](6@/Q(J16_6G0ALM0W,.!!2F?D<[?PL M.Q<`F>*Y$_I_IIM1(4NHB>MMK>&R<5QRTA23"V2>T6M\&5!NH4^1(\+6-V)N M'0XV$W4'8]?$O7%P2,7FSA+MY,J)-P%#[YDIND:O0--67:-:LKOOPFOT$M.K M]\7!WU#,]K_Y(Z%J9.%<8<*-JOZ.'U+^SR)6F0G;,>_I#,:^$M?\->P8TJX) MO5/Z"Q!()U=1OA$HFN8OAHI18=M44]A$GVA;&Q'2.K MOJDUZ)N_V+I;=TV*DL&X1A.,F8^4_:'CNZ"SK44D,'\?]#?OFAPB4[OC&Z&S M;>?\H6:3=\,.A9ODZ#G85<50D(VSS?-A:3@_IH@[07!ZDB]<1F,WRP_C<\]? MGN=CSMF$#N&A6Z&097V=>6CF)$&L!]W^]./`&BVI`MH:U&QVEY"F.YPMT?(% M84TP*U,[A'%!E\!N\H+.=I31@Y2W0`ZOMTM,9'F)%9CI1X9"CZ5<9;]E2YE) M&$NWIIO33[BR8\"RZB+,)5.*'$'NNWFT/O>0?\ZX%/LA95=G[R_RQ+E_H[_Z M?4*W]M(\C,"9;Y>CP@,%OYSN__V\-!FYRB^G/QQQX/OF2XK`2O]<_?0I`S-I[I*EF>Q!T[U[T>"9W-%"8!9*,1# MK_\/;41P[8T[&GQ%X#[UH9)I$K.\;>:9$@,KFW0LR*]S'48`XW592>D>FEL_ M0/B*Q3,C+#[EZJACP?:(YCZAMRN,[YVE\-.H#^L>NL]H[@39WI-7G\>`ZR.Z MAREWRCYMEB]1P(&H^O<=/(7"-L%5R*BVMUTF5_S4;)9\S@Q'2P5AM-TRXO&Z MDPA["/]R>O'^_;OW]/_HZ%27_<3L4N3]??^@I&CUYC5M.H" MM0^]1TV@`!4H?AP,BGM:-KT@4&/YU M(!CNJ>L%BO_1>Q3%_HX"RY]ZCR57']\A>/%^(`C*#;<"7R`%A^L=K6/--=FW M:.Y9!\4EA3K#/?]Y'2&!15,]N:WAJHO/S^=5MW"WKF+%`MW6!MG,(2\IE1-R M-G><56:5H2`FV]_4S;/\U[_GA8PLDV8:+Q!^1"[RUVEL\1[%.9.KF6YZ<]N; MF8=CE5>$J*%1&PP$-[4>RV58C:`+Q@-!GRR3-'";W@=6'X#1@GWF:Y250;.J M07HWIK-GYU6,D]8J()CNTK(?'#\M[USYL5-W<32-!H$\39`3`9K]$0ZNR0O3 MB%WA=:\.@H.SX:NLC`&'4HFH];$04+/&`RRCD_Z')4.MG2`M@8BO'(PW5!-+ M4P`%6*C-!<&JT"VE"-2'P<"ZJZADR8B\O$LA^,TS(3"Z1C-$;[:7UW[)/US! M8`O@OH]"5P?TTG@(Z&^6JR#:H&VAEK(^TSQO*`&Q]K2]8QDG<_:A99R;*D(W MKZS/!.5ROT:1]]T/1(J(TM1AA:K:T[ET^03D+(\`AI"UJ=G+)6X&FS_-1EP: ME!CEZ<"XR=F?)7;,5M2\ MO7EE/0'0UB>D8B^IS(3!*%I1G7;S$+".7Z''6,F*>?&HW!2B(ID"@<,C8M5Q MR-N6=Y:\*ZQAI^N+,%&8"($/OP$4%P-)2ZH0[P\$A9>7_2<8 M!`.GHL9CB8ZCK=6HZ#%'BZS)/74L*M/@?=J%:#[8%\)71TXN%`H<[0OBJ^.H M9F(6N-H7S5?'5:`L%LC9%\37_1)+V'RT+V*OY+,N(Z7H)BZB]O;E?&GCS%=[ M"A3MR_?21E$Q$EW@;+L44[V:I6&#EH04RHH8*_2V1S!X&F>]6Q!FZM_6F,JRB^TN0ZH';(*20@V MUP6U0UJ4[V)S:5`[3.7G"60<[A6;-L<`JI*GZGD?8*VI'D'J+BZ;BZ3T,%,7 MTN!54XWE)_+`D<4U*"J'J6C,/?=YK*PEJCJ%C2`5XH9)X%* M_D"!M;UZ\J$68!E+-079Q@JSZL.)L,GP%)8I3L'V4EY9/,B6;2O.CQ?.!$[O MSTI')TF\H#?CS^(@Q9CLS;`"`_;&D#KT^6@K(!?W6U*:,I3D\@Z@^?W#F!C^ M%M.Y.HNV;1N\]CS<9C)\2+\Q>(Q™.U])X^F#IUD;W7UUJ`\^YI9H;G6F M/GB46Z+([XD"Y4^VQ2D%9N;MORL/HX'7/2(-[1UD,T!*56OO7K&7C5T![/RQ MUD`]";W\:?&&O'+5V39@EL.DB,EVM%6V$P@=?Z4;$^:=I(P[O'F-*942GRPR MWL'REP04;9X'@@T*$78">D69L(Y--!JH=#\EVS;1-X--"#AW,"3<\J^M/FKT M%V5TH>I-\0D*:%<=`P(EU3(SAA#.2S)`!*]@-#3D&1&W^?1R+:AY'D@9^!:D M'!C1">R/LP+:!IJ+QX-"W_A]\D:"-0EH"$-G+:'I[S%R"+I&V7^;#N;PA6VB MQ]>0PA8PK]/?HL#+F13#91J67H_%/J%_NJ;_#.<9<@W&:V?;Z=%N_PD[]IO? M']/[K/;O&JU1 M$*5EMW*=1#X'!HLT,5/$:'9_AH2M@5?L#0.):KF(&B=^]#4D*^2FV0U<8[QY M?*^A/R@N^P9CH%M"16Z/".??D3]?,,?AFFI)7..-74 M#-U5+,)T#[@&#JJ]C,VXRCSF>FO`A<0T_>F5,A-^`*$/95(&L=ZYZ>&[O+R] MBFYE#TBMR0O7&0E?DM\QPCN+H0\%ZZTP58C]]*%.O17N0C]F'\K3&]UIU=1\ MJ3W^X5.7'U]:+`C6#2L&^BJXM-D'@W;Y2-[8Y5*TH.K2EF,=&Q!J. M.D?Q@\WQB;91TS;LJAY^L[@U=H=D$8?>=?MG@]6WL?[NMT'TG=Q1R#&BZ`/$ MP%G#1)1>B66$8__/U,9AY"6[9N4/&"W]9$F:'Z1IN1A$['_B_3/)]W^.'A$U MUUP_0!6=_SEB)_2`H[5/3_MR\Y4@JA'OC/V)&_OKS/?:\/YL%UN!="/)&F&E M)I_GQZP?]%W6(=B[3.+[*/YO%+.660(Z*$^'P6V03_-R(>,;=UK("9:`P/$: M4?O-]5->0W\.,@84>F4>),!-:>I8:5G$FYI%`'_L6!]JK"80$0F+K8\"@K3" M%.Y"R<,G8CPTUK`+R[S)MC9FVWG68%-KI*V#4'VJ'3AM6T>W08HWURZL\C"B M-D;;>79@(^YIKHR89`D[<-SI];E&W&`_:"Q@!W[YHT_;"\9]_$D95Z7%(&O& MI>*X-&2L%M_%U7C&;M[4M6SL"JBJL8#=^#65;^LO9!&^F?I_P'GR%K`;OW;G M*5O((GPYSB@]/'D+V(U?N_.TS6O'DE$HF,4U"[T="TECI\U=)!3G`V(WQ0\. MCO-_3-P_J,6>.N_K#_VF?Z)JQ(4<6?WEH/N"]*NC";5U4\?0=):V7V2])5FN MZU5$A)JA=`HD#L]1?@OJEZ,!$?$\*[`1/@.NBI9X`2OPXS\XK(8:=RX(5CAR M$?+27,7M%S&=E1J;BC!JG&$/($/>2QY M$85$%N,2#!Y[:@RG.\53LEIE!3%.L$TJN0MG$5ZF9]V@WZO.ADLCZC)7H_JT MI$HDN0^U#L>BF$X=ML4U#\RC6/R M+DY62Q]*/HY%(IW091_J1O1#L7)J2!-;BD8&]NH)I@FB%ODM*&.O2M#55=EE M!Q5$L%?D=T"$O:2B'1T^VBO63=-!EN12T,->$6V:'GLI3`41[!7"71%!NT9*%@/KHZQ MEZHL?>CJ:Z/2ARRJGJ9<6RGM)IJ:R0G6<[QK96FL5W<<%CMM!CB5Y4062FAB7 M":'?*2&L(R"9SA[HB3'\\ZS5IV2Y=/!F.GORYZ$_\UWF!,NR$-@3$5'@NTSX M>IZ?(5.BEEXC.L%CK5<191`X9IH^M7\0$;_+*A@)TC"K!HJ\F8MH-$P;K)+,-8&V;*T^6["L3T%@Z M!0*'6\?'J5YVN4E!640!Y7\D@_,J<`B1OMRJ/'W`N`$]4GOW,.5RU?V_][_Y MB$#*3/'<"?,$:&6AMZ?>EJ71@2M"%Q[VOPR4A3CSS(![9TE_?,9.2)PTRBE_ M0[IYXL#PT>8[@J_HR5T@+V&[M;K]O/HX<^N"E5CN3R]/Z?.0G8MP/)RQJJN5[!Z*$]E4\$5V M`TL3W8L$&50V=J=IANL.,,IDF-BZ+-%F?U='I)';L3:_MMD1082.()L39#JB MA:YKR>80RSNHF#_AGH_@P73?X6_%:G>H5:#+%*Y=>0;38 MA+CLZ,WBW>;(H4+..\Y79$_?1O@>I=GC]*?\6;;\%UL[XLH)W"0P%UI.=_'7 MZ`FYK!#&3Y-M@\1C.BEK&I/$>4.4^JNG4L>_@56'$A"U)>ACK.-S^25GKINP M.@8"BL\E;Z%C<&/O:__IO7[.O/'H(O??\% MD\M(O>4#"F$08[L]ICM]R?)_F"#]43ZA9\@NX8J&!V-=WI$LJ-+?DL]0) M?(1;H2*%X'W#`PL]Z?HF3`LN8_XL*!OE(:++Q#X599M]VMQ'<>DS*>R2,G'* MI@O(F\P4>D_]5.O?MS3[T,S:$%KC@9!?;O@+2%('NMRQAQ04&<_&E[>'-LQC M(TW1:IPV(%R`DEP%D5AIXJM\#C`6#SCO])9J4ZIX<&>!I+SGS0M3.*:IR)?B M(!X_>LML])85FN6!#%WZ:H+936#C($?03"J-2QK9.[@-HQ9'L8QN5H3>A"TH M3"MOE1B5X4]^@(ZX8QR#(;O/YO0K7155D)+'5Z%L=MD=@KA$XX+WOG5^UCRE M'SX)\ZTY';O5#GN<0]<]88ZB+NFFY$$Y=VON60/M"XS;]]NNSGH-!+BSH!H) M%*G=)0B+%/`'[+M(UD-`;?YH_YNU_QMS'/98`@OA34(O#WV('+QM5SDN]`K9 M%THKC!K#`9DB[>\:)S-$[<`':&P:(*6R7++9:#)(!PVI!FY3Z68`Z##&WD?W MB]H+WJL`$)H?NTBL!H1^5>Q-DU5$_%@>U9',@(E-+9?TPOE.\.#0F]<0D>*- MA8$:KR),:<@^[<*<:8!>-F=H^JB??A@90-G/=9BRW_Y>?$$B%5`R$`1.GK(G M&`32F*F`@6XE23'A#(2']XI^('/*_;-Z-WF'J>:)`\/GH"P(RRW%[<,R65\$ M@8CE6%A*\V#:^#0B(!UJQH+EK)R_V\S>N";U5#W%21#T_!IBY`0,!)8K/0T+ M$2J@JF0"+/S9R\\:\.]-`('_Z=>(6BMAVG1A%84D8J_LLF:]5%\GB&BH0JV6 M.I8OH5DO87:,2"L8H$=`C2`:3-QFLU\#607>"F[.'XRI"O>%CXB:QW*?1]N< MVJ"'9=-7"=0CIM'U)+?$>AS';49,9MR!=S113%44&Z9B#/GF$_B)JN48FD+8 MBN1`I5?)52W?:I1`ZDL#[^K4(>)F\2[*=/PD9TC M:^^9OHL"4L"9@KH#J4!L!YK`*%>8"!)JJ3[G)0^Q<,>"0#T&YJ!+W7I=L#>& M%TW3=,?8,CZWY=YUEOTUC%X(PFMV`^["51)O7V?V4RE_N4FG:[S>8GJ[D7:M MMP,J(B[:+SH!Z\W[M$`H_A5'R8IBDK]>Z`2[1P"OG%01$CX48VQ9X#>1BM.1 MQ*C%XX&AYQ%=5G2J-!48IWW5]S-:HT#M>&230?%*60-)@;F02E#9#%LP^*"- MP0?+,/BHC<%'&S#(A5#J*]^_ZFKB3&F-_B=XF*%\R=)N8D.. M%G^L%5#+GP\3C.XMY$"ZXT"3+G3>J>K(YJB_',_Q,?4A]'!4,JE&:NP-7!R7 M7`WQ'7L#'4Q#HTE`?77%7:6,>4;$3QW(;'2!YBHUR515<)* M-F=(=4D;95,%/,5*,5.GT4O'_=R,LS_XG!>E-!\KJ&5%CI!RPQ(=1VJ/\_K: MHJOKFP7/`#PF)>K?&/BC99TC+W`8Y8C_T!_VJ!!@X!ZZFO,5G!_HJ!\Z_F0N M37AA#9L+*SJEP(=]"MA7<-$I!3[N4V!L3W?<-RDE7GTI-[<14^GCDXL3QLT*9CY(4:6X9*?;U:..&5S0V)_22U@K\ALG8D>)1\3R]Y0`D5/ M@_>A=7L\B;#!51>.-5Z.53-?S@Q.`<<+(J_1+K MH`.H",$53L+F9SP#N8O0_R-!ZO5W76T[(%HJ.42ZV!*:ALDRRQ][],FW6XPH MCXT11B1^=&(5>DBGVX+;WY$_7\3(FZRIK)FCWR+VJCD]OHTFDO)U+'"!9YSN MBEY'/V8GHN8&WYLUNG@Z@M_A MB(>E8#[W('OHB`0K?^V]\L,`<0!%O0#<6],C4O+5QU[56T!04*2V@==AZ'O# M.K3'['4:OE'GCR#5RL;W1EEN'*?F2:3$J\P$;AO'X%)M%U<::U&SNV:X+7OG M59(?QQD(#Z^=[]*:PJ[)[RD:#0_Y]O6):['?23(!'O[]9^FET)>&]QAVH,8J M57!D_FG>R#ZWTQ2\%/4K^<85>[4_PKRHEED]T[`F>^]1/)T].Z^"DVN>-[IB M,TJQYWECM8Y4W*$VP"SE/H+!/84;B&>F:N,=(0GR1(I.98@1OC1UXX@RGN?O MT?,B2H@3>M3&??Z.@C6_J[/B)#.OZ\6L&]+<=R=!X+-Z7EXK4]G(CJ#@7BGY M6&L@*=]MD*Q=L6TB?M.[K/U8[C4Q@Z;=.;8-!HT8P>%'G#1(4V7W?8@.:2`G M])WT(<*C@:>"[MR'0$SK+[KJ$^A#Q*0UJE*W%'C(H[//5^R"[D/_SB8OB@1I M:_IN*D>S)$X7>X-0IK"3V]K@J>:FT>3IE_UIU=2`I-3ZL[POTV`[L,B<6+(/ MT$8\)8;;86A:8;@IR$6YEVSW#2IXA^#[+G)Y32!I^]551TE@(F M]:9S!H+D;;2'%\CS7SKY*V?EQTZ0)L42\340(*2]#C"VC<]>5L=9E`74LRR3Q9L\)4@ZAU(<8W)>7$+'WYS%Z7BH0N'0(\BA' M6%$MR,FT#P=Y^PVTL9?,H$)VO'#QAA*1?\E4Y/!?8A`J2''%79]"#RIGIU:.U2H>-->W%@F<'<&6T4P#C!"W$2$#CFV MS6&YSLG2J`38'+I3I4X+`Q(\>M<8+!#IRSV.9Y'GR^#"O:)'KCU316F&?*8IL6+PF]>5C[,>H7?A`Z*\S#-- M+N5]!TG-6@^+FU?VH"]I[OT#!E,?3R&U<[J^P+5-^DBG-^;K-(?%8Q0$]+-B M?^R>9.7->DXW`.ZGNON`*M`5TYEA%.OGZJ,[W,5U8#S MB]KR'-Y#$I3K?$'Q(O*B()IO)B\DQHYKO-!(8^?>4Y0R<>12CGWMKWV/,D_) MHV?=[PM&S9=FK%YTL'I&>"GJ,=KAAH.YC4J/\!UC9S-]14T"FG$AII>(4@R/ MLZ?-E!&6_W:Z7^^_/HU7/KO?UTIJ"BW70H\.O8?`"1O?$^ADJY%FVEN!]VOF M6FEFW"DR`H,'Y]4J9D"H8T>GIH$EJ'3I)-,W%8UXQ=H\=3C`N*M%U.=;LX.. MRUI(_3X^E0I)_XZ\#^"Q77ZCBF-9PT5#QDZ-S`&FZAW]F([Z$8*G]*EU,3B& M:\3>U%V[:"2P1N#;11B0:P>8Y\*>4-4PGFX#&-"6!7ND`HG877$4DWG\\710A-K3+ M4.+*[<_M5Q0B[`24$4R\)?T*F2B-_37*[Y(T7J\V%^9=3LH-T*XGR^?\/DBR M)60S+,)`ZD25SQD$%@=UF1Y6]@5K4$:UA07]_*[1&@71BI%+Y;M5F0G;K\8, MGU?K76-RKV-7NW4D=?FE;T8/98"V]1$/156+A'=.JT7*%.1U]>E`J5@!-W'5 M`F`FD;8CKM7\;2@I!&6LE:1<'Z(`VI@K:N;P'OB!13-;E-MWH*[TV']W-/HH M,5)=3QZ4B^J14A'LO-8$XJDI^1,J#[BF)BM\\TY^(X^;.58FIH;L* MA-D!@JFV(2M(LYPPL?`_5%2X#A<\P2`C>U_ZT1R%=QYRQ5OOC1E=;AD`?_<] M=!?.(KQ,F57I\[^A#`53AG25D)CR-=SH%&V]GI%;4'HN;O_XBS_VWVTCP/\1 MS1#.%+4]QCV98Y0R`#&%=*;#N)G2BR2Z?+L_FTD:=\)HYD_HDK'/9[?"8<`. M*\UOD%QN'G#D)6XJ+'*]2-5A97`O,ZS MDOX@"5/PQ\)9M2UUIUT"CQ;S!']N1.R'/52D"SRN)KG*D#VN)LE?"#SP=*+1 MM=*%8!V6:Z4;^C3()O#T*'LH)=6`@AQ7&`V1P.TD-NW\-F4[A'%M&5&C654+:N!0'/;I2BNUT1H%\OA>V) MEM"[B@)JU$9Y>ZF)Y_D9K"6I#!+O\/Y)!3^C^6V$)\L(Q_Z?&3`"?[]PO!F_ M_M;X%;E2J@/,[BEVG-2'`.U[4!I@SR)%8YRH_O]'AS:TTW#NT83C)RL>^;>4P\-@R&^R!HT]0_+%?RY M_)4UA=>,;F'HO)9+UGW1"7*1([G>@J$=P>$'B!K/(9+$;IHGP=RCW2O061?K MK+NU\$KP1QNC:KYXZ0X]4AIA/_V1^QB=UE1@"J?E>.M5: MKQ*,4^\W'V3!:`C(K]%+?!6%:X29@9+]1'GS74BO0,+84OF^BMK8:2X"A6M%2ID0-\43( MJ*53C-R*++[Z+ MH\?0>7;P'$D^"LEH>W/6!'O][>JWK?M+O.?^("-[4WN:?J!LURR69MFDC7.&6S&X>%P@[JXV8?BU6@>#S7YQ7?YDLI1ZUZA@0*/VP&5@X!$U#M/6I/6-?YGJ3#3<'S_/W M2`<>P7`S\&#D-CHD]P=!W.<''+D(>80E1A0.L`B+G&3B\?#0[VP[9O0IP5^= M8>CLHV@6S>C:+EK%33=1.!@D`YRY-"4YJ<7?P:"3MSLHC;`>0J#(5LEFG\[4 MW`_2*88J*^9)D&IVLO*)VAA[6G&4@@'T2TY;U#U'U*9B8>[;"$_C19ID5F^! MK-2L0W?MGE&%P2UM$F-F[9$JG+5-52;R@9%]R9+Q'4+$&N"5O3#JL.W-A+Q/ M2AU_S%*S[NW=1?*R?HM;TNQ^38T"5= M>L^<>58M/PWO$37.@[UB/+4Y;[M"ST`87ZT\S]A&8VW>H&KS#J'?;T[`(EBZ M/ER5:3!IPN('T MT;ZB$%.UN1QW97&4]KXI?RC:]9S1XJCM*Y4Q5X9=][046-O[L,?!)RW*HRR0 M!RHT/P+RLH!\@;]]'-L4_K)TH@+_GP:+OS18MR/`#_9I)48)((H.%@08LGP7 MAJ0*](?J@+L4=74<2IG'-C=\.`J!9*ER-C>,.-;'+,GX M@N\Y`4\>84D8^%.<%A!'GCT$WK;/`@I)B`+56PZ8'Q^6/E"0SUX/5;?D:\P0 M*$ADKQ.K4Q(UES+N2'1AKYNK:\XDZ7M3D,=>)UBG-TC2&*.@S1O5I[6:G!34 M>GL*ME;J84&H-ZQJ[W6***CR=G5L88>2@CAO5[V6%X,7%'JCNK9R2YF"4F]4 MK1:4RA=T>:.ZM((._>'MZM#2>L."0&]/BV[;EJB@V=O3KENT."K(!:5>#^RA M`L4FQX_URMB*4[1<]FD31I*FQ:H(V9ZY+"F]+6-4Z]I0?$;V:M)-&%6[912) M;/",0?HAF2R@;7X^6+O:$OZNJWV^5I.Q-TS#9(4N-]]4HV%1K-+B MVIQ,/[YU,O$*2G/:_,52152AY/Q-/2C&>W'K@WU!"#VDY*^D?;#/0ZZ'GNQ! ML8_VQ1_UD),\*/;1RD=.E1HQ'/4],:C'M!Y10,_8>W!PO"GC8>`%+4'7B4D0 M;@*'W]24,V`H/P9O&"]$[D?)DOL"0E*@X+E[_7O M?KPH3U%`K\VJ%E%B+\REANKGEJ\F=8H+->C*?Y$V;E1>`+8SEAJ@:LVO=-8: M8Y'F'+`BGEEHM559#E[Q)"Q:5.4A_$)$K;L\X%K#-E0\6([!UQBJ1AMU6;N( M3/8P"<7XH%G$K8CHM?#6M9!X@XJUM,2_S372C;*`/56=O!#T1\(*%]:IZZ`S MJ_H(K^&.MO5Q=&BH5S+&7J^=6$15%M!DM0J'6P"[M!DX?ZP%4$M-3-Y0&V#> M2%]O$(VV!'*I@TT\OM?0E[V$H^=AC/4>(;0&U3=%Z&1I$G45YPJ720_8=Z)# M'*6N.4#>$'7#4"*&AV#W-J#7*-E[E"G8@*I*0B1\P>+1#6PW?DB_.Y_UF*1?8IJJ,L5S)\S+ M`:ZBD$3;CIR3T'O`B-`Q>8-.SN3"C?5,P;ND6O@W/5?5Z#`ZCA%C_)3YMH_Q M;4`,OBU$C8Z8_8&@\$K=&-5!HR%ZH!TCO",545$[F2';+DH$,<^&>F3L<#]3 M8V;.4/6)![J`ZR/27J]HSUDO'>*3Z:P,-L7BR9^':0/W,)ZX+NOTXX?S+9A- M$O*@)8<2C&M_(KLV.5^0PZY)VLR,T6F3_6\3^=7GCYIC1K%[]+UT)3'E`0FU MW-.O58?PVLO`I%[6FPVIODC>-,\.;-2.JGD>B);+&O6DO6:OHB5+#,NDR"KG MH'$ M3-:.'S#J/T>E1QP64>"QWG(.\5W6D\X/$O:"3#I.H)H871JV7\&$$MQC<%&K M[0FY[!U/'Y&;5S=(Z#>19>(N5\DVOJFKO'6PT:C3C#K-J-/T7J!A&=\&)/%GWWGQ@]2%D2=H>]/PD;DUL!_.T[J3KV'T0A!>,]+=A:LD M9GG[E.B!GT;1E`6XR:U&N5^W(G9DSAQ/Z8N^C?36]%V8V&/4CD;M:-2.!J,= M&69`X-J4>;71J(0=LU(LTS998,AH4DE[J2$"A2\^1*/'`B$K];Q1@QDUF%&# MZ4)0"]DFN"XRRMJJK"WG-F?Y%VSL@%,Z1QG66QEV5#A5/PL1"JKS1PD]2F@( M'X/Z!1]E=E]E]K`B,P.3W#LGW\UR%40;A)X07OLNXO$=W9^]A]-< M2-]VJ5'O'WU7HV;<>\WX,'8"KB1W$'UL+UK!0VJ=4N,0P3J?I'RR)TNJ`QU<]=%88H[E6VM.C1CQJQ*-&W(6DUV*O MX(KP*+M;R^[17WS$EI!Y6W[6/VO_\>9F;Y7.]%$>C_)XE,>]E\?Z;&,4QI8) MXT<4T!^]!P?'FV&J)V:FS@'R98C."J/@'@7W*+A[+[A;,8]1 M=ELFNY^2%X+^2.B/-VOV[U%26RVIWY0<.R:!``5`!P` M&UL550)``.6K812EJV$4G5X"P`!!"4.```$ M.0$``.6]>W/D-K(G^O]&['?`]=ZX9R9"C3UCM40F\I?,7^*52/S[?_^V#]`+ MCA,_"O_VG?/]Y#N$PTVT]<.GOWWW\_WEU?WUY\_?_??_^*__Y=__K\M+]/4K M^A"%(0X"_(K^MRB,]J_HQGO$08)N_/"W1R_!%XC^[Q9%(?K/ M]U]OD/N]@]!SFAY^>/?N]]]__QYOG[SX,@H#/\3?;Z+].W1YF3?U#Z[4#VCQ MO4OTJOSE:W0,MS^@6>57US'V4O(TVA)U?D#NQ)E>.LZEXSXXLQ_^'W:?ZX\^X_?[JYWSSCO7?IATGJA9O:BU28Z%5GO5Z_8W_E3R?^#PF3 M8BTEGEF9"J=AH4Q,8 M4)M'L1`XD[7SDDX1UUQ7X%XFX9^GIQ:_ M!H_TI7U`7J'Q!X>7/]]_A_SMW[[SM[^ZB^E\/EO\NG2FD_GT5^=7Y[O_*&6A M7!CZ)1?W__T[U\,LM)3$)7PS/#[W-'Q7<=W_O'B3ZTE^[`"8/?%N$Y%046B%-]W.=F;.JT2M!1"YB@E%%,B*B428;E&H&83/67401WQ'#' MI>@1T$[/:P4,U#`5)!GOO%>JDA[[&@\#T*VN@6YX7[FS)K\R0>-@TQFHW!JJ M`QZ#GQ0\OHOQWC_ND\_A"T[2 M/=$VD7_94X399=0)&NJ&=C*><@K&\790M2%TNT-%4ZRSRQM#E=;,LE(T-8&S MS8P9IVJ2:(<.7"J=OONEX`L48F&$LLCI,ZC1X/RIEH6*"4?B*[[WZ`=^2D;1 MG1VEY'G+S!8JH=NQK*?+94E>(@I59('WF`:PN55L02D+FF-*5VO22&X&(*8< M]\>`1E8VVJ5K>#%^QF'BO^#/X2;:XYLHH2/?V]V#]TW^>7M)L5CGK1<;(0A"BD@@# M428+B'4&@+D-8` MM\H3B1*Z$QEWN>'](-`J\Q>SL> MB$,3$QR\U[UDA&R/2QT.66>3REBP?$H>HJ^8`O8#3+K"LE]\B*Z]Y/DNCE[\ M+=Z^?_TYP200W![8EPJ?KC:I_\)&QEU;=$,T!<)B<_KK]BASUYDW`T""'B)4 MZ,%&JM61*_DC50;EVJ#WKXCJ0SO70B-4J@2_N0AM7[=IWS2B>R.9?4-B7SH8 MIK^E/V^H<8_4H*13CPJ#>H4.XXA*YFDM#FB&OUF_6!@_!0F+<)/U=,+B&_W- MKU=/,<94N:MO?G/]6/"`X5BRCMYZFH^=6;37Z?,4_/7"7.) M@&%8*PJ(9RKO6%->&G+.1.#J(AB:[G(OIR25H#1+K0\1':0I[9L]`D8OWK[^ M%UZM6@3C(J`H=@*`)LF&!*!)LQ-0-(FF0&&7:G6O;Y.M@A5D5!\PX7A[_^S% M^#U-5*6+7CA,&%L^?J,_XL;7ZOFRS9&WED:Z$\[I>I*/I7.YB`E&3#*JBD:9 M;*`1L7G6[M<&HOKG,](%!^!IX^Y_P_A'' MPM!7>\!Z_U=M73/L3M;NR0C<"@*XKD[D MW&5'UP)W>C>7X,WW3]'+NRWV>0]'?FAV;.17OUX1;]^RM;/`>VI8O/UW"]U3 MJU'-2#R9K]=NYJ?YZXB^;]=+SU/?U5-_:%^5.@9U53%"D`%9F/I;/SBF_@N^ MQYMCS%8\/G[;!,>.(M)Z-$GG[0"-"ZZ9C/+^+ M4L(@WPN"5U28,"E-&$8I\L/,C&R/,]C0#?=LNX:]0OY2+*$>B#$3JA#H0-,D M)VOC4&,?Z0V&JO>O8@&")5@;+;Z=L*:"H..'^'.*]P/%OE+\VPETAT7J@-B M2KS-`'::#971JK#AKFG#Z"0;OI$8UR*HP8!6_TKCB5Y?O#T6[MMIOP8>;4I= M=%3C)V5!MAYQ7H3J-H&T/J^#5NX M+5MXW!:7;70G9]8>L^VK?)%UW[BZK/@N? ML7PZ#%=-/;L.K,SP;6.$<^B.,^&U9ZR[<\^:/+/UQ*EY\Z#'O?4B\2D0*@%Y MPU\?36!6G>MNX07W:JUHW7P6RLM[!KW)RIFM1=X^DAA^#BI>5ZOF^C^,QO>[ M0[L(.AP7/GE^_`\O.&):J"2(DF.,O]+Y?>R'S9R?'B]:9XE*&^WAKM/H(*A0 MQ*2B4BPJY$+RQQC>RK@([;%'!6V1EZ(=Q?["L$>(EFU]9#UA-6F!II9D^["73A9TBH5@;@,RPFK9RGO M-)4'S5P]"XJK\QWLI+#*W+Y,8Q4B!>G]?O?B[0-I194G4WO&9I]6;5A[%=,I MCBS3UQ%]'S9GY&04KC8*:WV.R%UJW4L++(17OZ=]\^WNCGS///!?A=M[_RGT M=_[&(Z/.5O'D!_PM?4]4^DWR%<\2:9$SY^BIO9*T1(>=[/WK"X>)-+0%2$W>'F6:H[#=4A!YMG`7$UOH&5H:;,W8N1IA`F M1)><%?!BAR&W?DHFG,GGD"W<;M\?TR]1^C]Q2DM]28*U]NL6NUI=G?3+MTVS M3*%,,JJ*1KEL1(0C(AT1\:QL'4SW.0CZ['07+QKM9?5;=U&,#C$M=9.^LFP$ M_*^C?Z`1%KQNZE"--K/G:(ZS<@]/O4BU.[X.>=X!_QDQ^R"H+#FD`C2)L& M[RK!P\;B'N&J'HAUC32>*'S'G(KT%S'V$OP!\__V\@*)"/"8+-9+^\JAY7K6 M%9IY"RAO`N5MP*1`#&8%EB%!RS/^99N]_E=Z6I9C9J=EWPR+U>[>36:%-:$X M7=%.F9,M?M8R2UL*Z([JG,,F,>1J:)^7F3KYE+\BC-V=Q,5!L\001+<%,2H@ M@E*FV_=JQ.DP!PA]`B\ARK#::LK#=8(';9*EU;INL)VL)MD1'2:#DH-)`3XR M=R8@MP04Z0"RQ@BI.]6((`9O9`OGFCQ"*!;(-W`:3]C>OJDWK[EQX$S6ZSG? MO,G?M[MS\_4#Z-:'9>[QNG8SZNNGZRY3&9\[4JG`V5<[$H[(X<-8`HBU8 M9O1`T)TV]"L8Z!W18"#\KOC3!QE^K\"_E>"V$TKZ<[J,,STM9SH(O>`KN@#S M8^R1AII;OAT/`P:8NB::P[W9:CV?M<+)"^$1E84R86"1XPQ,S3AA!9-V2#@# M&`L`7XZT#Z:#\TT-HL<@/LDAVF:_F$PBK@M,`C)CK6M4G+$OSR)T)6/VD6!S MCJNOEO9)KVE^X0BO#Q%K3^# M78/M[]NU>75/ZXV)OEG1C(WDS]4*&C<=U>F,-C&"`'"*WMH5UM:S54>$*.K9 M;*0QI%[0Y0:Z3!V8(9MC_Z8A\V(XABP)'9;.X:Q.W#KY>QF:<>SW.-[X7I!= M=ZE84I0\:G^V(=1#=_CJ3MQI/M=H"+(]PS@?AR/$`;K^:`"5J_UU+$TDE!RI M3"/DT`RNFN.2U7JPK!2*CF&1KYP2S>"LJ;0:0=Q!M">4MP M_!O.(&ZEYAHW2$-$>>&H&>U=MP0OL(0-KE[$@F:O.YO4V#.=W9^]>=@.-NW M/K$CXB1\AW)9B1D47=R;;S`SG[GQ;?Q?4KO8&6'=?*+$+J_F?1-&$+( MU-&^.FWE.`**$+'H-D9<<%;*K;A1`YPW1D!7F910J1?HX&6EVT9"JBXOE=!, M:1Y@XO&.\.J8/D>Q_T$R./`K(P8%%@#I]E.ROV&(4S+\]IDGJA5MYJ6'E*Y`QH**']C;[ M?#&1!X**P)%$@U,ARMD3J3&"44C@ATH>-2UC;!LP:Z62'?`5)VGLLQ_Y46[9 MEHW.JQ!;@AIZ:7K7 M>J$VAY9!?+?G_W-,ZK4$D:;Z!ALV:WH"0Z""Y12+78XOD![[S>,O/"5Q*`H M)G_V`DS$7:`HYJG,[&_1@=F/KN&FSSA_B/UI4PEDH'N5/6)#;<=2][L`CPB4 M-;6:C\'T_+UJ!DWFD[6`NL,5Q.K3P?='(AGGCV"8?\)7$8Q0_N_)]Y.)4ZZ< M_;^(Z',QX?_77@.X0#/G8KF<7T%WF@YX0_,(@]>1C)[D MA:5$GPJ1 M?US4[PJ"&P\8_LI"T$D/U/9BC391ZS%'SV`CB#T="1VB9^'B2[]4B)D[R@Y)L?%,V@(H64-E$_1P86':53+M,Z2 M**'228;TC*9!&L@A0]5I?*]&L!,,!Q78RDR7JT=ZDF`C&QY('K85=X$M/%N$G1XFIPC\,7@J3YEMW;US9?E0PL>M$R->NO:5[W.%DZ%%94A MZR]4#"`?SL#C]L-CDP=B9VI20(`=WOLKL:4<_-W%_@:K)H5Z[X-Q1:&4=O2= MS204JD;CRER`B1]H$LBN;/5?>K#+E`6FS2E/;'VM=EB`37P']AEI35HVC17/ M>16IG+:FN`,X>X@?#MLA=\3+[IN&E&]C18O+WI>6W)9#W)2T&W M.O0;Z&M<3$`3CU4ZH,%PJ>5L>)<4VORJ4![*(:AJ<[U(#AB+5^\/:Y?CJ[\C)7'P9A2ZJ!_ M?FT]$?.$RE)>5F^;)R>"$W4M%]WH8$C3]CDY91KV@"?,@^*$@NA),)H\],C@ MGZQ<=RX9>C$YH^!&?T3\JLW-,]X>>0$H>EKM,J7'"QLX$Q50&)H\R$XHR*P" M0PZ>>_H5O^!06N^I^9154M2:UHVJJ_6\F(MD:<*9!"@FG`[#K<&(Y3#L^;G0 M:>H^WL8[`O]6YYU)'H;S]G[96<[:D3D];-*9`52UE,Q#%*=9ZLIVO+10Y)4I M##("DM!K4OOPI/(\'%5*)?1//:Y="5M*8:,@S(G8A/W&!0IPDJ!-G4HCHDW; M^Q3,:5C&2,V"1A-?\29Z"GUUP=_.=VS7,>A22,^15M.Y.YWQB@8MDE1D@I3V M-0I1'`E5#\2N/J,H^3G` M](>K<'NUIS'W#Q%U>[UJM:_MUD?W",%T5J9CEU)1(181N:@J&*H+-@S9;4&F M=66]BCB$OQUPF`"/8?6=MMXO:YK+4!?]@H/HP#9^:;6*K9>*"RIT/6V_6Y:I MHAG%)ZNY,\\[Y$(6*H39[H*-P'&D<""K#!D"Y_;Z5I;ZV"[Z5'I7I1&,L[EY MHS<)(3?^AD;%JZ<88[8+IT5T?4&0,4!;2]V;&B:K<;G6?>^TD\U:0D53 M0#7*AC=(.\",P2#ZX6<8J[0CDYY51A&W>@<*84CK9U@ST>2XW7WTXM`/GY+\ELT;20*9*:G6X^#9*FMZ^\QQ)_F8*6NS M6LPC;Y7\@"KMTEK\>SEOQ%X=4=2NT5P[1K,3;8T%JC+T MFOD:(*LYQ5&GVQU5E?01'K^[*:#W(5]'29HP51^]!&_O>%6$I.LDZWE";:X` MG:6I]H'LQ2I/B"S/_!&*5%M$69.(M8G*1E'>*OPQ6GO&&A&R\=%5_WBFU^?R.^:\T7ULY;JSTD5T"_4MI@UV)15:N/"$)-FOP"=&6#N M*6_N!72LJ4L?M[A:+M-!=VEWOEQE1Q-$FT/`J]M&P+DG@;.U%MWET*1XO\U+/`DYBD<3"D/RA&#RD"*!K4/$G%@1+P M:`AP1<99=/<9;WOV'[*WH4G25DG_ZI?\F*B,-FR5/I,^NO[&!'K&KR\X14&4 M)&4UM!]&QS:YVW;R3V*B,3`RTTOS@^=/`S(N4T&[>,5LN98R+),U#C*=`JQ, M&EO,_B*KN6&=BT% MOC$115G76VT%$++L#T'TBG&6MW/C>X]^P+('U>4\NM^S29XN9;2/]J]F^>@M M$UDD>56$PA;\,`N6,>IJLXGIA3R;2B(7**=TG;+&+2V[0'+L'LR<]1]XR]>Q63:=;(]QJ%8`^&M(=>T:FDY>I*1@>Z9!.5]C MZ9V5G,]2"YH[6^J1[Y+PQ%GXFKR0)G7E)LW28ZM*7%1M&IUN4]O!R3";1:', MY,<##7R==XB+GH0(0/TOT)XOELMF$!G!]>#G(G(%B.Z(EL_$#=$=$3`*"JKO M`9?9`)P*MP=*6WU"U)Z'HD55">TEC?5J(B0'%S8FCIP,+RO"7;G.,6*B0&]_ MZ'0W*4]:=A@^<8(E=Y-QNJA\0Y%&Z,E;WV])A/*V`L^AUO\[7_@5YG]6\_9]-YFXSWN:7TR2E-6O")_G'4KUD MEP<*3?1]*#\^F_L0[_+Y>":[V+HB%XPBIK"Z$JP7FF`MTD?#.QMUY=/L&$"%`6U[ZR0]P?.VE^"F* MY4.=^E-6?;;6M/ZWGTQJKLNDH%P,E`.?CL7MA<6>-PO=I^[4;="V?/LK?O)I M!@^_3D?Z51J/6?7N>MOZ4[E5?11?BF&7'T'Y]QEHW'YH['FXV(GJ+B[`#;(0 MR93YI[_%E8-A67WG3P36QV_D&X9><'U,TFB/X\YMQY/EV5S(/%5)[3LLG?6B M1C;:5NWX8%[VG#:'\O90WN`8=@RMV(A1.+?%[C1;6%M$/9E:R[J;6Y/Y*L_P8>_#9V"?#L/5AF&-,4*7J=&@#1?.MS\G MR=$CH(KC1?OH*,]X4[UBW>_%>FC?B[EV5C46Y.(J.:-<(B0I#&!L;\[QF]DO MT,&+T8L7#'1GG<:=].:^(P-Y5[]['CX*J,G5C@D*2QBI%,=;D0UGA8_8KO_6 M:%_3"Q:KV30KP9MW!D,/)D7QZ6P$CDT$ZCIMY\!P>\"P4GM-XOA%F3416(., M$^WJM_X,P[0^6^/K]7JYKK-LP)W]#H+U5]RQI+@.K_IK[^II;Y%.K70$(3XS M-/IVP)L4;Q]PO$]N=SQ!IRBA+S2S^@WK9%.JHUOOW8?>L?5:__*)B8J]AXHO3K&MK4FXK/%0G]E:^ MZY\HUHJF2E::?/LQML^JZ^?P<$SIB<=P0\`S-.]?V>O7@9BK]5+;@Z(O1TMLCQIYA>P+%%/T.XH^!EHU.]679<3N--M8B/I/[#\] MTZ)_+SCVGO`_HH"$EX`F=_9CK%H.,'65RFE[L3MWE!S.6T%9,ZAL9V1D-F7^&>/TQS@Z'LCHXI,?DM_Y7G"?$AW9 MO=8>!Z.],'ZJ6(@P<**NVO675_-VSYZUB5BC*&\5%-%00KL[G+CMX4%S M^D\%@K/['(#MV;L4DGWN2=Q-3"J1%8#9(B*ZU@:*ZE48#DGUT=ZXG$RG(CI) MNM9Q[$B8PMWJ'!]/`0Y`P$X/EG!1;39@6A8__MTG@_QX\_QZ@U^(>;5Z--7+ M,-14:*1_)\]\*2)GY5^%<,2DCZ7K,P6^Q=`2[ZAZ1`W?E5"RRU+`I&0'*IZC M8$L^/L]1[;%5UO4Z##&5.FGOL;A+8;]9%8ZRO.-1[4F9Q-_:5,.IW@!G5^^H49SIMIQ/7O`W\>AAS.%5Y9F/C MDO*NF&Z3@+*)95DD63F]&&_]E.[>=GU>R5L0C!*KHK^?E]\=4?$U+A+E11.9 M4):L`$PJ`U!56Y<;#C0YQ-@#O;1,TSF%+%/8:`0\8[-)1UDQ7O4&'+^J:FAO M>2UG$QFW^/J(`UPYWA3(UL((EW>1PQP1F40>J"!2RR1C(9';FT3N.$CD]O2O MU7RN)I$[0A*=`K*#1.[82.3V(Y$[0A)->Y-H.@X237M>A;-K>5(N>O>3'OM"^7`ZAQ<(D<*V4 M75!2J*BV(#<-:&>H/GK'SJ3,NAL^2/`0'?IUZ<0D.>4\CO\9,?AAVH MK8]"3J.^<(1R@@'''O4Z3N+=Z&;-FVQJI/%25W_MV;"S7I\<3+M/YXXHYQ[* MN*U9DM"Z4U MH\DC@C(NOW#@F3Q(K.F'Z&.2^GN/GG.O6#S:H>LH?,%QZE-;?HE2\O"=]THU M^;.$/*W4)M-?"33T53+-[J+`W[SR_]6.9YWO0P2I+J5TR;&/`K.Z[JOD,A:1AH+.Y/V:1V]DS!:,H!9*E5,.S=])BCO M5FU`?'!M)`=CC%NBR5@]Q)#L[73O+@:K#6=F^YRX0/K\DT^`?@V]!R]^PJDP MIZ3K:>L;Z5)5-+UJM9K.%]EN.I.%F#!$I"$NSO)FNAE`C@(04(J,27AN&]Z7 MJPP>R+$"31:5V^AJ.T!TS3^2B'(3))60;'6+2M>J=G]R M_%",2*@ZF"CT\1O-XSGZR3-5ZG;W`3_*SG]VOV>9*4IE=-UKM:JR)D%<)B5. M72J]((?*A1EYFH7+^AD6']C=.#68T0YMC) M0"(+#LE(/K@*MU?;O1^RB^A3_P73NXS"1+;=V/66S:BB5D73]UQGMLB.[64" MV4T.=9$HDPD43PP"=:M`Z<4*7DTD*+_T'++&+@W+C)!;RJ,2>N^.AV=]C^?D M!\^[V09\CL(\[K=+/OG1"GTK&5DE^C'Y3;XH5/[1]AI0T;*F/RQ7[F+%EWQ^ M'.@LN'1YYS1=G4Q7R)6;TS3GK+O_'V!K,BV?+99@ZH",$.3OU_^X"@*?ID;+ MB=)^R#9A6AKH?=+5U'66,TX<(@+E,NPRZ#SE&9/^CJY1J3XDJ^/ M8?0YW`7>?D_?>NWNW3O?L1Y*.A32[7$6,V>:Q1`F\;(J$F@L8!2;4V)#0FR@ MH<(D4O>4KV@G-&@RKHP).G:!6(7Z'&ZB/::+SY$O.N(1*[PZ(=/MP<<\^.# M[_$NBC%_[L'[AI./W\CT/8JW?NC%K^S\S!=B+O(F,1W1[RF_ADNR9#)DBQ97 MO`:$H;TC,G'R(01KA.\04W50J0\J%4)<(Y0]S71"-:7X.3)45ZNX+6^8>!*E M7J!:8AN+H1?%SM,C-Z//S9C2%B&7Y2Q0N+J8-_3W@(N"Q34_'76394];CSXM M%?0/8DU6MOV$*HI@Z&A"!^"-R0@6'6G89$8^4APG4[\!SJ5^*_&R] M=#K9!'HRP!S,+D:-X#B`ED-JL`KX"HS*B//.\YME]61/6>=.T;3V$;#E:EIC M"Y^Y41&0Y#@-1Y4.;.J$#A(<=KV_Y39M?Z\#!O7P+'/B/0[QSE?/4]I/0WA\ M707==#1W-ILU/;_(_,ED`5/@#&`-*J!'.2#K7!`[F)`3`@L`<2/&7H(_8/[? MS^'59A,=PS2Y"K>WZ3..O^(-]MF)<,5\I8<,NSS25TR_8IY3]BM,+,KEH\\A MREM@V7>L#51I!"J??$!+L-QRNJ!%9]D)2[Z+&.Q8#=LB.?M[>(.R/6TW+B)G MM2YZ>T;^WB@(FRFCVU-,)W-'AZ2*.B!6>D.#:/G]USFP`WR!$VV/U"-;U2:C M(5A$'&WK*O2YT,W7X6F64,?[3'9>C57,XT*KM8]&A'9SL&<\XW!"]3P0"DG M\=%.UHF,,P[B?<`[',>G,4_T+BCU!`IIGSMR9RKNY9+'2+YS43/V%0!CNCA8 MCCQ'RT:%XZKI*#/7N/CX%;_@\*@_TFR^-PH>9LIH]P5%N0$U!S.Q8^/?*6B; MW),"@R=:PR/U2%:UR3@(]G%_"*)7C+_B@,WT3^CW%")`:2?72__T[P<_]8+N["A= M`:!TE6FEFVFT6KBJ(6LA'F7RQY!9-80)*J5K:>7:J,#M)0G.EE$KP]@?QL7@ M+N=6\U=IP'&P]R[&=(,U'Q%DFS7Y>N\5^T;:#J,E#)35.AIJ[PK,*CE?;89G M394#XWQCLMPOX>V-9ZO$O'78GDENB7+>ZDF!PU&]#Q/4M-]^('<8C5>MTKM;'^UAY6)2S&YSJ1D_$9&+"L$H MEPS52QO&[-8Q)QM\U#3,D"L8T<8\B#`LR/DWUCTL%UF"330 M#OVK:3'TY7(J?1X7!4:>`6!3GPSYU7KN-H@#F>5_(H#Z$`H^ MO;_M(B+G-I#8G^#-]T_1RSM>SIQ[,?^YZ;_\M[^6U<-O)!<<*QZTX,ORUK5K M6DX618YQ+@3P2F!#@-R>@(;V]6YWHA[?`1XF?A?E\VE_0B8L'_]U]-/7>WJ9 M&]LOZ-QMTA9@-?;K:J5]E'"Y6#1YE/!A%)UZ<_&HE#^"W:9!3-!@7G+!;>"= M8`-['5!?'Z]W3[WL"$QBFGK"E/R)5CI+:9IS2]UP>TV&D)X?/L0>7;OCJWD? M_&031/0NJ:Z;#P=K#B9`&,6@RZ7Y9#YOAQ.6Y95%E%(;`;'H`YE&*%,I7TLO ME1K!;8RC,',S9(TD%@U"54GD,F]\D$'Z@^#TD>0AB,%YK[O8EY/ULCTPA[B5 MW@".UG@<[AYXM=,(A^&P=[!7]"!-*8OYM!X$Z3'SUK4OV';GK:$SHD*`"_:< MA:?I\1UX[/?^VE^"F*_3]8KJGR"A:-%\'8(=)&V[M6;FMD MR+VK+A7XXA7#@)MCM)&4Y='U33FYI)8!(=O=K9I3Q=]M4B=O5-=AG'FQ2(_N MT"TT$4Y2/_-W,O+V`G1W?`S\#;K=[7!,!MZ@+M_TD)IGUZ">/P/88I_[+OFA MZ;+D5[_>X"%VP/% MT+ZKJK=A>5@/FZ?4QIJ5$NK]__B`,][+6M2O(SA?K-LLR M(>`=W"E@*EW:AK\^PJ%@PYDDG*C"'X?WZ_=+S1=`V=`W,6:^G,^DK!A37W,. M/G[,O$T1T//DW2ZGYLJ8>HQ/GA__PPN.N-QR_TIWY^F28/>G5;X-PR:52MI' MPN;K19M:5#)BHJOI+H5P<)X90]X:TNVQ1Z5MD9>B';7""[-"%"*/5LGE3:!' M+_''TG?IN+6$I)UF-')[YTT4/ODI/<7J!??DOZ^WNSN/-!^F]][^$.#D-OPI M>7C&L7=XE=_G>8(4VS=\]E=1\[9(9^:X$W[G9[4-Q!JA)XRR9E#6#CV,]%." MLJ;L7@4ZL!&<$XT`>6?HP"9Q#?K%T/'KS(!07#=ZHDE!1B!$5>(?>YH@V)&` M)'S4YMA"T+YV\OITN2K92:7P5%OP/*2S017\NBQ078PE'4GE7+5.7V:$,3!" M>2^8Y&%`5O2Z(FNR7*\FY^HHI3N"6<^<%1_9YE(1%TN'+TPP MHI)1Q_&"X<:SQL$Z\PU7CB-TJ8K!19Q\*%N-,;5M`]*,_>=_\_7&OS#BL M/V.QUZPUK#O>6CB.FQ.$O0Z<>W@Z"+<"`K(+%/I(M>=K0P1Q93_L=N7:,S9= MN=JP=A:JD^_D9:]#N_+)(-P*"%!7%OE(S95;$"%<^0M.K[WD^2Z.7OPMWKY_ M_3G!V\_A)S_TP@T]]K=)_1=5AF(/`19)H*^5=O'&^23+;Z1UDJAPE$M'[U\1 ME4\/[!8MH+()F)WP@4RPR$VPH28XY"9X?$6[`KJGA&Z+@?U=NTK/GN8;-W<[ M=MY/$#1*+OBG-\MHU;[_B98;$:H-Y/9]UT];*F,?-8X=8:_)69;MR\/:UG M5@D:)8_[YH)/UTN=<;>(SV/MF4U9A?7,MV^6T2?TS%V6`V(XOV[C)DH4G6_E M&;N\+!O6/GH[6TQ*RO'W$14`QJ(3,;@YAF`PY35Z]Q.57W0I;Y'1;0=OD+6! M$9R'5R^>']`J>P_1=;3?1V'U\.9[+_$W.M]+0PH4E[M5TZ[@3UH7LAT5;:"' M"/%6ZH>;63LC"`J&C5$+&WSHG$;L4N)CBM'6#X[T+N8P?X#T22AY]F+0JW-. M]'XIC35-:B09L&?#5^'V`_\&K(ZFK'JT4=&V4PH-Z:WI]M/E'K@[(3+`C";F(/+WDN]T[";9'O MP*X,N-4$@F(<4:7_M?7Y6O$[F590$;?QG=>G&;_N-K\Z^@G M/AU?-6_G9G^*\=91NU)_U7WM,]+"-/Y_:ITW'_P4MK7LXN*MWY*@@7\W?;GDD00$DZS+E"$ M*#:4?_3\,*$S$WD&@N1IN_P6J:!=P,TM-D8J@A"3A+BH07AYB*@'O'11\VQH M4T8]^C;Z"WW]KX@Z.ROYPZ^`('USZW)C0LM7.L$<%/F#1F0Z'SZO*(.3Y`?T M1(W`T&^>R9N8)D_4[$"Q#PI=)QB?#9D762L0TJ'(GMXY7ZOU9/NCDZ8>H^&Q M.Q5O#TIOY]\[:7WPI@V&,<&:FR#$3_0S#&Z"&:]70!?6.IFN`FRQNU7U.(W> M5&H?Z,Z2K^-]I`.9!'=/C#O>`^I`A'\"^;B_@I:U%+;,V7TDIL&AFBD@_J<)$?57+3RB%7ZE.UJ)X,X MJV+)B/:\_'6X&>")"/A(HS6.\)DH6.]ONTO=T1N(C>QYWV[2Z!''#[]'#\_1 M,?'"[56X??@=!R]87O.Q^R7;^]2=&FGZR'PYG<[X#G0F$A&9*!?*UD:YV&'+ M!D@WE`S:)UJV@)%5RPK5EMUA6;KGJ6@.CFBES8K-^5+;NTG[/8 MX;4:U^TS7'>=]7IE@G,N`R:3\SPHE;+_Y6@7*P#9ZOZD;E3M`\781^'U';,G M^?.0+.@]?5@OEC(V@$^2S*!K'&;(J0$Z,>IT-B5'P"="M_7YF>)\@NA)"'[T M3I5WUHN\7O]M2>59GA:9 MP>4`X>J8!9D!YU;`82HJH3\=6`5-N)E0)Y/**9#:#&:('3]Y879G.;UJC2<" MW^[N_:?0W_D;+TPK:7`TYS=UG/IWF>?[4] M?FMAEGM-*^^6;=82*[-6T2^T79Z@9GL5QIZ5G-%;J2-XV3.5.[2I[$1$(R&H MC)KGVQ]DSE!1^YJ,.(EBVQS#'?'2/(;=[K)L17K?".D*6$9RUUSKJ2#JU-IEQ*JV3-E5M(W*QN$7!:R;KA6%+AJV\YJVBTZRG;7YEDDF MUF9HQC[-FPM0Y;UN7:>,C#?S5L*60'?MVX'6KFC<=&($JURT"'^0"=2D+++1 M,WT)#5DUXWF5@5;4.=!ZL^%,P5MCD4WVE4""'$T2XEG>-`]<>;6W^%F;X4:D M@'9NR,K-RCOQQ*CLH$,I"(CO9V.J)'MY3`XH^53^5&.0%#<8#:ZC_2'&SW39 M[`67B\I?<'J[>_"^\9MHR.]C["7X`^;_[9J)G"_8-L'.TE9[(#V=S*MLK#5: MJVU`S]Z3GINTG%_9E+>-\L;AYR!V[59A_*9F-YI<#KN/:8Q'K5AQOGG'%%A^ M#HE^@?\'WOX]"K99XCC%TXN@><6YV$_(GSXCJPQ(@N)*VJ`4"TY:I=^U:"^A@^>S.NK$PT.\84MPO_LI+51"_-(+T.'X&/@;%.UVF`9Y2(;I.&B58YWV M@F390Y15.V@60>CX^/+W`/@F54;;'9>358-T#U%>%*1=+@2:>8;P,OI5ZZ)$ M.\*W7")H+Z;MGB*BJC[P-CO%:SBC M8J?*>97$E-K+2(KR';7A;8BOR:/^Q@L>8C+@EY_55CUN.[E8H8NF/ZUF--JS MS&$F#!%I*!>'F#R[F<"F(#DJ2)!'L$T!=/M^,RO)MAID*C)INRQACMT/OT=] MV"UY'(3=8EUTSZDLI^M9E=VT)`$XNPU`:3'5V*RQA MAMTQWF3R%9QN/62=R4T-=(]A3!:3O'=/FY+5;'>W;UF>+DA=LWR&OBD<7 ME&K9DM>0FY6F(;M5R'0-*>(I55S4")(I>SAK;;JJ:2<8_D4;C+?))P+T.@H( M^"BF;4D7C:3/6^6:1`GMPCP+9YDSC(M"5!:J"8,BE0ELV=7M?&OR>"!N3`@4 M\9/H![YZ`E7`U]#'XAT9]A_P5MT.,9T\S*EU_81DB&ZW)7PDK9Y2_GA MB<#?L)CJ/<48@R]4=]&P'D]4%H2/(D6EQP_X4=Y[R]\`BR0U-;3=<3:;B&-) M6?&2RAM#.#D=(`\HO`#I@;3A9"-A691;>[VH6*\*PZ'ZY;@\L*/_DY7-9U,;C)8'![ M=MH&OF\/Q.!)QMK\E`4:N;W&$VXT>^K&"^`!ID\W-G6*96%I9!E'/WT&ODYB M];C-`Y9@.EVXP%#0E+KW`IP7RB(S?3H\Y]FBMSNV29WJI6:<(1&(E#W5U%X8 MFD^$,W7:7%DFCJZ+E2VR?.2\S>'R.TZA]I!68MS/A-.S#'22FY#VQIK]<3YK M9''A%"L#!8Z=GRJJLU8>L$OKK%7MG*/5?%VPE+P[8`56#;:=HKR;7^,>2#2W M2(N&3S2\O(K.T!9I%.TB,CAENG6E/T@?MK]E*M%$@\N8(&=E_5!#:WWZ>RM-7:P9W*EJO*!D"]CSB;F81!>7"5 MOV*WAY+JH;^LN5P4?)%F[=-SX6`=F1F,;@UC+3=_#(LKG3[8Z/_41H$@TE=Z M;>35-U\VBBO_;I$B1:.ZPR!GGF?CL%?1+_1EH/HMIRGOZBAOR[-;3E%UXSH^ M,)\5#O-$3]CVVU[95\YTE8]\LH\/,M(Y%T#5>S]$>\\/X?VW/9:1H03Q8;R) MGD*?3^P_X!V.8[S]BE]P>&S>"J'UBDTO5^BA?49V[>0!NY3&5[&Y/)0)!.*! M*8B\*$V6PY(EKZ`P"B\W1*"?TN5K=(ABAC[FC?X!>[&DCF/6R-1E*B/S_*], ML!?0FN1I[*7XR=]Y?+1E2J!:+@%@Z$P.[TP0RXK#&4!%G#:H/F*^G4UD0QDI?!4,A=+$7WM M9BCZ/!T#^O2K*L0TGK$?1^H*Z%YV.G,7\SQ8Y!)L1X,S-'?JFL-R^@P<;O<7 ML$1.L:]7&"A`"3.$#NCA]#LO3E_YI$,ZFFL]:'6XW&Q==P0YF4[SN2&7@9@0 MY13+QMCX+#QN/SSVAKTR9ZH/=H78H;W_(?;"Q&.[Q/DUGG0KN?+KY)]^^EQ] M1>/CGB(5B%Q.>M4-;BX]!9KRTDU"'D#?CF=1+&N>^K([AXH8&:MY#V!? MB\%P]E`47.?7&T3A$RU>J3B$IW['*B\5BFAOZ\_GQ3[CH7*)0'8?!Y'(2[.: M/XZG7Y/5(%!>BS7VPXU_H#<%Y(AI0?/&'1W18^`_P6TM]G+1.N^ZK`7#M`03 MU,]7X?8#?L%!Q%)%K^*8)B_1'Z^CD(VS'Z(['.^B>/\IBIGZI(]_(-HI![@F M9%MEK@&%M8>$[KK8=N'-LDR"2L.HTC+*FZ8EFK/&$6F=!P0V?J8*``^;;9O/ MK9G/DYOOHK1?6MIO5]COHLMZ]L**03[6PX^IC_/&PA35O6/?UH3LMQ&F2H5U M;^]<3>>.N3#%60:\L6S;>L:CU"@VL@T2TE"<:GR>\<2I;+>NET/F[X#'E4P1 M[:U9=SGKB!>9Q#'1_Q20;5IO2X'CXV;#";LY5[7)Z+BD/I>C\>98>-7S&,QD M-M%C%_01'\.8WR;9%(>#-.UC*+%8U)@JR5CQO/V$8[DRNO%Z,2^3CR6T&90N MHNA@%IPZ)H!F*QM"J!Q%`^8Q=U.KDM/<88L!V4Z/@]/PLDGQEJXZZG^KUIOC MB`!-M73/KZS6*Z<1"YI3,BKZ`N7"V4+[&,+"68C5`8**M@#XE%!Q%FH6-`I< M?/]@AV+).`(=B,B1A1(9;SN"BM!JD*-XK0$[W-B\WY!T-F^MW8]CN'T"C'J_ M^N!]0]?LT#"Z]N+X=1?%OWLQ\%%AD0>)!M/@)X52SP_Q]J,7AW[XE%QM2,=V M9+OM'_#.W_CRK>O.%ZU2HDL;[;U=9U:L!7&9*!>**E)1)A:*.D;ANOQ"[A+< M5@[.'H-T';/.*BW#&!JSLI/\K#)E\[QM\D#K%\B2M'J_;G_TJJV;[MV5BUE^ M(V$FG)#XM3>'*X/8?@:# MZ=Z9CI5*)+H%=;K>L]JY=RC3XY3MHD[):HF=L=37,0F6D4\'F+UN7=,AZ[VZ MCDU,=NJ5IG[R`YRD48A_PNESM,TGJ,6OO[)+JBC=%5'U-'E`W?Y)RFHN<2Q6 M=XJ],CBK$#2'&J<;M6!8N,=COUHJ^<'V;/P,8TKHEV!9KU6Q2LN M##H,G0!)&F(&1-0W=)P`JQ86X@JL@Q064#BHKJ:UJ@!=%7,27HS%W^(4B\@O89<>\O>+3D54<$'Z:N=53H:CP'X;M_" M%'/7F=1]>`0U-\Z`4HW$OC(`/)I3PXZVM%K8?C=@7#S($TBEO,A'2M!](*T M]=L=N_7WB[R^,=OX5&0FD?B+/]Q<] M9KM#%NB@Z3C+^7*6W5+(A:!,BMW.]EP`3AL`9-[^N7#<$@Y8!ZEP_Z)/E.$$ MZ09)M^S%?O1SF!SPQM_Y>*ON_:3/V^ST9$IHG^]:+[)EP%P4JLB"[MZ,H'.K MZ"ZTX5GKR+K\KM9_*2T"0YMGO#W27O6*D'CK!\?4?\'W>)-=\_WQVR8X;O&6 M9A==1_O#D?="M[L\LY$,B.^?O1@_"#(/!FK$*D%-:JY=EM1=SW-6\_;IN+6J M`2I50+D./*^OH@5]J<@9)HH@I@GZA>D"%A/`#.K6#!II&'37-&C4UZ#VHM`0 M-*Z'+N,?[FW'NXYMQP$:>I-QK^]&WW(Y&33V0>^(`EN6W]8:;_1Z^[?O$"FJ]&+V][CN*4GG_\'+[@)&5I;,KC)`8%@X2Z4[75'H4L M\I3*:FBC+?+_J;3++T:D+?-2I96VP4]I`!F.#]^.^[T7O[(%3BK^LFF=<42@ MJQ;/AFK%^N:4<0C:I8^FTZQ:336ZB28\RFED M=;K#M;&TF";?+H,U::O#>#LF[=BW@[6K"V97.SN*@T7,Y.74%`%RSSL89XH:Z,$8-?$JD1K`+5DC#:X-:G^U_-R93Q MU,`&.P`U;H43X]D(QHS&37%B&!O-,*]/".@?O<:RC_QQ?PBB5XRSV]1S5?&6 M#C)QF+!0\A.UUU&2:JYNFFP+9('3(`#M;<_%1+#KDBN" M,DU*.A$*595!I3;TO5*?[(`Z8AJ-9:D3RKZMU4ZQ?2\?6_:]J!HX.LG`]A<] M!^"\>-W3]/?\4X1*[>UGT^V]Y9#9=\]UMEI9"9OCV<6&-#2/G_1WU3W$MP".?6'JIZ__]+?XBV(=TP11#5!%57R"H9\$3[7!A7JT"M% M4040TP!Q%5CTJBB!/C##YT),$5IZ*>KN[]\G` M<^=OO#"]VFRB(PG7X1.KY^6+!VSFY,+M?IRNM&9UU:GK+!?M/9%JNWQDE64$ MTS(/9=NH;!SEK4-OE5@R62NFC]5DNOLJENS6VFT9R&Z6-V'.CUJ"K9DS/PGL M"/0K9O>PW'EQ^EI-$'W_6ON+UDR[CRR0$64/!;4+^J_R>W2K;,G$(2:OGJ], M)L/UOXYD$CR4;5J;(7+;7-#)KK9Q[(_U3N"*>$S7U]:P(4*RWEC).W__6CYS MQVN\7]'+WO3"QKGR04+)F4IK%_U8%`5]*N%%OL]0/4A!(DWUP4P'Q)082]2Q M:<96))+MPM;-^/A:>U#;C/;CDR&BBF.6B2\UQCC&]IEN#RS^7I$P_.)GD5=_ MA>UDP2.*7-W::A>0@]446348S);J2W3[QIF_3EA"_:!M_GM MDH`@8),\LMW%_H;^\:=HBX.QA;?SV=P5ZL[\?(;7\YE>";W_.G[!VT]1_.F8 M'F/\F>A`K\[LOCGW5%%PJ_:]]-0^%2&.(MX;RYB`NV+5A M"W%`UK$%]-V[-JS#@BL9].R+D7!AEUW;+B-803\I3@@6S?N;%&2<)QR8ROIH M\<,VQUU"#72/73N+13YQDTS6@,8^YZ.J9)3R59S-6#)*E0Y6&T+(K3`>9E26 M@V2K0=5\AGQXYS&9GT6J,IS!=6I%.A%41;IWAWTS'^>-Q]!\ZN&/_@O_A:' MVZ]D7F[#Y87MOM7H*0*C795QZ78,GLZ.G<6MXKE^B"KX)XB;9]N=1\W,=3C:IV2<6EP<=-!8:OAG&S:>8?MZK'PI!(%' M2CM$'WS8*/@T9O8M32K+%P7HKO:-LMCDT&U:WPD=&)#N"OU\OG2S+5,6W3J& MAWD^)A*,#R\D8?`B6W3DN0N`Y2_'9/)A.QZK!N_8R!V3U=T1.;J=O6-+L;K< M9+;QNRRXH[YC,;;5C@KZ MA+"%0#QT_P1\S,8DJ*]^\MNG&.//(>$*3E);BU/"=M_JTI0(C/99%'>^'CC: M4O40U0_E"OY9UJ7.-CRO"T:D7.ZH??SBG*/Z1O&L\B[>KN;<0N3HP:-=7<:?&YL13K?YTU% MPBQ1FP#889\Z`DTY_OCMX,=,0O(YY.6X33NZ=KMO(3;J@M&E[WSES$P%R?Q0 M8B?:'VH0>+E,):?L/MNQX63GS`5 MC-]F>FY?HAL)E[T^SY\R;OX3^T_/Q'>N7G#L/>&/WW"\\1-,ZP@87QXTHM.? M*=ZJ@&K7DR#_#R06HUQ[E*F/+!:R]]]VX!,SSF0D M$QCY+8:FVV.:I%ZX]<,GOF0QD$^VVWE#`:JEO/;RFK,R=G`VCU$59;*%S4&B MU('Y]<=PT.GX>89EL^_<+%'%+%Z*[DF`P6S5=SJY0)0\`UKI/O7B=+QVFBOL M]`%O,C,YS$SNV^SRSC-0>P$\:EOK+7>'TBAOLD<4?X,WWBE^C8*`3%KH'X=W MW6IC;[-[K"#0WH"?3HROFU3[R%^H3BA3ZJVE,YBS,(MQV49HM,L#W)\DJ`E8 M.E!D:YK_C8N= M/?5X@YV1[37U/M_M3]Q=T9YY9VNDKJO(GZ\3JZ#37EF>+HT=N#BA/T,5E=_\ M\'^(3\.F!H41O\JW-X1 MU_OB[?&':._Y_>J*G]G4F*+N"?IKEX=<+"?Z<;7CSCS^OU0?EFE"-4)4)?0+ M5VJL*R=#VY=74?K7D=:6RDYY*`PRFI!X!D-[!;U3S?^VPMIM7OF)!^I!D_;, M*O$F0N$IR+03=6=NCW-Q'4$R'WT6FK[Y+#RX;Y*5I^.OCSO99)"X8";,GOR9 MWF0`KB?=0$3?'AJ\I="K#TM[^6\ZOO9Q9+0D\\BG5TQVE+-9.5_)>?HTQ MF3`7+;&I?5S?*,V$H6ZUAXM`O5"#DXI4!B&X3XK_I8K1* M/+47M@BF,`P8D3KG#C!#^UZS:_)3;5D8>B3<7_FR?QG)YI-Z+`D]U(OBE%[? M\0$_IFS!517Z1<]:]6:!`MICCY53[",3,?P^'"J(;UO`1OIS<;D%KLLTQW71 M!
"10^5N>#S`ZCH$;'5J3X:4AZ]-NP6JQF2H(`[^2=CTU%DE'LRBG]34D4 M\+VQ3)_/X0M.4K8,TO4AJX]"D*32ONXM!>YJ-6LQI"('F!JG(N)[*4GJ[VD! M';2C56E?:'G00?"\X/@Q&AB1TZ2ZK_Y(UBDNX(F0WTT#&+I;H2W]:D]^Y_]! MURR29F%"S9?LWW+0H9%F37=WNIY-^54%#\]^@OP4[U&,#T1IMK>0/F.T(>+H MP9=*4^CW9W_SC.@$R.7A"\H@`G M5*H7HBC$B%Y`B**8/1U&\=X+4'3`M+!%^(0VKYL`7_"F,&$.(OH%4?B$X[^2 M%C;!D:4PIK''_IO@S3'V4Q\G%V7UOGO7NOO MAEL4$7UBKGZ+0D3/E#_P.]TL"?R$QHT,,29C-J9[ZGV+PFC_^KWM*QE,NH4B MVJ-"*J)B02Y$,`F5QG MU<882@N`$N6FJXI[^T$(:MSTKA9.?FIR8@35TL_#X_;#8YT++6<2DN`&OLIX MKLKM[MI+GC\%T>_)U6-"QG8;::5PU2L0C!#HH;U5M2Z.K1:^1'H**@\Q@:2[ MR$1"\^1/PAF%/)+9!IA1G_S0"S>^%]Q%B<\VXK69)7\5AF%2 M?;1/;2V7K5Z(,*V0BW+!8V*<&=1MYO5&#<#`3N>5,%%M,U!&WF]PZ,5^I#,- MJCT+P;FJ`MKNMEI.FR3+Y8QCXG,R*DZB;BS6F2)R*B$U6M!!N2"ZDU;R$(3W M][@>D\P(5M/6K!_DPE`#,)H3&[B+.-4N(W1QX"LOZ5I"+4-+^GE:#UKU\6;K MN@ZR6BZ*,50I(\NK&\;3H]0+U)Y^%I@%V_^@C?`BAD6N()9BLN?V,F^JN[X0 M_SCE=#)F(?(1:V`T MG#-A``$%Y5TO'`,['%A-2)6=P/CY.4F.>/OA&/OA$S_`QG*8DR_X=_8G^61> MZV7;S.S42'O",%FM*[1$7##BDO/CIEPV(L+YWZ'RQ8%\U@XX+;7] MML5)/4.-CI#LCXWC_=+*=OT%C86H0NUT77>ZG*YT2FLMQ>9M(MR;@ZQ4_^YBH(?'I1F.AXI>I)ZXF50C4T'6B^7B]F/)NR MD(,*04,N?8N"B"D\#@">CMR_\T&Y_4'92?Y3$J;,^)-;8"#>"@\`J9^%YVZO M@S+3Y7JY4+!WR#-`/?A[`B8Y@T'.-9D#)FQ6,IHPB6-@R(GH!+R8T24J'N5@@\5[",@0V<2 MK^QQ.$KT36N=+)?+F9@5(TC;-8%-R(W1).MV.)R"*B-(TFTHU+G-)WT>D"^] M=['FL]5"2ACX33LC\,2<&1-1U#MR2B.,@"K*O$'1HW`$Z95\-UVNIK(A%F@J MX;F8)!.0$>05*AQ+00G@',.&,AVUJR1/`W*B9YVGR=*53=#A"U@9@"9FQUA* M6*F=3442\#)6;7W4A:RDS\-RI5_!I_EJIF8+;#4K(_!4C!E#/:LNQ^M@S0C6 M@/VM[\6O]UZ`-MTDI+)>W9P-S);[>H M""Y/@:.*[!&LGYG'[K:P;\ND9<+##;7$CEK"+UN")60OCZ[34]]^IY,UP9OO MGZ*7=UOL_KL%BK4:U5V7G1<%([+7$7_? M+DO.4]_54W]H+YF`UZ,O- M9"0U[>=P0Q-FHI@6MY,,IQ0/VDY*$VJA6]!U/INY/".M)F;H<9&(VX;`.-;! MJ-/0SD?D]D5D)?],R9(B^4R.'J*/^SF,L1=057[T_/`VO"_*LDH"LN(%B[V= M7`OM0^CKO/I\*0M18>@V1*4XF%[/$#Q7``]T0[3;VZJ=6H<58.ER$R5)+[JT M7@"A2U,+[3+G3EZ`HN)/5-B0=-$_GV0*X$R`4(S*/F5D'B>FC-`.()1)R,@T MK_8OI4G](9O4J+6LO:R[=G,Z)&R^5$@`ZC!.1^'F**(.%-8\7N@P-2]OHP7Q M[/L?HQ<W#"PHD;R M4RUK9,7C'Z07W?*+5'<_^03\U]![[T=[+_X-QT(J:[]F>S5$0R=-CURZ9%[! MUT9*H;3W8V(1D8L*P78724QC=+0P`L6>01"[)W]5*VLK/?A8K+3HF@AB[-"X MA_W+D6ISN_O@!T?R6UXGX/:8)JD7TIT02>_35XK%$4-/U?0KPJZR?)&\`92U M@'@3U'&S1O):&I5F8`8)0]J"\3:3!-GMG^C0U1[_%#.-B+LM!3OR3GJ+@6>O M5#?]&SSFTT[ZMFD+GI0RJ#WMTVT/Q`:H!"G**#K;@=V M71IY!K0,Y*EW9-%-2JZX?_V2DFS),DF1$F7*%!?8 MN=4Q7PX?D8?GC>?\_%^OR^AL#1`.8?S+F_-W']Z<@=B'01@O?GGS[>GMY.GJ M]O;-?_WG/__3S__K[=NSQ\>S+S".012!S=G??1`!Y"7@;.:]PA@N-V,_M_@C/SI[Y>/=V<7[\[/SEZ29/7Y_?L?/WZ\`\'" M0V]A'(4Q>.?#Y?NSMV^W$_Z6D_;Y[-_?71#J*K\\PC0./I_]5/G3%0+YS`$A MZO/9Q8?SCV_/S]^>7\S.?_I\\9?/'_[R/]76<+5!X>(E.?M7__^0QA_^[2WM M',VB:*S1]H+GSV2M:(U"-X5@T;%>L\(IC'^ MY4UEB:_/*'H'T>(]F>;C^VW#-__\3V=YX\^O.-SK\./CMOGY^[]_O7OR7\#2 M>QO&./%B?Z\C'8S5]?S3IT_OLU_SUCC\C+-1[J"?H21!X!FW!?VOM]MF;^F? M",QO/YZ_>\7!F_^D$_Z,8`0>P?PLH^%SLEF!7][@<+F*P)OB;R\(S']Y@Q81 MSI#_\.GC!]K_7[Y`/UW2;10'UW$2)IO;>`[1,J/ZS1D=]]OC[1[Y""S2*,7H M-=L_2;$=W].F[X6CO>]*ZR/I^?L3V?&`SC&=WX0Q^4*A%SU`'-(IKB(/XW`> M@D"==,EQC[F(!P^!%A]!8?#D!22A[T7ZEW5+.-L23*($H)A\_C7HM([#T;03 M?.7AEYL(_L"W<1`BX">="#X_%R<3W"0M/R$WS`*/0#P&>!$&V(;RHVX$_`E$:D=N1 M,0G^D>*$?JL;B.Y!<@@G1B%!M:.T' M1FK\/O;^TPM$R0R@Y6V\!OD^Q%KV-7-@C2NX\4+TFQ>EX*\AD861_[(AIV:" M,4@P83%WH?<<1MFV^0H\VCZ8)+LNT_B1[BI$N$W&H;HL6"L=&O&Y>O'B!2!7 MSC5.0K*!0%!..[^"Y*.@)'R.`#E5`#]X&^\YZG1T6\W7QWXH<,XVG/9SJC"+ MSF_)AD_[ZI3FT;J^Y1+&3PGTOV]U.W*(;M*$_':+<9JI7IW6)3&^3NY*9YJN M,G'')Y<8T7TZ\53&4KL*M4R`&'<7!=DC:J3Y$:Q!G((;!)=/ M"34<+4)_$D5AUW,E'%X8H0TL_IV\]I];O%M&+E&CGR6:& M/+(S_'X6JS:15CGT&8,_4G*+7J][N;#E)M!C0,CNS!GKD1T=\+8\+_J1[%G]L*;HN^E91H=T44#@'!^PFC;GAJMWSCE"9MG?^4-/)^V&' MW$F*Y:TJ:AB-F-I;)VD,XH"&CN1_I9/I"7S))B?3$U+V9HQH=!!$^]`6$V8A M0!CX[Q9P_3X`X7N*-OU'!OO;#^=%`-"_D#_]/B%3!YD_.?(6V^'((0#1+V\. M?W_?.SU7*:+!)3=DHWG1?P,/7;@AZ5]^WWZ6">.S3)YQ M@CP:Y[%'E'R__G'$=(D*9S8]';?X=^<>'W>YX],W(L`*RLI_[IR8[HT25G>4>[0-R]G\_$CV; M*P(`HD;G`+S^/[#AT770[FCTE2[2S%J%IVE"8UZI#8!/K*C3L2C_`I=>&'-I M+'X^%C4W8030%?4<0<3_RONMCD7;(UB$]+J*DWMOR3T:]6;]4W<'%EZ4SSUY M#5D,N-ZB?YH*\]?39OD,(P9%^[_OZ*D*E1.T3YN'_.U`Y)\'$N5^G'?1XOTJ MB\Q]Z[^$T4X8G2.X5)%-ME1`%@,\@X@HR]D3!/+_WIR1%T90D1(^.7-Q9NS%)/5P57N:C."C^P]OX5E_Q8K43D?-2HU;:*$ MY6+4L'!$LA*>CPX>E@Y0`O23`XBMS)40_=NH(:K=P"4L_SYJ6-BB7(G.7QPZ MA\I6"<]_C!H>OBVN1.C3J!%B:G$[<,['+2++F`I*K.P3G)FFI2TX!UJLS8J5 M$`GQEMK"\N&#C#OGY?=W=U;<33/()=6M#SMS#SQDB*7Z[ M\+Q5;LT!48*W?ZF;=8H__UX\-:6Q3M/D!:!'X(-PG7E_[T%27)$UDX]:W_;F MJ>ZK*M[LR"VCUM@0W2@%U8=RC:1SVANB/EVFF6L]VP_T!0<"+R#&X1KD#]7I MNTZR-Z;SF??*7Y/2*$96N@NEL35-/4$#3FEOP/#5=;>Q&-59DD5QY"&R)/9T&: MG%7(]36RJE)#$"Z@WLP,K;LWKS1)%7TII,CB=9[XX'(:#X#N M>QC[*J17VIN@_GJYBN`&;)_22S62SNPUQ+0U"C'1W MPVL3L[^!Z'&'9,BC/P0Y,E,;"P[7=&^RVQJCNH*D'.GL#B;H?T!@1=3;ZU>: MM0%L;4(R^I),3S,K@BLBTVX>(B\/*B*L9$6M>.3>Y"Y%T,7$&AX!?;\(@NT# MW(IUA8B,H1_R5B+1T<1ZV"FZF"L0)-TZ,LU;Z^^!+ZE.\6%#H_0RK-4--X%4 M5Z-K8D5"82GA:QM6N`GJ$U`$E&092(V7S72^`EI>N7:-E\\\OL M+AXN;6[ZX;+Q`4=\F=D@JC;MZIX1V6#+#62G1-0%-RD/=BE2MMAX)W'S=8%0 MX'HN@;,KGED';"+[?8F;72\%-7.Z*E!MW@P.]V[4`92H=8F;G:J.I@W&<9.7 MZ+5Y97A2NTY!&:H'3]OZW+DU2KQ0;5L?/K<#2B(6S-:'T.T`XX4LVOH6NAU* MXGW4QCXS?#[.=R0?FAL8LH%ESZ'54)&7(&Q]']W&O;\O?^Z[T&TWW[!#!D;W MPK49#M%!M/>!JWP$Q+Y]JOX:I%.R@9,P1JDAQ'U;9VOB@98PJ3ZVM#4703OX M9.(B2\3L5'B[FI^J"/5MKAOJF_W]8N%FGQ<26J8H(SO([I:R"'$^+?_%(;>G MX0>3>4J529J\D-WQ9_DA^2LYZ#&(%="ZFO+4%ZT'03D_\ZU4%UN>Z]GUM,T% MI)]X0+J+ZAB`'BPT-TE=R[9[5)2A.KSO;?>EM(1H*U!T\IRDZ<1==9=*VTZ!K5^G,CVB0B%,=9R31#ZGW=K->0/TW4PT@NF%KIWTL/ASZ' M=G;;P5`]B8,O89020:Y!ZY#M/825%31)KF3;VA;%OCV.OY*),36Q$V$COGY- M"$IIB%]RWD%CCSF(-O0[),X)2!/5P!E%P:^!'.("M9(N"+`Y"L@C]QK1'9"F^R:H\&[I">Y M$@A]B]N8W`$`\[YHGS.:0W!W$S;P.EYK$GVYYR;XH+7VE!6K^R# M;]]2Y;1Q"6%K<].??[$>G\&P@7+]1D MN"92Q@+%&4XV1D=UE`&M]("X!@ZD/,R0URJRE:N-8=+/I&A+WWL\ MR'8>='NP.WS/G$;$=N9]VQ,5-E@MQ^CW=K%;M3TB;0^JY6]DFF:[Y7&R'*R= M[M4N6=&G'*68;-ZD:&L73A+>PTY9BFS=7UQ;=*?41"<1"==H4-U_WR2TB-B> MD$@)JT;?=[>L1):AQ?!"=,L^-/R\"_I,ZP<)PWHQ4-N>>9-GC-QG@%MCJO4A MY$WF3@J+NA?`/4Y@;S7;DQ7)X2*X,D83;2\'4-6![!(420K^+F=1[Z&,W=(< MV;(7N1&#G=*R6+,#:P%JW5*PV+)G=*@#]F=CD7RVQW_=TBW]BBV;3=H5U"T7 MBRT[2MV+;'N5&&%\QIY7C*]'VNX7<@]#VSX,W=]4N[>A#IEQ)4%L&[S3AG77 M8T#:E*\:-Z3\Z+'C5;@R^K2;5HZ[B>`/?$O6C0`!ST`0&,T@#[(-M80H"?_, MEDP_#MX5(WM`8!FF2]Q<[+CE8":"WR;!/])B_AE\!#Z,_3`">YKF#-(O](#@ M.B1?^W+S#0.B2^U,:A,_"=>Y&T0<#-C+5$;RLN5)4#,C11`FM(S1;5Y>)KA, MDWN8_#=(:+I4#@[2W2OX=Y8PU#JJ\E;,VJ:XN>4+ITFZ^VMAM70[-&TI`R0F:YS>)@QT(REU=S>B7)_@97 M-T4/'DJ*_YCX?Q"-/4NH3&Y@+U[0`O-%H47Z$Q$CSL6+51_.=,*LTTKU173= MS#`TG6=9P&F"=!K6?@4Q5S(4=C&YAADL=D%]Z6D49#5ZT1>XVGD.T]&0*ATGV-ADBUF?SF(#R'FR1:VU_,^%KYMXTC;/4%S M.YS-L1G13.T>L#F`#P%6<7C;_@Y.W?DO1E(82E5F]E&1Z4YI"^N&4RY2H<35 M5@&NKVVZBX4K(;3S@7X/`!Z$W^TP_&BG"*8;0U$H68FEG2_Z=6-Y$&18`FAG MPJF^`.3L0KND'Y?*N)X]M75,6'5727C[RAUE:XGQ/J&LV>L^VOE660^"#:ZT M$D25M\FG)#-KVHC"2)@215LU.CTHJL04EYC:F4JM?;PJ:U\VQ,NT2TUMP095 MA;-+:(CM&:U[VK&""+9V.;!'N&V;8QS;5?<9'Y0JSR2Z5?\YV2M*T<]0#3:S M/<^S'L3Z\0#9GD):#_8JSVILSSRM_"1E+PVI=':=4M*WT^G0"<;V#V=VL/YD MI[%..MER>TYI>_;2-L@)Y2G;\P=V0DYH+#E>DL`A(Z>6"*M;29[AW[]=,#M( MBM:ILN(J^P*$'I2,!K+?+]H66MP#[3H>N-XL!YETX+_M%1:ER['(RGR=BBR> M$F""YSEC+"0L?OKC\J2[;.#[N*B]O&+5#ZZIV[;6H.L"5"U[X_'*'!X_=3=] MRQ!!G")PF6)RDC"F2>#Q=/Y0_69Q\)0NEQ[:3.=/X2(.YZ%/W31YX"@MDPFC MT*>:3!"$^8(J6*ME`*?E%+-WAQ\^??R0O3K,"BQ>07*)HH3:..YA`O"VEF+> MM7AA*&II)*-OC11QMDE>:S-Y>I^3G!Y,OF!!&55?R;%)L^H4689[&@'!S\^B M.(C+W4O5D&2S#2O9UB6:+.DIXV`L[&)B#3=>B#+-Z7*3D?("(\(]<4[G5>1A MS,1?N;N1+((/4R;?.?S]]/,'44.>2, M##X@T\-,IHLB?A($U4+KN4!P#WYD/_$SCDAU-I,9XQF'04@V3^5PB+X+M[V6 MD_,M]FDM[]1`*%1/MDW M-,FQ*ELM*CW!*M9UCF=RL0),KJ'!UE"[GG!4-7O8&DW7$[PJ;^):1=,-%U%U M96O/)%T:'FS-!:9=TQN=[ZP7!"44&VM+$_<+J$B'WT+J]J@,I%INJQ'XCINM M1M4-*J^`V\I0I8TZ>^=:XH*W%;!FF]/NN.KA`<<#TJ1G?@=)^23H!J)[D#VG M(O\JBHX7?]BJTE=>Y*>1/@]\-DNX!D_`IZ]AP^PE1Y0&5#VBZ2?3I$B/>.VA MF'RJ'2%"[X^&48UX:FO4-*0\YC:WQ><]%*^EGJ^[]\B.\TGWVQBGGR9=4B,,I;:.8V^R$/.=?V:L@$)SZ2V M68S)`_KNC=KKFNH1+04!N\*G^T2P.3]W"T?&"M(GB6LP&R>FJBS95C^'K)S$ MT`?T\55;U2SG\65;DW3?R&.W(/>!IS;F>TQ[G4GE_P&289+0BZ+-(6SW,*D@ M5RK\U0]2M0FH&0+T".\30GT@OY,.;@Q1]+.>L4VH-!TIO]RP!Q"$FO4YXPDB MR+-*:1]^.-A0>[0PH+>QVX`>T0@#\<5]#*_B87M19?J`[#J8O<9I^NQ`>Y%E M/L-PFEWR0OSY[9WA=HB&VU)V[1<6R.Y52S%?5WSMMXZ MSE!0\8<[0:J;7$@M9PUS%ZF M4+[8J%)8ONQY0Z`-1VAJY_N,TOSD#5JMXL8.[B4:`3.*@\-3Q_!%M1SDN M]1*1;%(C#%T#:86*K6*@4R_8<1.J)YUC!6!?P[9:FC1BJ"``V&J(ZL"]1Z?- M=L2J]<8=B\93ONAB524TH>I0=D!?EA&^2NO(9C'+8C^\H(>9:(+E$B`_]*(' M;P500PP!JZT9JM$*(H(A9="EM:"!>E$?VY28,#L8.4'YO^LTY7_]O3Q!/+U! MT-!(ZLSRR-,O651X3#85FYQ8D548P,AW8&E`G$9F\9^1J01A@HR&YNF]VKXH M]AI#=B0Z6FMLV!:JS3.4<2Y+,G?Z`-W6ON; M:?=H[&0"SV\Q`EY$2:`OOJ9QR3PYJ`HZF*6?VM"5Z#_H8(3^IU\AT4#C+)78 M"L88$FG_FA9F(!(\!EA!,&HUE`GUJEEBV6E1PZC8'QYM'TR279=I_$BW#RU:D55U-)+^(2-U1U*YL!UI'`.71$X!SWNC'=,;:HJZE[.K,U1KV(UA!Y>@$@^17!=$76<1/&Y&_D[.\J MA%]YV77.+4.I;5C#]5;+;R/P[_/;&Z:>!;HH#8-45\-K.A3>[L`:1'*?1]39 MZ+I*4:PI:$?8Q>@:,N:&,T#/A?>8J,=05G"AO(*+@:W@H_(*/@YA!<4UFOE( M#H^KW(4L-<;IARSI0;ZB[[90*65[&PUUHO)R0XP>N^T@J!87C.:T=J$XAFKK M]J1[[-F%V?82VST.1X58UKECI[_BN%`WN(3L]&\<%6(I1Y)ES@\30'=U/]E5 M:4.W;6DO2XJ$#\3VM'M]X"JM#=@>JM=H!&06=M3.8VR/O5&Q5HXN\J\M2*IF M4VMC!#4"6&<"UM83[HH9Q^JRQ>O"X<7;8VUOS*H[E)!`XG M#@,4;.K1H*;BG&#"R/*1V?KXKE?T+@[1L^M17J_H?3Q$SZX'>P..?#64MU;D M"Q.*;Z-%J'M>^?.^&;K)*.JK%R]>T#*#US@)E_1=:ADD/><@U#Y:VKH811?) M=!*13"<:1<-XQ%`W1DZ?HW"1<8C&[:8XVFA7_OO%X-?>8((^\`UT`$9ZJA/' M3"JB5M"AQGT'(6VVUB9W(/B="=+?(G7RG7\<#S9/5 MMP3JHB1Z`-1%5)@$6RNC&I&WO&>7D5WNR@&[C`:1+*6ZF327V+/.N"]*)E/A M7*0!D4+1'B.C_7.V"/R7./PC!?*/[/N:UB(LI8QU?4QI&L-TF<>-/8;X^PT" MA+43%@1P\N@E,G@(NP]E;7\#X>(E`<%D3:ZX!?@-1N13D,^W45RD>!SG7M/B M7LNY]14Y4F%"=Y6W$TD85'Q+?%K3T:"1F2Q577N]_*-;3TASL++#N1FQVIKMO%J2?A+0_-99X6C.,KT M-)S"F-(EF[JXTG9`B9>;Z=YK;8+R_>KU@@![1D/S]%:0S/^)R4',=-1SJ66( M^IM?79-S@]?:/.7;THI?^,9E00?S]-][2W%N06YS\[2+W#BLEBXYNED/`J<. M\*_X._/RJ_UHIEIV;@:9QK4;^!XDT_G,>^6`UMS/>2QRI.Y@O$CDLK,RFPZ! M9B'_Y#0VXQTB(M@MQBD(>$+#7A,MIWOJ)Y`A/XFBD.:U8"7X%[7LB0KFAA*W-6FXX$O657,%7^ZPU=0@ M*>ONN_JJ1]36*+L6P'#U3ML==`H824@KMOO1%-`2Z7&V.[Q:PR0T0W3R6)&Q MGJ%%N$D9+&W/UMYD:Q``-I8LZP*3QFB]EPV8B'5'ZU_=2*+#DLJMSU?:@(U0 MZ[,^.6FKC7/G7/!\%SP345NY\X`]YV9VB\AV*;JGQHK/H>PG:R&TM0Z,A!52 M<&W9OH^DK*,[?"INI.-5LS$;LK-5GS+ MP<\ND*#R:.O2PR`@G&L%8EQ(*(@F**;:V>6F;$)80F84^>&AX#ZEIXQ<0QFS MGJR],*+`$F[]*^G+VVV]37=2V$WS5T/3-,$)D=O#>)$O3S=HW'F,H+6KPE*1 M7T15A;GM32IG?"FM7I>S)BW8[I26`X9YI=ONBY;=,W*)\2UU0;.%E9V:NG>U M6ZVYB\>6UWWO4/:*`?9^B!5%MD6=@);_?L\)65T'FL1$!+RHK6^ M:A$N[/-FKW/1^!2Z'Q&WYR!,LA"=.+A^784HSQU_&S]DR=][,D(VSVLE MFK4$7=>O`/DA;D[99XRF4_P*F:;=]P:N37**.(W,X7"J:!DJA:=Q'8\PB@@; MHC_V#UIULA/'S+-U;V*=6Y7TZMH MJ9>(D\1Y7\XS`;("!68".:#_/7]L_R6E*1%S.G.O3L7ZMMLLW).O/I#1=T!: M+'I[+@Y]EA];C=_."U#W`NBV%H[.^=@KDCK-EO;Z]O0;=WL*C]E39&T-2SB9 MKR&M:-B>_:!?4\W10LW:E%\YE5+,I_.)ZM9SV\-QC_AE6FA*[>)\/^7HQT2& M2\#`BS>?SLF0\)6VBYMUG^LH=\U^.?06X;?[W)_^%#(7SOU/DR`]?84!6 M;,`ME]NCQ;4`]ML8*45B55B\IMPF^0:2SW"RU]X%]=<)&D10?UM.S2HO2R[D MKR!Y@0&,X*(IH57/*JN: M`;3DE4CI<4)K=F.]?/?Q]F-M9CT%6G02FG,A*I\=.!NK*9YZGW/(R'`37_4Z MW\F?/G;Q]O[/'G/>0:+)-0B5^D0W%@6L9>I3-H%F%J7'FN;"%S;8[/T MQ5H>@>':^C%<[*4N(Z"Z4J?%ZB=_V]F>GM\U>KQ%,(`H!(#6H0\X M)SS_CN1?T_DC\.$B#O\D]&!Z9OF:Q)>*A_7?[%<0`>1%AIY-@&<8A MW4))N`;%F1)&DLCU-;&JVYAP1;!+)H<)9HM MG(@J+V3;?@%K$,$5!4MFO\OT-)OV4P]_E$L!JG,N.QQ$/7\/6Q7DGD6(/;58 M4@JUW8DA<3]686NXC&S?F%)W<14OJ2O&=G>+,FJ2HJBMK@[G(^=FU>E!K!F= M&?IHJ$K=,=8:I(\.LW:IZ9CF9Y.VT4=R,\[`>P)3 M^9<9^1U[3.(XC;3,?1G"!8AO`^#SISYH MX^Q^.0%_"P-P&\\A6A8J[^Y(7)-#ALA!O4IQ0M@X:K3,MAY/RR[X%;/+>M=^ M/'T;&&?]CQF+SH3G`V8V62"0'7\^0BK=S=CL,EO,@X>2396)-?A1&KN964MV M*'@':?>SGO(E-'9E-%2#IF*]LS7R M0@T0AD'=UG`!-6`.K?VVA@-(&3/V8IM4[0;'8\MFGT`N?DVTKK38Q\*>=L'JBSF3/S%6D2^E[$G[?6 M0L^L53Y)OO`=4:%B7)J1K[/4'\&7PSQ7RMUUT[L&$P2\/&G\0=W(AL8F3F2- MFOK!\CD_5T_9@?&Z=ERU3J'I>RV7-%NT%Q6,7["].4U[HB.,`-'S8R!PFC9W M,K./EDL89P\_\^I`>=4@[I9@M]:&:C%X90\]$HQ0F/US6_J&C:U,5\,(9^^Y MFZ'-FQFAM;!638)U)OM>I8@J'#R2.:V-/*P%S\D5C-=$SR"?._\7XI M#5J$O8K93F,?393MWH1,H+5V:NHW&D-FDR-4?B`7BGG]1TH( MH#R(,EVRT3*F1-3AE,NHA5VT[(IJLBH\G>?),W;?CO7Y&WIHH6J70^4V7J4) MYA]D=D,]-,`4)2]?0Q_!Q]B;>6@!!(="T'JX@:^B@IFW7-&"./%7/'L!R%MM^/BU&,4$G__JO8;+ M="FTJ.VW,4)E&#=3N==&RT[(KXL9O,ZL_E^])*4>!9YA2=!:"S4/+QX&TQAL M;6HS%(I,;Z+F^NB9_8`J]'":ZZ$'`;_1('G8R,1^?D#0!R#`-(:C-(!!Q#.2 M\=N;IWZGVU&E3XK^_1Z:OCV$_FZ,.G$" MFDH+,T]7=OKP="ZGV@N[:'KZM$BC3&H2O6^JM1E.XJ&*H9VP30X72+4R(I6=L3;N418IHQPK:]T@13:I9U>3E M:3OH:7(W2>7QTHMFW6*X\P;E25ZWT.S^3)J"<,TKM-1IO)Y6Q#>W]&LO?80; M+THV9$B?1@LM\OP&T_@>$`4O.GA)*==GW,\K-;B"Y=Y6:IO(/:RTZF%E%_Q^ M\R+J!5&U`\IT,_KPLS'ZC_W*3-]9MCI0GQD-6$9''>L6%?DE=^#]9)?$ MJA4\GA.U!,_);VSYC>OU*Z%SOSQ=\.\*;X;5OS;!P%7%&PHJUY M.OH&5B)>S_94'WU#RWT,:&LI\F,!*XZ+LSW':M_H"@!U@H'RW=4M4*F$WD[C M9K_0-\8QE?#::?_L%=[F![\[>,_MM)#VS8D%^9U*:.VTG_:Z0>Z9$U.EN'1'=SY=4`NO4MC;`BM-: ME.BVT.'6`#W#L>*KEEJKQ-DI;,HH<]*-E)@Z+4V#_>$`U@NGG76WG-?>BI?@ M.OVLG1%2+1U=B7<+O6W4]UN+Q'@EV"U4MQ7$(:5QF&B[BESUBESU'`Y[CIAJ M"H51(,$/F*HE\BG/B)WJ3!,:^\F7RD!C.XT]6G--L,+P.J9KL/YLZLQJP0R= M5TC561Y].XUN_8`MSMA1,A`[-W!_J0)<*<9>(!7F-QA1%<8^L&7(GB,JO-@K MHGKDE.W7N'!?H\O7X.3WV*+[T:';FC/7LD]L(?W)0=IEP^JU0;DZKN+L1+8* M:%))F83%2B_L"D15`T1:EVD5A7#[ M0=60G=^DR>0I?<;@CY1,<[W.K$F]F4H.S7F'UI*#-LY@,D2#B:EZ>:YB1R_* M[#X+:#*><)L/@'9A22=VVP%0W63BX38?`.U"RP:KZ1!H%M?)X[4>".5""S6_ MO3,8#<_QZ6(K]+J%+$O(4T33SA.%@4W10LO+IXY7L$8PVU"_DD]J M)D\]REYS<<^:MB?HX`RG0S2<:M^E['VA?1HCIH\M18T&R<.&1ND5FL3V&YU0 M*>':ZFR]B9W)JBZ2<(]A=7OH9VRV!_6PV<5X=7`N'**-:+>7_GC2[O8&&*_4 MVY[^2P^'>#JOPDZ^PE.XB+/*:G%R2&^3_-9I2%LD__9?9)>2\ROPZ#;/TDQ3 MG#;Y_VV"7[Z_TVMRQ.[!C\J61(2'I;&?HM9B)*$%!ZFM49.FQ^:=N&T^5;:?#>1=C2:NQ##.@.Q_>67 M'"H2XH;UT3PM@1*4.+0K2X@:4*U$/MO+;&R7>7541AX#;+OI M[#O3B3.=2(J(`E8\&KN(DP6=+*A-%LS0,Q*88%XB=#*5POO[>Y#HF!/"`TA6N MP1/P4$;0H"O7_TH)>D4'J?PJ"H\M_$:X*3X)ZUC3#C45P]]!PE%[_J/E"RD/'[D MQRN`$L+\9\@+R'F;8`PT/UPH"F6)-3&,#P^O3NG$8T]$YW M^IJHTSA.0>-0YP=.!W$ZB*3XJ1G)ST/17KNZFUP,O0Q96C+Y,"R M'*J'7^C_IY"MO0CD5=Z>7B!*9@`M*]@*?1<:!W9RL9.+G5SLY.(6]N3VS,Q) MP$X"=A(P1P+>/=XHI5CLC,"'.2`J\#2(K,(N0UF#=.X*9A\G:CO1\ABL7.;T M.6'2"9.J#Q79C-#)B4Y.=')B&SG1F3LME!;O0N\YC#(#3O&P.YC&C]2H@$X MD>7V^!;#9PS0FG[^VWB5)C3/`-DX49CM36DA4^=43C:M6TYV,.?NBDD<2."M M:!'6,8>3X)T$[R1X)\%+F8.U,+712/QR:I'6&]]%;3MMRFE3'&V*.DH'4BUF MGY0&;873V(0DQ(-0AG"7J&3@NHN3RGMEUN(S[^1Q)X]+BHY<)CP:R=I)?T[Z M4Y7^JJ^*\U@YVM8]PF,E3\G@:4J9LM_(25$CE**.2J?L\>4M0;:_T00;S)/G M9$,G&\K::N6/B9,6G;3HI,6NTJ*+PG`RH[ZH@>OE*H(;`)X`6H<^8-='F$09 M+5D&GZ+&Q)\@>`#D?)%V.&F,,^YO/K/HL4P)/_"1N"A MX/'@;2A;F_SP4%`EFWH@\V^,<;K,_]8:FPZ3:$DB6:,)/P+J-`7!#40W:4*8 M]BV9GS!ZT)PTLNU03N.TSV[O=#*GD[5/==B:*8U&/1/KLQHN]]$$Q2@CV44L M<*7>>A;=1U,BSMEGG'U&U3YS!2,B,4+DT4RW$X2\>)'],)#X+A7RV`*PR@@N MGFJ(5ITI6GB$O6?'XHI4\RTF<,_DC)/Z_7]+^=9#EHR7)4LLHQZ:P=@P9)G=M\ M"+0WOC+@MG=2XI#N+Z$$)/CH3MYQ\LZ@Y!U#N#2P]&%H64Q9\.?WE,)G#P/R M'_\?4$L#!!0````(`#4P;D,Y5O07=@X``#&,```1`!P`QML6CA?K8%D'=ANT>M+P4BTS5N)=$DJB?O7WY#Z,"U*BN1\ MJ8!>`EF<&<[P-R*'(VKR^<>',$!W1$C*V8/]@#Q'F<9^RQ+]/><'HV M&NW]^,,W__C\SUX/32;HG#-&@H"LT6\>"8C`BJ`9?N",AVLT]98DQ-^A6RR) MCSA#OYU.KM#A_@"AI5*KXW[__OY^G_@++'J"8`74R`"H-QCT!H>SP?OCP^^/#[[_W:;F MJ[6@BZ5"[[QO@?C@0T]SH,G^9-\RZU]HRID$ZG"%V1H-@P!--)=$$R*)N"/^ M?B)4&FL1#"&3)WN6@?='^UPL^M#%H/_;]54\*GO?_`/%M,M#M3AR61*W!IT^?^J;5HHYD;X'Q*J.?8WEKJ).& MOAG<@T'O:+#-I=8K(@O93$LQGU@$VR,FR"(*(BD>C#]HGH-/1P<6!P-\HK!X M!'PE^KJS/A#U@(H(ZMFLC_,Y/)K&5QF;/=@?^G&C1>V!:RJQWB:7Q-M?\+M^ MTE@\$%XD!#QP9:Q)J^8]='A]0HO9H*&X-_+@+8M9=$LQ#V5W1*IBKKBMF$^J ME2CFTBV:9V#Q*"P61'W!(9$K[)&ZO@$34$B8NN0B/"=S'`6@Z)\1#NB<$G\/ M8:4$O8T4V2*(V(;D!RWE,V:,*S.3F-_ZSFI%V9PG/^&&?ER.!0_(#!P&Z8M? M)J,*-54R)?8U:?^<>Y%6%#/_@BFJUB,0+D+3Y1ZB_LE>)46F1JJ(3^:44:/P MX&"`>BAEMR]!%(IE(4O8YWY>0EYX!'/WF/U@KCT<>%%@&*_@=\*<4%0QK@1, MEDSMP+G1K)PON9OB\5PP34%?XU#C^25E,`-3'-QP:90Y"["4B5]IP";`\$=- MAFK\C@"T3!#2ZQ3S"=,+Z"D.]#*`IDM"E.R0>RIR-QBF4[4DBL+H-(;1<#^" MY?N:6*)W6[I\VV%;"]L1Q*8A&0:*"`9&W)%B$%VR:M0^E**6W96(S]%XI>-= MJL-#/;GJ$%&0)5!"%^B*R^X1K0?C&9;+RX#?RQ'SJ2">*H;1):N&\6--&+5< M9`1W>)7C]84K(F<\FQ`W8S@6"\SH7\8<&&/)`^J;'T/FWUBF6K/IAOF<2B_@ M,A)D1A[4:<"]KQ;ZK]AIM2]]KR.IC`M^G&))C??8G9EI8!J%(19KW3:E"P9K MA8?!_X:>B?QA)XUN0%F/DL[==G*W"RP8C**\(6*ZQ$W]IIR[V@'^DW>`+T29 M.1Z!)&1$=7#N`N?(;!J3RW-RJ^`!OL;B*U'X-B`7?T:P89D2V/J"XD1"XQD1 M"E,V$UBGI892DMUGD1?KO-J9/N6=R=*C\Z)=O.@24_$K#B*R&5;9S!6J)53B M.3C(XZF%(2,-71.L;W;8[HRM?BYW?<#+>*OQ'.3QA`CC#IY\"I,",IVA&[S6 M4T2'Z"Z(3A5@L.2!3X2,)UE-NRO&]:55HWZ81]T6_&\4B^X`WP7P,QX$^)8+ ML_L>"H'9PC3L"GD3>=6@'[F@ZW=8"^KI5SU4YVC2W7W6)6PW.C?8Q0TF!`;! M9,[4&D(H)K%G1G-7-V@BK]H-WN?=(!&-C&QD"^^@WVG*CVXE^3."RXL[_;OA M%%_*70WK!^?IS@2A6%*'9AM2/FE&Y$U2/UGGU;[T\2520.A=>M7E_)\W&S33 MX7D]AWI,1K5?.*E!-S.$WL62.HQ;E2)JX"(OK$*UASFY1TN;SK5>+F_4P#_J MR*D&V*U\1`,_:"ZUVA.<-&2] MW$3G&W6.X&7C>AI)RHB4)IP?S^U@'M;Q))0?SZU`?A/'I\'[T/>-&3AP3_*] M0D?5;N3D-5-%OGN>+4P/;;2RCQ:B=^<0'M'N-%,]/\P<8.C_+XJCNTLN8#.A M]Q)P=4Z#2!$_N9'N5J\\YY&WG,#JQ(\ES@(UF9\807:[$=@R1HQ+XA\XH^8-<;C>;$/Y#WI>857 M>Y63B;4Z1VGO:-.]?A^'4@4095L^!)Y8X6V=AS7QL!R,M9:\6CS5_N"D<`O2 M*]T*]+PKT'3)A9H1$5J)AM+5I9"X&E,GE6I'&UI<3\O;3G-T2#9`,DM'_$R) MP,);KF&]CY-0$&I>47Q+`S-[)ID%?Z@REC&;Z,E50(QGPL,\\,\JN]I/G-2J ME1/)>CMAQA7GZTIW.)W:8<.UE9*TAH MP%D-?^T4:AZ`?R;@PY`SDY=./X*'&.`R M4M`VDC(R'ZL[@-?@J0:ZX%BFEADGR+//\4T\$,M%J>`.WV8;`3V@XY7)3'JP MWZ9J[83_!235Z!4?KT2Q#)0*Z9!JA!3$O5%H1E#^`EW/>!KF6+&4!140Z=`[ MP-[7J;<$43*^?R.H!PW7W"=!'NF7Z*+:4YS$HJ4"TCH@Q;-X+A?.V4ZEB4V$ MKY7I)=JD#I?H@XQ"G=NDK8:/B=;E\A"#PQPUVGK[ M6ROZWEE.-?IN7J_>"^LN+'^F9[SX.'PMEVC&7.T'3MZN_#1]A_TSS0RY$_+U MIH%:3-58.SDWYXA]!S'K@MGG"8W?HE6J82E(/.3/5V1K9?6UOH#./8?PB`E M453I7NP7K5J0_`[A(-CKM]?R;1AK&`X,!8:?9V+^)G;#6DN"FB8#;8')5UK" MW\3:_&->PVA@*3!ZZU!4@>V?^W9=./BU73?N,YC.A4*LL(Q=28E'%%>1O.*> M$53!HG_U4KZ>OM4;'/:.!OL/TD]4;*+!9J2;:9#R-=6@L(9BW;Y3!MWIAUK= M55:B+.O6=%E8^K)/`B4S6;V-K.:C[Y2=K#4(>2X]$I_T\`\^/D4%JV)F0S4X M^[*;)E6E19\`C+[3%)?'"G56JE/$E_YXFB(%93_K:6(S9K]Z&S'-=&SX]$LC-A5*<$]+(;TTK81L`Z'.G6GP2/5G$GOCKV::AK M['&F.WI$]W,>8LJ*M$];8OWC>L+'OKGYH@;08UJN=L#6`0ZO27A+A*WT]OU6 MJ:Q[^YTPXF%7;;>M3:J?4KX@;.03S]'<;6J3XF<0<^DRH8[:^896*6VG_,Q! M,4\78\R>QPNFB"#^.5;$MJ@)5VQN&I0=ZRKPT](9:8X#^:I6ZT^"")8_"0PZ M^\4VYFGLR97"K041;VE+"`&>_N0I^?C>];\RBG8Y8EY)&L":S)D^L?BH00YM MVTQ+SEA8.=8)T>NRN;PQ/><,K,5A>V*J\UNZXO;IH0+@B@G:A-8YF1,(R?WD M%=F$>'P1IY4;0Z>6QHG=U]_Y[H$3N%%MZ1\YWKQL"(>Q'[Z M`Q@YGBI9F.)Y-XI9+J/3^VPW5V%,PW:-GE\'$?- M^,6#(KK$6^S0N:QD%5&[`A:[5F;M(C-%L?Y3!;5H:W"SQ)*,&4FSY3-!"W+I ME51M\EBC*#Q>-\W"MK:I3KGZ&G&UR]R%/LD(H6B!3?FF=BDNB:Z"H&.'39JQP(@JLO8;=!-@ M9B<\'C7-96C7NESUB8TL#2@;<;4M:'3?760OTZZ)6G(_Q2N[#:2$WN52>$\3 M8WL!Q.!$01#3:$CB`YJ%QLG)E;W@:Z#,ON>PA*]Q8':# MGCY&NR#F*[XQ@WW1%&=%-6.+'B5-W!E\>143O9TG3S'CT6:WTW./Y$L);F:C?&)I_ M397;S!?MIG9A;M$.JK;ZY=Y1C['ER.^T*2X?DZ>(:_E(&8QE:>&/THAG9PEM MBWY2)]_^&-XJ$GVZWI#QG!Z^-7XPR\JZQS M&+Z&UL550%``.6K812=7@+``$$)0X```0Y`0``4$L! M`AX#%`````@`-3!N0^F[V#-)#@```[$``!4`&````````0```*2!C*D``')G M;',M,C`Q,S`Y,S!?8V%L+GAM;%54!0`#EJV$4G5X"P`!!"4.```$.0$``%!+ M`0(>`Q0````(`#4P;D/XE'WS\"X``'%Z`P`5`!@```````$```"D@22X``!R M9VQS+3(P,3,P.3,P7V1E9BYX;6Q55`4``Y:MA%)U>`L``00E#@``!#D!``!0 M2P$"'@,4````"``U,&Y#-!I%8^18```UW@0`%0`8```````!````I(%CYP`` M&UL550%``.6K812=7@+``$$)0X```0Y`0`` M4$L!`AX#%`````@`-3!N0X(6MFLC,0``M0,$`!4`&````````0```*2!ED`! M`')G;',M,C`Q,S`Y,S!?<')E+GAM;%54!0`#EJV$4G5X"P`!!"4.```$.0$` M`%!+`0(>`Q0````(`#4P;D,Y5O07=@X``#&,```1`!@```````$```"D@0AR M`0!R9VQS+3(P,3,P.3,P+GAS9%54!0`#EJV$4G5X"P`!!"4.```$.0$``%!+ 4!08`````!@`&`!H"``#)@`$````` ` end XML 46 R33.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stock-Based Compensation (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

Stock-based compensation expenses $ 978 $ 414 $ 2,524 $ 732

Research and development

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

Stock-based compensation expenses 594 278 1,664 461

General and administrative

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

Stock-based compensation expenses $ 384 $ 136 $ 860 $ 271

X

- Definition

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 47 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stockholders' Equity (Tables)
9 Months Ended

Sep. 30, 2013

Common Stock Reserved for Future Issuance

The following shares of common stock are reserved for future issuance at September 30, 2013:

 September 30,
2013 December 31,
2012

Common stock options outstanding
 4,160,215 4,661,549

Common stock options available for future grant
 2,161,410 946,403

Employee Stock Purchase Plan
 460,283 150,000

Convertible note payable
 1,400,848 1,366,787





Total common shares reserved for future issuance
 8,182,756 7,124,739





Stock Option Activity

The following table summarizes our stock option activity under all stock option plans for the nine months ended September 30, 2013 (in thousands):

 Number of
options Weighted
average
exercise
price

Options outstanding at December 31, 2012
 4,720 $ 2.11

Granted
 361 $ 7.91

Exercised
 (720 ) $ 0.80

Canceled/forfeited/expired
 (201 ) $ 3.44



Options outstanding at September 30, 2013
 4,160 $ 2.78

Assumptions Used to Estimate Fair Value of Stock Options Using Black-Scholes Option Pricing Model

Stock-Based Compensation

The following table summarizes the weighted average assumptions we used in our Black-Scholes calculations:

 Three months ended
September 30, Nine months ended
September 30,

 2013 2012 2013 2012

Employee Stock Options:


Risk-free interest rate
 1.7 % * 1.4 % 1.1 %

Expected dividend yield
 0.0 % * 0.0 % 0.0 %

Expected volatility
 72.7 % * 67.8 % 71.0 %

Expected term (years)
 6.1 * 6.1 6.1

* No stock options were granted during the three months ended September 30, 2012.

Stock-Based Compensation

The following table summarizes the allocation of our stock compensation expense (in thousands):

 Three months ended
September 30, Nine months ended
September 30,

 2013 2012 2013 2012

Research and development
 $ 594 $ 278 $ 1,664 $ 461

General and administrative
 384 136 860 271









Total
 $ 978 $ 414 $ 2,524 $ 732

X

- Definition

Schedule Of Shares Reserved For Future Issuance Table

+ References

No definition available.

+ Details

Name: rgls_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock

Namespace Prefix: rgls_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 48 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8

Basis of Presentation and Summary of Significant Accounting Policies (Policies)
9 Months Ended

Sep. 30, 2013

Basis of Presentation

Basis of Presentation

The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management’s opinion, the accompanying financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results for the interim periods presented.

Interim financial results are not necessarily indicative of results anticipated for the full year. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and footnotes included in the Annual Report on Form 10-K for the year ended December 31, 2012 for Regulus Therapeutics Inc. (“we,” “us,” “our,” or the “Company”), from which the balance sheet information herein for the year ended December 31, 2012 was derived.

On September 7, 2012, our board of directors approved a one-for-two reverse stock split of our common stock. The accompanying condensed financial statements and notes to the condensed financial statements give retroactive effect to the reverse split for all periods presented. No further splits (or reverse splits) of our common stock have been contemplated as of September 30, 2013.

In October 2012, we completed an initial public offering and concurrent private placement of 18,980,982 shares of common stock at an offering price of $4.00 per share. In addition, principal and interest of $10.8 million from convertible notes outstanding were automatically converted upon the closing of the initial public offering into an aggregate of 2,703,269 shares of our common stock. We raised a total of $70.0 million in net proceeds from our initial public offering and concurrent private placement, after deducting underwriter discounts, commissions and other offering expenses.

In July 2013, we completed a public offering of 5,175,000 shares of common stock at an offering price of $9.50 per share. The shares were registered pursuant to a registration statement on Form S-1. We raised a total of $45.8 million in net proceeds, after deducting underwriting discounts, commissions and other offering expenses.

Use of Estimates

Use of Estimates

Our financial statements are prepared in accordance with GAAP. The preparation of our financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions.

Revenue Recognition

Revenue Recognition

As of September 30, 2013, we have ongoing strategic alliance agreements and collaborations with GlaxoSmithKline plc (“GSK”), Sanofi, AstraZeneca AB (“AstraZeneca”) and Biogen Idec MA Inc. (“Biogen Idec”). Our revenues generally consist of upfront payments for licenses or options to obtain licenses in the future, research and development funding and milestone payments. We recognize revenues when all four of the following criteria are met: (1) persuasive evidence that an arrangement exists; (2) delivery of the products and/or services has occurred; (3) the selling price is fixed or determinable; and (4) collectability is reasonably assured.

For these multiple element arrangements, deliverables under our agreements are accounted for as separate units of accounting provided that (i) a delivered item has value to the customer on a stand-alone basis; and (ii) if the agreement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item is considered probable and substantially in the control of the vendor. The allocation of consideration amongst the units of accounting under our strategic alliance agreements and collaborations are derived using a “best estimate of selling price” if vendor specific objective evidence and third-party evidence of fair value is not available.

Milestones

We recognize revenue from milestone payments when earned, provided that (i) the milestone event is substantive in that it can only be achieved based in whole or in part on either our performance or on the occurrence of a specific outcome resulting from our performance and its achievability was not reasonably assured at the inception of the agreement; (ii) we do not have ongoing performance obligations related to the achievement of the milestone; and (iii) it would result in the receipt of additional payments. A milestone payment is considered substantive if all of the following conditions are met: (i) the milestone payment is non-refundable; (ii) achievement of the milestone was not reasonably assured at the inception of the arrangement; (iii) substantive effort is involved to achieve the milestone; and (iv) the amount of the milestone payments appears reasonable in relation to the effort expended, the other milestones in the arrangement and the related risk associated with the achievement of the milestone. Any amounts received under the agreements in advance of performance, if deemed substantive, are recorded as deferred revenue and recognized as revenue as we complete our performance obligations.

Generally, the milestone events contained in our strategic alliance agreements and collaborations coincide with the progression of our product candidates from target selection, to clinical candidate selection, to clinical trial, to regulatory approval and then to commercialization. The process of successfully discovering a new development candidate, having it approved and ultimately sold for a profit is highly uncertain. As such, the milestone payments we may earn from our partners involve a significant degree of risk to achieve. Therefore, as a product candidate progresses through the stages of its life-cycle, the value of the product candidate generally increases.

Deferred Revenue

Deferred Revenue

Amounts received prior to satisfying the above revenue recognition criteria are recorded as deferred revenue in the accompanying condensed balance sheets. Amounts not expected to be recognized within the next 12 months are classified as non-current deferred revenue.

Stock-Based Compensation

Stock-Based Compensation

We account for stock-based compensation expense related to stock options granted to employees and members of our board of directors by estimating the fair value of each stock option on the date of grant using the Black-Scholes model. We recognize stock-based compensation expense using the accelerated multiple-option approach. Under the accelerated multiple-option approach (also known as the graded-vesting method), we recognize compensation expense over the requisite service period for each separately vesting tranche of the award as though the award was in substance multiple awards, resulting in accelerated expense recognition over the vesting period.

We account for stock options granted to non-employees other than members of our board of directors, which primarily consist of members of our scientific advisory board, using the fair value approach. Stock options granted to non-employees are subject to periodic revaluation over their vesting terms.

Fair Value Option

Fair Value Option

Applicable accounting guidance permits entities to choose, at specified election dates, to measure specified items at fair value if the decision about the election is: 1) applied instrument by instrument, 2) irrevocable, and 3) applied to an entire instrument.

In July 2012, we amended and restated our $5.0 million convertible promissory note originally issued in February 2010 to GSK (“2010 GSK Note”), which was accounted for as a debt extinguishment of the original note. We elected to measure the 2010 GSK Note under the fair value option. Upon initial measurement, the difference between the carrying value of the original note and the fair value of the 2010 GSK Note was recorded as a loss on extinguishment of debt to non-operating earnings. Thereafter, any change to the fair value of the 2010 GSK Note is recorded as a gain (loss) from valuation of convertible note payable to non-operating earnings.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

In February 2013, the FASB issued Accounting Standards Update No. 2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income (“ASU 2013-02”). This update will require companies to present information about amounts reclassified out of accumulated other comprehensive income and their corresponding effect on net income in one place and reference the amounts to the related footnote disclosures. Current accounting standards present this information in different places throughout the financial statements. ASU 2013-02 was effective for us for the nine months ended September 30, 2013. The adoption of ASU 2013-02 had no impact on our financial condition, results of operations, or cash flows.

In July 2013, the FASB issued Accounting Standards Update No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (“ASU 2013-11”). This update provides explicit guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. This guidance is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013, with an option for early adoption. We intend to adopt this guidance in 2014, and do not believe the adoption of this standard will have a material impact on our financial condition, results of operations or related financial statement disclosures.

X

- Definition

The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.

+ References

No definition available.

+ Details

Name: us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.

+ References

No definition available.

+ Details

Name: us-gaap_FairValueMeasurementPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.

+ References

No definition available.

+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for recognizing unearned income or deferred revenue related to transactions involving the sale of a product or performance of services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section B

-Paragraph Question 1

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.B.Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2197196

+ Details

Name: us-gaap_RevenueRecognitionDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section B

-Paragraph Question 1

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.B.Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18823-107790

+ Details

Name: us-gaap_RevenueRecognitionPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b),(f)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2228939

+ Details

Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6143-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6132-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6061-108592

+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 49 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8

Summary of Adjustment for Net Loss for Diluted Net Loss per Share Calculation (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dilutive Securities Included In Computation Of Earnings Per Share [Line Items]

Net loss $ (2,164) $ (5,685) $ (16,741) $ (10,532)

Less: gain from change in valuation of note payable 671 (331) (3,787) (331)

Net loss used to compute diluted net loss per share $ (2,835)

X

- Details

Name: rgls_DilutiveSecuritiesIncludedInComputationOfEarningsPerShareLineItems

Namespace Prefix: rgls_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1377-109256

+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate amount of gains or losses resulting from nonoperating activities (for example, interest and dividend revenue, property, plant and equipment impairment loss, and so forth).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 9

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7,9)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_NonoperatingGainsLosses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 50 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8

Strategic Alliances and Collaborations (Tables)
9 Months Ended

Sep. 30, 2013

Revenue from Strategic Alliance

The following table summarizes the amounts included in our revenues which resulted from our strategic alliances and collaborations (in thousands):

 Three months ended
September 30, Nine months ended
September 30,

 2013 2012 2013 2012

Sanofi
 $ 5,422 $ 2,500 $ 10,828 $ 7,530

GSK
 144 186 1,634 1,809

AstraZeneca
 465 94 1,394 94

Biogen Idec
 87 29 259 29









Total
 $ 6,118 $ 2,809 $ 14,115 $ 9,462

X

- Definition

Revenue from Strategic Alliances Table

+ References

No definition available.

+ Details

Name: rgls_RevenueFromStrategicAlliancesTableTextBlock

Namespace Prefix: rgls_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 51 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8

Document and Entity Information
9 Months Ended

Sep. 30, 2013

Nov. 08, 2013

Document Information [Line Items]

Document Type 10-Q

Amendment Flag false

Document Period End Date Sep. 30, 2013

Document Fiscal Year Focus 2013

Document Fiscal Period Focus Q3

Trading Symbol RGLS

Entity Registrant Name REGULUS THERAPEUTICS INC.

Entity Central Index Key 0001505512

Current Fiscal Year End Date --12-31

Entity Filer Category Smaller Reporting Company

Entity Common Stock, Shares Outstanding 41,777,326

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Details

Name: dei_DocumentInformationLineItems

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

XML 52 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8

Business, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)
1 Months Ended 9 Months Ended 1 Months Ended

Jul. 31, 2013

Sep. 30, 2013

Sep. 30, 2012

Oct. 30, 2012

Jul. 31, 2012

Oct. 30, 2012

Convertible Notes

Oct. 30, 2012

Initial Public Offering

Organization And Summary Of Significant Accounting Policies [Line Items]

Common stock shares, issued 5,175,000 18,980,982

Common stock shares, par value $ 9.50 $ 4.00

Outstanding principal amount $ 10,800,000 $ 5,000,000

Conversion of convertible notes into common stock shares 1,256,232 2,703,269

Proceeds from issuance of common stock $ 45,800,000 $ 46,562,000 $ 102,000 $ 70,000,000

X

- Details

Name: rgls_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems

Namespace Prefix: rgls_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.16)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16(a))

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 16

-Article 9

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20, 22

-Article 5

+ Details

Name: us-gaap_ConvertibleNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_DebtConversionConvertedInstrumentSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount per share or per unit assigned to the consideration received of equity securities issued for development stage entities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 215

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6472370&loc=d3e38297-110927

+ Details

Name: us-gaap_EquityIssuancePerShareAmount

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

Condensed Statements of Operations and Comprehensive Loss (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenues:
Total revenues	$ 6,118	$ 2,809	$ 14,115	$ 9,462
Operating expenses:
Research and development	7,106	5,248	21,710	14,735
General and administrative	1,917	1,093	5,545	2,998
Total operating expenses	9,023	6,341	27,255	17,733
Loss from operations	(2,905)	(3,532)	(13,140)	(8,271)
Other income (expense):
Interest and other income	72	20	207	74
Interest expense	(7)	(110)	(25)	(294)
Loss on extinguishment of debt		(1,738)		(1,738)
Gain (loss) from changes in valuation of convertible note payable	671	(331)	(3,787)	(331)
Loss before income taxes	(2,169)	(5,691)	(16,745)	(10,560)
Income tax benefit	(5)	(6)	(4)	(28)
Net loss	(2,164)	(5,685)	(16,741)	(10,532)
Other comprehensive loss:
Unrealized gain on short-term investments, net	37	10	8	44
Comprehensive loss	(2,127)	(5,675)	(16,733)	(10,488)
Net loss per share:
Basic	$ (0.05)	$ (15.98)	$ (0.45)	$ (41.03)
Diluted	$ (0.07)	$ (15.98)	$ (0.45)	$ (41.03)
Weighted average shares used to compute net loss per share:
Basic	40,154,812	355,735	37,367,368	256,682
Diluted	41,555,660	355,735	37,367,368	256,682
Strategic Alliances and Collaborations
Revenues:
Total revenues	$ 6,118	$ 2,809	$ 14,115	$ 9,462

Net Loss Per Share - Additional Information (Detail) (USD $) In Millions, except Per Share data, unless otherwise specified	Sep. 30, 2013
Schedule Of Earnings Per Share Basic And Diluted [Line Items]
Convertible notes payable	$ 5.4
Conversion price per share of convertible notes payable	$ 4.00

Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets measured at fair value on a recurring basis	$ 123,790	$ 96,911
Convertible Notes Payable
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Liabilities measured at fair value on a recurring basis	13,921	10,134
Cash Equivalents
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets measured at fair value on a recurring basis	33,377	39,363
Corporate Debt Securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets measured at fair value on a recurring basis	68,617	44,856
Commercial Paper
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets measured at fair value on a recurring basis	999	6,492
Certificates of Deposit
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets measured at fair value on a recurring basis	13,770	6,200
US Government-Sponsored Agencies Debt Securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets measured at fair value on a recurring basis	7,027
Fair Value, Inputs, Level 1
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets measured at fair value on a recurring basis	33,377	39,363
Fair Value, Inputs, Level 1 \| Cash Equivalents
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets measured at fair value on a recurring basis	33,377	39,363
Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets measured at fair value on a recurring basis	90,413	57,548
Fair Value, Inputs, Level 2 \| Corporate Debt Securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets measured at fair value on a recurring basis	68,617	44,856
Fair Value, Inputs, Level 2 \| Commercial Paper
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets measured at fair value on a recurring basis	999	6,492
Fair Value, Inputs, Level 2 \| Certificates of Deposit
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets measured at fair value on a recurring basis	13,770	6,200
Fair Value, Inputs, Level 2 \| US Government-Sponsored Agencies Debt Securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets measured at fair value on a recurring basis	7,027
Fair Value, Inputs, Level 3 \| Convertible Notes Payable
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Liabilities measured at fair value on a recurring basis	$ 13,921	$ 10,134

Stock Option Activity (Detail) (USD $) In Thousands, except Per Share data, unless otherwise specified	9 Months Ended
	Sep. 30, 2013
Number of options
Options outstanding at December 31, 2012	4,720
Granted	361
Exercised	(720)
Canceled/forfeited/expired	(201)
Options outstanding at September 30, 2013	4,160
Weighted average exercise price
Options outstanding at December 31, 2012	$ 2.11
Granted	$ 7.91
Exercised	$ 0.80
Canceled/forfeited/expired	$ 3.44
Options outstanding at September 30, 2013	$ 2.78

Summary of Short-Term Investments (Detail) (USD $) In Thousands, unless otherwise specified	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Investment [Line Items]
Amortized cost	$ 90,443	$ 57,590
Unrealized Gains	20	7
Unrealized Losses	(50)	(49)
Estimated fair value	90,413	57,548
Corporate Debt Securities
Investment [Line Items]
Maturity	2 or less	2 or less
Amortized cost	68,649	44,898
Unrealized Gains	18	7
Unrealized Losses	(50)	(49)
Estimated fair value	68,617	44,856
Commercial Paper
Investment [Line Items]
Maturity	1 or less	2 or less
Amortized cost	999	6,492
Estimated fair value	999	6,492
Certificates of Deposit
Investment [Line Items]
Maturity	2 or less	1 or less
Amortized cost	13,770	6,200
Estimated fair value	13,770	6,200
US Government-Sponsored Agencies Debt Securities
Investment [Line Items]
Maturity	1 or less
Amortized cost	7,025
Unrealized Gains	2
Estimated fair value	$ 7,027

Subsequent Events - Additional Information (Detail) (Biogen Idec, USD $) In Millions, unless otherwise specified	9 Months Ended	1 Months Ended
	Sep. 30, 2013	Oct. 31, 2013 Subsequent Event
Subsequent Event [Line Items]
Payment received pursuant to the terms of collaboration and license agreement	$ 0.8	$ 0.1

Condensed Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	41,774,442	35,831,808
Common stock, shares outstanding	41,774,442	35,831,808

Subsequent Events	9 Months Ended
Subsequent Events	Sep. 30, 2013
Subsequent Events	9. Subsequent Events In October 2013, we received a payment of $0.1 million from Biogen Idec for work performed pursuant to the terms of our collaboration and license agreement based on our research to discover microRNAs as biomarkers for MS.

Condensed Balance Sheets (USD $) In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 33,490	$ 40,552
Short-term investments	90,413	57,548
Contracts and other receivables	95
Prepaid and other current assets	1,288	829
Total current assets	125,286	98,929
Property and equipment, net	3,981	3,310
Intangibles, net	1,145	1,154
Other assets	178	125
Total assets	130,590	103,518
Current liabilities:
Accounts payable	1,140	311
Accrued liabilities	1,705	658
Accrued compensation	1,228	1,348
Current portion of deferred revenue	9,454	10,451
Total current liabilities	13,527	12,768
Convertible notes payable, at fair value	13,921	10,134
Deferred revenue, less current portion	7,138	17,756
Other long-term liabilities	1,558	767
Total liabilities	36,144	41,425
Stockholders' equity:
Common stock, $0.001 par value; 200,000,000 shares authorized, 41,774,442 and 35,831,808 shares issued and outstanding at September 30, 2013 (unaudited) and December 31, 2012, respectively	42	36
Additional paid-in capital	171,608	122,528
Accumulated other comprehensive loss	(44)	(52)
Accumulated deficit	(77,160)	(60,419)
Total stockholders' equity	94,446	62,093
Total liabilities and stockholders' equity	$ 130,590	$ 103,518

Convertible Notes Payable - Additional Information (Detail) (USD $)					1 Months Ended
	Sep. 30, 2013	Dec. 31, 2012	Oct. 30, 2012	Jul. 31, 2012	Oct. 31, 2012 October 2012	Oct. 31, 2012 October 2012 Convertible Debt GSK
Debt Instrument [Line Items]
Convertible notes issued						$ 5,400,000
Outstanding principal amount			10,800,000	5,000,000	5,000,000
Accrued interest on convertible notes					400,000
Conversion rate					Oct. 09, 2015
Conversion price per shares	$ 4.00				$ 4.00
Convertible note payable, at fair value	$ 13,921,000	$ 10,134,000

Strategic Alliances and Collaborations - Additional Information (Detail) (USD $)	1 Months Ended	9 Months Ended		9 Months Ended																				9 Months Ended				1 Months Ended				1 Months Ended		9 Months Ended		1 Months Ended	9 Months Ended				9 Months Ended
	Jul. 31, 2013	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013 GSK	Sep. 30, 2013 GSK Immuno-Inflammatory Alliance	Sep. 30, 2013 GSK HCV Alliance	Sep. 30, 2013 GSK Preclinical Immuno-Inflammatory Alliance	Sep. 30, 2013 GSK Preclinical HCV Alliance	Sep. 30, 2013 GSK Clinical Immuno-Inflammatory Alliance	Sep. 30, 2013 GSK Clinical HCV Alliance	Sep. 30, 2013 GSK Regulatory Immuno-Inflammatory Alliance	Sep. 30, 2013 GSK Regulatory HCV Alliance	Sep. 30, 2013 GSK Commercialization Immuno-Inflammatory Alliance	Sep. 30, 2013 GSK Fourth Micro RNA Targets Immuno-Inflammatory Alliance	Sep. 30, 2013 GSK Development Candidate Immuno-Inflammatory Alliance	Sep. 30, 2013 GSK Phase One Clinical Trial Immuno-Inflammatory Alliance	Sep. 30, 2013 GSK Phase One Clinical Trial HCV Alliance	Sep. 30, 2013 GSK Phase Two Clinical Trial Immuno-Inflammatory Alliance	Sep. 30, 2013 GSK Phase Two Clinical Trial HCV Alliance	Sep. 30, 2013 GSK Proof-of-Concept Trial Immuno-Inflammatory Alliance	Sep. 30, 2013 GSK Proof-of-Concept Trial HCV Alliance	Sep. 30, 2013 GSK Commercialization Milestones HCV Alliance	Sep. 30, 2013 GSK Development Commercialization And License Agreement	Sep. 30, 2013 GSK Minimum Immuno-Inflammatory Alliance	Sep. 30, 2013 GSK Minimum HCV Alliance	Sep. 30, 2013 GSK Maximum Immuno-Inflammatory Alliance	Sep. 30, 2013 GSK Maximum HCV Alliance	Jun. 30, 2013 Sanofi	Sep. 30, 2013 Sanofi HCV Alliance	Sep. 30, 2013 Sanofi Preclinical HCV Alliance	Sep. 30, 2013 Sanofi Clinical HCV Alliance	Jul. 31, 2013 Sanofi Development Commercialization And License Agreement	Jul. 31, 2013 Sanofi Research and Development	Sep. 30, 2013 Sanofi Minimum HCV Alliance	Sep. 30, 2013 Sanofi Maximum HCV Alliance	Oct. 31, 2012 Astra Zeneca	Sep. 30, 2013 Astra Zeneca Agreement	Sep. 30, 2013 Astra Zeneca Preclinical	Sep. 30, 2013 Astra Zeneca Clinical	Sep. 30, 2013 Astra Zeneca Commercialization	Sep. 30, 2013 Astra Zeneca Minimum	Sep. 30, 2013 Astra Zeneca Maximum	Sep. 30, 2013 Biogen Idec	Sep. 30, 2013 Biogen Idec Research Tax Credit Carryforward	Sep. 30, 2013 Biogen Idec Identification Of Micro Rna Biomarker	Sep. 30, 2013 Biogen Idec Validation Of Micro Rna Biomarker	Sep. 30, 2013 Biogen Idec Longitudinal Study Of Patient Samples On Ms Therapy
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Option expiry date																												2013-12
Option extension period																												30 days
Initial upfront option payment																																$ 2,500,000	$ 25,000,000				$ 3,000,000						$ 800,000
Upfront payment creditable against future accounts receivables																																1,250,000
Upfront payment non-creditable portion recognized																																1,250,000
Deferred revenue																							3,700,000										10,100,000				4,300,000
Revenue through milestone payments					432,500,000	144,500,000	15,500,000	5,500,000	87,000,000	29,000,000	150,000,000	50,000,000	180,000,000	500,000	5,000,000	4,000,000	4,000,000	5,000,000	5,000,000	20,000,000	20,000,000	60,000,000							165,000,000	15,000,000	33,000,000						498,000,000	5,000,000	123,000,000	370,000,000				1,300,000	250,000	500,000	500,000
Royalties based on percentage of net sales																								10.00%	10.00%	20.00%	20.00%							8.00%	12.00%						10.00%	20.00%
Deferred revenue recognition period				8 years
Acceleration of remaining amortization of upfront payment				1,100,000
Number of collaborative areas granted																																					3
Collaboration and license agreement date																																					August 2012						August 2012
Expected term of research and development plan																																				4 years
Common stock issue		42,000	36,000																																		25,000,000
Common stock issued		41,774,442	35,831,808																																		6,250,000
Price per share	$ 9.50																																				$ 4.00
Number of days during which AstraZeneca could not sell, transfer, make any short sale of, or grant any option for the sale of any common stock																																					365 days
Restricting common stock valuation measurement period																																					1 year
Revenue recognition period																																											2 years
Issued promissory note		$ 5,000,000
Conversion to common stock		1,256,232
Conversion rate		$ 4.00

Related Party Transactions - Additional Information (Detail) (Alnylam, USD $) In Millions, unless otherwise specified	3 Months Ended	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2013
Alnylam
Related Party Transaction [Line Items]
Service agreement	$ 0.1	$ 0.5

Common Stock Reserved for Future Issuance (Detail)	Sep. 30, 2013	Dec. 31, 2012
Equity [Line Items]
Common stock options outstanding	4,160,000	4,720,000
Total common shares reserved for future issuance	8,182,756	7,124,739
Common Stock
Equity [Line Items]
Common stock options outstanding	4,160,215	4,661,549
Common stock shares available for future grant	2,161,410	946,403
Employee Stock Purchase Plan
Equity [Line Items]
Common stock shares available for future grant	460,283	150,000
Convertible Notes Payable
Equity [Line Items]
Total common shares reserved for future issuance	1,400,848	1,366,787

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2013
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management’s opinion, the accompanying financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results for the interim periods presented. Interim financial results are not necessarily indicative of results anticipated for the full year. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and footnotes included in the Annual Report on Form 10-K for the year ended December 31, 2012 for Regulus Therapeutics Inc. (“we,” “us,” “our,” or the “Company”), from which the balance sheet information herein for the year ended December 31, 2012 was derived. On September 7, 2012, our board of directors approved a one-for-two reverse stock split of our common stock. The accompanying condensed financial statements and notes to the condensed financial statements give retroactive effect to the reverse split for all periods presented. No further splits (or reverse splits) of our common stock have been contemplated as of September 30, 2013. In October 2012, we completed an initial public offering and concurrent private placement of 18,980,982 shares of common stock at an offering price of $4.00 per share. In addition, principal and interest of $10.8 million from convertible notes outstanding were automatically converted upon the closing of the initial public offering into an aggregate of 2,703,269 shares of our common stock. We raised a total of $70.0 million in net proceeds from our initial public offering and concurrent private placement, after deducting underwriter discounts, commissions and other offering expenses. In July 2013, we completed a public offering of 5,175,000 shares of common stock at an offering price of $9.50 per share. The shares were registered pursuant to a registration statement on Form S-1. We raised a total of $45.8 million in net proceeds, after deducting underwriting discounts, commissions and other offering expenses.
Use of Estimates	Use of Estimates Our financial statements are prepared in accordance with GAAP. The preparation of our financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions.
Revenue Recognition	Revenue Recognition As of September 30, 2013, we have ongoing strategic alliance agreements and collaborations with GlaxoSmithKline plc (“GSK”), Sanofi, AstraZeneca AB (“AstraZeneca”) and Biogen Idec MA Inc. (“Biogen Idec”). Our revenues generally consist of upfront payments for licenses or options to obtain licenses in the future, research and development funding and milestone payments. We recognize revenues when all four of the following criteria are met: (1) persuasive evidence that an arrangement exists; (2) delivery of the products and/or services has occurred; (3) the selling price is fixed or determinable; and (4) collectability is reasonably assured. For these multiple element arrangements, deliverables under our agreements are accounted for as separate units of accounting provided that (i) a delivered item has value to the customer on a stand-alone basis; and (ii) if the agreement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item is considered probable and substantially in the control of the vendor. The allocation of consideration amongst the units of accounting under our strategic alliance agreements and collaborations are derived using a “best estimate of selling price” if vendor specific objective evidence and third-party evidence of fair value is not available. Milestones We recognize revenue from milestone payments when earned, provided that (i) the milestone event is substantive in that it can only be achieved based in whole or in part on either our performance or on the occurrence of a specific outcome resulting from our performance and its achievability was not reasonably assured at the inception of the agreement; (ii) we do not have ongoing performance obligations related to the achievement of the milestone; and (iii) it would result in the receipt of additional payments. A milestone payment is considered substantive if all of the following conditions are met: (i) the milestone payment is non-refundable; (ii) achievement of the milestone was not reasonably assured at the inception of the arrangement; (iii) substantive effort is involved to achieve the milestone; and (iv) the amount of the milestone payments appears reasonable in relation to the effort expended, the other milestones in the arrangement and the related risk associated with the achievement of the milestone. Any amounts received under the agreements in advance of performance, if deemed substantive, are recorded as deferred revenue and recognized as revenue as we complete our performance obligations. Generally, the milestone events contained in our strategic alliance agreements and collaborations coincide with the progression of our product candidates from target selection, to clinical candidate selection, to clinical trial, to regulatory approval and then to commercialization. The process of successfully discovering a new development candidate, having it approved and ultimately sold for a profit is highly uncertain. As such, the milestone payments we may earn from our partners involve a significant degree of risk to achieve. Therefore, as a product candidate progresses through the stages of its life-cycle, the value of the product candidate generally increases.
Deferred Revenue	Deferred Revenue Amounts received prior to satisfying the above revenue recognition criteria are recorded as deferred revenue in the accompanying condensed balance sheets. Amounts not expected to be recognized within the next 12 months are classified as non-current deferred revenue.
Stock-Based Compensation	Stock-Based Compensation We account for stock-based compensation expense related to stock options granted to employees and members of our board of directors by estimating the fair value of each stock option on the date of grant using the Black-Scholes model. We recognize stock-based compensation expense using the accelerated multiple-option approach. Under the accelerated multiple-option approach (also known as the graded-vesting method), we recognize compensation expense over the requisite service period for each separately vesting tranche of the award as though the award was in substance multiple awards, resulting in accelerated expense recognition over the vesting period. We account for stock options granted to non-employees other than members of our board of directors, which primarily consist of members of our scientific advisory board, using the fair value approach. Stock options granted to non-employees are subject to periodic revaluation over their vesting terms.
Fair Value Option	Fair Value Option Applicable accounting guidance permits entities to choose, at specified election dates, to measure specified items at fair value if the decision about the election is: 1) applied instrument by instrument, 2) irrevocable, and 3) applied to an entire instrument. In July 2012, we amended and restated our $5.0 million convertible promissory note originally issued in February 2010 to GSK (“2010 GSK Note”), which was accounted for as a debt extinguishment of the original note. We elected to measure the 2010 GSK Note under the fair value option. Upon initial measurement, the difference between the carrying value of the original note and the fair value of the 2010 GSK Note was recorded as a loss on extinguishment of debt to non-operating earnings. Thereafter, any change to the fair value of the 2010 GSK Note is recorded as a gain (loss) from valuation of convertible note payable to non-operating earnings.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In February 2013, the FASB issued Accounting Standards Update No. 2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income (“ASU 2013-02”). This update will require companies to present information about amounts reclassified out of accumulated other comprehensive income and their corresponding effect on net income in one place and reference the amounts to the related footnote disclosures. Current accounting standards present this information in different places throughout the financial statements. ASU 2013-02 was effective for us for the nine months ended September 30, 2013. The adoption of ASU 2013-02 had no impact on our financial condition, results of operations, or cash flows. In July 2013, the FASB issued Accounting Standards Update No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (“ASU 2013-11”). This update provides explicit guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. This guidance is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013, with an option for early adoption. We intend to adopt this guidance in 2014, and do not believe the adoption of this standard will have a material impact on our financial condition, results of operations or related financial statement disclosures.

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2013	Nov. 08, 2013
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q3
Trading Symbol	RGLS
Entity Registrant Name	REGULUS THERAPEUTICS INC.
Entity Central Index Key	0001505512
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		41,777,326